Novel strategies in the approach to primary immunodeficiencies to discover new pathogenic mechanisms and complex clinical phenotypes by Giardino, Giuliana
 
 
 
 
1 
UNIVERSITY OF NAPLES 
“FEDERICO II” 
 
 
SCHOOL OF MEDICINE AND SURGERY 
DEPARTMENT OF TRANSLATIONAL MEDICAL SCIENCES 
 
PhD Program 
“Human Reproduction, Development and Growth” 
 
Director 
Prof. Claudio Pignata 
 
PhD Thesis 
 
Novel strategies in the approach to primary immunodeficiencies to 
discover new pathogenic mechanisms and complex clinical phenotypes 
 
 
Student     Tutor 
Dr. Giuliana Giardino         Prof. Claudio Pignata 
 
Academic Year 2015-2016 
 
 
 
 
2 
 
BACKGROUND AND AIM .................................................................................................................... 4 
CHAPTER I ............................................................................................................................................ 12 
“Targeted Next Generation Sequencing (TNGS): a powerfull tool for a rapid diagnosis of PIDs” ....... 12 
1.1 Targeted next generation sequencing revealed MYD88 deficiency in a child with chronic 
Yersiniosis and granulomatous .............................................................................................................. 13 
1.2 Diagnostics of Primary Immunodeficiencies through targeted Next Generation Sequencing........ 25 
 
CHAPTER 2 ........................................................................................................................................... 38 
“STAT1 gain of function mutation in the pathogenesis of chronic mucocutaneous disease in the context 
of a complex multisystemic disorder” .................................................................................................... 38 
2.1 Novel STAT1 gain of function mutation and suppurative infections................................................ 40 
2.2 Heterozygous STAT1 gain-of-function mutations underlie a broad clinical phenotype: an 
international survey of 234 patients from 140 kindreds ...................................................................... 46 
2.3 Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: presenting as 
treatment-resistant candidiasis and chronic lung disease .................................................................... 63 
 
CHAPTER 3 ........................................................................................................................................... 94 
“Ectodermal disorders and PIDs” ........................................................................................................... 94 
3.1 B cells from nuclear factor kB essential modulator deficient patients fail to differentiate to 
antibody secreting cells in response to TLR9 ligand. .......................................................................... 98 
3.2 Insight into IKBKG/NEMO locus: report of new mutations and complex genomic 
rearrangements leading to incontinentia pigmenti disease. .............................................................. 105 
3.3 Unraveling the Link Between Ectodermal Disorders and Primary  Immunodeficiencies ............ 120 
3.4 FOXN1 in organ development and human diseases. ......................................................................... 135 
 
 
 
 
3 
3.5 FOXN1: A Master Regulator Gene of Thymic Epithelial Development Program ........................ 150 
 
CHAPTER 4 ......................................................................................................................................... 163 
“Rare genetic syndrome involving immune system” ............................................................................ 163 
    4.1 Severe combined immunodeficiencies – an update .................................................................... 163 
4.2 Phenotypic characterization and outcome of paediatric patients affected with haemophagocytic 
syndrome of unknown genetic cause ................................................................................................... 184 
4.3 Intergenerational and intrafamilial phenotypic variability in 22q11.2 Deletion syndrome subjects
 194 
4.4 Gastrointestinal involvement in patients affected with 22q11.2 deletion syndrome. .................... 204 
 
TECHNOLOGIES ................................................................................................................................ 211 
REFERENCES...................................................................................................................................... 226 
SUMMARY .......................................................................................................................................... 260 
CURRICULUM VITAE ....................................................................................................................... 263 
 
  
 
 
 
 
4 
BACKGROUND AND AIM 
Primary immunodeficiency disorders (PIDs) are a group of inherited disorders of the immune 
system, resulting in an increased rate and severity of infection. Malignancy and immune 
dysregulation, the latter resulting in autoimmune disease and aberrant inflammatory 
responses may also feature these syndromes (1). PIDs differ from secondary 
immunodeficiencies occurring during certain viral infections, after immunosuppression, 
during treatment of systemic autoimmune disease, or in association with cancer 
chemotherapy (1).  
The overall prevalence of PIDs is about 1:2000 live births (2, 3) with an estimated 
prevalence of the severe forms of PIDs of 1:58000 live birth (4). The male/female ratio of 
PIDDs is approximately 5:1 in infants and children but approaches 1:1 in adults (2, 5). PIDs 
are classified according to mechanistic and clinical descriptive characteristics. In particular, 
according to the mechanistic characteristics, they may be divided in defects of innate 
immunity, disorders of immune dysregulation, autoinflammatory syndromes, phagocyte and 
complement system defects, or defect of adaptive immunity. The last group can be further 
subdivided into humoral deficiencies, and combined deficiencies affecting both humoral and 
cellular mechanisms. Recently, anticytokine autoantibodies have been identified in the 
pathophysiology of some Mendelian PIDs. PIDs characterized by antibody deficiency are the 
most frequent group, accounting for approximately half of all patients with PIDs (2, 6).  
Increased susceptibility to infections represent the main clinical feature of PIDs. The 
organ systems involved and the typical pathogens vary with the specific type of immune 
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defect (7, 8). Other features include autoimmune disease and malignancy, which may be 
often observed in a variety of immunodeficiencies (9, 10). Hypersensitivity to environmental 
and/or food allergens, may also feature a variety of PIDs (11).  
A careful identification of the foci of infections, of the organisms, and of the response to 
treatment are necessary to point the diagnosis through a specific PID. Any other conditions 
that might predispose to infection, including anatomic defects, allergy, and metabolic 
disorders, should be also ruled out (12).  
The clinical presentation usually guide the initial evaluation with a stepwise approach 
(screening tests followed by advanced tests) that ensures an efficient evaluation of 
mechanisms of immune dysfunction underlying the clinical presentation (2, 13). In some 
case, diagnosis may be difficult and may require costly sophisticated tests. First line 
laboratory assessment includes evaluation of serum immunoglobulin levels and leukocyte 
and lymphocyte subpopulations, and evaluation of the specific immune response including 
responses against vaccine antigens, or responses to natural exposure or infections. 
According to the severity of clinical manifestations combined immunodeficiencies are 
classified in severe combined immunodeficiency (SCID) or combined ID with a ‘‘less 
severe’’ clinical presentation (14). Patients with SCID show a complete absence of specific 
immunity and are prone to develop infections caused by the entire range of possible 
pathogens, including opportunistic organisms (15-17). SCID is a life threatning condition 
and diagnosis is an urgent medical condition since if not treated these infants can succumb 
to severe infection at any time. Definitive hematopoietic stem cell therapy (HSCT) should be 
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performed as soon as possible (18-22). A variety of additional genetic defects leading to 
impairment of T- and B-cell function have been described, including hyper-IgM Wiskott-
Aldrich, DiGeorge, ataxia-telangiectasia, hyper-IgE syndromes, and others. Many of these 
diseases are characterized by peculiar clinical features that might influence or guide the 
diagnostic approach.  
The principal clinical manifestations of humoral immunodeficiency are recurrent bacterial 
infections of the upper and lower respiratory tract (23, 24).  
The disorders of immune dysregulation include the hemophagocytic syndromes, 
syndromes with autoimmunity and hypersensitivity, and lymphoproliferation. The 
hemophagocytic syndromes are characterized by fulminant acute presentations triggered by 
viral infections (25, 26). These patients usually require aggressive chemotherapy followed 
by HSCT to prevent immediate fatality (25, 26).  
Phagocytic cell defects can present with severe pyogenic bacterial and fungal infections 
of the respiratory tract, skin, and viscera and gingivostomatitis. Laboratory evaluation might 
show neutropenia, normal neutrophil numbers, or marked neutrophilia (mainly in cellular 
adhesion defects) (27, 28).  
Disorders of innate immunity are rare and include defects of Toll-like receptor (TLRs) 
signaling, such as nuclear factor kB essential modulator (NEMO) syndrome, often exhibiting 
ectodermal dysplasia along with infection susceptibility with a narrow (eg, predominantly 
pyogenic bacteria or fungi) to a wide range of pathogens (29, 30). This category also includes 
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several defects associated with herpes simplex encephalitis and chronic mucocutaneous 
candidiasis (CMC) (31). 
More than 200 distinct genetic disorders responsible of well-characterized PIDs have been 
identified to date (32). Alterations in such genes, implicated in immune function, underlie 
very complex phenotype. Early diagnosis of PID is useful in order to prevent significant 
disease-associated morbidity and mortality (33). However, to date the diagnosis of a specific 
PID based on the analysis of the individual clinical and/or immunological phenotype remains 
often difficult, and a considerable delay between the onset of symptoms and the time of 
diagnosis of PIDs is often reported. About the 40% of patients with these disorders do not 
reach a diagnosis until adulthood despite the presence of serious chronic health conditions 
prior to diagnosis, such as sinusitis, bronchitis, and pneumonia (34).  
Thanks to the progress in molecular technologies, a remarkable improvement of the 
knowledge in the field of PIDs, concerning both their etiopathogenetic mechanisms and 
clinical features, has been observed in the last 20 years, leading to a complete revisitation of 
the classical paradigms of PIDs (35). PIDs, in fact, were initially thought to be conﬁned to a 
few rare, familial, monogenic, recessive traits impairing the development or function of one 
or several leucocyte subsets and resulting in multiple, recurrent, opportunistic and fatal 
infections in infancy. A growing number of exceptions to each of these conventional 
qualiﬁcations have accumulated over the years, particularly over the last two decade (Table 
I) (35).  
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Table I: Multiple paradigm shifts in human primary immunodeficiencies (35). 
 
Until 2010, the traditional approach to PIDs diagnosis has included Sanger sequencing of 
candidate genes, single nucleotide polymorphisms (SNPs), linkage analysis, and has 
involved an array of specialized functional tests including lymphocyte proliferation and 
cytotoxicity assays, flow cytometry, measurement of serum immunoglobulin levels, 
neutrophil function tests. With this traditional approach a definitive diagnosis is not possible 
in many cases (34). 
In the very last years, genetic identification of immunodeficiency syndromes has become 
more efficient with the availability of whole-exome sequencing (WES), expediting the 
identification of relevant genes and complementing traditional linkage analysis and 
homozygosity mapping (Table II) (36, 37). Only in the last two years, 34 new gene defects 
have been identified (Table II and III) (32, 38). 
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Table II: Selected key advances in basic and clinic immunology in 2013 (38) 
 
Table III: Novel gene defects as a cause of primary immunodeficiencies identified in 
2014 (modified by (32)) 
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In this context, this thesis will be focused on novel insight into diagnostic approach to 
PIDs and on the definition of novel clinical and laboratory features of new and old PIDs. 
Moreover, novelties in the fields of inheritance of PIDs will be discussed. This thesis reports 
the results obtained during my PhD course in “Human Reproduction, Development and 
Growth” (XXVIII Cycle) from 2013 to 2016. During the past 3 years, my research has been 
focused in the study of the following lines of research: 
 Characterization of novel aspect of the pathogenesis of already known 
immunodeficiency, diagnosed conventionally or through Next Generation Sequencing 
(NGS). In particular, my research was focused on the study of the role of Myeloid 
differentiation factor 88 (MyD88) deficiency, identified through Targeted NGS, in the 
pathogenesis of the immunological and clinical features observed in a patient who had an 
atypical presentation characterized by chronic Yersiniosis and granuolomatous 
lymphadenitis; 
 Better characterization of the clinical phenotype of a complex syndrome caused by 
STAT1 gain of function mutation, whose hallmark is autosomal dominant Chronic 
Mucocutaneus Candidiasis (CMCD) and definition of the role of such mutations in the 
pathogenesis of clinical manifestations associated to the syndrome; 
 Definition of the role of T-independent B-cell immunity in susceptibility to infections 
from encapsulated bacteria in Hypoidrotic Ectodermal Dysplasia with 
immununodeficiency (HED-ID); 
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 Characterization of skin and skin annexa abnormalities associated to PIDs, which 
represent alarm signs that should lead the clinician to consider a deeper immunological 
assessment; 
 Study of the functional role of  FOXN1 transcription factor in the T-cell ontogeny; 
 Rare genetic syndrome involving immune system paying a particular attention to SCID, 
hemophagocytic lymphoistiocitosis (HLH) and Di George Syndrome (DGS). 
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CHAPTER I 
“Targeted Next Generation Sequencing (TNGS): a powerfull tool for a rapid 
diagnosis of PIDs” 
PIDs represent a vast group of monogenic diseases including more than 250 genetically 
defined diseases (39). Most of the genetic defect have been identified in recent years. The 
rapid advance of the knowledge in the field of functional immunological studies and genetic 
diagnostic tools, contributed to this extraordinary rapid evolution (32, 38). However, despite 
the breadth of current knowledge, the early genetic diagnosis underlying PIDs, still remains 
a difficult task with the traditional stepwise diagnostic approach, based on functional studies 
followed by Sanger sequencing (34). Early diagnosis in severe forms of PIDs is crucial to 
establish a proper treatment and improve the overall outcome (34). Moreover, diagnosis at 
the molecular level is desirable to: 1. establish unequivocal diagnosis, 2. permit accurate 
genetic counseling, 3. allow planning of future pregnancies or their outcomes, 4. better define 
genotype/phenotype associations, and 5. identify candidates for gene-specific therapies.  
The traditional approach to PIDs, often represents a time consuming strategy, which 
require the sequencing of multiple genes by the classic Sanger method, and may lead to 
delayed diagnosis. In fact, different mutations in the same gene can lead to different clinical 
phenotypes (32, 38). For example, a specific recombination-activating gene 1 (RAG1) 
variant protein with partial recombinant activity might produce Omenn syndrome, a leaky 
SCID or a Common Variable Immunodeficiency (CVID) phenotype. Moreover, defect in 
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different genes may lead to very similar clinical phenotype. Furthermore, not all the PIDs 
causing genes are known and many PIDs represent extremely rare conditions. 
In this context, NGS technology may represent a powerful diagnostic tool for the rapid 
detection of the genetic alteration, particularly in complex cases (40). In the field of PIDs, 
targeted sequencing approach may be tailored on a peculiar functional alteration, that 
characterizes a specific disorder, allowing an easier management of the data sets, along with 
lower cost, than the most complex WES analysis (41-43). 
The NGS approach represent a very powerful tool for the rapid gene identification of 
typical phenotypes, for the identification of new genetic defects associated to classical 
phenotypes, for the definitions of new clinical presentation of a known gene alterations and 
for the identification of new genetic defects associated to  new clinical phenotypes. 
 
1.1 Targeted next generation sequencing revealed MYD88 deficiency in a child with 
chronic Yersiniosis and granulomatous 
 
MyD88 deficiency is a very rare PIDs affecting the innate immunity, inherited as an 
autosomal recessive trait (44, 45). MyD88 is a cytosolic adapter molecule, linking TLRs and 
interleukin-1 receptors (IL-1Rs) to the IRAK complex. MyD88 and IRAK-4 deficiencies are 
responsible for very similar clinical phenotypes (45) (Figure 1).  
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Figure 1. MyD88- and IRAK-4-signaling pathways (46).  
PBMC from MyD88- and IRAK-4-deficient patients show impaired responses to the 
stimulation with TLR ligands (other than TLR3 ligands) (47, 48) and IL-1R agonists (44, 
45).  The MyD88- pathway is implicated in the synthesis of inflammatory cytokines (IL-1β, 
IL-6, IL-8, tumor necrosis factor [TNF]-α, interferon [IFN]-α/β, and IFN-λ) (49). 
MyD88 deficiency is characterized by increased susceptibility to invasive bacterial 
disease (InvBD) caused by Streptococcus pneumoniae (S. pneumoniae) and Staphylococcus 
aureus (S. Aureus), and to non-invasive bacterial disease (NInvBD) caused by S. Aureus and 
Pseudomonas aeruginosa (P. Aeruginosa) (50). Recurrent invasive pneumococcal diseases 
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represent a hallmark of this PID (45). Due to the very weak inflammatory signs, which 
usually appear late, infections in Myd88 deficiency may be very difficult to diagnose. 
NInvBD usually involve to the skin (S. Aureus) and the upper respiratory tract (P. 
aeruginosa). By contrast, during InvBD several sites are involved, and abscesses of inner 
organs, lymph nodes and saliva glands, meningitis, and septicemia may be frequently 
observed. Involvement of gastrointestinal and urogenital system is very rare (50). On the 
other side, MyD88-deficient patients display a normal resistance to common fungi, parasites, 
viruses, and to a large fraction of bacteria (46). Even in cases of severe infections, clinical 
and laboratory signs of inflammation usually develop very slowly and a frank neutropenia 
may develop from the onset of infection as consequence of impaired polymorphonuclear 
neutrophil mobilization, perhaps secondary to the lack of IL-8 production (50). MyD88 
deficiency may be life-threatening in infancy and childhood, with a mortality rate of about 
38%. Thanks to the development of adaptive antigen-specific T- and B-lymphocyte 
responses, infections in Myd88 deficient patients are rarer with age, and no death has been 
recorded after the age of 8 years and no invasive infection after the age of 14 years, even 
when antibiotic prophylaxis and IgG replacement therapy are discontinued (50).  
In this paper published as Letter to the Editor on Journal of Allergy and Clinical 
Immunology we report on the case of a 2-year-old female born to consanguineous parents of 
Rom ethnia. Since the age of 7 months the patient experienced chronic Yersiniosis, recurrent 
granulomatous lymphadenitis, and episodic neutropenia. TNGS panel, with customized 
analysis for immunodeficiency genes, lead to the identification of a homozygous in-frame 
deletion, p.Glu66del in the MYD88 gene.  
Letter to the EditorTargeted next-generation sequencing revealed
MYD88 deficiency in a child with chronic yersi-
niosis and granulomatous lymphadenitis
To the Editor:
Yersiniosis is a food-borne illness, usually self-limited. Severe
clinical courses may occur in chronic conditions, particularly in
immunocompromised individuals.1
Here, we report on the case of a 2-year-old girl born to
consanguineous parents of Roma descent (a traditionally itinerant
ethnic group living mostly in Europe and the Americas,
who originate from Northern India), with chronic yersiniosis,
recurrent granulomatous lymphadenitis, and episodicneutrope-
nia. Using a targeted next-generation sequencing panel for
immunodeficiency genes, a homozygous in-frame deletion in
theMYD88 gene was found. MyD88 is a key downstream adapter
for most Toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).2
MYD88 deficiency has been associated with life-threatening
and recurrent pyogenic bacterial infections, including invasive
pneumococcal disease.3,4
The child was born at term from a pregnancy complicated by
maternal syphilis, which required a postnatal treatment with
benzathine penicillin. During the treatment, she developed a
severe neutropenia, from which she spontaneously recovered.
A congenital syphilis infection was excluded by serological,
blood culture, and cerebrospinal fluid examination, cerebral
ultrasound, and long bone x-ray image. Familial history was
significant for 3 brothers who died in childhood of infectious
diseases, 2 of meningitidis and sinusitis and 1 of enteritis (Fig 1,
A). No further information was available about the brothers’
clinical history. At the age of 7 months, she developed an episode
of upper left arm edema associated with fever followed by an
intestinal occlusion. Exploratory laparotomy revealed severe
stenosis of the ileal tract from 10 to 40 cm proximal to the
ileocecal valve, associated with mesenteric adenitis. Intestinal
wall histology revealed conspicuous infiltration of bacilli
(Fig 2, C and D), vast areas of marginal necrosis, full-thickness
massive edema, and inflammatory infiltrates (Fig 2, E and F).
Cultures of stool and of the bowel wall were negative for bacteria,
parasites, and mycobacterium tuberculosis. Cytomegalovirus,
human immunodeficiency virus (HIV1/HIV2), Salmonella/
Brucella, and Treponema pallidum (Rapid plasma reagin/
treponema pallidum hemagglutination assay, T pallidum
IgM/IgG) were also excluded by serological examinations. At
the age of 13 months, she developed a new episode characterized
by fever, abdominal pain, diarrhea, and vomiting. On this
occasion, blood culture grew Yersinia, which required treatment
with amoxicilline/clavulanic acid.
At the age of 8 months, she developed axillary (Fig 2, A and B)
and epitrochlear suppurative lymphadenitis of the left arm. The
histological examination of the 5-cm diameter cold axillary
colliquative lymphadenitis revealed a mixed inflammatory
reaction characterized by T and B lymphocytes, plasma cells,
and eosinophils. Histiocytes, mixed with multinucleated giant
cells arranged in a palisading pattern, were observed, consistent
with a granulomatous inflammatory process. Cultures from the
purulent exudate grew Staphylococcus aureus sensitive to
amoxicilline/clavulanic acid. The patient never experiencedeczema or any other cutaneous lesion, and abscesses developed
on an otherwise healthy skin. Laboratory examinations revealed
microcytic hypocromic anemia (hemoglobin, 8.9 g/dL; mean
corpuscular volume, 60 fl; mean corpuscular hemoglobin, 18
pg), eosinophilia (750 cells/mL), and normal inflammatory index
(C-reactive protein, 0.1 mg/dL; ferritine, 73.8 ng/mL). After
unsuccessful intravenous antibiotic therapy, surgical drainage
was required. Prophylactic treatment with cotrimoxazole and
amoxicilline/clavulanic acid was then given for potential
recurrence of S aureus lymphadenitis.
An immunodeficiencywas suspected on the basis of the clinical
features and familial history. Other genetic disorders, not directly
involving the immune system, were ruled out by the clinical
history and routine laboratory examinations. First-level
immunological examinations revealed normal IgG, IgM, and
IgA levels, increased IgE levels (1190 IU/mL), normal levels of
standard lymphocyte subpopulations (CD31 57%, CD41 41%,
CD81 12%, CD561 14%, CD191 19%, CD31HLA2DR 3%)
(for absolute numbers, see Table E1 in this article’s Online
Repository at www.jacionline.org) and of adhesion molecules
(absolute monocyte number was 440 cells/mL and CD11a/
CD18, CD11b/CD18, and CD11c/CD18 on the leucocyte gate
was 99%). Specific antibodies were detectable, and the prolifera-
tive response to mitogens was normal. The study of the response
to Prevenar13 revealed an impaired IgM, but not IgA and IgG,
response against pneumococcal polysaccharides, as previously
reported by Maglione et al.5 This finding, associated with the
evidence of a low titer of isohemagglutinins, suggests an impaired
response against T-independent polysaccharidic antigens (see
Table E2 in this article’s Online Repository at www.jacionline.
org). Nitroblue tetrazolium chloride and dihydrorhodamine 123
assays ruled out the chronic granulomatous disease.
AT1B1NK1 combined immunodeficiency due to hypomorphic
RAG1/2mutation, consistent with the presence of granulomatous
inflammation of skin, was excluded by molecular analysis.
Hyper-IgE syndrome score was ruled out through the molecular
analysis of STAT3.
At the age of 11 months, she again developed a severe
neutropenia, which eventually required G-CSF treatment.
Congenital neutropenia was ruled out with negative ELANE
gene sequencing.
After written informed consent from the parents for molecular
genetic studies, a targeted next-generation sequencing panel
(TaGSCANv.2: Targeted Gene Sequencing and Custom Analysis),
including 572 genes and customized for 55 immunodeficiency
genes,was run (see theMethods section andTableE3 in this article’s
Online Repository at www.jacionline.org).6 A homozygous known
pathogenic in-frame deletion, c.196_198del GGA (p.Glu66del; also
referred to as E65del andE52del3,7,8), was identified in exon 1 of the
MYD88 gene. This variant has been previously reported in several
affected families, at least 2 of which were of Rom descent with
consanguineous parents. This deletion removes a single conserved
glutamic acid residue in the Death domain, resulting in greatly
diminished protein levels.7 Sanger sequencing was used to verify
thefinding and confirmcarrier status of bothparents (Fig 1,A andB).
We studied the effect of MYD88 deficiency in TLR and IL-1R
responses of PBMCs from the patient. Il-6, il-1, ccl2, and
ccl3 mRNA induction following TLR4 or IL-1R agonists1
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TNF-a and TLR3 stimulation (Fig 1, C-F). Fibroblasts from
the MYD88-deficient child and a healthy control were
transiently transfected with an expression vector encoding
the wild-type MYD88 gene. Cells from MYD88-deficient
patient regained IL-1b and LPS responsiveness after
transfection with the wild-type MYD88 gene, as shown by the
levels of IL-1 and IL6 production (Fig 1, G and H) (see the
Methods section).
In MYD88-deficient patients, impaired polymorphonuclear
neutrophil mobilization and/or frank neutropenia may occur
from the onset of infection, presumably related to the lack of
IL-8 production. Gastrointestinal infections are rare.9 Moreover,
TLRs play a key role in the immunological response to
flagellated Gram-negative bacterium, thus explaining why the
patient developed chronic yersiniosis.10 Of note, Yersinia
enterocolitica is able to deactivate TLR-induced signaling
pathways, by cleaving Myd88, triggering apoptosis in
macrophages.11 This mechanism may increase Yersinia
virulence in immunocompetent hosts also. In a recent article by
von Bernuth et al,12 MyD88-deficient mice were found to be
susceptible to almost nearly all the microbes tested, including
bacteria, viruses, protozoa, and fungi, highlighting the impor-
tance of TLR in the immune response to different pathogens. In
contrast, patients with MyD88 or IRAK-4 deficiencies have
been shown to be susceptible to invasive and noninvasive infec-
tions with only a few Gram-positive and Gram-negative bacteria,
maybe as a consequence of the redundancy of the immune system.
However, the predominance of Gram-positive bacteria in patients
with MyD88 and IRAK-4 deficiencies may result, at least in part,
from a limited exposition to the different antigens in certain
geographic areas. The evidence of chronic yersiniosis in this
patient expands the list of organisms that can lead to infections
in subjects affected with this syndrome. Even though we were
not able to grow Yersinia from the bowel wall, it was suspected
as being responsible for the terminal ileitis and mesenteric
adenitis on the basis of the histological staining indicative of a
bacillus infection.
In this study, we reported on a patient affected with chronic
yersiniosis, recurrent granulomatous lymphadenitis, and
neutropenia associated with an homozygous p.Glu66del variant
in MYD88. This finding was unexpected because Myd88
deficiency is characterized by high susceptibility to invasive
bacterial disease caused by Streptococcus pneumoniae and
S aureus, with invasive pneumococcal disease being the
hallmark of the syndrome.9 Noninvasive bacterial diseases
caused by S aureus or Pseudomonas aeruginosa have also
been described.9 The atypical presentation of our patient,FIG 1. MYD88 deficiency impairs TLR and IL-1R respon
indicated with an arrow. Healthy persons are shown
crossing. B, Genomic sequence analysis of MYD88
c.196_198del GGA (p.Glu66del). Both parents are het
PCR analysis of the mRNA extracted from the patient’s
(I:C) (TLR3 ligand) revealed reduced levels of IL-6, IL-
control, in response to LPS and IL-1 stimulation, while
stimulation. G and H, Fibroblasts from a healthy contr
transfected with an expression vector encoding wild-ty
regained IL-1b and LPS responsiveness after transfectio
of IL-1 and IL6. Y-axis values, on the right side, are ref
anti–FLAG-specific antibody to verify the transfection
MYD88.characterized by chronic yersiniosis and recurrent neutropenia
in the absence of recurrent invasive pneumococcal disease,
made the diagnosis difficult. In these contexts, targeted
next-generation sequencing may represent a rapid and
low-cost tool to achieve an early diagnosis.
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FIG 2. Clinical features. A and B, Axillary suppurative lymphadenitis of the left arm. C and D, Grocott stain
revealed conspicuous infiltration of bacilli in the intestinal wall. E and F, Intestinal wall histology revealed
vast areas of marginal necrosis, full-thickness massive edema, and inflammatory infiltrates.
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11. Novikova L, Czymmeck N, Deuretzacher A, Buck F, Richter K, Weber AN, et al.
Cell death triggered by Yersina enterocolitica identifies processing of theproinflammatory signal adapter MyD88 as a general event in the execution of
apoptosis. J Immunol 2014;192:1209-19.
12. von Bernuth H, Picard C, Puel A, Casanova JL. Experimental and natural
infections in MyD88- and IRAK-4-deficient mice and humans. Eur J Immunol
2012;42:3126-35.
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METHODS
Targeted next-generation panel, ‘‘TaGSCANv.2’’ (Targeted Gene
Sequencing and Custom Analysis) was run, which includes 572 genes.
Briefly, samples were prepared for sequencing using TruSight Rapid Capture
with TruSight Inherited Disease Oligos (Illumina, San Diego, Calif); the MT
genome is covered at 10003 by the addition of MToligos during enrichment
(Integrated DNATechnologies, Coralville, Iowa). Samples were sequenced to
at least 2.5Gb on an Illumina MiSeq with TruSeq v3 reagents, yielding paired
250 nucleotide reads. Alignment, variant calling, and analysis were performed
as previously described.E1 In this case, analysis was customized for immuno-
deficiency, which limited the genes examined to 55 (see Table E3). Variant
analysis was confined to coding and splice variants with a minor allele
frequency of 1% or less in the Children’s Mercy Hospital internal database.
Two variants remained after filtering. One variant, in the FERMT3 gene
associated with leukocyte adhesion deficiency type III, was not pursued
because the minor allele frequency is 0.96 in European Americans (National
Heart, Lung, and Blood Institute database). No second variant was identified,
and there was limited phenotypic overlap. In addition, a homozygous known
pathogenic in-frame deletion, c.196_198del GGA (p.Glu66del; also referred
to as E65del and E52del in the literatureE2-E4), was identified in exon 1 of
theMYD88 gene. This variant has been previously reported in several affected
families, at least 2 of which were of Roma descent with consanguineous
parents. This deletion removes a single conserved glutamic acid residue in
the Death domain, resulting in greatly diminished protein levels.E4 Sanger
sequencing was used to verify the finding and confirm carrier status of both
parents (Fig 1, A and B in the text).
PBMCs were isolated from patients by density gradient centrifugation over
Ficoll-Hypaque (Biochrom, Berlin, Germany). For the cytokine mRNA
production, PBMCs were cultured in RPMI 1640 supplemented with 1%
FBS, for 24 hours without stimulation and then stimulated with LPS 1 ng/mL,
IL-1b 10 ng/mL, TNF-a 20 ng/mL, or poly(I:C) (TLR3 ligand) 25 mg/mL.
The mRNA, extracted from the PBMCs, was analyzed by real-time PCR and
standard procedures.
For the complementation of patients’ fibroblasts with plasmids carrying
wild-type MYD88, fibroblasts were incubated with a mixture containing
Lipofectamine 2000 reagent (Invitrogen #52887) and plasmids, as previously
reported.E2 This complexwas then removed and fibroblasts were incubated for
18 hours in Dulbecco modified Eagle medium supplemented with 10% FBS
before stimulation. Cytokine mRNA production was assessed in fibroblasts
cultured in Dulbecco modified Eagle medium supplemented with 10% FBS,
incubated for 48 hours without stimulation and then with TNF-a, IL-1b, or
poly(I:C) for 6 hours.
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TABLE E1. Absolute number of cell subpopulation
Cell subpopulation
Absolute number
(reference value)
Leukocytes 8,960 (6,700-14,000)*
Lymphocytes 5,320 (1,800-18,700)
T cells (CD31) 3,032 (1,400-11,500)
CD4 cells 2,181 (1,000-7,200)
CD8 cells 638 (200-5,400)
CD3 HLA-DR 159
B cells (CD191) 1,010 (130-6,300)
Natural killer cells (CD561CD32) 745 (68-3,900)
NA, Not available.
*Normal reference value.E5
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TABLE E2. Immunologic humoral evaluations of the patient
Laboratory evaluation
Immunoglobulins (mg/dL)
IgG 1180 (351-919)*
IgA 104 (10-85)
IgM 88 (38-204)
IgE (KU/L) 1190
Specific antibodies
HBV antigen antibodies (mIU/mL) 143.9
HSV (IgG/IgM) 1/2
VZV (IgG/IgM) 1/2
CMV (IgG/IgM) 2/2
Rosolia (IgG/IgM) 1/2
Antibody response to pneumococcal polysaccharides
(IgG/IgA/IgM)
IgG 8.0
IgA 27.2
IgM 0.7
Isohemagglutinins Anti-A 1:32
Anti-B 1:4
CMV, Cytomegalovirus; HBV, hepatitis B virus; HSV, herpes simplex virus; VZV,
varicella zoster virus.
*Normal reference values.
Data indicate the fold-increase in the antibody titer after the booster. A positive
response is defined as a threefold increase in the antibody titer.
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TABLE E3. List of the 55 studied genes
ADA
AP3B1
ATM
BLM
BLOC1S6
BTK
CD19
CD247
CD3D
CD3E
CD3G
CD40LG
CFP
DCLRE1C
DOCK8
ERCC2
ERCC3
FERMT3
FOXN1
FOXP3
G6PC3
GTF2H5
ICOS
IFNGR1
IFNGR2
IKBKG
IL12B
IL12RB1
IL1RN
IL2RG
JAK3
LIG4
LYST
MPV17
MYD88
NHEJ1
ORAI1
PRF1
RAB27A
RAG1
RAG2
RMRP
SH2D1A
SLC35C1
SP110
STAT1
STIM1
STX11
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Conclusive remarks 
The atypical presentation of our patient, characterized by chronic Yersiniosis and recurrent 
neutropenia in the absence of recurrent invasive pneumococcal disease, made the diagnosis 
very difficult. In these contexts, NGS may represent a rapid and low-cost tool to achieve an 
early diagnosis. 
1.2 Diagnostics of Primary Immunodeficiencies through targeted Next Generation 
Sequencing  
Vera Gallo, Laura Dotta, Giuliana Giardino, Emilia Cirillo,Vassilios Lougaris, Roberta 
D’Assante, Alberto Prandini, Rita Consolini, Carol Saunders, Alessandro Plebani, Raffaele 
Badolato and Claudio Pignata 
 
Introduction 
NGS technology represent a powerful, cost-effective, first-line diagnostic tool for a rapid 
detection of a genetic alteration, particularly in complex cases (40). Through NGS 
technology sequence of million DNA fragments, ranging from selected genes to the entire 
human genome (whole genome sequencing) may be amplified simultaneously and with a 
high grade of accuracy, in a reasonably short time. The whole exome, which includes only 
the coding regions of the genome, accounts for about 2% of the entire genome, containing 
about 85% of genetic alterations associated to human diseases (51). Thus, WES may 
represent a valuable and rapid alternative to the whole genome sequencing when NGS fails 
to identify the genetic alteration.  
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In this study, we used NGS sequencing panel, including 571 targeted genes and WES 
to study a cohort of patients affected with complex clinical phenotypes, suggestive of severe 
inherited forms of PID of unknown genetic origin, in which a diagnosis was not obtained 
through current diagnostic procedures.  In four patients we found alterations of genes 
associated to already genetically defined PIDs. In four patient alterations of already known 
PID genes, were associated with unusual clinical phenotypes. Functional and molecular 
studies confirmed the correlation between the genetic alteration and the alteration of the 
immunological function. In 8 patients we identified a total 22 gene variants in genes 
implicated in the immune response but not previously associated to any known PID. In these 
cases, we will perform functional studies to found a correlation between the genetic alteration 
and its relevance in the pathogenesis of immunological and clinical features, extended to 
larger cohort of similar patients.  
 
RESULTS 
Patients 
The patients who presented one or more of the following clinical criteria, associated to one 
or more immunological alteration, highly suggestive for primary immunological defect, were 
included into the study. Clinical criteria included: opportunistic infections; granuloma; CMC; 
intractable diarrhea; bronchiectasis; severe autoimmunity; variably associated to syndromic 
features and/or familiarity for similar phenotype. Immunological alterations included: 
abnormal lymphocyte subsets (absolute count < 2 SD of normal values according to ESID 
criteria); proliferative response to mitogens <10% of the CTR; absent/poor specific antibody 
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response; hypogammaglobulinemia; high IgE levels (>2000 KU/l); absent cytolytic activity; 
alteration of class switch recombination (CSR) with or without hyper-IgM. We identified 
fourty-five patients, heterogeneous for ethnic origin, age and sex who fulfilled the inclusion 
criteria. In 27 patients 571 genes, including genes involved in immunological pathways, were 
analyzed through NGS technology. In 18 WES was performed. After the detection of the 
variants, bioinformatics analysis of NGS results was performed through searches in variant 
databases, such as the Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS). 
Subsequently, additional variant filtering criteria were established and optimized in order to 
streamline likely causative mutations (Figure 2). All the variants defined as potentially 
responsible for the clinical phenotype according to the phenotype-based filtering criteria, 
have been validated by classical Sanger sequencing and, subsequently, functionally tested in 
vitro. 
Figure 2: Flowchart of filtering strategy 
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Genetic alterations 
The alterations identified were divided into four groups, on the basis of NGS results, 
functional alterations and consistency between genotype, phenotype and immune 
functionality.  
A fully satisfying molecular diagnosis of PID was achieved in 8 of 45 patients (17%). 
The first group includes 4 subjects in which we identified a genetic defect associated 
to a well-known PID. In particular, mutationss in CD40L, BTK, STAT1 and JAK3 genes 
were identified and confirmed by Sanger sequencing (Table IV).  
Table IV: Genetic variants associated to typical PIDs 
Patients Gene Mutation Protein Zigosity Inheri
tance 
Clinical and immunological 
phenotype 
001 
 
CD40L c.373C>T  p.His125Tyr Hom XL Severe 
hypogammaglobulinemia with 
hyper IgM, neutropenia, P. 
carinii pneumonia, CMV 
infection, intractable diarrhea 
002 
 
STAT1 c.847T>A  p.Leu283Met Het AD Chronic mucocutaneous 
candidiasis, recurrent 
pneumonia, hypothyroidism, 
lymphopenia, poor vaccine 
response 
003 BTK c.1105C>
T  
p.Leu369Phe Hom XL Agammaglobulinemia 
 
004  
 
JAK3 c.856C>T 
 
p.Gln286Ter Hom AR T-B+NK- SCID, chronic 
diarrhea, pathological 
proliferative response to 
mytogens , IgA deficiency 
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The second group includes 4 subjects in which alterations of genes responsible for a 
well-known PID, were associated with atypical clinical features, which made very difficult 
the diagnosis through conventional strategies (Table V). In particular, in patient 005 we found 
a homozygous mutation in MYD88 gene (c.192_194del; p.Glu66del). This patient was of 
Rom ethnia and resulted to have inherited the deletion from his unaffected consanguineous 
parents. Their familiar history was characterized by early infant deaths due to severe 
infections. The proband suffered from chronic yersiniosis, terminal ileitis, recurrent pyogenic 
adenitis without any inflammatory signs, high IgE levels (1190 IU/ml) and intermittent 
neutropenia. In reported cases, MYD88 mutations are associated with susceptibility to 
invasive bacterial infections, particularly caused by gram-positive bacteria. Functionally, 
known mutations result in impairment of cytokine production after TLR stimulation. Patients 
006 and 007 were found to carry homozygous deleterious mutations in PLDN and 
DOCK8/CLEC7A gene, respectively, whose phenotypic peculiarity has already been 
described in detail (41, 52). Briefly, patient 006 presented with partial oculocutaneous 
albinism, pyogenic dermatitis and impairment of NK cytotoxic activity that were associated 
to mutations of PLDN gene. In patient 007, who had chronic diarrhea, eczema, lymphopenia 
and elevated IgE levels, homozygous mutations of both DOCK8 and CLE7A genes were 
discovered (41, 52). In patient 008 we found a heterozygous (c.683C>T p.Pro228Leu) variant 
of unknown significance of CASP10 with exon 10 not covered at splice junction, associated 
with a heterozygous likely pathogenic variant of UNC13D (c.335G>C p.Cys112Ser). This 
patient had a clinical phenotype consistent with an autosomal dominant autoimmune 
 
 
 
 
30 
lymphoproliferative syndrome type II (ALPS-II) with the peculiarity of 
hypogammaglobulinemia and malignancies (LLA). Even though the CASP10 variant alone 
in the in silico prediction programs, Polyphen2 and Sorting Intolerant From Tolerant, was 
predicted to be tolerated and was observed in 35 healthy individuals (ExAc), its significance 
in association to a second deleterious variant has never been described and could be 
potentially relevant. 
Table V: Genetic variants associated to novel presentation of PIDs 
Patient
s 
Gene Mutation Protein Zigosi
ty 
Inherit
ance 
Clinical phenotype 
005 
 
MYD88 c.192_194
del 
p.Glu6
6del 
Hom AR Chronic yersiniosis and 
terminal ileitis, recurrent 
severe cutaneous 
granulomatous abscesses, 
hyper IgE, hypereosinophilia, 
neutropenia 
006 PLDN c.232C>T p.Q78X Hom AR Partial oculocutaneus 
albinism, nystagmus,  
recurrent cutaneous 
infections, 
thrombocytopenia, 
leucopenia, NK deficiency  
007 DOCK
8/CLE
C7A 
c.3193del
A 
p.Ser10
65Alafs
X17/p.
Tyr238
X 
Hom/
Hom 
AR Intractable diarrhea, eczema, 
malignancies, food allergies, 
hyper IgE, lymphopenia 
008  
 
 
CASP1
0 
c.683C>T 
 
p.Pro22
8Leu 
Het AD Acute lymphoblastic 
leukemia treated with 
allogenic HSCT, ethmoiditis, 
recurrent lymphoadenopathy, 
autoimmune cytopenia, 
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arthritis, 
hypogammaglobulinemia, 
hyperIgM, IgA deficiency 
 
In the third group we included 4 patients, in which NGS revealed multiple genetic 
variants, that were consistent only with some features of the clinical phenotype (Table VI).  
In the patient 009 we found a heterozygous mutation in CASP10 gene causative of 
the ALPS-II, characterized by autoimmune manifestations, particularly cytopenia, 
lymphoadenomegaly, splenomegaly and expansion of TCRαβ+ CD4/CD8 double negative T 
cells in the peripheral blood. His brother, with a similar phenotype, died at 1 year of age for 
haemophagocytic syndrome. The patient phenotype was characterized by spleen and liver 
enlargement, alopecia universalis, enamel tooth dysplasia, type 1 diabetes (T1D) and hyper-
thyreotropinemia. In addition, the patient also had developmental delay, microcephaly, 
peculiar facial dysmorphism and skeletal abnormalities. His immunological phenotype was 
characterized by very high IgE levels (>2000 UI). The functional analysis of Fas-induced 
apoptosis in PHA-activated T cells from the patient confirmed that the apoptotic pathway 
was impaired, since cell survival upon triggering of Fas was 92% (normal values: median 
60%, 95th percentile 82%).  
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Table VI: Genetic variants that are not causative of PID, with possible impact on the disease 
Patients Gene Mutatio
n 
Protein Zigosity Major clinical features 
009 
 
CASP10 c.1202_
1208del 
p.Cys401Leu
fsTer15 
Het Alopecia universalis, 
hyperthyrotropinemia,  type I 
diabetes mellitus, dental enamel 
hypoplasia, developmental 
delay, short stature, candidiasis, 
hepatomegaly, multiple skeletal 
abnormalities, myopia, 
dysmorphic features, 
microcephaly 
010 
 
DOCK8 
TRL3 
c.1907A
>G  
c.2672A
>G  
p.Lys636Arg 
p.His891Arg 
Het Inflammatory bowel disease, 
short stature, aspergillosis, 
EBV infection, low CD4+ 
lymphocyte subset , increased  
CD4 CD8 double negative  T 
cells ,       normal antibody 
response                 
011 
 
ADA 
 
 
ERCC6 
c.377C>
A 
c.1047A
>G  
 
c.3262A
>G 
c.2697G
>A  
p.Pro126Gln 
(reported in 
late onset 
SCID)              
p.K349 
p.Ser1088Gl
y 
p.T899 
Het T-B+NK+ SCID treated with 
bone marrow transplantation, 
Pneumocystis carinii 
pneumonia, recurrent otitis, 
absent ossicular bone  with 
hypoacusis of the right ear, 
mild brain and cerebellar 
atrophy, speech delay, 
idiopathic scoliosis 
 
012 
 
AP3B1  
PRF 
 
ADAMT
S13 
c.787G>
T 
c.695G>
A 
c.272C>
T 
c.2701G
>T 
 
 
 
p.Gly263Cys 
p.Arg232His 
p.Ala91Val 
p.Ala901Ser 
Het 
Interstitial lung disease                           
CMV infection,esophageal 
candidiasis, strabismus,  
abnormal expression of 
perforin in NK cells, reduction 
of CD4+ lymphocyte subset 
with increase of CD19+ and 
HLA-DR, normal proliferative 
response to mytogens, normal 
antibody response 
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The last group of patients includes patients with a complex disorder not classified in 
any known syndrome, associated with a number of genetic variants, each of them, on an 
individual basis, was not proved as relevant for the pathogenesis (Table VII). In this group, 
due to the limited number of cases observed, it was not possible to find out whether the array 
of the variations, on the whole, could be implicated in the pathogenesis. In these cases, we 
will perform functional studies to found a correlation between the genetic alterations and 
their relevance in the pathogenesis of immunological and clinical features, extended to larger 
cohorts of similar patients. Eventually, in the remaining 23 patient NGS, including 9 T-NGS 
and 14 WES, did not reveal any variant at all.  
 
 
 
 
 
 
 
013 
 
CFTR c.2991G
>C  
p.Leu997Phe Het Hypogammaglobulinemia late 
onset, recurrent pneumonia, 
bronchiectasis, chronic 
sinusitis, cervical and 
mediastinum 
lymphoadenopathy, recurrent 
abdominal pain, hepatomegaly 
with low grade steatosis, 
splenomegaly 
      
 
 
 
 
34 
Patients Gene Mutation Protein Zigosity Major clinical features 
014 
Sample 
1089 
SYCE2 
LYST 
c.577G>A  
c.10235G>A 
 
 
p.Val193Met  
p.Arg3412His 
Het t(11;18)MLT1-AP12 gastric 
maltoma HP +, persistent 
oral candidiasis, sinusitis; 
lung cystis, chronic cough, 
recurrent fever, 
hypereosinophilia, reccurent 
itch, reccurent myofasciitis, 
hyper IgM, altered somatic 
hypermutation, absent 
CD19+ CD20- IgG+ 
(mature), low CD19+ CD27+ 
IgM+ (memory),  absent 
CD19+ CD27+ IgM-
(switched memory) 
015 
Sample 
1028 
 
ATR 
ARSA 
CASP10 
IKBIKG 
MEFV 
SP110 
UNC13D 
c.5257A>G 
c.869G>A 
c.683C>T 
c.1165C>T 
c.460T>C 
c.1114C>T 
c.335G>C 
p.Ile1753Val 
p.Arg290His 
p.Pro228Leu 
p.Pro389Ser 
p.Ser154Pro 
p.Arg372Ter 
p.Cys112Ser 
Het 
Het 
Het 
Het 
Het 
Het 
Het 
 
Severe aplastic anemia, 
hepatomegaly, Legionella p. 
and Aspergillus recurrent 
pneumonia, metacarpal 
deforming alterations with 
bone demineralization, 
abnormal lymphocyte 
proliferation, dilated 
cardiomyopathy, early 
retinophaty 
016 
Sample 
1020 
ATRX 
 
MYD88 
DOCK8 
c.2247_2249del 
c.2133_2135del 
c.10_28del 
c.2920C>A 
c.3016C>A 
c.3220C>A 
p.Ser750del 
p.Ser712del 
p.Ala6ProfsTer39 
p.His974Asn 
p.His1006Asn 
p.His1074Asn 
Het 
Hom 
Het 
Het 
Het 
Het 
Autoimmune adrenal 
insufficiency, autoimmune 
thyroiditis, 
lymphadenopathy, 
autoimmune 
thrombocytopenia and 
neutropenia 
017 
Sample 
972 
 
TYK2 c.3488A>G  p.Glu1163Gly Het 
Hypogammaglobulinemia,  
familial IgA deficiency, 
hyper IgE, multiple  
bronchiectasis, candidiasis 
018 
Sample 
848 
 
TLR3 c.634-10C>A  Het 
Familial IgA deficiency, 
multiple bronchiectasis, 
recurrent respiratory 
infections, low  IgM levels  
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Table VIII: Genetic variants that are not causative of PID with undetermined  impact on the 
disease 
Discussion 
The advent of NGS technologies, enabled physicians to investigate multiple genes in a single 
assay, providing great opportunities for diagnosing patients affected with complex disorders 
of the immune system with a heterogeneous genetic background. In this study, NGS panel 
with customized analysis for genes related to immunodeficiencies or immune functions was 
used to identify disease-causing mutations in patients affected with clinical phenotypes 
highly suggestive of an inheritable PID, still undiagnosed after using the traditional 
diagnostic procedures. Thanks to this novel diagnostic approach, a defined diagnosis of PID 
was achieved in a timely manner, in 8 out of 45 subjects.  
Genetic alterations identified have been divided into 4 categories: I) genetic 
alterations associated to a canonical PID phenotype; II) novel or already described alterations 
of genes causing previously defined PIDs associated with novel clinical features; III) 
functionally relevant genetic alterations partially consistent with novel clinical phenotypes; 
019 
Sample 
1051 
 
CASP10 
 
ERCC5 
GJC2 
c.1094A>C p.Tyr365Ser Het 
 
Het 
Het 
Mild 
hypogammaglobulinemia, 
undetectable CD16+ 
lymphocyte levels, pervasive 
developmental disorder 
020 
Sample 
1029 
 
CD3-
ZETA 
OCRL 
c.301C>T  p.Gln101Ter Het Hypogammaglobulinemia, 
recurrent pneumonia, 
previous alopecia, behavioral 
disorders, oropharyngeal 
candidiasis 
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IV) multiple genetic variants not consistent with functional alterations individually, in whom 
the link between the genotype and that new phenotype is still missing.  
In patients included in the first group, an extensive traditional diagnostic approach, 
according to worldwide accepted protocols (53), had been carried out but not allowed to 
reach a diagnosis in a timely manner. Giving the overlapping of clinical and laboratory 
among different PIDs, the possibility to sequence many different genes simultaneously, 
through NGS, may allow a rapid identification of the underlying molecular alteration (37). 
In the second category of patients, the molecular definition of the diagnosis greatly 
contributed to expanding the overall knowledge of pathogenetic mechanisms underlying that 
specific disorder.  In these cases, the atypical presentation may lead to diagnostic delay. In 
the fourth group, no genotype-phenotype relationship was possible based on the current 
knowledge. The creation of a worldwide database might improve the interpretation of NGS 
results in those cases currently interpreted as no causative of the disorder. The identification 
of different individuals with same phenotypes and mutations in the same array of genes, 
would suggest that the sum of variations of different genes, is of some pathogenic 
significance, as either causative or modifier factor.  
It should be considered that in the majority of the patients, NGS approach 
unfortunately resulted not suitable to detect neither novel nor known genetic alteration 
responsible for the clinical phenotype. Different aspects should be considered to interpret this 
finding: further genes in the NGS test panel could be required; in some cases, these genes 
may have not been proven as causative of a PID; in NGS technology only coding regions are 
amplified, while mutations could be located in intronic, promotor or regulator regions. 
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Moreover, all NGS techniques, due to the generation of short reads (54), show a low 
sensitivity to detect complex structural variations (deletions, insertions, inversions), repeat 
sequences or complex rearrangement. To overcome these technique limitations, WES or 
whole genome sequencing might be better strategies to deeply investigate these cases (40, 
55) as a second line diagnostic tool.  
Despite the above mentioned limitations, NGS technology represents a cost-effective 
and rapid first-line genetic approach for the evaluation of complex cases of PIDs. The 
advantage of this technique is the simultaneous sequencing of a panel of genes, which might 
allow clinicians to rapidly identify an affected gene, that, probably, would be never sought 
using the traditional approach based on a functional driven hypothesis. Prompt diagnosis may 
allow physicians to get started with the more appropriate treatment, which may often be life-
saving. 
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CHAPTER 2 
“STAT1 gain of function mutation in the pathogenesis of chronic mucocutaneous 
disease in the context of a complex multisystemic disorder” 
CMC is a heterogeneous group of disorders characterized by noninvasive persistent Candida 
species infections of the skin, nails, and mucous membranes (56). Different immunological 
alterations may lead to susceptibility to Candida infections. Among secondary 
immunodeficiencies, infections with the human immunodeficiency virus and the prolonged 
use of glucocorticoids or antibiotics are able to predispose to fungal infections. CMC may 
also be an important feature of rare PIDs caused by alterations of genes implicated in cell 
mediated immunity necessary for fighting Candida infections (56-59).  
Recent studies suggests the role of T helper 17 (Th17) cells and their effector cytokines 
interleukin 17 (IL-17) and interleukin 22 (IL-22), essential for mucocutaneous anti-fungal 
host defense (60-62) in the pathogenesis of CMC. Patients affected with the autosomal 
dominant form of hyper IgE syndrome (HIES) due to the deficiency of signal transducer and 
activator of transcription 3 (STAT3), which usually suffer from CMC (63-66), show a 
profound reduction of the numbers of IL-17 producing circulating T cells. Autosomal 
recessive mutations in the caspase recruitment domain-containing protein 9 (CARD9) also 
suffer from dermatophytosis and Candida meningitis (67). In autoimmune 
polyendocrinopathy candidiasis and ectodermal dystrophy (APECED)-syndrome CMC 
seems to be due to high titers of neutralizing autoantibodies against IL-17A, IL-17F and IL-
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22 (68-70). Impaired IL-17 signaling observed in patients with IL17F, IL17RA or IL17RC 
mutations also lead to CMC (71, 72).  
Gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 
(STAT1) have been recently identified through WES in a cohort of patients affected with 
CMCD (73). Heterozygous STAT1 GOF mutationsactually represent the most frequent 
underlying cause of CMCD patients (50 to 100% of the CMCD patients recruited, according 
to the various centers asked).  Mutations have been identified in either the coiled-coil domain 
(CCD) or in DNA-binding domain (DBD) of STAT1.  GOF mutations impair STAT1 nuclear 
dephosphorylation, in response to the stimulation with STAT1-dependent cytokines (IFN-
α/b, IFN-γ, and IL-27), and STAT3-dependent (IL-6 and IL-21), leading to increased STAT1 
phosphorylation (73-76). Alterations in the development of IL-17A- and/or IL-17F-
producing T-cell lead to CMCD. Intracellular dimorphic fungal infections, disseminated 
coccidioidomycosis, and histoplasmosis have been also described in patients carrying 
STAT1 GOF mutations (77). Since 2011, a great number of patients with STAT1 GOF 
mutations have been described (73, 76-90). However, most reports have focused on the 
molecular and cellular defects of one or a small series of patients. This provides useful but 
incomplete clinical information. The comprehensive clinical features and outcomes of 
patients with STAT1 GOF mutations remain undefined. 
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2.1 Novel STAT1 gain of function mutation and suppurative infections 
 
In this Letter to the Editor published on Pediatric Allergy and Immunology, we report on a 
17-year-old patient with CMCC, recurrent herpetic infections and suppurative eyelid 
infections carrying a de novo heterozygous GOF mutation in exon 14 (p.T387A) of STAT1 
in the DBD. This mutation has not been previously reported (91, 92). As previously 
described, the underlying pathogenic mechanism involves gain of STAT1 function due to 
impaired STAT1dephosphorylation. Consistently with previous reports, laboratory 
evaluation revealed persistently elevated IgE levels (684 KU/L), normal to low-normal 
lymphocyte cell counts, and reduced levels of switched memory B cells (89). STAT1 GOF 
mutations are considered responsible for very complex and variable phenotypes, 
characterized by susceptibility to herpetic (93) and fungal infections (77), autoimmunity, 
enteropathy, cardiac and vascular alterations, bronchiectasis (94), parodontitis and failure to 
thrive (75, 89).  
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Novel STAT1 gain-of-function mutation and suppurative
infections
To the Editor,
Chronic mucocutaneous candidiasis (CMCC) is a heteroge-
neous group of disorders characterized by non-invasive persis-
tent Candida species infections of the skin, nails, and mucous
membranes. Heterozygous dominant gain-of-function (GOF)
mutations in signal transducer and activator of transcription 1
(STAT1) have been described as causing impaired STAT1
dephosphorylation, diminished IL-17-producing T-cell num-
bers, and CMCC (1, 2). Here, we report on the case of a 17-
year-old boy who presented to our Department for CMCC. He
was born preterm (36 weeks) to healthy non-consanguineous
parents from Italy, by a pregnancy complicated by threatened
miscarriage and gestosis. Since childhood, he suffered from
undocumented dermatologic alterations and, at 7 years of age,
he was diagnosed as affected with mucocutaneous candidiasis.
At 8 years of age, he suffered from a severe varicella infection,
and since 11 years of age, the patient experienced recurrent
herpetic infections of the genitals and limbs. Since the same
period, he also suffered from recurrent suppurative eyelid
infections (Fig. 1a) and cutaneous abscesses, unusual in
this immunodeficiency, which developed on an otherwise
healthy skin. The patient only experienced cutaneous abscess
formation, while lymph nodes and inner organs were never
involved. At 10 years of age, the patient presented with a
prolonged (20 days) and severe gastroenteritis, which eventu-
ally led to severe dehydration. Familial history revealed no
members with relevant fungal infectious diseases or immun-
odeficiencies. At the first evaluation, the patient showed oral
thrush, onychomycosis (Fig. 1b), suppurative eyelid infection
(Fig. 1a), furunculosis, and periodontitis. Cultures from the
oral lesions, the nails, and the esophageal mucosa grew
Candida albicans, sensitive to Azoles. Esophageal biopsy
revealed the presence of fungal hyphae and chronic inflamma-
tory infiltrate. Given the high susceptibility to Candida
infection, a daily prophylactic treatment with fluconazole was
started with a dramatic decrease in frequency and severity of
fungal infections. Full-length sequencing of STAT1 genomic
DNA identified a T387A STAT1 heterozygous mutation in the
DNA-binding domain (DBD; Fig. 1c). This mutation has not
been previously reported (3). None of the parents carried the
mutation (Fig. 1d). To evaluate STAT1 phosphorylation,
patient whole blood sample was stimulated with IFN-a
(40,000 U/ml) or IFN-c (1000 U/ml) and analyzed by flow
cytometry. Both stimuli resulted in increased STAT1 phos-
phorylation in the patient CD3+ T cells and CD14+ mono-
cytes, respectively, compared with control values (Fig. 1e).
Routine laboratory evaluation revealed a normal or low–
normal lymphocyte count and a normal T- and B-lymphocyte
enumeration. The proliferative response to common mitogens
(phytohaemagglutinin, PMA plus ionomycin, CD3 cross-
linking) was normal. Total Ig and Ig subclasses levels and
response to protein vaccines were normal. IgE levels were
persistently elevated (684 kU/l). The study of the B-cell
compartment revealed a number of CD19+ cells within the
normal range. The patient showed a normal representation of
transitional (CD3 CD19+ CD24+ CD38hiCD27; 8.2%),
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mature (CD3 CD19+ CD24 CD38dim/loCD27; 79.8%),
and memory (CD3 CD19+ CD24+ IgM+ CD27+; 12%) B-
cell subsets. However, memory B cells mostly included IgM
and only a few cells were switched memory B cells (88% and
12% of the memory B cells, respectively). The function of B
cells was studied in vitro by evaluating the response to the Toll-
like receptor 9 ligand CpG. B cells from the patient carrying
the STAT1 mutation adequately proliferated in response to
CpG, and CD27bright terminally differentiated plasma cells
normally developed (Fig. S1). Accordingly, adequate levels of
IgG and IgM were detected in the supernatants, even though
only small amounts of IgA were secreted in the patient,
differently from the control. The study of the T-cell compart-
ment revealed normal representation of CD4 and CD8 na€ıve
and memory T cells (CD4: 18.3% and 16.2%; CD8: 21.2% and
8.7%, respectively). We then evaluated the percentage of
CD4+ IL-17A+ and CD4+ IFN-c+ cells following PMA plus
ionomycin stimulation for 6 h, to evaluate TH17 and TH1
development. The patient showed a lower number of
CD4+ IL-17A+ cells than controls (0.25% vs. 1.66%) and
increased percentage of CD4+ IFN-c+ cells (34.15% vs.
20.70%; Fig. 2a,b). We also studied TH17 in vitro differenti-
ation and found a reduced (2.97% vs. 6.59%), but not
abolished TH17 development in the patient (Fig. 2c). Finally,
we studied the transcription levels of some STAT1 target genes
(CXCL9, CXCL10, CCL5, and ICAM-1). The levels of
CXCL9, CXCL10, CCL5, and ICAM-1 were higher than in
the control either in unstimulated PBMC or following IFN-c
stimulation (Fig. 2e). The patient also had increased surface
expression on unstimulated monocytes of MHC class II, whose
transcription is under STAT1 control (Fig. 2d).
In this study, we reported on a patient with CMCC,
recurrent herpetic infections, and suppurative eyelid infec-
tions carrying a de novo heterozygous GOF mutation in exon
14 (p.T387A) of STAT1 in the DBD. This mutation has not
been previously reported (3, 4). As previously described,
the underlying pathogenic mechanism involves STAT1 gain
of function due to impaired STAT1 dephosphorylation.
Consistently with previous reports, laboratory evaluation
revealed persistently elevated IgE levels (684 kU/l), normal
(a) (b)
(c)
(e)
(d)
Figure 1 Clinical features. (a)
Suppurative eyelid infection. (b)
Onychomycosis. (c) Genomic
sequence analysis of STAT1 gene
showing a T387A heterozygous
mutation in the DNA-binding
domain (DBD). (d) Family pedigree.
The proband is indicated with an
arrow. (e) Patient whole blood
sample stimulated with INF-a
(40,000 U/ml) or IFN-c (1000 U/ml)
and analyzed by flow cytometry.
Both stimuli result in increased
STAT1 phosphorylation in the
patient CD3+ T cells and CD14+
monocytes, respectively, compared
with control values.
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to low–normal lymphocyte cell counts, and reduced levels of
switched memory B cells (5).
STAT1 GOF mutations are considered responsible for
very complex and variable phenotypes, characterized by
susceptibility to herpetic (6) and fungal infections (7),
autoimmunity, enteropathy, cardiac and vascular alterations,
bronchiectasis (8), parodontitis, and failure to thrive (5, 9). In
our patient, the clinical phenotype is dominated by recurrent
furunculosis, parodontitis, and suppurative eyelid infections,
mostly caused by Staphylococcus infections (10). As the
hallmark in the infectious history of GOF mutations of
STAT1 is considered the Candida infection, the case herein
described further extends the complexity of the phenotype
observed in these patients. In this patient, we also found an
(a) (b)
(c) (d)
(e)
Figure 2 STAT1 GOF mutation impairs TH17 development and increases the expression of STAT1-regulated genes. (a) Percentage of CD4+ IL-
17A+ and CD4+ IFN-c+ cells following PMA plus ionomycin stimulation for 6 h. The patient shows a lower number of CD4+ IL-17A+ cells than
the control (0.25% vs. 1.66%) and increased percentage of CD4+ IFN-c+ cells (34.15% vs. 20.70%). (b) Percentage of CD4+ IFN-c+ and
CD4+ IL-17A+ cells in 20 healthy controls (values expressed as mean  SD). (c) CD4+ IL-17A+ and CD4+ IFN-c+ cell development after
stimulation of CD4+ cells, separated by positive selection using human CD4 microbeads, with anti-CD28, anti-CD3 X-L, IL-6, IL-1b, TGF-b1, IL-23
for 6 days in the patient and a healthy control. After 6 days, cells were split and cultured for further 6 days with the addition of IL-2. The patient
shows a reduced (2.97% vs. 6.59%), but not abolished CD4+ IL-17A+ development. CD4+ IFN-c+ development is comparable in the patient and
control (23.7% vs. 24.7%). (d) MHC class II surface expression on unstimulated monocytes or after stimulation with IFN-c. The patient shows
increased MHC class II surface expression on either resting cells and after stimulation with IFN-c as compared to the healthy control. (e) Real-
time PCR analysis of the mRNA extracted from the patient PBMCs showing higher levels of CXCL9, CXCL10, CCL5, and ICAM-1 than in the
control either in unstimulated PBMC or following IFN-c stimulation.
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increased transcription of pro-inflammatory molecules, as
CXCL9, CXCL10, CCL5, and ICAM-1, which could help
explain the pathogenesis of some features of this complex
phenotype.
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Supporting Information
Additional Supporting Information may be found in the online version of this article:
Figure S1. PBMCs cultured with medium or CpG were stained with antibodies to CD27 and IgM at day 7.
Daily subcutaneous administration of human C1 inhibitor in
a child with hereditary angioedema type 1
To the Editor,
Hereditary angioedema (HAE) is a rare autosomal-dominant
inherited disorder, caused by local elevations of bradykinin due
to a quantitative or qualitative deficiency of C1-INH resulting
in recurrent mucosal or subcutaneous swelling attacks. Hered-
itary angioedema attacks can occur in all locations of the body
and are potentially life-threatening if the face or larynx is
affected. The diagnosis of HAE is based on clinical symptoms
(e.g., severe abdominal pain or recurrent non-pruritic swelling
of the skin or submucosal tissues lasting for 2–7 days) and
laboratory screening with C4 (usually decreased in patients
with HAE), C1-INH antigenic protein (decreased in HAE
type 1) and C1-INH function (decreased in patients with HAE
types 1 and 2). The majority of the patients benefit from an on-
demand therapy (for review, see Ref. (1)). However, depending
on the severity of disease, frequency of attacks, patient’s
quality of life, availability of resources, and failure to achieve
adequate control by appropriate on-demand therapy, prophy-
lactic treatment should be considered. Long-term prophylaxis
with plasma-derived (pd)C1-INH concentrate requires fre-
quent i.v. injections, in most cases twice per week (2, 3). S.c.
infusions of pdC1-INH concentrate are thought to reduce this
burden. First pre-clinical studies in adult patients with HAE
reported on the safety and feasibility of s.c. administration of
pdC1-INH concentrate with a bioavailability of functional C1-
INH of 39.7% compared to i.v. administration (4). Recently,
Pediatric Allergy and Immunology 27 (2016) 214–230 ª 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 223
Letters to the Editor
 
 
 
 
45 
Supporting information 
Figure S 1. PBMCs cultured with medium or CpG were stained with antibodies to CD27 and 
IgM at day 7. Mature B cells are identified as IgM+CD27-  in CD3- CD19+ gated cells. IgM 
memory B cells express IgM and CD27, whereas switched memory lack IgM. Plasma cells 
are bright for CD27 and have or lack IgM. B cells from   the   patient   carrying   the  STAT1  
mutation   adequately   proliferated   in response   to   CpG,   and   CD27 bright terminally   
differentiated   plasma   cells normally developed. 
 
Conclusive remarks 
In our patient, the clinical phenotype was dominated by recurrent foruncolosis, parodontitis 
and suppurative eyelid infections, mostly caused by Staphylococcus infections. Since the 
hallmark in the infectious history of GOF mutations of STAT1 is considered the Candida 
infection, the case herein described further extends the complexity of the phenotype observed 
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in these patients. In this patient, we also found an increased transcription of pro-inflammatory 
molecules, as CXCL9, CXCL10, CCL5 and ICAM-1, which could help explain the 
pathogenesis of some features of this complex phenotype. 
 
2.2 Heterozygous STAT1 gain-of-function mutations underlie a broad clinical 
phenotype: an international survey of 234 patients from 140 kindreds 
 
Julie Toubiana, Jean-Laurent Casanova, and Anne Puel in collaboration with working group 
on CMC 
 
Introduction 
STAT1 GOF mutations have been identified for the first time in 2011 in a cohort of patients 
affected with autosomal dominant CMC.  Since their discovery a wide range of other clinical 
signs, including infectious and autoimmune diseases, cerebral aneurysms and carcinoma, has 
been described in patients from all over the world. Given the high variability of the clinical 
presentation and the fact that only small series of patients have been till now described, the 
comprehensive clinical features and outcomes of this syndrome remain, to date, undefined. 
 In this international survey, which has been submitted to Blood as Full Paper, Dr. J. 
Toubiana, in collaboration with the working group on CMC, described a large cohort of 
patients affected with CMC in order to better define the clinical features, the outcome, the 
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response to preventive and curative treatments, and immunological and hematological 
features of  this complex syndrome. 
 
RESULTS  
Demographic features  
A total of  234 patients from 140 kindreds originating from 35 countries on all the five 
continents were involved. The cohort was composed of a quite equal number of male and 
female with a M/F ratio 0.95. Median age of the patients at the time of the study was 23 years 
(range: 1 - 71 years).  
 
Genetic features 
A total of 65 different mutations in STAT1 gene were identified. In the 63% there was a 
familial inheritance. In most cases (62%) the mutation involved  the CCD, and in the 33% 
the DBD. The transactivation domain, the N-ter domain and the SH2 domain were affected 
in 2, 2 and 1% of the case, respectively.  
 
Basic immunological phenotype 
Immunological parameters including T cell proliferation to Candida were normal in most of 
the 199 analyzed patients (Table VIII). Low lymphocyte cell counts, or IgG/A levels were 
significantly associated with lower respiratory tract infections (LRIs), low proportions of 
CD19+ or CD4+ cell subsets with viral infections, and or low proportions of B and T-cell 
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subsets, hypogammaglobulinemia, and/or weak antibody (Ab) response with mycobacterial 
infections. Low levels of IL-17A-producing T cells were observed in 81% of the 32 patients 
tested.  
 
Table VIII. Immunological investigations in patients with STAT1 GOF mutation 
 
Biological 
investigations 
Patient
s tested 
(n) 
Norma
l (%) 
Lo
w 
(%) 
Hig
h 
(%) 
Total lymphocyte 
rate  
199 83 17 - 
CD4+lymphocyte
s  
184 73 27 - 
CD8+ T 
lymphocytes  
176 81 17 2 
CD19+ or CD20+ 
lymphocytes  
175 81 19 - 
CD27+CD19+ 
memory B 
lymphocytes  
41 58 42 - 
CD16+CD56+ 
lymphocytes  
126 73 24 3 
CD3+IL17A+ 
lymphocytes 
32 19 81 - 
T-cell 
proliferation 
(mitogen and/or 
antigen) 
106 69 31 - 
IgG levels (g/L) 195 76 4 201 
IgA levels (g/L) 183 82 14 4 
IgM levels (g/L) 183 100 - - 
IgG1 levels (g/L) 83 100 - - 
IgG2 levels (g/L) 83 63 37 - 
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IgG3, 4 levels 
(g/L) 
83 51 49 - 
IgE levels 
(kIU/L) 
119 96 - 42 
Antibodies 
against protein 
antigens3 
88 78 22 - 
     1IgG>15 g/dL; 2IgE>140 kIU/L: 3tetanus, diphteria toxoid, or poliovirus 
 
Fungal infections  
As expected CMC was the most frequent clinical feature, observed in 97% of the patients. 
The remaining six patients, in which CMC was not identified, suffered from invasive fungal 
infection (1 patient), severe bacterial infections (5 patients), hypothyroidism (4 patients), and 
cerebral aneurysm (1 patient). The 26% of the patients developed different other superficial 
and invasive fungal diseases. The median age at the onset of CMC was one year (range: birth 
- 24 years) (Figure 3).  
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B  
Figure 3. Kaplan-Meier curves for onset of CMCD and outcome. (A) Onset of CMCD. * 
Age at onset of CMC was available for 213 patients. (B) Overall survival curves. * Age was 
available for 224 patients, ** patients with severe complications are patients who displayed 
invasive infections, aneurysms and/or tumors. 
 
CMC affected the oral mucosae in the 94% of the cases (Table IX). Skin, esophageal/genital, 
and/or nail were involved in 61, 57, and 57% of the patients, respectively (Table IX). The 
culture of various specimens (skin, nails, throat, genital/esophageal mucosae) grew different 
Candida spp. (Table X). As expected, C. albicans was the species most frequent species, 
representing the 95% of the Candida isolates. Superficial dermatophytic infections of the 
scalp, skin or nails  were suspected in 16% of the patients and were microbiologically 
confirmed (Trichophyton spp., Microsporon spp.) in 50% of these patients. The 10% of the 
patients experienced invasive fungal infections (Table IX). Invasive candidiasis was 
identified in 9 patients, and fungal pneumonia was observed in 14 patients (Cryptococcus 
Age (Yrs.) 
S
u
rv
iv
a
l 
(%
) 
0      5     10    15     20    25    30     35     40    45    50    55    60    65     70     75   
100 
 
 
 
80 
 
 
 
60 
 
 
 
40 
 
 
 
20 
 
 
 
Without severe complication 
With severe complications**  
Log-rank p=0.002 
Number at risk* 
Without complication 140         109             64            39              21             5               2              0      
With complications     84           70              57            41              29            16              4              1    
0 
 
 
 
 
51 
spp. (n=2), Pneumocystis jiroveci (n=5), Aspergillus spp. (n=5), and Histoplasma spp. 
(n=2)). Two patients had fungal nephritis (C. curvatus and Trichosporon asahii), two patients 
suffered from cryptococcal meningitis, and two patients displayed disseminated fungal 
disease (Coccidioides spp. or Mucoraceae) (Table X). 
 
Bacterial infections  
Bacterial infections were observed in the 74% of the patients studied (Table VIII). LRIs, 
including recurrent lobar pneumonia, recurrent bronchitis, and/or interstitial pneumonia were 
reported in the 64% of the patients (Table IX). The most frequent causative pathogens were 
Streptococcus pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, and S. 
aureus were (Table X). Recurrent or chronic, sinusitis or otitis media were observed in the 
42% of the patients. Other bacterial infections included tonsillitis and recurrent 
conjunctivitis/keratitis observed in 13% of the patients, and blepharitis or ectropion in the 
2% of the patients. Recurrent skin infections were found in the 36% of the patients (Table 
IX). Skin infections mostly included folliculitis, followed by cellulitis, abscesses, and 
paronychia. S. aureus was isolated in most cases. Severe gastroenteritis, sepsis, or bone and 
joint infections have also been described. Mycobacterial diseases, including lung and skin 
disease and adenitis caused by tuberculosis and non-tupercolosis Mycobacteria, developed 
in the 6% of the patients.  
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Viral infections  
Severe or atypical viral infection, including  recurrent mucocutaneous viral infections, severe 
chickenpox, history of shingles during childhood, Molluscum contagiosum or warts, and 
severe systemic infections were observed in 38% of the patients (Table IX). The main causal 
agent was herpes simplex virus (HSV-1 or HSV-2; Table 3). Cytomegalovirus (CMV) and 
Epstein-Barr virus (EBV) were the viruses most frequently found in severe systemic 
infections (Table X). Five patients had CMV disease with proven organ infection, including 
one patient with retinitis, two with ulcerative digestive infections, and two with lung 
infections, one of whom also had encephalitis. Chronic active EBV infections were also 
observed and were less severe, not requiring any specific treatment.  In few cases severe 
HHV-6 and parvovirus infection leading to severe sepsis or hemophagocytosis were 
described. In one BK-virus urinary tract infection with functional consequences was 
obsetved. Severe disease due to live virus vaccines was observed in 2 patients displayed 
(small-pox and measles). Two patients had chronic hepatitis C infection leading to cirrhosis.   
 
Table IX. Sites of infection in patients with STAT1 GOF mutations 
Type of infections 
Patients, (%) 
Total  
n=234 
Mucocutaneous fungal infections 228 (97) 
    Thrush 214 (94) 
    Cutaneous mycosis 137 (61) 
    Onychomycosis 131 (57) 
    Esophageal / Genital mycosis 129 (57) 
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    Aphtous stomatitis 100 (44) 
    Scalp mycosis 49 (21) 
Invasive fungal infections 24 (10) 
     Invasive candidiasis 9 (41) 
     Other invasive infections 20 (83) 
Bacterial infections1  174 (74) 
     LRI 110 (64) 
     ENT 99 (59) 
     Skin 63 (36) 
     Other2 18 (10) 
Mycobacterial infections 15 (6) 
     Lung disease 5 (33) 
     Adenitis / skin disease 6 (40) 
     Disseminated disease 4 (27) 
Viral infections1  90 (38) 
      Cutaneous 78 (87) 
      Systemic 20 (22) 
LRI: Lower respiratory tract infection; ENT: ear, nose and throat. 1Probable or proven 
bacterial / viral infection. 2Severe acute gastroenteritis, septicemia, bone and joint 
infections 
 
Table X. Documented infections associated with STAT1 GOF 
Associated pathogens 
Documented 
infections (%) 
Mucocutaneous fungal infections n=149 
    Candida albicans 121 (81) 
    Dermatophytes spp. 19 (13) 
    Other1 9 (6) 
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Invasive fungal infections  n=29 
    Candida spp. 9 (31) 
    Pneumocystis jiroveci 5 (17.2) 
    Aspergillus spp. 5 (17.2) 
    Cryptococcus spp. 5 (17.2) 
    Histoplasma spp. 2 (7) 
    Trichosporon spp. 1 (35) 
    Coccodioides spp. 1 (35) 
    Apophysomyces spp. 1(35) 
Bacterial infections  n=72 
    S. aureus 19 (26) 
    Streptococcus spp. 16 (22) 
    Enterobacteriaceae 12 (17) 
    Pseudomonas aeruginosa 9 (12.5) 
    Haemophilus influenza 7 (10) 
    Other2 9 (125) 
Mycobacterial infections n=15 
    M. tuberculosis 4 (266) 
    M. bovis or BCG strain 4 (266) 
    M. avium 3 (20) 
    Other3 4 (266) 
Viral infections4 n=138 
    Herpes simplex 42 (31) 
    Varicella-Zoster 40 (29) 
    Molluscum contagiosum /Warts 25 (18) 
    Cytomegalovirus 12 (85) 
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    Epstein Barr virus 10 (7) 
    Other5 9 (65) 
Parasitic infections6 n=2  
1C. glabrata, C. tropicalis, C. kefir, C. membranaefacie,  C. famata and Malassezia furfur; 
2Campylobacter spp., Stenotrophomonas maltophilia, anaerobic pathogens, Neisseria 
meningitides; 3M. fortuitum, M. mucogenicum or not identified; 4Clinically probable or 
microbiologically confirmed; 5HHV6, Parvovirus, BK virus, hepatitis C, live virus vaccine 
disease; 6Giardiasis, visceral leishmaniasis 
 
Autoimmune and inflammatory diseases  
In the 44% of the patients, clinical autoimmunity and/or laboratory autoimmune markers 
were documented (Table XI). Median age at the onset of the autoimmune manifestations was 
24 years (range: 35 years -71 years), with a slight prevalence in females (M/F sex ratio 074). 
The 39% of the patients displayed clinical autoimmune manifestations, and 17% of these 
patients had more than one clinical autoimmune disorder. The most frequent autoimmune 
manifestation was autoimmune thyroid disease with hypothyroidism, requiring hormone 
substitution. Other autoimmune manifestations included T1D, vitiligo, alopecia, or psoriasis, 
systemic lupus erythematosus (SLE), scleroderma, pernicious anemia , celiac disease, 
autoimmune, hematologic autoimmunity (chronic hemolytic anemia or autoimmune 
thrombocytopenia during childhood), ankylosing spondylitis, multiple sclerosis, 
inflammatory bowel disease (Crohn’s disease, enteropathy with lymphocytic infiltration, and 
ulcerative colitis). Auto-Abs were found in the 43% of the patients. Auto-Abs were detected 
in the absence of clinical symptoms in 21% of the patients tested, mostly anti-nuclear Abs 
(87%) and anti-thyroid antibodies (13%).  
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Table XI. Other clinical features and outcomes of patients with STAT1 GOF mutations 
Non-infectious phenotypes 
Patients, (%)  
Total 
n=234 
Autoimmunity/inflammatory disease 92 (39) 
    Hypothyroidism 54 (59) 
    Other endocrine disease1 14 (15) 
    Skin disease2 25 (27) 
    Gastrointestinal disease3 9 (10) 
    Autoimmune hepatitis 6 (7) 
    Autoimmune cytopenia4 8 (9) 
    Other5 3 (3) 
Aneurysm  17 (7) 
    Cerebral 14 (82) 
    Extracerebral 3 (19) 
Tumor  13 (6) 
    Benign 2 (15) 
    Squamous cell carcinoma 8 (62) 
    Gastrointestinal carcinoma 2 (15) 
    Other6 2 (15) 
Other clinical features   
    Asthma / eczema 40 (17) 
    Bone fragility 5 (2) 
Clinical outcome  
    Death 27 (12) 
    Dysphagia/ esophageal stenosis 22 (9) 
    Failure to thrive 17 (7) 
    Bronchiectasis  48 (21) 
1Diabetes mellitus, Addison’s disease, GH deficiency; 2SLE, vitiligo, psoriasis, alopecia, 
scleroderma; 3Biermer anemia, celiac disease, colitis; 4Immunologic anemia or 
thrombocytopenia;  5Multiple sclerosis, ankylosing spondylitis; 6Melanoma, basal cell 
carcinoma 
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Other clinical features  
Patients included in this study displayed an unexpected high number of aneurysms 7% (Table 
XI) with a median ageat the diagnosis of 23 years (range: 3-50 years).  The rate was higher 
as compared to the standard population (~3%), with no difference between the sexes. 
Aneurysms were more frequent in patients with underlying autoimmunity, and in particular 
with endocrine (27% vs. 6%, p<001). Diagnosis was based on symptoms and radiologically 
confirmed in 15 patients. Systematic radiologic investigations identified two additional 
patients. Cerebral imaging  was also carried out for 20 other asymptomatic patients and 
yielded normal results. Symptoms included hemorrhages in 50% of the patients, and 
abdominal pain, and neurological signs, such as hemiplegia, seizures or attention lapses in 
the remaining. In most cases aneurysms were multiple and located in the cerebral vascular 
system (82%) (basilar trunk, vertebral arteries, and cerebral and intracranial carotid arteries). 
Extracerebral aneurysms were found in the abdominal aorta, iliac arteries, and lung arteries. 
Histological and microbiological investigations performed in one patient were (P19) 
negative. Other neurological signs included cerebral vasculitis, epilepsy, polyneuropathy, 
and cognitive disability. Carcinomas of the skin, gastrointestinal tract or larynx were 
observed in the 10% of the patients (adjusted to the 2000 US Standard population) with a 
slight predominance of female patients (56%, Table X). The frequency of cancer was higher 
than those observed in the standard population (~3%) (95). Tumors were more frequent in 
patients with a history of esophagitis (10% vs. 2%, p<001). Asthma and eczema, and signs 
of allergy were observed in the 17% of the patients, with a frequency similar to the general 
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population and without unusual severity (96).  Failure to thrive was observed in 7% of the 
patients. 
 
Preventive and curative treatment   
Most of the patients (72%) patients needed systemic long-term antifungal treatment (Table 
XII). Fluconazole was the major agent used for first-line treatment, followed by itraconazole 
or posaconazole. The 41% of the patients displayed clinical resistance to at least one 
antifungal, and the 11% of patients showed resistances to more than one antifungal. Most of 
these patients required second- or third-line treatments, such as voriconazole, echinocandins, 
terbinafine or liposomal amphotericin B. Clinical resistance to antifungals was related to a 
more severe phenotype (recurrent LRIs: 62% vs. 47% p=004, systemic fungal infections: 
16% vs 7% p=003, mortality: 20% vs. 5%, p=0001). The 24% of the patients with recurrent 
LRI or cutaneous staphylococcal disease also received antibacterial prophylaxis; 
cotrimoxazole was the mainly used agent. The 14% of the patients received polyvalent IgG 
infusions. GM-CSF infusions, interferon alpha, and then acitretin, did not improved CMC or 
herpes virus infections. Only in one patient G-CSF, lead to a marked improvement in CMC 
lesions. Three patients underwent allogeneic hematopoietic stem cell transplantation (HSCT) 
because of severe CMCD and recurrent bacterial infections; two of them died several months 
after HSCT, one from disseminated CMV at 30 years (P135, HLA- identical HSCT), and the 
other from interstitial lung disease at 2 years (P165, HLA-identical sibling HSCT). The last 
one is currently alive without serious complications (P136, HLA-identical cord blood 
transplantation). Five patients underwent immunosuppressive treatment (cyclosporine, 
 
 
 
 
59 
aziathoprine, corticosteroids or mycophenolate mofetil) for severe autoimmune disorders, 
and had a good clinical response, without serious infectious complications.  
Table XII. Treatments of patients with STAT1 GOF  
 
Treatment Patients, 
(%) 
n=234 
No antifungal treatment 6 (3) 
Intermittent antifungal treatment 45 (20) 
Current long-term antifungal treatment 168 (72) 
    Local treatment only 7 (4) 
    Oral fluconazole 112 (66) 
    Oral  posaconazole / itraconazole 49 (29) 
    Oral voriconazole 13 (8) 
    I.V. echinocandins 5 (3) 
    Oral terbinafine 3 (2) 
   I.V. amphotericin B 3 (2) 
Antibiotic prophylaxis 57 (26) 
    Cotrimoxazole 38 (67) 
    Macrolides 15 (26) 
    Other* 10 (18) 
Antiviral prophylaxis 4 (2) 
Polyvalent immunoglobulins 30 (13) 
Immunotherapy** 5 (2) 
Immunosuppressive therapies*** 5 (2) 
Hematopoietic stem cell transplantation 
(HSCT) 
2 (1) 
* nebulized colimycin, topical fucidic acid, tetracycline, amoxicillin 
** GCSF/GM-CSF, interferon alpha/gamma 
*** cyclosporine, aziathoprine, corticoids or mycophenolate mofetil  
 
 
 
 
60 
Clinical outcome  
Secondary gastrointestinal complications, such as severe dysphagia or esophageal stenosis 
developed in the 10% of the patients and in in most cases they were associated with a history 
of recurrent esophageal candidiasis. Pulmonary complications including bronchiectasis and 
cystic pulmonary lesions developed in the 21% of the patients. All the patients had a previous 
history of recurrent pneumonia or bronchitis (Table XI), and displayed acute secondary 
infectious episodes caused by P. aeruginosa, S. aureus, non-tuberculous mycobacteria or 
Enterobacteriaceae. One patient also had an associated pneumatocyst, and three patients 
underwent lobectomy.  
The 12% of the patients died (Table X) at a median age of 30 years (range: 2-58 years). 
The main causes of death were severe infections (including disseminated BCG disease, 
histoplasmosis, coccidioidomycosis, CMV, or bacterial LRI), cancer, and cerebral 
hemorrhage due to aneurysm. These three complications were the strongest predictors of 
poor outcome (25% mortality, versus 4% otherwise) (Figure 3). Also low total lymphocyte 
count was associated with a higher mortality rate (16% vs. 5%, p=0008). The other patients 
died from fulminant hepatitis (1 patient from an unknown cause, and 1 from autoimmune 
hepatitis), complication of HSCT (in two patients) and unrelated causes (in four patients).  
 
Discussion  
This study confirmed that CMC is the most common infectious manifestation in patients 
carrying STAT1 GOF mutations, with a very high penetrance, (only six STAT1 GOF patients 
never had CMC at a median age of 31 years). In many cases Candida may be resistant to 
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azole treatments. This study also showed that these patients may often suffer from viral, 
bacterial, and other fungal infections. Autoimmunity, as well as aneurysms and carcinomas, 
were much more frequent in this cohort of patients than the general population. The presence 
of these complications accounts for a poor outcome. CMC typically begins in the first year 
of life. However, it may also appear for the first time up to the third decade of life.  Clinical 
features are very variable within and between families (73). CMC probably develop as 
consequence of impaired IL-17A and IL-17F immunity (58, 71-73, 75, 81, 86, 91, 92, 97). 
Fungal infections also included superficial dermatophytosis (98), and invasive infections by 
a variety of yeasts and moulds (75, 77, 85, 87). Bacterial infections included cutaneous and 
bronchopulmonary infections caused by S. aureus. The occurrence of staphylococcal skin 
suggests that impaired STAT3-dependent IL-6 signaling may also be involved (73, 99). Low 
IgA, IgG2, and IgG4 levels as well as a poor Ab response, may favor respiratory tract 
infections as documented in some patients (100, 101). Viral disease might be due to 
exhaustion of virus-specific T cells (102), and mycobacterial disease to refractory responses 
to IFN-γ (77). 
Autoimmunity, aneurysms, and tumors also features this syndrome. Autoimmunity is not 
observed in patients with inborn errors of IL-17A/F immunity or in patients with AD HIES. 
The enhanced autoimmunity observed in such patients likely result from stronger IFN-
signaling, as some of these autoimmune signs are observed in patients treated with IFN-
 (e.g. thyroiditis) and in patients with type I interferonopathies (e.g. SLE) (103). The 
outcome of patients with STAT1 GOF mutations is poor. Premature death may results from 
infections (33%), aneurysms (19%), cancer (19%), or fulminant hepatitis (7%). Infections 
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represent the major cause of premature death in these patients (59, 104). The proportion of 
patients with cerebral aneurysm has probably been underestimated, since radiological 
investigations were performed for only 37 patients, including in 15 patients with clinical 
signs suggestive of aneurysm. Given the high morbidity and mortality of cerebral aneurysms, 
systematic radiological screening would be warranted in all patients. The pathogenesis of 
aneurysms may due to conjunctive tissue abnormalities, as in patients with STAT3 deficiency 
(104), autoimmune, as in cerebral vasculitis, or infectious, as in systemic Candida infection 
(59). In this cohort, patients with aneurysms did not differ markedly from the others in terms 
of invasive fungal infection rates (p=06), but they seemed to display more endocrine 
autoimmune disorders (p=002). The frequency of skin and ENT carcinomas was high. These 
conditions probably result, at least in part, from CMC and the muco-cutaneous inflammation 
(especially esophagitis) (105). Patients with esophagitis and dysphagia should be regularely 
screened for tumor by sequential biopsies of the esophagus. Taken together, STAT1 GOF 
mutation-associated AD CMCD should not be considered benign and should be handled at 
centers with experience in the diagnosis and management of such patients. 
The heterogeneity of clinical care for the patients in this cohort makes it difficult to issue 
uniform recommendations concerning optimal management. The high rate of CMC 
resistance to antifungal treatments is a major issue. IgG infusion should be considered for 
patients with recurrent LRIs, with or without detectable signs of Ab deficiency. GM-CSF and 
G-CSF treatments have been proposed as a way of enhancing IL-17 T-cell differentiation 
(106-108). However, despite an encouraging recent report (83),  these adjuvant therapies 
were useful in only one of the five patients in which they were tried. IFN-α/β blocking 
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antibodies, may alleviate autoimmune features. Treatments targeting the JAK-STAT 
pathway, such as the JAK1/2 inhibitor ruxolitinib, which has been approved for 
myelofibrosis treatment, or inhibitors of STAT1 activity for specific use in patients with GOF 
STAT1 mutations, have shown significant clinical efficiency and might become the treatment 
of choice (76). The options must be weighed up carefully, bearing in mind the various anti-
infectious, anti-tumor, and autoimmune effects of each cytokine. HSCT does not appear to 
be a viable option at the present time. It was performed in three patients with severe and 
recurrent fungal and viral infections, but two of them died. In conclusion, STAT1 GOF 
mutations are the most common known genetic etiology of CMCD and are found in about 
half the patients studied (59, 109), and is associated with significant clinical pathology. 
Disease severity results from the deleterious impact of CMCD on quality of life, and the poor 
outcome associated with infections, autoimmunity, aneurysm, and carcinoma.  
 
2.3 Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: 
presenting as treatment-resistant candidiasis and chronic lung disease 
 
In this Article published on Clinical Immunology, we report on nine patients carrying already 
known or novel GOF-STAT1 mutations. Three novel mutations were identified in the CCD, 
and in the DBD. As expected, CMCD represents the main manifestation and feature of 
suspicion at onset, but its severity largely varies from chronic recurrent and debilitating 
infection to mild forms, detectable after detailed collection of medical history, or occurring 
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only during antibiotic therapy. In some patient, a high risk of developing resistance to oral 
antifungal treatment, associated to high MIC to azoles (i.e. fluconazole), was observed and 
resulted in chronic infection with Candida. Development of antifungal resistance was not 
associated to any specific STAT1 mutations. Intermittent regimens of antifungal treatment 
or use of azoles at suboptimal doses might favor the selection of azole-resistant strains of 
Candida. For this reason, we suggest that antifungal prophylaxis with fluconazole or 
itraconazole should be started in all patients at the time of diagnosis, regularly continued and 
strictly monitored by pharmacokinetic measurements and susceptibility tests, in order to 
optimize control of diffuse candidiasis, prevent the development of inadequate dose-related 
resistance, and guarantee efficient treatment. Development of azole-resistance may require 
use of alternative regimens including caspofungin, or liposomal amphotericin B, which are 
administered by an intravenous route. As observed in the international survey patients may 
suffer from a broad spectrum of infection including recurrent bacterial infections since early 
childhood, and viral diseases mainly with herpes family viruses (88, 90, 93, 94). These 
infections may cause high morbidity and may increase the mortality risk. Lymphopenia, or 
autoimmunity may also complicate the prognosis. In our cohort, lymphozpenia (reduction in 
CD3+, CD4+ and CD8+ lymphocytes subsets) was not always present, but might progress 
by adulthood. Thus, a careful monitoring of the main lymphocyte subsets could help in 
clinical management by early detection of patients developing severe lymphopenia that might 
require to be evaluated for hematopoietic stem cell transplantation (HSCT). Lung disease 
represented a major complication as it may slowly evolve in adulthood to permanent lung 
damage predisposing to recurrent pulmonary exacerbations and higher morbidity. Early 
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recognition of lung damage at initial stage associated to prompt aggressive treatment of 
pulmonary infection and daily respiratory physiotherapy might prevent progression of the 
disease. The role of antibiotic prophylaxis, could be controversial because of increased risk 
of progressing candidiasis. Autoimmune manifestations represent common features of the 
disorder and extensive autoimmune assessment should be regularly performed: consistently 
with what previously reported, thyroidopathy represents the most common  disorder (73, 91).  
 
Conclusive remarks 
Similarly to what observed in the international survey, in this small cohort of Italian patients 
we observed a great heterogeneity of age distribution and phenotypes. 
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In 2011, autosomal dominant gain-of-function (GOF) mutations in
signal transducer and activator of transcription 1 (STAT1) gene have
been identiﬁed as a cause of chronicmucocutaneous candidiasis disease
(CMCD) [1,2]. To date,more than 100 patients have been reported, with
37 different mutations affecting the coiled–coiled (CCD) or the
DNA-binding (DBD) domains of STAT1. This transcriptional activator
plays a major role in various signaling pathways, particularly of IFNs,
IL-27, IL-21, IL-6, and IL-17 immunity [3,4]. STAT1 loss-of-function
(LOF) mutations were already known to account for rare autosomal
recessive (AR) immunodeﬁciencies [5], resulting respectively in fatal
mycobacterial and viral diseases (when complete gene deﬁciency
occurs [6]), or milder phenotypes (when deﬁciency is partial [7]).
Autosomal dominant (AD) LOF mutations were identiﬁed as a cause of
Mendelian susceptibility to mycobacteria infections [8]. GOF-STAT1
mutations were ﬁrstly described among patients affected with severe
2 L. Dotta et al. / Clinical Immunology 164 (2016) 1–9CMCD of the skin, nails, and mucous membranes, associated to autoim-
mune diseases; life-threatening conditions such as squamous-cell
carcinoma, cerebral and, recently, aortic aneurysms [9] were also rarely
reported. Disseminated fungal (coccidioidomycosis, histoplasmosis,
mucormycosis) and viral (herpes virus family, a case report of orf virus)
infections were also described [10–13]. Mutations of STAT1 have been
identiﬁed by next generation sequencing also in patients with IPEX (im-
mune dysregulation, polyendocrinopathy, enteropathy, X-linked)-like
features [14], and in patients with severe, fatal phenotypes resembling
combined immunodeﬁciency [10,15]. Any evidence of any genotype–
phenotype correlation is emerging, and data about long-term morbidity
and prognosis may be controversial. Herein, we report nine
patients diagnosedwith previously reported and novel GOF-STAT1muta-
tions, showing large heterogeneity for age distribution and phenotypes.
2. Material and methods
2.1. Patients
We report nine patients whowere diagnosed as affectedwith CMCD
and evaluated for genetic analysis and in vitro functional studies from
their peripheral blood, according to approved protocols of Spedali Civili
in Brescia, Italy. Cases are described in details in [16]. Written informed
consent was obtained from all patients or their parents (for minors),
and for healthy controls. Medical history and clinical data were retro-
spectively collected from medical records. In all patients extended
immunological assessment was performed. For patients under the
care of the Department of Brescia a pulmonary evaluation, including
assessment of pulmonary function tests and imaging, was carried out.
2.2. Molecular genetic analysis
Whole exome sequencing (WES) was performed at Children's Mercy
Hospital and Clinics, Kansas City, Centre for Pediatric Genomic Medicine
(Professor Kingsmore Stephen F) for P1. STAT1mutationwas subsequent-
ly conﬁrmed by Sanger sequencing in both P1 and his mother P2. In pa-
tients P3–P9 Sanger sequencing was used to analyze STAT1. DNA was
isolated from whole blood using QIAamp DNA Blood Mini Kit (Qiagen).
STAT1 gene was ampliﬁed by PCR and products were sequenced using
BigDye Terminator Kit (Applied Biosystems). Sequences were analyzed
with 310 Genetic Analyzer (Applied Biosystems). Sequence variants
were identiﬁed relative to a reference sequence, GenBank accession no.
ENST00000361099 for the STAT1 cDNA, in which the c.1 position corre-
sponds to the Aof theATG translation initiation codon.Mutations are des-
ignated as recommended by den Dunnen and Antonarakis [17].
2.3. Analysis of phosphorylated STAT1 (pSTAT1) by ﬂow cytometry
Peripheral blood was left unstimulated and stimulated with IFNγ
(1000 U/ml), or IFNα (40,000 U/ml), for 30 min. Cells were lysed,
permeabilized, and stained, as indicated by the manufacturer (BD
Phosﬂow). Speciﬁc phycoerythrin-labeled antibody for phosphorylated
STAT1 (pSTAT1) (pY701; BD Bioscences) was used. pSTAT1 was
evaluated in both lymphocyte and monocyte gates. Cells were acquired
using FACSCalibur (BD Bioscence) and analyzed by FlowJo version 7.5
Software (TreeStar).
2.4. Cytoplasmic and nuclear extracts preparation, Western blot and EMSA
After stimulation with IFNγ or IFNβ for 30 min, cells were lysed in
cold buffer (150mMNaCl, 50 mMTris–HCl pH 7.4, 1% NP40, and prote-
ase inhibitors -Roche-containing 0.2 μg of aprotinin, leupeptin and
1 mmol/L of sodium orthovanadate) on ice for 15 min. For Western
blot analysis, cytoplasmic extracts were resolved on 8% polyacrylamide
and subjected to immunoblots by standard procedures. Nitrocellulose
membranes were ﬁrst blocked for 1 h at room temperature in TBSTcontaining 5% BSA, and then incubated overnight at 4 °C with speciﬁc
primary Abs (pSTAT1, STAT1) in the same buffer. Antibodies against
phospho-tyrosine STAT1were purchased from Cell Signaling Technolo-
gies (Denver, MA, USA). Antibodies against total STAT1 (sc-346) were
obtained from Santa Cruz, and antibodies against β-actin were obtained
from Sigma-Aldrich. Detection was carried out using HRP-conjugated
anti-mouse or anti-rabbit IgG (Amersham Biosciences), and revealed
using ECL system (Amersham Biosciences). For EMSA, after stimulation
with IFNγ and/or IFNβ for 30min, EBV transformed B cells (5 x 106/con-
dition)were diluted in ice-cold PBS and centrifuged twice at 300 X g for
5min at 4 °C. Nuclear extractswere prepared using amodiﬁcation of the
method of Dignam et al. [18]. Transcription factor-binding analyses
were performed as described previously [18]. Nuclear extracts were in-
cubated in binding buffer in the presence of the labeled oligonucleotide
STAT-binding probe from the GRR element locatedwithin the promoter
of the FcγRI/CD64 gene (5-CTTTTCTGGGAAATACATCTCAAATCCTTGAA
ACATGCT-3) or from the interferon-stimulated response element
(ISRE) (5-GATCGGGAAAGGGAAACCGAAACTGAA-3).
2.5. Mutagenesis assay
eGFP STAT1 WT vector (Addgene) was used to obtain mutated
STAT1 form carrying L351F and L400V variants. Mutations were gener-
ated by site direct mutagenesis QuikChange Site-Directed Mutagenesis
Kit (Agilent Technologies).
2.6. Luciferase reporter assay
U3C cells were seminated into 96-well plates (1 X 104/well) and
transfected with 100 ng/well reporter plasmids and plasmids carrying
alleles of STAT1 (L351F and L400V) or amock vectorwithArrest-in (Ther-
mo Scientiﬁc). After 6 h, cells were transferred into medium containing
10% FBS and cultured for 24h. Cells were stimulatedwith IFNγ at different
concentration (10, 100, 1000 UI/ml), and IL-27 (100 ng/ml) for 16h. Lucif-
erase production was assesed with Dual-Glo luciferase assay system
(Promega) and normalized with respect to Renilla luciferase activity.
Data are expressed as fold inductions with respect to unstimulated cells.
2.7. Statistical analysis
Statistical signiﬁcance of in vitro immunological studies was
analyzed by nonparametric two-side Mann–Whitney U-test with 95%
conﬁdence bounds. For all analyses p b 0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using GraphPad Prism
Version 5.0 (GraphPad Software, San Diego, CA).
3. Results
3.1. Genetic ﬁndings
We identiﬁed a novel familial STAT1 mutation (L283M) in P1 (by
WES) and in his mother P2. Other two previously unreported sporadic
mutations were detected respectively in P3 and P9 (L351F), and in P6
(L400V). P3 had been previously analyzed for AIRE (autoimmune regu-
lator) gene, showing a heterozygous variation 769C N T (R257X) he
inherited from his healthy mother. Other mutations were: T385M in
P4 and P5 [19], A267V in P7 [2], and T387A in P8 (Pignata personal
communication; Higgins et al. [20]). All are heterozygous missense
mutations (Table 1). Novel STAT1 mutations affect both CCD and DBD
domains.
3.2. Novel mutations result in increasing STAT1 phosphorylation
We investigated IFNα- and IFNγ-induced pSTAT1 by cytometry
from peripheral blood mononuclear cells (PBMCs) of our patients
compared to healthy controls (Fig. 1 in [16]). Overall, we observed
Table 1
STAT1mutations in CMCD patients.
Sex Age (years) Mutation (c.DNA) Mutation (aa change) Exon Affected domain
P1 Male 11 c.(847 T N A) L283M Exon 10 CCD
P2 Female 45 c.(847 T N A) L283M Exon 10 CCD
P3 Male 33 c.(1441 G N T) L351F Exon 12 DBD
P4 Male 15 c.(1542 C N T) T385M Exon 14 DBD
P5 Male 10 c.(1542 C N T) T385M Exon 14 DBD
P6 Female 7 c.(1198 C N G) L400V Exon 14 DBD
P7 Female 14 c.(801 T N A) A267V Exon 10 CCD
P8 Male 18 c.(1159 A N G) T387A Exon 14 DBD
P9 Female 8 c.(1441 G N T) L351F Exon 12 DBD
CMCD= chronic mucocutaneous candidiasis disease; aa = amino acid; CCD = coiled-coil domain; DBD = DNA-binding domain.
3L. Dotta et al. / Clinical Immunology 164 (2016) 1–9higher levels of pSTAT1 compared to healthy controls, following both
IFNγ stimulation, in CD14+ monocytes (**p b 0.01), and IFNα stimula-
tion, in CD3+ lymphocytes (***p b 0.001), also conﬁrmed for novel
STAT1mutations (P1 and P2, P3 and P9, P6). Our results are consistent
with data of published studies and conﬁrm for novel heterozygous
alleles the association with a dominant phenotype of gain of STAT1
phosphorylation and function.
3.3. L351F and L400V variants lead to a gain of STAT1 function
We analyzed pSTAT1 in Epstein–Barr Virus (EBV)-transformed lym-
phoblasts of P3 carrying the novel L351F mutation. As illustrated in
Fig. 2A, Western blot showed that STAT1 level was normal in patient
cells. pSTAT1 had been undetectable in unstimulated cells derived
from P1 and P6, and its level had increased in response to both IFNγ-
or IFNβ-stimulation (data not shown). In order to prove the gain of
function of L351F variant, P3 EBV-transformed lymphoblasts were
treated with IFNβ or IFNγ in the presence of the 32P-labeled oligonucle-
otide STAT-binding probe derived from the IFNγ response region, or
type I ISREs. In the presence of both probes, we observed that treatment
with IFNs resulted in increased STAT1-binding activity to DNA (Fig. 2B).
Moreover, novel mutations L351F (P3 and P9) and L400V (P6) were
evaluated by transfection of STAT1-deﬁcient U3C ﬁbrosarcoma cells
with STAT1mutants constructs obtained by site-directed mutagenesis.
Responses to cytokine stimulation were investigated by measuring
the luciferase activity of the reporter gene under the control of theTable 2
Clinical and laboratory features of nine patients with STAT1-CMCD.
Age
at
onset
Age at
diagnosis
CMCD Treatment
resistance
Bacterial Infections Viral infections
P1 1 yr 9 yrs + + URTI, pneumonias None
P2 1 yr 43 yrs + + URTI, pneumonias, skin
abscesses
None
P3 6 mo 28 yrs + − URTI, pneumonias, otitis
media, skin abscesses,
Leihmaniasis,
Cryptococcosis
Recurrent
molluscum, skin
HPV
P4 5 yrs 14 yrs + − URTI, pneumonias None
P5 2 mo 9 yrs + + URTI, pneumonias, otitis
media, sepsis
None
P6 2 yr 7 yrs + − URTI, pneumonias, otitis
media
None
P7 6 mo 14 yrs + − URTI, pneumonias None
P8 7 yrs 17 yrs + − Parodontitis, skin
abscesses, suppurative
cyclid infection
Severe chicken
pox, recurrent
herpetic
infections
P9 5 mo 8 yrs + +/− Pneumonia, episcleritis Recurrent zoster
and herpetic
infections
“+”=present; “−”=absent; NK=not known; yr.(s)= year(s);mo=months; CMCD=chr
human papilloma virus; SLE = systemic lupus erythematosus; ANA = antinuclear antibody; dγ-activated sequence (GAS) promoter. After stimulation with IFNγ or
IL27, cells transfected with L351F or L400V alleles responded stronger
than those transfected with wild-type allele. In addition, stimulation
with increasing concentrations of IFNγ (10, 100, 1000 U/ml, respective-
ly) resulted in two to ﬁve times stronger responses in cells transfected
with novel mutant alleles (Fig. 2D). These results demonstrated how
novel heterozygous alleles are GOF for GAS-dependent cellular
responses to IFNγ.
3.4. A broad spectrum of infections may manifest beyond chronic
candidiasis
3.4.1. Fungal and parasite infections
All patients (mean age 17-year-old, median 14-year-old) presented
with recurrent or chronic infection with Candida albicans since early
childhood (median age at onset b1-year-old) (See Table 2). Oropharyn-
geal candidiasis manifested in all cases at onset, 5 patients (55%) devel-
oped nail infection by their ﬁrst decade, 4 patients (45%) had
oesophageal candidiasis by their second decade, while skin and genital
candidiasis were reported in 2 (P1 and P6) and 1 (P7) patients, respec-
tively. In P4 candidiasis manifested only in a mild form, as oral thrush
recurring during antibiotic therapy, well responding to topical antifun-
gal medication (miconazole). Mucocutaneous candidiasis was treated
with oral azole antifungal drugs (i.e. ﬂuconazole, itraconazole,
voriconazole), while treatment of oesophageal candidiasis in P2, P3
and P5 required intravenous antifungal therapy (i.e. ﬂuconazole,Bronchi-ectasis Hypo-thyroidism Other autoimmune
manifestations
Lympho-penia Poor
vaccine
response
− + None − −
+ − None + +
+ + SLE-like skin
disease, ANA and
ds-DNA antibody
positivity
+ +
+ − Vitiligo, ANA
positivity
+/− +
− − None +/− −
+ − None − −
− − None +/− −
NK − None − −
NK + None − −
onicmucocutaneous candidiasis disease; URTI= upper respiratory tract infections; HPV=
s= double-strand.
Table 3
Pulmonary ﬁndings, current treatment and results of last spirometry of GOF-STAT1 patients.
Age (yr) Chronic Lung
Disease
Site of bronchiectasis Age at diagnosis
(yr)
Respiratory physiotherapy Age at
starting
(yr)
FVC
L/%pred
FEV1
L/%pred
FEV1/FVC
%
FEF
25–75%
L/s
P1 11 − NA NA − NA 2.26/96 2.13/106 94 NK
P2 45 + L lower lobe, lingula 21 PEP-mask device + short acting bronchodilators,
2 times per day, regularly
30 3.05/88 2.62/84 81 3.42
P3 33 + L lower lobe, lingula 10 PEP-mask device + short acting bronchodilators,
2 times per day, intermittently
12 3.05/68 2.17/58 71 1.49
P4 15 + L lower lobe, lingula,
R middle lobe
14 PEP-mask device + short acting bronchodilators,
3 times per day, regularly
14 3.54/92 2.66/80 75 2.19
P5 10 − NA NA PEP-mask device + short acting bronchodilators,
initially intermittently (i.e. during pulmonary
infection), then 2 times per day, regularly
4 1.76/92 1.66/98 94 2.72
P6 7 + L lower lobe, lingula,
R middle lobe
6 PEP-mask device + short acting bronchodilators,
2 times per day, regularly
6 NP NP NP NP
P7 14 − NA NA − NA 2.76/80 2.72/90 99 4.88
P8 18 − NA NA − NA NP NP NP NP
P9 8 − NA NA − NA NP NP NP NP
“+”=present; “−”=absent; yr. = years; NA=not applicable; NK=not known; L= left; R= right; PEP= positive expiratory pressure; FVC= forced vital capacity; L= liter; pred=
predicted; FEV1 = forced expiratory volume in 1 s; FEF = forced expiratory ﬂow; NP = not performed.
4 L. Dotta et al. / Clinical Immunology 164 (2016) 1–9amphotericin B, caspofungin), followed by oralmedications (i.e. ﬂucona-
zole, itraconazole, or voriconazole). All patients were started on continu-
ous dosing-regimen: ﬂuconazole was initially the drug of ﬁrst choice for
most of the patients, but changed to itraconazole in P1, P2, P3, and P5 fol-
lowing clinical (persistent or relapsing mucocutaneous candidiasis) and
microbiological evidence of resistance. The latter has been monitored
with susceptibility testing performed on Candida spp. cultured fromFig. 1.GOF-STAT1mutation is associatedwith increased STAT1 activation. A and B. Summary of
in IFNγ-stimulatedmonocytes (B). C and D. Intracellular staining of phosphorylated tyrosine 70
not stimulated and IFNγ-induced monocytes (D). Each experiment was independently repe
intensity ﬂuorescence; HD = healthy donor.oropharyngeal swabs, routinely performed in the majority of patients
with clinical evidence of infection, and resulting in a minimal inhibitory
concentration (MIC) forﬂuconazole from8 to 256mcg/ml in resistant pa-
tients. In addition, themajority of patients have been followedwithmon-
itoring of serum azole level to concurrently adjust the dosage of
medication (target of N500 ng/ml when prophylaxis or N1000 ng/ml
when therapy regimen, respectively). We observed, speciﬁcally in P2,mean intensity ﬂuorescence (MFI) of pSTAT1 in T-lymphocytes inducedwith IFNα (A) and
1 STAT1 (P701-YSTAT1) in not stimulated (NS) and IFNα-induced T lymphocytes (C), and
ated at least three times for each patient: representative cases are shown. MFI = mean
Fig. 2.Novelmutants L351F and L400V STAT1 alleles are dominant for GAS-dependent cellular responses. A and B. Response of P3 EBV-B cells (L351F) byWestern blot (A) and EMSA (B). C
and D. Induction of GAS-dependent reporter gene transcription activity in U3C cells transfectedwithWT ormutant alleles of STAT1 (L351F and L400V): cells were stimulatedwith IFNγ or
IL27 (C) and increasing doses of IFNγ (D). Results derived from one representative experiment of three independent experiments. HD = healthy donor; NS = not stimulated.
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oropharynx, nails, esophagus), that intermittent regimen treatment and
use of suboptimal dosage predisposed to persistent infection and devel-
opment of resistance to azoles (initially limited to ﬂuconazole, but ex-
tended to itraconazole and voriconazole, with current sensitivity for
posaconazole). Interestingly, in addition to Candida infection, P3 also de-
veloped an intracellular pathogen infectionwithCryptococcus neoformans
(Fig. 3), presenting as disseminated granulomatous necrotizing lymphad-
enitis at the age of 14 years, well responding to intravenous ﬂuconazole.
Moreover, at the age of 28 years, the same patient suffered from dissem-
inated visceral leishmaniasis, was initially treated with amphotericin B,
but the latter caused drug-related nephropathy, and was replaced with
miltefosﬁne.
3.4.2. Bacterial infections
The majority of patients (no relevant episodes in P8 history) had a
history of recurrent upper respiratory tract infections and experienced
pneumonias (See Table 2), variably associated with bouts of obstructive
bronchitis, since their childhood, often requiring hospitalization for in-
travenous antibiotic therapy. Haemophilus inﬂuenzae, Streptococcus
pneumoniae, or Staphyloccocus aureus were the pathogens usually de-
tected in the sputum, when culture was available. Moreover, some pa-
tients had recurrent pulmonary exacerbations with opportunisticpathogens. P2, P4 and P6 had been suffering from intermittent infection
with Pseudomonas aeruginosa; in P4 bronchopneumonia with Serratia
marcescens recurred twice when he was 14-year-old. The recurrence
of pulmonary infections has currently led to permanent lung damage
in 4 patients of our cohort (P2, P3, P4, P6), as diagnosed by chest
computed tomography (CT)-scan (Pulmonary ﬁndings summarized in
Table 3; see Fig. 2 in [16]). All patients had been commenced on
pneumonologist follow-up, together with regular respiratory physio-
therapy, in order to enhance clearance of bronchial secretion and con-
trol pulmonary exacerbations [21–23]. The analysis of spirometry
results [24] in these patients developing chronic lung disease shows a
tendency to develop obstructive pulmonary disease, with a forced expi-
ratory volume in 1 s (FEV1) generally below normal range, associated to
a reduction in the forced expiratory ﬂow during the interval 25–75% of
the forced vital capacity (FEF 25-75%). These changes of FEF 25-75% con-
stitute a sensitive parameter in the detectionof obstructive small airway
disease [25]. Speciﬁcally, P4 has experienced a rapid decline of his lung
function (Forced Vital Capacity -FVC- from3.17 to 2.17 L, FEV1 from2.35
to 1.68 L, and FEF 25-75% from 1.78 to 1.49 L/s) in a eight-months time
characterized by pulmonary exacerbationswith Serratia: in this patient,
in few months, we have currently observed a return of his pulmonary
tests to normal values (FVC 3.54 L, FEV1 2.66 L, FEF 25-75% 2.19 L/s)
and no pulmonary exacerbations, likely related to the increase of daily
Fig 3.Necrotizing granulomatous lymphadenitis (blue arrow), containing numerous mucicarmine-positive cryptococci (red arrow) (Hematoxylin-Eosin; inset: mucicarmine stain). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
6 L. Dotta et al. / Clinical Immunology 164 (2016) 1–9respiratory physiotherapy and the start of antibiotic prophylaxis with
azithromycin, following the rationale of a reduction of pulmonary
exacerbations in patients with non-cystic ﬁbrosis bronchiectasis by
using low-dose macrolide [26].
Among other bacterial infections, our cohort features abscesses and
sepsis. Three patients (P2, P3, and P8) suffered from skin abscesses: in
P3 a coagulase negative Staphylococcus was detected and infection re-
solved after intravenous antibiotic and surgical excision, while P8 had
recurrent S. aureus-positive abscesses requiring systemic antibiotic
treatment, and P2 was alternately treated with oral or intravenous
antibiotics for recurrent boils. P5 had a Streptococcus viridians sepsis,
concomitantly to a Pneumocystis jirovecii pneumonia, at the age of four
months (lymphocyte subsets had been performed few months after
the acute episode with normal results), while P2 sepsis was caused by
Difteroides spp. when 28-year-old.
3.4.3. Viral infections
We observed abnormal response to viral infections in some patients
(See Table 2). P8 had varicellawith severe involvement ofmucosa at the
age of 8 years. Both P8 and P9 presentedwith recurrentmucocutaneous
infections with herpes simplex viruses and severe episodes of varicella-
zoster infection. P3 had molluscum and human papilloma virus cutane-
ous lesions.
3.5. Autoimmune manifestations may be part of a heterogeneous
phenotype
In our cohort, hypothyroidism manifested in three patients (P1, P3,
and P9; see Table 2): all cases had negative auto-antibodies
(antithyroglobulin, antithyroid peroxidase, anti thyroid-stimulating
hormone -TSH- receptor antibody), but typically presented a
dysomogeneous ultrasound appearance of the gland. All patients started
the treatment of hypothyroidismwith levothyroxine by their ﬁrst decade
of life. On autoimmune screening, antinuclear antibodies tested positive
in P3 (title increasing from 1:160 to 1:320) and P4 (stable title 1:320),
in P3 also associated to positivity for anti-double strand DNA antibodies
(138–122%, normal value b35%): P3 has developed Systemic Lupus
Erythematosus (SLE)-like skin face lesions, while P4 suffers from a mild
form of vitiligo. Despite cerebral vasculitis and cerebral and aorticaneurysms have been reported [19], none of our patients ever had signs
or symptoms suggesting investigation for cerebral or heart complications.
3.6. The immunological phenotype: risk of progressing lymphopenia
Analysis of lymphocyte subsets in each patient of our cohort (Fig. 4;
see Table 1 in [16]) revealed persistent lymphopenia in two adult
patients. In P2, total lymphocytes range from a maximum of 1250
cells/mmc to 810 cells/mmc (mean below 1000 cells/mmc), with low
counts of both T and B lymphocytes (normal CD4+/CD8+ ratio and NK
cell counts in the normal range). P3 developed lymphopenia in his
twenties, with total lymphocytes ranging from 700 to 1130 cells/mmc,
low numbers of CD3+ (375–730 cells/mmc), CD4+ (233–421 cells/
mmc), and CD8+ (128–272 cells/mmc) cells, but normal B cell count
(261–335 cells/mmc). Interestingly, P3 also showed low NK cells
count, that was persistently below 50 cells/mmc (11–44 cells/mmc).
In P4 we observed transitory reduction of CD4+ T cells (382 cells/mmc),
out of a speciﬁc infectious episode, in P5 low CD4+ T cells (1153 cells/
mmc) during his ﬁrst year of life, but out of his episode of sepsis, and in
P7 a single determination of low CD19+ cells (152 cells/mmc). Moreover,
lymphocyte subsets analysis in six patients showed a low percentage of
memory B cells, with reduction of both un-switched (median 3% of B
cells) and switched subsets (median 1% of B cells) (see Table 1 in [16]).
Three patients (P2, P3, P4) also had defective antibody response to tet-
anus toxoid (b0.05UI/ml),withunprotective title conﬁrmedafter booster
vaccine. Overall, serum immunoglobulin levels, TRECs, and lymphocyte
proliferation assays to mitogens did not show abnormalities (data not
shown).We observed low immunoglobulin (Ig) M level only in P1 in dif-
ferent determinations (IgM31mg/dl -range 56–261- at the age of 6 year-
old; IgM 46 mg/dl -range 61–276- at the age of 10), with normal IgG
(1040 mg/dl -range 707–1919-) and IgA (143 mg/dl -range 60–270-).
4. Discussion
4.1. Novel mutations conﬁrm the increased STAT1 phosphorylation
We describe nine patients of Caucasian origin and Italian nationality
with heterozygous GOF mutations in STAT1. Three novel mutations
were identiﬁed: L283M in the CCD, while L351F and L400V in the
Fig. 4. Lymphocyte subsets for each CMCDpatient are shown as a single value per age range. Normal ranges of lymphocyte counts, we have illustrated in the chart background,were based
on age-matched healthy control subjects. The complete series of lymphocyte counts is shown in the Table 1 in [16].
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lation resulting in a gain-of-function of GAF in response to various cyto-
kines. Consistently with previous reports, levels of pSTAT1 are high in
CD3+ and CD14+ cells, gamma-activated sequence binding activity
increases following stimulation with IFNγ, and cellular response is en-
hanced to cytokines such as IFN-α/β, IFN-γ, and IL-27, which potently
inhibit development of IL-17–producing T cells via STAT1 [1–3,27].4.2. CMCD represents the hallmark of GOF-STAT1 phenotype with high risk
of resistance to treatment
In the clinical phenotype of the majority of patients, CMCD repre-
sents the main manifestation and feature of suspicion at onset, but se-
verity largely varies from chronic recurrent and debilitating infection
to milder form, detectable after detailed questioning of medical history,
8 L. Dotta et al. / Clinical Immunology 164 (2016) 1–9or occurring only during antibiotic therapy.We show high risk of devel-
oping resistance to oral antifungal treatment, associated to high MIC to
azoles (i.e. ﬂuconazole), and resulting in chronic infectionwith Candida.
Development of antifungal resistance in our patients was not associated
to any speciﬁc STAT1 mutations. Conversely, STAT1 patients displaying
mild forms of candidiasis may suggest that genetic or environmental
factors could contribute to their susceptibility to fungal infections. In
particular, intermittent regimens of antifungal treatment or use of
azoles at suboptimal doses might favor the selection of azole-resistant
strains of Candida. Development of azole-resistance may require use of
alternative regimens including caspofungin, or liposomal amphotericin
B, that are administered by an intravenous route. In addition, case report
studies have suggested that immunomodulatory treatment with
cytokines such as granulocyte-colony stimulating factor (G-CSF) or
granulocyte monocyte-colony stimulating factor (GM-CSF) may restore
the generation of Th17 cells and parallel enhance recovery from fungal
infections [28]. However, these preliminary ﬁndings should be con-
ﬁrmed in larger cohort of patients. Until then, our study suggests that
antifungal prophylaxis with ﬂuconazole or itraconazole should be com-
menced in all patients at the time of diagnosis, regularly continued and
strictly monitored by pharmacokinetics measurements and susceptibil-
ity testing, in order to optimize control of diffuse candidiasis, prevent
developing of inadequate dose-related resistance, and guarantee
efﬁcient treatment.
4.3. A broader spectrum of infections, the occurrence of chronic lung
disease, lymphopenia, or autoimmunity may complicate the prognosis
GOF-STAT1 patientsmay typically experience also recurrent bacteri-
al infections since early childhood, and present viral diseases mainly
with herpes family viruses [12,13,15,29], causing highmorbidity and in-
creasing themortality risk. Speciﬁcally, Sherfe et al. reported of three pa-
tients who died of overwhelming viral infections (Cytomegalovirus,
Epstein–Barr virus, and Jamestown Canyon virus, respectively), inter-
estingly presenting with a combined immunodeﬁciency (CID)-like im-
munological phenotype (progressive loss of T cells and natural killer
cells, plus humoral defect). In our cohort, we observed that lymphope-
nia, manifesting with reduction in CD3+, CD4+ and CD8+ lymphocytes
subsets, may not be constantly present, but might progress by adult-
hood. Consistentwith that, carefulmonitoring ofmain lymphocyte sub-
sets could help in clinical management by early detection of patients
developing severe lymphopenia that might require to be evaluated for
hematopoietic stem cell transplantation (HSCT). Interestingly, we re-
port a reduction in both un-switched and switched memory B cells in
the majority of our patients, supporting a previous observation in the
case report by Frans et al. [30]. Currently, any genotype–phenotype cor-
relation seems consistent, even thoughwe observed same characteristic
features in patients with same mutations. Particularly, in our cohort an
increased susceptibility to viral infections manifested in patients carry-
ing L351F and T387A variants. Meanwhile, we observed how T385M
variant differently manifested in two patients with similar age and
sex: P4 suffered from severe and recurrent lower respiratory tract infec-
tions and developed bronchiectasis and chronic lung disease in his ado-
lescent age; P5 presented with early severe reﬂux disease, required
Nissen fundoplicatio, and had jatal hernia, concurrently with oesopha-
geal candidiasis. Similarly, in previous reports [30], this mutation vari-
ably presented with mainly gastrointestinal or respiratory phenotype,
but also with progressing combined immunodeﬁciency predisposing
to fatal infections [15,19,31]. For other novel mutations herein identi-
ﬁed, major phenotypic manifestations include early development of
bronchiectasis in patient carrying the L400V variant, and lymphopenia
and chronic lung disease progressing by adulthood in the familiar vari-
ant L283M. These phenotypes may add new characteristic manifesta-
tions, but are insufﬁcient to hypothesize any certain correlation with
the genotype; indeed, the paucity of reported cases likely suggests any
observed association still as serendipity. More important, we showhow lung disease represents a major complication as it may slowly
evolve by adulthood to permanent lung damage predisposing to recur-
rent pulmonary exacerbations and higher morbidity. Early recognition
of lung damage at initial stage associated to prompt aggressive treat-
ment of pulmonary infection and daily respiratory physiotherapy
might prevent progression of the disease. The role of antibiotic prophy-
laxis, including low-dose macrolide, could be controversial because of
increased risk of progressing candidiasis. Finally, autoimmune manifes-
tations represent common features of the disorder and extensive auto-
immune assessment should be regularly performed: consistently with
what previously reported, thyroidopathy represents the most common
disorder [1,19], variably onsets by theﬁrst or second decade of life, asso-
ciates to no thyroid antibody or signiﬁcant alterations of B subsets, but
gland abnormalities, supporting the hypothesis of an increased re-
sponse to type I IFNs and the role of IFNs signature in the disease [3,
32]. Recently, Oftedale et al. redeﬁned a “non-classical” form of autoim-
mune polyendocrine syndrome type 1 (APS-1) where a milder, less
penetrant autoimmune phenotype associates to dominant heterozy-
gous mutations in AIRE [33]. Even though AIRE p.R257 mutation is
known to behave in a recessive manner, further characterization could
be pursued to rule out the role of AIRE mutation in our patient P3 who
features CMCD together with a mild autoimmune phenotype.5. Conclusion
GOF-STAT1 disorder represents an emerging primary immunodeﬁ-
ciency and analysis of larger cohort of patients is warranted to better
characterize clinical and genetic heterogeneity, long-term complica-
tions, and prognosis of the disease.References
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2.4 Impaired NK cells functions in patients with STAT1 gain-of-function mutations 
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Pignata, Vassilios Lougaris, Alessandro Plebani, Laura Dotta, Marco A. Cassatella, Silvia 
Parolini, Raffaele Badolato 
Introduction 
The identification of STAT1 GOF mutations have contributed to reveal the role of Th17 cells 
in the immune response against Candida infections (110). Th17 cells are important for the 
defense against microbial infections at the mucosal barrier and secrete IL-17F, IL-17A, IL-
22, and IL-21. In several PIDs the evidence of CMC has been associated with impaired Th17 
development (59). Increased and persistent phosphorylation of STAT-1 in CMCD results in 
impaired response to the cytokines that promote Th17 differentiation (73, 81). STAT1 act 
downstream type I IFNs and other cytokines regulating the transcription of genes involved 
in the response to viral infections (111). Previous studies revealed the importance of STAT1 
signaling in the activation of Natural killer (NK) cells (112, 113) which play an important 
role in the immune response against intracellular pathogens and virally infected cells (114). 
STAT1 expression and phosphorylation are induced during early viral infections. In response 
to stimulation with type I IFNs, NK cells acquire effector functions and secrete 
immunomodulatory cytokines (i.e. IL-15), that regulate NK cell expansion (113). 
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Apart from fungal infections at the mucosal barrier CMCD patients may also present viral 
infections, including recurrent mucocutaneous infections due to reactivation of varicella-
zoster and herpes simplex viruses, debilitating orf infection, or severe invasive infection due 
to chicken pox, cytomegalovirus (CMV) or Epstein-Barr virus (EBV) (88, 90, 93, 94). These 
observations suggest that also NK cells might play a role in the pathogenesis of CMCD. 
In this study, submitted to Journal of Allergy and Clinical Immhnology as Full Paper, we 
investigated STAT1 and STAT5 signaling in response to specific cytokines, cytotoxic 
activity, cytokine production and proliferation in NK cells from eight CMCD patients. We 
observed that STAT1-GOF mutations result in increased STAT1 phosphorylation, and 
reduced STAT5 activation, in response to IL-2 and IL-15. These alterations lead to impaired 
proliferation in response to IL-2 or IL-15, and to reduced IFN-γ secretion in response to IL-
15. 
 
Results 
Eight patients with gain-of-function STAT1 mutations were included into the study (Table 
XIII). 
Table XIII. Genetics and main phenotypical features of eight patients with gain-of-function 
STAT1 mutations  
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NK functional activity and phenotype in CMCD patients 
NK cytotoxicity was evaluated in three CMCD patients and three healthy subjects by using 
a chromium release assay. A significant reduction of cytolytic activity of cells from CMCD 
patients as compared to normal controls was observed (Figure 4, A and B). However, the 
evidence of the broad variability in the number of NK cells observed in CMCD patients might 
account for the impaired cytotoxicity of cells. Therefore, the cell surface upregulation of the 
degranulation marker CD107a on CD56+CD3- was evaluated by flow cytometry after 
exposure to the NK cell susceptible human erythroleukemia K562 cell line, before and after 
overnight culture in the presence of IL-2. A reduction of the degranulation activity of resting 
NK cells as compared to healthy controls was observed in CMCD (p>0.05). Similarly, a 
significant reduction of degranulation activity as compared to healthy subjects was observed 
 
 
 
 
78 
in IL-2 activated NK cells (p<0.05) (Figure 4, C and D). Intracytoplasmic perforin content 
was normal in NK cells from patients with STAT1-GOF mutations. The analysis of NK-cell 
subsets, on the basis of CD56 and CD16 expression and the pattern of activating and 
inhibitory receptors on NK cells revealed a reduced expression of CD57 on CD56dullNK 
cells in 3 out of 9 CMCD patients, while KIR and NKG2A molecules were expressed at 
normal levels. Both CD56bright and Cd56dim subsets of NK cells showed normal expression 
of NKG2D, the activating NK receptors NKp46 andNKp30, and several other co-
receptors(115). Likewise, the expression profile of the chemokine receptors CXCR1 and 
CCR7 of the two CD56 subsets were normal. 
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Figure 4: Impaired NK cell cytotoxicity in CMCD patients. (A and B) Freshly isolated 
PBMCs derived from three control subjects (triangle) and from three patients (circle) were 
tested against the K562 target cells line overnight incubation, either without IL-2 (A) or with 
IL-2 (B) at different E/T ratios. Data from the control group show the mean ± SD of three 
replicates (C and D). Degranulation assay (as measured by CD107a expression) of freshly 
CD56+ CD3- gated NK cells derived from eight CMCD patients (square) and ten healthy 
donors (circle) after stimulation with the human K562 cell line. PBMCs were incubated 
overnight without (C, p>0.05) or with IL-2 (D, p<0.05). 
 
STAT1 and STAT5 phosphorylation in NK cells of CMCD patients 
STAT1 and STAT5 phosphorylation in response to IFN-α (40000U/ml for 30 minutes), IL-
2 (100ng/ml for 12 minutes), IL-15 (50ng/ml for 12 minutes), or IL-21 (50ng/ml for 15 
minutes) was evaluated by flow cytometry in NK cells from healthy controls and CMCD 
patients. Increased STAT1 phosphorylation in response to IFN-α as compared to control 
values was observed in CD56+CD3- NK cells of CMCD patients, suggesting that STAT1-
GOF mutations result in abnormal STAT signaling also in NK cells (Figure 5 A). The study 
of STAT1 phosphorylation in IL-2 activated NK cells revealed increased STAT1 
phosphorylation in response to both IL-2 and IL-15 in NK cells from CMCD as compared to 
healthy controls (Figure 3, B and C, p<0.05). STAT1 protein expression was analyzed in 
order to investigate the mechanism leading to the increased STAT1 phosphorylation. Up to 
three fold increase of protein levels in resting CD56+CD3- NK cells from CMCD patients as 
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compared to those from healthy control individuals was observed by flow cytometry (Figure 
5 D). 
Western blot analysis of STAT1 in IL-2 activated NK cell from the patient P7 revealed 
an increase of STAT1 protein levels of about three fold in the cells from the CMCD patient 
(Figure 5 E, left panel). This is accord with the analysis of STAT1 expression by flow 
cytometry in the same patient (Figure 5 E, right panel). IFN-α induced higher level of 
pSTAT1 in IL-2 activated NK cells from patient P7 as compared to cells from the healthy 
control. A strong STAT1 phosphorylation was observed, in the same patient, also in response 
to IL-2 and IL-15 stimulation (Figure 5 F). Analysis of STAT1 phosphorylation in response 
to IL-21 did not reveal STAT1 activation neither in control nor in cells from the CMCD 
patient. 
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Figure 5: GOF-STAT1 mutations in CMCD patients are associated with increased STAT1 
activation. (A) NK cells derived from three CMCD patients (P3, P7, P8) and three healthy 
controls were stimulated with IFN-α (40000U/ml) for 30 minutes, or were left unstimulated. 
Cells were stained with anti-CD3, anti-CD56, anti-pY701 STAT1 and analyzed by flow 
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cytometry after gating CD56+CD3- cells. The extent of pSTAT1 intensity, expressed as 
Mean Fluorescence Intensity (MFI), of a representative patient is shown. (B) NK cells from 
five patients (P3, P5, P6, P7, P8) and six healthy controls were stimulated with 100ng/ml IL-
2, or 50ng/ml IL-15 for 12 minutes, or were left unstimulated. Cells were stained with anti-
CD3, anti-CD56, anti-pY701 STAT1 antibodies and analyzed by flow cytometry after gating 
on CD56+CD3-. A representative patient is shown. The extent of pSTAT1 expression is 
calculated as MFI. (C) STAT1 activation in NK cells derived from CMCD patients (square) 
and healthy donors (circle) after stimulation with IL-2 or IL-15. The extent of STAT1 
phosphorylation was calculated as MFI after subtracting the MFI level of unstimulated cells 
stained with an isotype-matched mAb. Mann-Whitney U-test statistical analysis shows a 
significant difference in the extent of STAT1p expression between CMCD patients and 
control subjects (p<0.05). (D) NK cells derived from three CMCD patients (P3, P4, P7) and 
healthy control were stained with anti-CD3, anti-CD56, and anti-STAT1 and analyzed by 
flow cytometry after gating CD56+CD3- cells. The extent of STAT1 intensity is expressed 
as MFI. (E) STAT1 expression in NK cells from a healthy control subject (HD) and patient 
P7 was evaluated by Western blot (panel left) using an anti-STAT1 mAb. Actin was used as 
a loading control reference. STAT1 and actin expression in NK cells were calculated by 
densitometric analysis; STAT1/actin expression ratio was calculated in cells from the CMCD 
patient and control subject. STAT1 protein expression was also evaluated also by flow 
cytometry (right panel) using (PE)-conjugated mouse anti-STAT1. The extent of STAT1 
expression is calculated as MFI. (F) Analysis of STAT1 phosphorylation by Western blot. 
NK cells from a healthy control subject (HD) and from patient P7 were stimulated with IFN-
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α (10000U/ml) for 30 minutes, IL-2 (100ng/ml) for 12 minutes, IL-15 (50ng/ml) for 12 
minutes, IL-21 (50ng/ml) for 15 minutes, or medium alone. STAT1 phosphorylation was 
evaluated with an anti-Tyr-701-phosphorylated STAT1 mAb. Analysis of actin expression 
was used to measure protein loading. Both long or short film exposure are shown in figure. 
 
The analysis of STAT5 phosphorylation of IL-2-activated NK cells by flow cytometry 
revealed reduced pSTAT5 levels in all CMCD patients tested in response to both IL-2 and 
IL-15 as compared to healthy control cells (Figure 6, A and B , p< 0.05). On the contrary, 
the expression of STAT5 was comparable in resting CD56+CD3- NK cells from both the 
patients and healthy control (Figure 6 C). In order to assess the expression levels of STAT5, 
a western blot analysis was carried out (Figure 6 D). WB analysis on NK cell cultures derived 
from patient P7 and from a healthy donor after withdrawal of IL-2  showed similar levels of 
STAT5 expression. Conversely, WB analysis of STAT5 phosphorylation in NK cells from 
patient P7 showed a decrease, by approximately fifty percent, of pSTAT5 levels (Figure 6 
E).  
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Figure 6. GOF STAT1 mutation in CMCD patients are associated with reduced STAT5 
activation. (A) NK cells from five CMCD patients (P3, P5, P6, P7, P8) and six healthy 
controls were stimulated with IL-2 (100ng/ml) or IL-15 (50ng/ml) for 12 minutes, or were 
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left unstimulated. Cells were stained with anti-CD3, anti-CD56, anti-pY694 STAT5 
antibodies and analyzed by flow cytometry after gating CD56+CD3-cells. A representative 
case is shown. The extent of pSTAT5 expression is calculated as MFI. (B) STAT5 activation 
in NK cells derived from CMCD patients (square) and healthy donors (circle) after 
stimulation with IL-2 or IL-15. The extent of STAT5 phosphorylation was calculated as MFI 
after subtracting the MFI level of unstimulated cells stained with an isotype-matched mAb. 
Mann-Whitney U-test statistical analysis shows a significant difference in the extent of 
pSTAT5 expression between CMCD patients and control subjects (p<0.05). (C) NK cells 
derived from CMCD patients P4 and P7 and healthy control were stained with anti-CD3, 
anti-CD56, and anti-STAT5 and analyzed by flow cytometry after gating CD56+CD3- cells. 
Panel includes STAT5 intensity as Mean Fluorescence Intensity (MFI). (D) Western blotting 
analysis of STAT5 expression was carried out on unstimulated NK cells derived from healthy 
control subject (HD) and from patient P7. Actin expression was evaluated as a loading control 
reference. STAT5 and actin expression in NK cells were calculated by image densitometry 
analysis; STAT5/actin expression ratio was calculated in cells from the CMCD patient and 
from the control subject. (E) Analysis of STAT5 phosphorylation by Western blot. NK cells 
derived from healthy control subject (HD) and from patient P7 were stimulated with IFN-α 
(10000U/ml) for 30 minutes, IL-2 (100ng/ml) for 12 minutes, IL-15 (50ng/ml) for 12 
minutes, or IL-21 (50ng/ml) for 15 minutes, or medium alone. STAT5 phosphorylation was 
investigated by using an anti-Tyr-694-phosphorylated STAT5 mAb. Analysis of tubulin 
expression was determined to measure protein loading. 
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Abnormal STAT1 and STAT5 DNA binding activity in NK cells of CMCD patient 
A chromatin immunoprecipitation (ChIP) assay in NK cells from patient 7 and in cells from 
a control subject was performed in order to evaluate the direct binding of STAT1 and STAT5 
to specific genomic regions containing the canonical ISRE binding site or the STAT5 binding 
motif such as the IFIT1 and the IL2RA promoters (116, 117) (Figure 7). In unstimulated NK 
cells from the CMCD patient we identified STAT1 binding to the IFIT1 promoter, probably 
due to the presence of a constitutively activated form of STAT1 in these cells (Figure 7 A). 
Moreover, IL-15 stimulation of NK cells from the patient induced a stronger recruitment of 
STAT1 to the IFIT1 promoter as compared to NK cells from healthy donor (Figure 7 A). 
Conversely, STAT5 binding to IL2RA, a gene strictly dependent on STAT5, was increased 
by IL-15 stimulation only in NK cells from the healthy donor, but not from the patient (Figure 
7 B), in accordance with the low level of phosphorylation of STAT5 observed in IL-15 
stimulated NK cells from patients (Figure 6). 
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Figure 7. Abnormal STAT1 and STAT5 DNA binding activity in IL-15 stimulated NK cells. 
(A and B) NK cells derived from healthy control subject (HD) and from patient P7 were 
stimulated with IL-15 (50ng/ml) for 45 minutes, or left unstimulated. ChIP assay was then 
performed using STAT1 (A) and STAT5 (B) Abs; co-immunoprecipitated DNA samples 
were amplified by IL2RA, IFIT1 and PRL promoters specific primers. Data are expressed as 
percentage of the total input. A representative experiment of two performed is shown. 
 
Gene expression in NK cells of CMCD patient  
Real Time PCR was performed in NK cells activated with IL-2 from patient P7 and from a 
healthy control to address the effects of GOF STAT1 mutation on gene expression. STAT1 
mRNA leves were already elevated in unstimulated cells of the patient as compared to the 
healthy control, thus explaining the finding of increased STAT1 protein levels in NK cells 
from the same patient. After stimulation with IL-2 and IL-15 a further increase of mRNA 
expression was observed in the patient as compared to the control (Figure 8 A). The 
expression of IL2RA mRNA was evaluated since the cells of patients show a decrease in 
phosphorylation of STAT5 after stimulation with IL-2 and IL-15. A greater increase in the 
expression of IL2RA mRNA was reported in the patient’s cells after treatment with IL-2 or 
IL-15cells as compared to the control (Figure 8 B). SOCS3 mRNA upregulation was 
observed in the patient, but not in the control subject after stimulation of NK cells with IL-2 
and IL-15 (Figure 8 C). Conversely, stimulation with IL-15 lead to a significantly lower 
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increase of IFNG and SOCS1 mRNAs expression in the cells from the patient as compared 
to healthy control (Figure 8, panels D and E). 
 
Figure 8. Abnormal gene response in NK cells of CMCD patients to IL-15. (A - E) IL-2-
activated NK cells of patient P7 and a healthy subject (HD) were stimulated in vitro for 24 
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hours with IL-2 (100 ng/ml) or IL-15 (50 ng/ml) or were left unstimulated (-). The 
transcription of STAT1 (A), IL-2RA (B), SOCS3 (C), IFNγ and SOCS1 (E) was measured 
using RT-PCR. Target gene expression was normalized to the housekeeping gene (GAPDH) 
expression and presented as n-fold of the expression in unstimulated cells from the healthy 
control. The experiments shown are representative of three independent experiments. Data 
are presented as mean ± SE. 
 
NK cell proliferation and IFN-γ production 
Activated NK cells release cytokines that can modulate various effector functions of the 
immune system. A significantly reduced production of IFN-γ in response to IL-15 
stimulation was reported in NK cells from CMCD patients as compared to healthy controls 
(p<0.05) (Figure 9 A, left panel). In contrast, IFN-γ production after IL-12 and IL-18 
stimulations was normal, suggesting a selective defect of NK response to IL-15 stimulation 
(Figure 9 A, right panel). 
The expression of the proliferation marker Ki67 on CD56+/CD3- cells after stimulation 
with IL-15 or IL-2 was significantly lower (p< 0.05) in cells from CMCD patients as 
compared to control NK cells (Figure 9 B). Moreover, Ki67 expression was considerably 
decreased in NK cell derived from patients P3, P7 and P8 after activation for 48h with IL-2 
or IL-15, as compared to response of NK cells derived from a representative healthy donor 
(Figure 9 C). These results suggest that NK cells derived from CMCD patients display an 
impaired response to cytokines that signal through STAT5, such as IL-2 and IL-15. 
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Figure 9. Reduced IFN-gamma production and Ki67 expression by NK cells in CMCD 
patients. (A) IFN-γ production was measured by intracellular staining from freshly isolated 
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CD56+CD3- NK cells derived from eight STAT1 patients (black square) and ten healthy 
donors (black circle) after overnight stimulation with IL-15 (A, left panel, p<0.05) or IL-
12+IL-18 (A, right panel). (B) Ki67 expression by intracellular staining was measured in 
CD56+/CD3- NK cells in PBMC that were freshly isolated from three CMCD patients 
(square) and five healthy donors (circle) after stimulation for 72 hours with IL-15 (B, left 
panel, p<0.05) or IL-2 (B, right panel). (C) NK cells derived from three CMCD patients (P3, 
P7, P8) and one representative healthy donor were kept in culture with IL-2, maintained for 
16 hours in complete medium without IL-2 and then stimulated with IL-2, IL-2 and IL-15, 
or IL-15 alone. After 48 hours, the expression of the intracytoplasmic protein Ki67 was 
analyzed by flow cytometry. The experiment we show herein is representative of three 
experiments that were performed. 
 
Discussion 
In CMCD patients STAT1-GOF mutations result in impaired generation of Th17 cells and 
increased risk of fungal and bacterial infections. In this study, we report that in CMCD 
increased rate of viral infections may be associated with abnormal NK cell functions and 
proliferation. Abnormal NK cells functioning have been previously reported in different PIDs 
such as Wiskott-Aldrich syndrome, DOCK8 deficiency or Hermansky-Pudlak type 2 
syndrome (118-120). In all these conditions, the addition of IL-2 was able to correct the NK 
cytotoxicity defect, suggesting that the immunomodulatory activities and the response to IL-
2 were preserved (120, 121). 
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In this study a reduced cytolytic activity against susceptible human erythroleukemia K562 
cell line was reported IL-2-activated NK cells and, to lower extent, in unstimulated cells. 
This finding was not related to abnormal expression and/or functioning of NK receptors or 
to reduced perforin expression. Differently from what reported in other different PIDs, an 
impaired proliferative response to both IL-2 and IL-15, and an impaired IFN-γ production 
were observed in NK cells from CMCD patients. While IFN-γ release was normal in 
activated NK cells after stimulation with IL-12 or IL-18 (122).  
Different soluble immune mediators, including IL-15 and IL-2, are able to modulate in 
vivo NK cells functions. IL-15 promotes survival of mature NK cells (123), controls NK 
homeostatic proliferation as well as proliferation following bacterial, viral, or fungal 
infections and synergizes with IL-12 and IL-18 to induce IFN-γ production by NK cells 
(122). IL-2 and IL-15 intracellular pathways share several signaling components, including 
the Janus Kinases (Jak) 1 and 3 molecules, bound to IL-15Rβ and common γc receptors and 
STAT5a and b transcription factors. Studies in mice and humans highlighted the importance 
of the STAT5 pathway for IL-15 biological activities on NK cells (124-126). A significant 
reduction of the extent of STAT5 phosphorylation in response to IL-2 or IL-15 was reported 
in NK cells from GOF-STAT1 patients, suggesting an impaired cellular response of NK cells 
to these cytokines. NK cells from such patients expressed normal levels of STAT5. 
Interestingly, strong STAT1 phosphorylation after IL-15 or IL-2 stimulation was 
observed in NK cells from CMCD patients. In normal NK cells, signaling response to IL-2 
or IL-15 can be detected only after prolonged exposure of the membrane. The increased 
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sensitivity of NK cells to STAT1-mediated signaling, observed in CMCD patients, might 
interfere with STAT5-dependent responses to IL-15 or IL-2. In conclusion, this evidence 
suggests that, persistent STAT1 phosphorylation, induced in response to various cytokines 
in different cell types, can interfere with important steps in the differentiation and functions 
of T and NK cells, resulting in impaired generation of Th17 cells and reduced proliferation 
of NK cells. The reduction of NK cell proliferative response associated to lower IFN-γ 
production in response to IL-15 or IL-2 might confer to CMCD patients an increased risk to 
develop invasive viral infections.  
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CHAPTER 3 
“Ectodermal disorders and PIDs” 
The description, in the last decades, of several novel forms of PIDs lead to discovery of new 
clinical and genetic aspects. Evidence shows that the skin represent the first defenses to hosts. 
In fact, it is the primary boundary for germs, and represent the main site of environment–host 
interactions. Recent studies suggest that it is also directly involved in the developmental 
process of the immune system. As a matter of fact, abnormalities of skin and skin annexa, 
leading to skin dryness, brittleness of hair, nail abnormalities and abnormal dentition, are 
often associated with different immunodeficiencies.  
Ectodermal dysplasia (ED) is a group of rare (7 out of 10,000 live births) inherited 
disorders that involves two or more tissues of ectodermal origin. To date about 200 different 
forms of ectodermal dysplasia have been described. In patients affected with ED, skin is 
usually dry, thin and hypopigmented, and prone to rashes, eczema or infections. Sweat glands 
may also be involved and may function abnormally, or not develop at all. Abnormal sweating 
may alter the control of body temperature, leading to overheating, especially in hot 
environments. The involvement of airways seromucous glands may reduce the normal 
protective secretions of the mouth and nose, predisposing to recurrent respiratory infections. 
The involvement of meibomian/tarsal glands may cause dryness of the eye, cataracts, and 
vision defects. Hair is usually hypopigmented, thin and sparse. Teeth are usually congenitally 
absent, peg-shaped or pointed. The enamel may also be defective. Other clinical features 
include typical cranial-facial features (frontal bossing, longer or pronounced chins and 
broader noses) and abnormalities in the ear development leading to hearing problems. 
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The most common form is hypoidrotic ED (HED - incidence of 1:10,000 live birth) (127) 
which could be inherited as an autosomal dominant (AD), autosomal recessive (AR) or X-
linked trait (XLHED). HED is caused by mutations in the ectodysplasin-A (EDA) signaling 
pathway, implicated in the development of the skin and skin appendage. Most of the cases of 
HED (approximately 80%) derives from mutations in the EDA gene on X-chromosome 
(OMIM 305100, XLHED, ectodermal dysplasia, type 1, ED1). A smaller subset derives from 
mutations in the EDA receptor (EDAR), the adapter protein (EDARADD), or WNT10A [2, 
3], being inherited in an a.r. (ectodermal dysplasia anhidrotic; EDA; OMIM 224900) or AD 
manner (ectodermal dysplasia type 3; ED3;OMIM129490).  
EDA plays a key role in organogenesis, from the initiation to the terminal differentiation 
(128, 129). Upon the binding of EDA ligand to the trimeric EDAR receptor, EDARADD 
adaptor is recruited, leading to the activation of the NF-kB pathway. In unstimulated cells, 
NF-kB is sequestered in the cytoplasm by the inhibitor of the kBproteins (IkB). NF-kB 
essential modulator (NEMO), is  required for the activation of NF-kB pathway. IkB 
phosphorylation by NEMO, results in IkB degradation and NF-kB translocation into the 
nucleus (130). 
Hypomorphic mutations in the IKBKG/NEMO gene on the X-chromosome result in HED 
with immunodeficiency (HED-ID,OMIM300291) (131-133). Differently from mutation in 
EDA pathway, mutations in IKBKG/NEMO gene are responsible for a heterogeneous and 
severe immunodeficiency. Even though recurrent bronchial or eye infections are described 
in patients with XLHED, in such patients recurrent infections do not result from PID but 
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develop as consequence of reduced bronchial or meibomian/tarsal gland function. In fact, the 
involvement of both NEMO and EDA-1 in the ectodysplasin pathway explains the similarity 
in the cutaneous involvement. However, NEMO is also involved in signaling pathways 
downstream to different receptors, including TLRs, interleukin-1 (IL-1Rs), tumor necrosis 
factor (TNFRs), and B- and T-cell receptors (TCR and BCR), thus explaining the wider 
immune defect in HED-ID and its complexity.  
HED-ID patients suffer from recurrent, severe, and life-threatening bacterial infections. 
Infections usually involve lower respiratory tract, skin, soft tissues, bones and gastrointestinal 
apparatus. Meningitis and septicemia may develop in early childhood. Infections by Gram-
positive bacteria (S. pneumoniae and S. aureus), followed by Gram-negative bacteria 
(Pseudomonas spp. and Haemophilus influenzae) and mycobacteria usually feature this 
syndrome. Patients usually show hypogammaglobulinaemia with low serum IgG (or IgG2) 
levels, and variable levels of other immunoglobulin isotypes (IgA, IgM and IgE). Elevated 
serum IgM levels may also be observed, featuring the hyper-IgM6 phenotype (134, 135). The 
hyper-IgM phenotype may derive from a defective ability of B cells to switch in response to 
CD40 ligand (CD40L).  
Antibody response to polysaccharide and proteic antigens is also impaired. Alterations of NK 
activity have also been reported in some (136, 137) but not all (136, 137) patients with EDA-
ID. Poor inflammatory response, due to impaired cellular responses to TLR and pro-
inflammatory cytokines (IL-1β, IL-18andTNF-α) (138) are often reported, thus explaining 
the occurrence of severe mycobacterial disease in these patients. 
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Different NEMO mutations have been associated with distinct disorders. Loss-of-function 
mutations cause incontinentia pigmenti (IP), which is lethal in males nad specifically affects 
females, being (139). Hypomorphic mutations cause two allelic conditions, namely HED-ID 
and a clinically more severe syndrome, in which osteopetrosis and/or lymphoedema associate 
with HED-ID (OLHED-ID; MIM 300301).  
Mutations in other genes involved in NF-κB pathway are responsible for different forms 
of HED-ID. Gain-of-function mutations of IκBα are able to enhance the inhibitory capacity 
of IκBα through the prevention of its phosphorylation and degradation, and result in impaired 
NF-κB activation. The developmental, immunologic and infectious phenotypes associated 
with hypomorphic NEMO and hypermorphic IKBA mutations largely overlap and include 
EDA, impaired cellular responses to ligands of TIR (TLR-ligands, IL-1β and IL-18), and 
TNFR (TNF-α,LTα1/β2 and CD154) super family members leading to severe bacterial 
diseases. Recently, mutations in NF-kB2 gene  have been described as responsible for the 
early onset of CVID, inherited as an autosomal dominant trait. In the cases so far identified, 
ectodermal abnormalities, including nail dystrophy and alopecia together with endocrine 
alterations, have been reported. 
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3.1 B cells from nuclear factor kB essential modulator deficient patients fail to 
differentiate to antibody secreting cells in response to TLR9 ligand. 
 
Mutations in IKBKG/NEMO gene lead to heterogeneous and severe immunodeficiency 
characterized by hypogammaglobulinemia, defect in the antibody response to polysaccharide 
and proteic antigens and elevated class M immunoglobulin (Ig) levels (140, 141). 
Immunodeficiency results in susceptibility to encapsulated pyogenic bacteria, such as 
Streptococcus pneumoniae and Haemophilus influenzae, mycobacteria, and herpes virus 
infections (142, 143). The involvement of NEMO in different cellular pathways helps 
explaining the complexity of the immunological phenotype, However, to date, little is known 
about the pathogenesis of the humoral defects. In fact, humoral alterations may be explained 
only in part by the involvement of NF-kB in the CD40 signaling pathway. In fact, evidence 
shows that, in a large cohort of patients, in which hypogammaglobulinemia occurred in 59% 
of the patients, impaired CD40 signaling was reported only in patients carrying Zinc Finger. 
Recent studies show that there is a relationship between T-independent B-cell immunity and 
the response against polysaccharides of encapsulated bacteria (144). In fact, patients at higher 
risk of recurrent infections caused by encapsulated bacteria usually show alterations of IgM 
memory B cells, of T-independent B cell differentiation and of the ability to generate anti-
pneumococcal polysaccharide IgM (145, 146), similarly to what happens in splenectomized 
or asplenic patients (144). TLR9 signaling is required for a proper differentiation of 
transitional B cells into IgM memory B cells (147). Defect of other molecules implicated in 
Toll–IL-1R (TIR) signaling pathway, acting upstream NEMO, such as IRAK-4 and Myd88 
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deficiencies, have been associated to increased susceptibility to invasive bacterial infections 
caused by S. pneumoniae (148). Moreover there is evidence that deficiencies fewer 
IgM+IgD+CD27+ B cells, reduced serum IgM antibody recognizing T-independent bacterial 
antigens, and impaired TLR-induced proliferation of IgM+IgD+CD27+ B cells in vitro may 
be found in patients affected with IRAK-4 and Myd88 (149).  
Conclusive remarks 
This evidence could suggest that also in HED-ID patients, bacterial diseases may be due, at 
least in part, to the impact of NEMO mutations on the TIR signaling pathway. To date, little 
is known about the role of T-independent B-cell immunity in susceptibility to infections from 
encapsulated bacteria in HED-ID. In this study published as Article on Clinical Immunology 
we investigated B-cell differentiation and Ig secretion induced by the TLR9 specific ligand 
CpG in HED-ID patients. We also studied a patient with HED due to mutations in the EDA 
gene on the X-chromosome (XLHED), which is not implicated in TIR signaling pathway. 
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CpGHypohidrotic ectodermal dysplasia (HED) consists of disorders resulting from molecular alterations of
ectodysplasin-A (EDA) pathway. Hypomorphicmutations inNF-kB essentialmodulator, downstream EDA, result
in HED with immunodeﬁciency (HED-ID), characterized by susceptibility to encapsulated pyogenic bacteria in-
fections. Increased susceptibility to pneumococcal infections and poor response to polysaccharide antigens are
associated with defect in T-independent B-cell immunity. We investigated B-cell differentiation and immuno-
globulin secretion induced by the TLR9 ligand CpG in two HED-ID and in a HED patient caused by EDAmutations
(XLHED). In HED-ID, only few B cells differentiated into plasma cells upon TLR9 stimulation and memory B cells
did not produce IgG and IgA, but small amounts of IgM. Unexpectedly, memory B cells from XLHED patient failed
to produce normal IgAor IgG amount upon TLR9 stimulation.Ourﬁndings expand the knowledge about thepath-
ogenesis of humoral alterations in HED patients and help explain the susceptibility to pneumococcal infections.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Hypohidrotic ectodermal dysplasia (HED) is a group of rare
inherited disorders that affect tissues of ectodermal origin with an
incidence of seven cases per 10,000 live births [1,2]. HED derives
from mutations in the ectodysplasin-A (EDA) signaling pathway,
which leads to the expression of genes implicated in the development
of the skin and skin appendage. Mutations in the EDA gene on X-
chromosome cause approximately 80% of cases of HED (OMIM
305100, XLHED, ectodermal dysplasia, type 1, ED1). A smaller subset
of cases is caused bymutations in the EDA receptor (EDAR), the adapter
protein (EDARADD), or WNT10A [3], being inherited in an autosomal
recessive (ectodermal dysplasia anhidrotic; EDA; OMIM 224900) or
autosomal dominant manner (ectodermal dysplasia type 3; ED3;
OMIM129490). Hypomorphic mutations in the NF-kB essential
modulator (NEMO) encoded by the IKBKG/NEMO gene on the X-
chromosome, result in HED with immunodeﬁciency (HED-ID, OMIM
300291) [4–6]. HED-ID has estimated incidence of 1:250,000 live male
births [7]. Due to the pleiotropic role of NEMO, mutations in IKBKG/
NEMO gene lead to heterogeneous and severe immunodeﬁciencyonal Medical Sciences, Unit of
1 Naples, Italy.characterized by hypogammaglobulinemia, defect in the antibody
response to polysaccharide and proteic antigens and elevated class
M immunoglobulin (Ig) levels [8,9]. Immunodeﬁciency results in sus-
ceptibility to encapsulated pyogenic bacteria, such as Streptococcus
pneumoniaeand Haemophilus inﬂuenzae, mycobacteria, and herpes
virus infections [10,11]. Even though NEMO has been shown to be
involved in different pathways, thus explaining the complexity of the
immunological phenotype, little is known about the pathogenesis of
the humoral defects. The involvement of NF-kB in the CD40 signaling
pathway may explain only in part the humoral alterations. In fact, in a
large cohort of patients, hypogammaglobulinemia occurred in 59% of
the patients, but only in Zinc Finger mutations it was correlated with
impaired CD40 signaling. Growing body of evidence demonstrates the
role ofT-independent B-cell immunity in the response against polysac-
charides of encapsulated bacteria [12]. Recurrent lower respiratory
tract infections caused by encapsulated bacteria might cause perma-
nent organ damage in patients with commonvariable immunodeﬁcien-
cy (CVID). Despite the profound hypogammaglobulinemia, some
patients donot experience bacterial pneumonia. Studies suggest that al-
terations of IgM memory B cells, T-independent B cell differentiation
and the ability to generate anti-pneumococcal polysaccharide IgM
[13] discriminate patients at higher risk of recurrent infections caused
by encapsulated bacteria [14], similarly to what happens in
splenectomized or asplenic patients [12]. Recent evidence indicates
132 G. Giardino et al. / Clinical Immunology 161 (2015) 131–135that the differentiation of transitional B cells into IgM memory B cells
requires a proper Toll-like receptor 9 (TLR9) signaling [15]. Although
TLR9 signaling can activate memory B cells directly, additional signals,
like RP105, seem to be required for efﬁcient naïve B cell responses
[16]. Intriguingly, patients with IRAK-4 and Myd88 deﬁciencies, which
are implicated in Toll–IL-1R (TIR) signaling pathway, acting upstream
NEMO, are also highly susceptible to invasive bacterial infections caused
by S. pneumoniae[17]. Recent studies show that patients affected with
IRAK-4 and Myd88 deﬁciencies have fewer IgM+IgD+CD27+ B cells,
reduced serum IgM antibody recognizing T-independent bacterial anti-
gens, and impaired TLR-induced proliferation of IgM+IgD+CD27+ B
cells in vitro [18]. This evidence could suggest that also in HED-ID
patients, bacterial diseases may be due, at least in part, to the impact of
NEMO mutations on the TIR signaling pathway. To date, little is known
about the role of T-independent B-cell immunity in susceptibility to infec-
tions from encapsulated bacteria in HED-ID. In this study we investigated
B-cell differentiation and Ig secretion induced by the TLR9 speciﬁc ligand
CpG inHED-ID patients.We also studied a patientwith HED due tomuta-
tions in the EDA gene on the X-chromosome (XLHED),which is not impli-
cated in TIR signaling pathway.
2. Methods
2.1. Patients
Patients herein reported are in follow-up at the Federico II Universi-
ty. For each patient, routine examination, serum Ig concentrations
andleukocyte counts were evaluated through standard methods and
compared with laboratory-speciﬁc age-related normal values. All
studies were performed with informed parental consent.
2.2. IKBKG and EDA-1analyses
Genomic DNAwas prepared bymeans of phenol–chloroformextrac-
tion, RNA by means of Trizol reagent (Invitrogen, Carlsbad, California),
and cDNA by means of Superscript reverse transcriptase PCR system
(Invitrogen), all according to manufacturer recommendations.
IKBKG-speciﬁc primers were used to evaluate the full cDNAwith the
following primer sets, as previously described [19]: forward, 5#-CCCT
TGCCCTGTTGGATGAATAGGC-3#; reverse, 5#-AGGCGGGAGAGGAAAG
CGCAGACTG-3#; and forward, 5#-AAGCTGGCCCAGTTGCAGGTGGCCT-
3#; reverse, 5#-AGGTGGCATCCCAGTTGTGG-3#. Western blotting of
NEMO or actin was performed with 4% to 12% bis-Tris NuPage gradient
gels, NuPage buffer systems, and polyvinylidene diﬂuoride membranes
(Invitrogen). Membranes were blocked for nonspeciﬁc protein binding
by the use of 1% BSA in phosphate buffered saline (PBS) with 0.1%
Tween-20 for 1 h at room temperature, followed by overnight incuba-
tion with anti-NEMO or anti-actin antibodies.
The eight exons of EDA-1 and EDA-2 were ampliﬁed through PCR
using the following primer sets, as previously described [20]: forward,
5#-GTCGGCCGGGACCTCCTC-3#; reverse 5#-GCCGCCGCCCCTACTAGG-
3#; forward, 5#-ATGTTGGCTATGACTGAGTGG-3#; reverse, 5#-CCCT
ACCAAGAAGGTAGTTC-3#; forward, 5#-GATCCCTCCTAGTGACTATC-
3#; reverse, 5#-CAGACAGACAATGCTGAAAGA-3#; forward, 5#-AAAA
AAGTAACACTGAATCCTATT-3#; reverse 5#-CTCTCAGGATCACCCACTC-
3#; forward, 5#-GGAAGTCAAAAGATTATGCCC-3#; reverse, 5#-CTAC
CCAGGAAGAGAGCAAT-3#; forward, 5#-CTGAGCAAGCAGCCATTACT-
3#; reverse, GGGGAGAAGCTCCTCTTTG-3#; forward, 5#-ACTGAGTGAC
TGCCTTCTCT-3#; reverse, 5#-GCACCGGATCTGCATTCTGG-3#; forward,
5#-TGTCAATTCACCACAGGGAG-3#; reverse, 5#-CACAGCAGCACTTAGA
GG-3#.
2.3. Immunological assays
PBMC was isolated from patients by density gradient centrifugation
over Ficoll-Hypaque (Biochrom, Berlin, Germany). Cells were stainedwith the appropriate antibody (CD45-APC, CD3-PerCP, CD19-PerCP,
CD56-PE-Cy7, CD8-PE-Cy7, CD4-FITC, CD27-APC, CD24-FITC, IgD-PE,
IgM-PE, CD45RO-FITC [BD Biosciences, San Jose, California], CD45RA-PE,
CD38-PE, CD31-PE [Miltenyi Biotec, Bologna, Italy]) at 4 °C for 30 min,
washed and ﬁnally analyzed using a FACSCanto II ﬂowcytometer
(BD Biosciences).
The relative proportion of the following lymphocyte subpopulation
was studied: T cells (CD3+), helper T cells (CD3+CD4+), cytotoxic
T cells (CD3+CD8), B cells (CD3−CD19+), Natural Killer cells
(CD3−CD56+), naïve helper T cells (CD3+CD4+CD45RA+),memo-
ry helper T cells (CD3+CD4+CD45RO+), naïve cytotoxic T cells
(CD3+CD8+CD45RA+), memory cytotoxic T cells (CD3+CD8+
CD45RO+), transitional B cells (CD3−CD19+CD24+CD38hiCD27−),
mature B cells (CD3−CD19+CD24−CD38dim/loCD27−), IgMmemory
B cells (CD3−CD19+CD24+IgM+CD27+), and switched memory B
cells (CD3−CD19+CD24+IgM−CD27+).
B cells were labeled with 5-chloromethylﬂuorescein diacetate at the
ﬁnal concentration of 0.1 mg/mL (Molecular Probes, Eugene, Oregon)
and cultured at 1–2 × 105 cells per well in 96 round-bottom plates
(BD Biosciences) in complete RPMI-1640 (Invivogen, SanDiego, Califor-
nia) supplemented with 10% fetal calf serum (Hyclone Laboratories,
Logan, Utah). Human CpG oligodeoxynucleotides (Hycult Biotechnolo-
gy, Plymouth Meeting, Pennsylvania) was used at the optimal concen-
tration of 2.5 mg/mL. Cell proliferation was measured on day 7 by a
FACSCalibur Flow Cytometer (BD Biosciences). To evaluate B-cell func-
tion a lymphocyte gate based on forward and side scatter characteristics
was used. The B cell gate was based on CD19 expression. The CMFDA
ﬂuorescence of CD19+ B cells was then evaluated. Secreted Ig was
assessed at day 7 by ELISA. Brieﬂy, 96-well plates (Corning Incorporated,
New York, USA) were coated overnight with puriﬁed goat antihuman
IgA, IgG or IgM (Jackson ImmunoResearch, West Grove, Pennsylvania).
After washing with PBS/0.05% Tween and blocking with PBS/gelatin 1%,
plates were incubated for 1 h with the supernatants of the cultured
cells. After washing, plates were incubated for 1 h with peroxidase-
conjugated fragment goat anti-human IgA, IgG or IgMantibodies (Jackson
ImmunoResearch). The assay was developed with o-phenylenediamine
tablets (Sigma, St Louis, Missouri) as a chromogenic substrate. Immuno-
globulin concentration in the supernatants was measured by interpola-
tion with the standard curve. As standard, human IgA, IgG and IgM
(Jackson ImmunoResearch) were used. The standard curve was generat-
ed measuring seven successive 1:3 dilutions of each standard. Also for
each supernatant seven successive 1:3 dilutions were tested.
The proliferation of PBMC was determined through the incorpora-
tion of tritiated thymidine during 72 h of culture after stimulation with
8 μg/mL PHA or CD3 cross-linkingwith anti-CD3 (1 or 0.1 ng/mL)mono-
clonal antibody precoated plates.
3. Results and discussion
3.1. Diagnosis of HED-ID or XLHED
Three male patients, of 5.0, 4.3 and 7.2 years of age were enrolled
into the study. IKBKG/NEMO genetic analysis revealed a c.509TNC
mutation in patient 1 and a c.1167dupT mutation in patient 2 (see
Supplemental materials). While the c.1167dupT was previously found
in a patient with HED-ID and osteopetrosis [21], the c.509TNC has
been never reported before [5]. Patient 3 carried ac.1133CNT 140
mutation in EDA-1 gene. Array-Comparative Genomic Hybridization
(Array-CGH) was performed in patient 2 and showed a partial trisomy
of chromosome 22q11.1.
As shown in Supplemental Table I, all the patients had phenotypic
hallmarks of HED at the diagnosis and reduced sweating after pilocar-
pine stimulation. Patients 2 and 3 suffered from recurrent impetiginized
eczema requiring only topical therapy. Patient 2, also carrying a 22q11.1
trisomy, had further atypical dysmorphic features, as downward-
sloping palpebral ﬁssures, microstomia, retrognathism and elf ear and
133G. Giardino et al. / Clinical Immunology 161 (2015) 131–135showed a neurological involvement, characterized by reduced visual
evoked potentials, mental retardation and pericerebral liquoral space
dilatation on magnetic resonance imaging (Supplemental Table I).
Although no conclusive explanation is available, developmentalFig. 1. B-cell phenotype and function of HED-ID and XLHED patients. (a)The left pane
(CD3−CD19+CD24+CD38hiCD27−), and mature B cells (CD3−CD19+CD24−CD38dim
panel the staining for CD24 and CD27 in CD3−CD19+ gated cells is shown. The frequency of C
with antibodies to CD27 and IgM at day 7. Mature B cells are identiﬁed as IgM+, CD27− in CD
switched memory (Sw mem) lack IgM. Plasma cells are bright for CD27 and have (IgM PC) or
column indicates the concentration measured in μg/mL.delay has been already associated with 22q11.1-q11.2 alteration
[22]. Neurological manifestations may also be found in 30% of HED
patients, representing one of the major causes of mortality of this
disorder [23].l shows the identiﬁcation of memory (CD3−CD19+CD24+CD27+), transitional
/loCD27−) in CD3−CD19+ gated cells using the CD24 and CD38 markers. In the right
D27+memory B cells is indicated. (b)PBMCs cultured with medium or CpG were stained
3−CD19+ gated cells. IgM memory (IgM mem) B cells express IgM and CD27, whereas
lack (sw PC) IgM. (c)In the supernatants, IgM, IgG and IgA were measured by ELISA. Each
Table 1
Major immunologic ﬁndings of the patients.
Patient 1 Patient 2 Patient 3
Immunoglobulins (mg/dL)
IgG 160
(231–947)a
56
(222–846)a
1410
(528–1959)a
IgA 20 (8–74) 6 (6–60) 82 (37–257)
IgM 10
(26–210)
92 (28–39) 77 (49–292)
IgE (KU/L) b2 NA 1501
Speciﬁc antibodies
HBV antigen antibodies (mIU/mL) Absent Absent 209.7
Antibody response to pneumococcal
polysaccharide (IgG/IgA/IgM)b
Pre 271/32/302 NA 88/75/94
Post 237/36/200 NA 280/286/302
Isohemagglutinins Absent Absent Anti-A 1:64c
Anti-B 1:256
NA,not available.
a Normal reference value.
b ng/mL; a positive response is deﬁned as a threefold increase of the antibody titer.
c Anti-A and anti-B isohemagglutinin titers.
134 G. Giardino et al. / Clinical Immunology 161 (2015) 131–1353.2. Infections
In spite of the similarity of the cutaneous involvement, difference in
the susceptibility to infections and in the immunological pattern,
between HED-ID and XLHED patients, was documented. Patients 1 and
2, carrying IKBKG/NEMO alterations, suffered from severe infections in-
cluding sepsis and severe gastroenteritis, requiring hospitalization and
total parenteral nutrition. Patient 1 also suffered from S. pneumoniae
meningitis and recurrent urinary tract infections. Recurrent upper and
lower airway infections were reported in patients 1 and 3 (Supplemental
Table II). Predisposition to bronchial infections has alreadybeendescribed
in patients with XLHED. In these patients alterations of the airways
seromucous glands have been identiﬁed and suspected to predispose to
bronchial disease [24,25].
All patients suffered from chronic mucocutaneous candidiasis
responsive to oral treatment. Fungal infections have been described in
the 10% of the patients affected with HED-ID [11]. The pathogenesis of
susceptibility to fungal infections in HED-ID has not been completely
clariﬁed. It should be noted that CARD-9 (caspase recruitment
domain-containing protein 9), which plays a key role in immune
response against fungal infections, activates NF-kB pathway (see
Supplemental Fig. 1). This activation depends on the presence of
NEMO for the recruitment of IKK complex, andNF-kB nuclear transloca-
tion and activity. This evidence supports a role for NEMO in the activa-
tion of innate anti-fungal immunity [26]. Interestingly, low IL-17 T cell
counts have been shown in a patient with HED due to IKBA mutation,
involved in Nf-kB signaling [27]. Notably, TLR is also implicated in the
differentiation of IL-17 T cells, which play a very important role in the
response to fungal infections [28]. As for XLHED patients, little is
known about the predisposition to fungal infections. Even though ac-
cording to some authors, the decreased salivary secretion could increase
the risk of oral fungal infections [29], it is very difﬁcult that such an
explanation is per se sufﬁcient to account also for the predisposition
to esophageal infections, observed in our patient. In patients with
XLHED, an immunodeﬁciency has never been described, even though
the evidence of recurrent and often severe bacterial and fungal
infections (pneumonitis and esophageal candidiasis) could suggest the
presence of immunological alterations,which deserve further investiga-
tions on a larger cohort of patients.
3.3. Immunological ﬁndings
Leukocyte counts were persistently elevated in patient 1 with a
median white blood cell (WBC) count at the initial diagnosis of
17,410 cells/μL. In patients 2 and 3 leukocyte counts were normal.
All patients had normal CD3+, CD4+, CD8+, naïve and memory
CD4 and CD8 T cells (see Supplemental Table III). The study of the
B-cell compartment revealed a normal number of CD19+ cells in
all the patients. As shown in Fig. 1A, patients 1 and 2 showed a
marked reduction of CD19+CD24+CD27+memory B cells, different-
ly from patient 3 who had a normal memory B-cell subset but reduced
transitional cells (Fig. 1a left panel). In patients 1 and 2, memory B cells
mostly included IgMmemory cells (95% and 80% of thememory B cells,
respectively, data not shown). In patient 3, the relative proportion of
switched and IgM memory was normal (52 and 48% of B cell memory,
respectively, data not shown). As observed in other humoral immuno-
deﬁciencies, the defect of the B-cell compartment mainly involves
terminal steps of B-cell differentiation [13,30].
In vitro B-cell differentiation and Ig production were studied stimu-
lating PBMC with the TLR9 ligand, CpG. As previously reported [15],
since the PBMCwas analyzed after 7 days of culture, only a fewmemory
B cells survived under unstimulated conditions (Fig. 1b, medium). As
shown in Fig. 1B, B cells from the two patients carrying IKBKG/NEMO
mutation proliferated in response to CpG, but they did not terminally
differentiate into CD27bright plasma cells, differently from the control
and patient 3. Consistently, IgG and IgA were not detectable in thesupernatants and only small amounts of IgM were secreted in patients 1
and 2, differently from the control (Fig. 1c). Unexpectedly, memory Bcells
from XLHED, which adequately differentiate into plasma cells, fail to pro-
duce normal amount of IgA or IgG upon TLR9 stimulation, as compared to
the healthy control. Patients 1 and 2 had hypogammaglobulinemia, re-
quiring IV-Ig therapy, differently from patient 3. Since 20 months of age,
thepatient 2 showed IgM levelsN95th centile for age,which later normal-
ized during the follow-up, while patient 1 since 2.9 years of age showed
IgA levels N95th centile for age (data not shown). Isohemagglutinins
were undetectable in patients 1 and 2. Only patient 3 had detectable
hepatitis B-speciﬁc IgG (209.7 mIU/L). In patient 1, no speciﬁc antibody
response to any of the 14 polysaccharide antigens was observed after im-
munization with pneumococcal polysaccharide vaccine, differently from
patient 3, who had a normal response (Table 1). Of note, IgM memory B
cells and natural antibodies have been shown to play an important role
in the defense against encapsulated bacteria [14].
Lymphocyte proliferative response to PHA or stimulation through
CD3 X-L was decreased only in patient 1, being 27.6 and 0.57% of the
control, respectively.
In both HED-ID, no terminal differentiation of mature B cells into
plasma cells and switched memory B cells was induced following
TLR9 triggering, differently to what observed in XLHED. Moreover a
marked reduction in the B-cell memory compartment was observed in
both HED-ID patients.The difference between HED-ID and XLHED
immune defect may rely on the distinct pathways in which NEMO and
EDA-1 are involved. In fact, while both molecules are involved in the
ectodysplasin pathway, thus explaining the similarity in the cutaneous
involvement, NEMO is also involved in signaling pathways downstream
to different receptors, including TLRs, IL1Rs, TNFRs, and B and T-cell
receptors. The participation of NEMO to these pathways explains the
complexity of immune defect in HED-ID.
In conclusion, in this study we report for the ﬁrst time on an im-
paired B-cell differentiation in response to CpG signaling through
TLR9, suggesting an alteration of the T-independent B-cell activation
in HED-ID. This ﬁnding further expands the knowledge about the path-
ogenesis of humoral alterations in HED-ID patients and helps explain
the high susceptibility to infections from encapsulated bacteria in such
patients. Unexpectedly, also B cells from XLHED failed to produce
normal amount of IgA or IgG, upon TLR9 stimulation, suggesting that
an immunodeﬁciencymay play a role in the predisposition to bronchial
infections described in such patients. This ﬁnding needs to be conﬁrmed
in a study on a larger cohort. Moreover, in this study we found for the
ﬁrst time a newNEMOmutation (c.509TNC) in patient 1. This mutation
was associated with the most severe immunodeﬁciency, suggesting a
potential role for this alteration as a negative prognostic factor.
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3.2 Insight into IKBKG/NEMO locus: report of new mutations and complex genomic 
rearrangements leading to incontinentia pigmenti disease. 
 
Incontinentia pigmenti (IP; MIM #308300) is an X-linked disorder of the skin.  The 
inheritance pattern is X-linked dominant, being lethal in males. Skin lesions evolve through 
four stages: a vesicobullous, verrucous, hyperpigmented, and finally a hypopigmented stage 
(150, 151). Apart from skin, also other different tissues of ectodermal origin including teeth, 
hair and nails, eyes, and central nervous system (CNS) may be affected. The severity of the 
disease depends on the extension of neurological and/or ocular involvement. Neurological 
manifestations may range from a single-seizure episode to severe motor and intellectual 
disability. Ocular involvement may lead to strabismus, retinopathy, congenital cataract, and 
microphthalmia (152-154).  IP derives from mutations of IKBKG/NEMO gene (155, 156), 
which are in most of the cases loss-of-function (LoF), although also hypomorphic mutations 
have been reported (153, 156). NEMO/IKKgamma, the product of IKBKG/NEMO, is 
required for canonical NF-kB pathway activation (157, 158). The large heterogeneity of 
defects and the severe clinical presentations of IP might be due the pleiotropic role of NF-kB 
pathway (158). Hypomorphic IKBKG/NEMO mutations in male patients lead to EDA-ID, in 
which cutaneous involvement is associated with a severe and life-threatening Immune 
Deficiency (EDA-ID; MIM #300291) (159-162). EDA-ID and IP have completely different 
clinical presentations.  
In this update, accepted for the publication as Article on Human Mutation we present 21 
previously unreported IKBKG/NEMO mutations (nine small indels, and 12 SNPs) found in 
 
 
 
 
106 
IP patients. All variants, including relevant clinical data, were entered into the new IP locus-
specific database at http://IKBKG.lovd.nl.  
Conclusive remarks 
The IKBKG/NEMO locus predispose to genomic instability leading to high frequency of de 
novo complex rearrangements observed in IP patients. The analysis of the effect of 
IKBKG/NEMO IP-associated missense mutations on the NF-kB signaling may help 
understanding the patho-physiological aspects of this rare NF-kB-related disease. 
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ABSTRACT: Incontinentia pigmenti (IP) is an X-linked-
dominant Mendelian disorder caused by mutation in the
IKBKG/NEMO gene, encoding for NEMO/IKKgamma,
a regulatory protein of nuclear factor kappaB (NF-kB)
signaling. In more than 80% of cases, IP is due to recur-
rent or nonrecurrent deletions causing loss-of-function
(LoF) of NEMO/IKKgamma. We review how the local
architecture of the IKBKG/NEMO locus with segmen-
tal duplication and a high frequency of repetitive el-
ements favor de novo aberrant recombination through
different mechanisms producing genomic microdeletion.
We report here a new microindel (c.436_471delinsT,
p.Val146X) arising through a DNA-replication-repair
fork-stalling-and-template-switching and microhomology-
mediated-end-joining mechanism in a sporadic IP case.
The LoF mutations of IKBKG/NEMO leading to IP in-
clude small insertions/deletions (indel) causing frameshift
and premature stop codons, which account for 10% of
cases. We here present 21 point mutations previously un-
reported, which further extend the spectrum of pathologic
variants: 14/21 predict LoF because of premature stop
codon (6/14) or frameshift (8/14), whereas 7/21 predict
a partial loss of NEMO/IKKgamma activity (two splic-
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ing and five missense). We review how the analysis of
IP-associated IKBKG/NEMO hypomorphic mutants has
contributed to the understanding of the pathophysiologi-
cal mechanism of IP disease and has provided important
information on affectedNF-kB signaling.We built a locus-
specific database listing all IKBKG/NEMO variants, acces-
sible at http://IKBKG.lovd.nl.
Hum Mutat 35:165–177, 2014. C© 2013 Wiley Periodicals, Inc.
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Introduction
Incontinentia pigmenti (IP; MIM #308300) is an X-linked mul-
tisystem disorder, affecting the skin in all patients, but also other
ectodermal tissues comprising teeth, hair and nails, eyes, and central
nervous system (CNS). Skin lesions are highly diagnostic, from the
initial manifestations in neonates followed by the typical evolution
through four stages over months to years, namely, a vesicobullous
stage, verrucous stage, hyperpigmented stage, and finally a hypopig-
mented stage usually lasting a lifetime [Landy and Donnai, 1993;
Scheuerle and Ursini, 2010]. The severity of the disease is related to
neurological and/or ocular impairment. Overall, the prevalence of
functional CNS manifestations is approximately 30% [Fusco et al.,
2004; Meuwissen and Mancini, 2012; Minic´ et al., 2013a] rang-
ing from a single-seizure episode to severe motor and intellectual
disability. Ophthalmologic abnormalities comprising strabismus,
retinopathy, congenital cataract, and microphthalmia are present
in approximately 20%–37% of IP patients [Hadj-Rabia et al., 2003;
Fusco et al., 2004; Minic´ et al., 2013a].
The inheritance pattern is X-linked dominant, with usually male
lethality. However, some affected males have been reported; few of
them present X chromosome somatic mosaicism, and in others a
concomitant diagnosis of Klinefelter syndrome was demonstrated
[Scheuerle, 1998; Aradhya et al., 2001b; Kenwrick et al., 2001; Fusco
et al., 2007].
C© 2013 WILEY PERIODICALS, INC.
Inhibitor of Kappa light polypeptide gene enhancer in B-
cells, Kinase Gamma/Nuclear factor kappaB, Essential MOdulator
(IKBKG/NEMO) gene (HGNC-approved symbol IKBKG; GenBank
NM 003639.3,MIM#300248),mutations are the cause of IP [Smahi
et al., 2000; Fusco et al., 2008]. In most patients, the disease is due
to loss-of-function (LoF) mutations, although hypomorphic muta-
tions have been reported [Fusco et al., 2004, 2008]. IP is the first
inherited disease affecting one of the core components of nuclear
factor kappaB (NF-kB) signaling [Courtois and Gilmore, 2006].
The IKBKG/NEMO encodes for NEMO/IKKgamma a regulatory
subunit of the inhibitor of the kappaB (IkB) kinase (IKK) complex
required for canonical NF-kB pathway activation involved in many
fundamental physiological and pathologic functions including cell
survival [Hayden and Ghosh, 2004; Nelson, 2006]. In fact, the ab-
sence of NEMO/IKKgamma protein makes the cells sensitive to
apoptosis, which produces skewed X inactivation in females [Fusco
et al., 2004], whereas in males, extensive apoptosis is responsible for
early foetal lethality [Courtois et al., 2001]. The large heterogeneity
of defects and the severe clinical presentations of IP might be due
to an X-inactivation in heterozygous IP females, coupled with the
pleiotropic role of NF-kB pathway that is always affected in this
pathology [Nelson, 2006].
The second for frequency inherited disease due to IKBKG/NEMO
mutations is Ectodermal Dysplasia, Anhidrotic, associated with a
severe and life-threatening Immune Deficiency (EDA-ID; MIM
#300291) inmales [Aradhya et al., 2001b]. In EDA-IDmale patients,
the disease is always associated with hypomorphic IKBKG/NEMO
mutations, because the absence of gene produces male lethality
during embryogenesis [Zonana et al., 2000; Do¨ffinger et al., 2001;
Dupuis-Girod et al., 2002]. EDA-ID and IP have completely differ-
ent clinical presentations.
Since the discovery that IKBKG/NEMOmutations cause IP, it has
been increasingly clear that most of alterations are the consequence
of the local genomic instability due to structural architecture in
which the gene is located [Aradhya et al., 2001a, 2001c; Fusco et al.,
2009, 2012a]. Indeed, IKBKG/NEMO partially overlaps, on the
5′-side, with Glucose-6-Phosphate Dehydrogenase (G6PD, GenBank
NM 000402) gene and on the 3′-side, with low-copy-repeat
(LCR1) (Fig. 1A). In addition, in the same locus, a nonfunctional,
highly conserved pseudogene copy (IKBKGP/NEMOP) maps in
the LCR2 (the inverted paralogous sequence of LCR1) and is
involved in rare inversion/gene-conversion events causing the
repositioning/copying of mutations from pseudogene to gene
[Fusco et al., 2012a].
Moreover, the presence ofmultiple SINEs (Short INterspersed El-
ements) and LINEs (Long INterspersed Elements), micro-/macro-
homologies, and tandem repeats in both LCRs increases genomic
instability of the locus promoting aberrant recombinations that
account for both recurrent and nonrecurrent deletions (Supp.
Fig. S1).
Although a recurrent deletion (IKBKGdel), removing the exon
4–10 and causing a LoF of IKBKG/NEMO is frequently associated
with IP (78% of cases), the molecular diagnosis of heterozygous
females is quite complicated because of the IKBKGP/NEMOP and
also because mutations are scattered all along the gene [Fusco et al.,
2012b]. However, we and others have expanded the catalog of differ-
ent alterations that could affect IKBKG/NEMO [Fusco et al., 2009,
2012a; Hsiao et al., 2010; Fryssira et al., 2011]. In this update, we
present 21 previously unreported IKBKG/NEMO mutations (nine
small indels, and 12 single-nucleotide substitutions) found in IP
patients including a new indel mutation (c.436 471delinsT) that al-
ters the open reading frame of NEMO/IKKgamma by a premature
stop codon (p.Val146X). Moreover, we will provide an overview of
all IKBKG/NEMO submicroscopic genomic rearrangements found
in IP patients in the recent years, integrated with an extensive de-
scription of different genomic mechanisms likely involved in their
generation, including the “DNA-replication/repair-based” mech-
anism that probably has generated the de novo c.436 471delinsT
mutation, here reported. All variants, including relevant clini-
cal data, were entered into the new IP locus-specific database at
http://IKBKG.lovd.nl.
Taken together, past and present data demonstrate that the ar-
chitecture of the IKBKG/NEMO locus facilitates genomic instability
generating the high frequency of de novo complex rearrangements
observed in IP patients. Moreover, we illustrate how, in recent years,
the analysis of the effect of IKBKG/NEMO IP-associated missense
mutations on theNF-kB signaling has contributed to understanding
the patho-physiological aspects of this rare NF-kB-related disease.
The IKBKGMutation Database
We have established a Web-based IP-specific locus-specific
database that gives a complete overview of the variants identified
in IKBKG, and we have transferred to the Web-accessible all
available information on IKBKG mutations and their IP carriers.
This database is included in the Human Genome Variation Society
(www.HGVS.org) list of locus-specific databases. The database
contains all the IKBKGmutations, unclassified variants, and benign
variants, which have been published in the medical literature,
including those presented in this article. It is IP-patient-based
and mutation-based database, because it contains information
about the clinical phenotype of the patient (if provided) and about
the effect of pathogenicity of the mutation (if defined). Indeed,
this IKBKG mutation database has been constructed to aid both
clinicians and scientists.
The database will be freely accessible online at http://
IKBKG.lovd.nl. It can be updated with any reported variant from
any team, worldwide. It is highly recommended that new as well
as previously reported variants are submitted to the database be-
cause additional data will improve its value, for example, for the
interpretation of unclassified variants and phenotype—genotype
correlations.
Summary of Clinical Findings in Unpublished
Patients
Fifty-three IP patients (14.8%) with point mutations (21 pre-
viously unreported mutations and 32 reported mutations) in the
IKBKG gene were identified in 358 IP patients analyzed by the CNR-
IGB and Necker Hospital Laboratories between 2008 and 2013. In
this cohort, the 72% (258/358 IP patients) carried the recurrent
deletion (IKBKGdel), whereas the 13% (47/358 IP patients) did not
show any alteration in IKBKG gene. The patients were referred from
other European countries for analysis, and their clinical information
was collected by using a clinical extensive questionnaire (approved
by The International IP Consortium, www.ipif.org) reporting all as-
pects of IP phenotype: skin, hair, teeth, nails, eyes, and CNS defects.
All the IP patients analyzed in this study met the 1993 revised crite-
ria for the classification of IP [Landy and Donnai, 1993; Scheuerle
and Ursini, 2010; Minic´ et al., 2013b].
All affected females underwent skin biopsy obtained from the
limbs, usually from the legs. The cutaneous lesions (erythema,
vesicles, and pustules in the first stage, followed by verrucous and
keratotic lesions in the second stage, linear hyperpigmentation in
the third stage and pale, hairless, scarring patches in the fourth
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Figure 1. A: Genomic structure of the IP locus in Xq28. The square arrows represent LCRs (LCR1 and LCR2). G6PD exons (light gray boxes),
IKBKG exons (black boxes), IKBKGP exons (dark gray boxes). The exons are numbered for each gene. The long arrows indicate the transcriptional
direction for each gene, whereas the small arrows indicate the MER67B repeated sequences. B: Overview of the recurrent and nonrecurrent
rearrangements at the IP locus. The location and size (kb) of each deletion is illustrated by horizontal dotted line. Microhomology sequences
(extention_bp and percentage of homology) and repeat sequences used as substrates in each rearrangement are reported. In IP-43, a NAHR event
between two AluSx repeats has caused the deletion of genomic fragment because two defined homology regions with 86% sequence identity,
enriched by two long tandem repeats and by a high density of Alu repeated sequences, were mapped at the breakpoint junctions. C: Schematic
representation of the coding region of IKBKG gene (from exon 2 to exon 10). The position of mutations (as reported in Table 1) causing IP disease
is shown in exon/intron box. The symbol (∗) indicates the new mutations reported in this paper, whereas numbers in brackets indicate how often
the recurrent mutations were reported. The shaded rectangle represents the duplicated region (LCR1).
stage) were observed in all patients (Table 1). The other major clini-
cal findings associated with mutations are provided in Table 1. Data
relating to the onset of IP were available for 10 patients.
IP Sporadic Cases
The IP syndrome is typically a sporadic condition, familial recur-
rence is rare, and most of IKBKGmutations occur de novo (65% of
cases) [Smahi et al., 2000; Aradhya et al., 2001c; Fusco et al., 2004;
see also Nelson, 2006].
Thirteen de novo mutations reported in the literature (Table 2)
and seven of the new cases reported here (Table 1) are confirmed to
be de novo.
Mutation Spectrum in IP Locus
Point Variations in the IKBKG Gene
Mutations are named according to HGVS nomenclature guide-
lines (www.HGVS.org), numbered with respect to the IKBKG
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Table 1. Genetic and Clinical Summary of novel IKBKG/NEMOMutations Reported in IP Patients
IP
Nucleotide change
NM_003639.3
Protein change
NP_003630.1 Exon
Mutation
type Inheritance XIC
CNS
defects
Ocular
defects
Dental
defects
Hair
defects
Nail
defects
1 c.151del p.Leu51SerfsX64 Exon 2 Frameshift nd nd – Present Present Present –
2 c.262del p.Glu88ArgfsX27 Exon 3 Frameshift S SK – Present Present Present Present
3 c.358C>T p.Gln120X Exon 3 Nonsense F SK – – – Present –
4 c.382dup p.Leu128ProfsX10 Exon 3 Frameshift nd SK – Present Present Present –
5 c.433C>T p.Gln145X Exon 4 Nonsense S SK – Present Present – –
6 c.436 471delinsT p.Val146X Exon 4 Nonsense nd SK Present – Present – –
7 c.484del p.Ala162LeufsX119 Exon 4 Frameshift S SK – – Present – –
8 c.502C>T p.Gln168X Exon 4 Nonsense nd SK – – Present – Present
9 c.509T>C p.Leu170Pro Exon 4 Missense F SK – – – – –
10 c.511G>T p.Glu171X Exon 4 Nonsense S – – – Present – –
11 c.518G>Aa p.Arg173Gln Exon 4 Missense nd SK – – Present – –
12 c.518+2T>G nd Intron 4 Splice site nd nd – Present Present – –
13 c.519–3 519dup nd Intron 4 Splice site nd R Present – Present Present –
14 c.570 574del p.Leu191AlafsX61 Exon 5 Frameshift nd SK – – Present – –
15 c.653 659dup p.Ser221GlyfsX35 Exon 5 Frameshift nd SK – Present Present – –
16 c.685C>T p.Gln229X Exon 6 Nonsense S SK – – Present Present –
17 c.940G>C p.Ala314Pro Exon 8 Missense S R – – Present Present –
18 c.965T>C p.Leu322Pro Exon 8 Missense S SK – – – – –
19 c.1135dup p.Leu379ProfsX16 Exon 10 Frameshift F SK Present – Present – –
20 c.1237C>T p.His413Tyr Exon 10 Missense nd R – – Present Present –
21 c.1258T>C p.X420GlnextX27 Exon 10 Frameshift nd R – – Present – –
aThis mutation is predicted to alter also the splicing-site exon 4/intron 4.
Skin defects are present in all patients.
Present/–, presence/absence of complications for each tissue.
CNS defects (seizures, spastic paresis, motor retardation, mental retardation, or microcephaly); ocular defects (strabismus, cataracts, optic atrophy, retinal vascular pigmentary
abnormalities, microphtalmous, or pseudogliomas); dental system defects (partial anodontia, delayed dentition, cone/peg shaped teeth, or impactions); hair defects (vertex
alopecia, wooly hair naevus, or eyelash and eyebrow hypogenesis); and nail defects (onychogryphosis, pitting or ridging).
nd, not detected; XIC, X-inactivation chromosome test on lymphocytes of the patient [Allen et al., 1992]; SK, skewed, R, random, X-inactivation profile. S, sporadic case; F,
familial case.
gene reference sequence (AJ271718.1 covering IKBKG gene tran-
script NM 003639.3), and nomenclature of all mutations have been
checked using Mutalyzer (www.LOVD.nl/mutalyzer/) [Wildeman
et al., 2008]. All base changes are predicted to be pathogenic based
on their location in functional domains.
Forty-eight unique point mutations or small indels have been
reported previously in the literature (Table 2) and this paper adds
other 21 (Table 1) to the list of mutations identified in IP patients
(69 IP mutations). Most reported mutations, inclusive of the data,
are indel mutations 54% (37/69), whereas the 46% (32/69) are
single-nucleotide substitution. Moreover, the effects predicted on
the mutated protein show that 52% (36/69) cause a frameshift, the
26% (18/69) a premature stop codon, the 15% (10/69) are missense
mutations, the 6% (4/69) are splice-site mutations, and only 1%
(1/69) is an in-frame amino acid deletion (p.Lys90del, Table 2).
Themajority ofmutations have only been reportedonce, andonly
10 mutations have been reported at least twice (Fig. 1C). The vari-
ants p.Glu390ArgfsX5 (c.1167dup, exon10) and p.Glu390ArgfsX61
(c.1167del, exon10) have been reported three and four times, respec-
tively (Fig. 1C) [Zonana et al., 2000; Aradhya et al., 2001b; Do¨ffinger
et al., 2001; Lee et al., 2005; Pachlopnik Schmid et al., 2006; Tono
et al., 2007; Chang et al., 2008; Fusco et al., 2008; Mancini et al.,
2008]. Both mutations are located in the same stretch of cytosine
of exon 10 that is prone to generate errors during the DNA replica-
tion by slippage mechanism [Fusco et al., 2008]. The p.Asp113Asn
(c.337G>A, exon3) was described as a polymorphic variant of the
IKBKG gene in Fusco et al. (2004) and, more recently, in Tarpey
et al. (2009). Moreover, in Salt et al. (2008), it was reported in unaf-
fected female and in her son associated with selective susceptibility
to Pneumocystis and Cytomegalovirus infections without any signs
of ectodermal dysplasia. These observations exclude any correlation
of this IKBKG variant with IP. Mutations in regulatory domains or
intronic regions outside the sequence immediately flanking the ex-
ons have not been described,most likely because these regions of the
gene are not routinely screened or have yet to be fully characterized.
Splice-site mutations
To date, only two splice-site mutations have been reported in IP
(Table 2). They are a single-nucleotide substitution at the splice
donor site, c.399+1G>C (intron3) and c.518+2T>A (intron4).
We report here two new splice-site mutations, both in intron4,
c.518+2T>G (splice donor site) and c.519-3 519dup (splice acceptor
site) (Fig. 1C, Table 1). We predicted the effect on the splicing
by NetGene software (http://www.cbs.dtu.dk/services/NetGene2/)
and we observed that aberrant transcripts would be generated.
Moreover, we found in IP patient (IP-11 in Table 1) a previously
unreported mutation c.518G>A due to a single-nucleotide substi-
tution in the last position of IKBKG exon 4 nucleotide. The effects
that we could predict are two: amissensemutation (p.Arg173Gln, as
reported in Table 1) and an abnormal transcript because the splice
donor site is affected.
Thepredicted sequenceofmutatedproteins results in apremature
termination that causes the LoF of the NEMO/IKKgamma. It might
be also speculated that aberrant splicing products may have an
accelerated degradation of mutated mRNA by the mechanism of
nonsense-mediated decay [Baker and Parker, 2004].
Large Variations in the IKBKG Gene
IKBKG comprises nine coding exons (exons 2–10) and four al-
ternative noncoding first exons (Fig. 1A). Transcription from exons
1B and 1C is directed by the strong bidirectional promoter B (b
in Fig. 1A), in the CpG island, whereas transcription from exons
1D and 1A is directed by a weak unidirectional promoter A (a in
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Table 2. IKBKG/NEMOMutations Reported IP Patients
IP
Nucleotide change
NM_003639.3
Amino acid change
NP_003630.1 Exon
Mutation
type Inheritance
Clinical
diagnosis References
1 c.117 127dup p.Ser43CysfsX76 Exon 2 Frameshift F IP [Smahi et al., 2000]
2 c.133C>T p.Gln45X Exon 2 Nonsense F IP [Fusco et al., 2008]
3 c.169G>A p.Glu57Lys Exon 2 Missense F IP [Aradhya et al., 2001c]
4 c.184C >T p.Arg62 X Exon 2 Nonsense F IP [Fusco et al., 2008; Smahi et al., 2000]
5 c.214del p.Leu72Cys fs X 43 Exon 3 Frameshift ND IP [Aradhya et al., 2001c]
6 c.220del p.Glu74Ser fsX41 Exon 3 Frameshift ND IP [Aradhya et al., 2001c]
7 c.229del p.Glu77Arg fs X 38 Exon 3 Frameshift S IP [Fusco et al., 2008]
8 c.256C>T p.Gln86 X Exon 3 Nonsense F IP [Fusco et al., 2008]
9 c.266 268del p.Lys90del Exon 3 InFramedel S IP [Fusco et al., 2004]
10 c.292C>T p.Gln98 X Exon 3 Nonsense ND IP [Aradhya et al., 2001c]
11 c.337G>A p.Asp113Asn Exon 3 Missense S IP [Fusco et al., 2004, 2008]
12 c.367C>T p.Arg123Trp Exon 3 Missense F IP [Fusco et al., 2004]
13 c.399+1G>C ND Intron 3 Splice site ND IP [Aradhya et al., 2001c]
14 c.454del p.Glu152SerfsX129 Exon 4 Frameshift F IP [Fusco et al., 2008]
15 c.515 516insC p.Arg173SerfsX15 Exon 4 Frameshift F IP [Fusco et al., 2008]
16 c.516del p.Arg173GlyfsX108 Exon 4 Frameshift ND IP [Aradhya et al., 2001c]
17 c.518+2T>A ND Intron 4 Splice site ND IP [Aradhya et al., 2001c]
18 c.523dup p.Arg175ProfsX13 Exon 5 Frameshift ND IP [Aradhya et al., 2001c]
19 c.G549C p.Gln183His Exon 5 Missense S IP [Hsiao et al., 2010]
20 c.551 588del p.Leu184ArgfsX57 Exon 5 Frameshift ND IP [Aradhya et al., 2001c]
21 c.570del p.Leu191CysfsX90 Exon 5 Frameshift ND IP [Aradhya et al., 2001c]
22 c.638 642dup p.Met215SerfsX68 Exon 5 Frameshift ND IP [Aradhya et al., 2001c]
23 c.639 645del p.Arg214SerfsX65 Exon 5 Frameshift ND IP [Aradhya et al., 2001c]
24 c.662C>A p.Ser221X Exon 5 Nonsense ND IP [Fusco et al., 2008]
25 c.706C>T p.Gln236X Exon 6 Nonsense S IP [Aradhya et al., 2001c]
26 c.715C>T p.Gln239X Exon 6 Nonsense S IP [Fusco et al., 2004]
27 c.723C>G p.Tyr241X Exon 6 Nonsense ND IP [Aradhya et al., 2001c]
28 c.766C>T p.Arg256X Exon 6 Nonsense F IP [Fusco et al., 2008]
29 c.792dup p.Gln265ThrfsX19 Exon 7 Frameshift S IP [Martinez-Pomar et al., 2005].
30 c.868C>T p.Gln290 X Exon 7 Nonsense ND IP [Aradhya et al., 2001c]
31 c.896del p.Pro299ArgfsX3 Exon 7 Frameshift ND IP [Aradhya et al., 2001c]
32 c.943dup p.Glu315GlyfsX80 Exon 8 Frameshift F IP [Fusco et al., 2004]
33 c.967G>C p.Ala323Pro Exon 8 Missense S IP [Sebban-Benin and Pescatore et al., 2007]
34 c.994C>T p.Gln332X Exon 8 Nonsense S IP [Fryssira et al., 2011]
35 c.1078del p.His360MetfsX91 Exon 9 Frameshift S IP [Fusco et al., 2004]
36 c.1110del p.Ala371ProfsX80 Exon 9 Frameshift ND IP [Fusco et al., 2008]
37 c.1110dup p.Ala371ArgfsX24 Exon 9 Frameshift F IP; EDA-ID [Smahi et al., 2000]
38 c.1115dup p.Ala373CysfsX22 Exon 9 Frameshift F IP [Fusco et al., 2008]
39 c.1116del p.Ala373ProfsX78 Exon 9 Frameshift S IP [Fusco et al., 2004]
40 c.1127 1131del p.Ser377ProfsX16 Exon 10 Frameshift F IP [Fusco et al., 2008]
41 c.1136 1137del p.Leu379ArgfsX15 Exon 10 Frameshift S IP [Fusco et al., 2008]
42 c.1150C>T p.Gln384 X Exon 10 Nonsense S IP [Fusco et al., 2004]
43 c.1163 1175del p.Pro388HisfsX59 Exon 10 Frameshift F IP [Aradhya et al., 2001b, 2001c].
44 c.1166 1178dup p.Asp394ArgfsX5 Exon 10 Frameshift F IP [Aradhya et al., 2001b]
45 c.1167del p.Glu390ArgfsX61 Exon 10 Frameshift F IP [Aradhya et al., 2001b, 2001c; Fusco et al., 2008]
46 c.1167dup p.Glu390Argfs X5 Exon 10 Frameshift F IP; EDA-ID [Zonana et al., 2000]
47 c.1183 1184del p.Phe395LeufsX11 Exon 10 Frameshift F IP; EDA-ID [Fusco et al., 2008]
48 c.1259A>G p.X420TrpextX27 Exon 10 Nonstop F IP;
OL-EDA-ID
[Smahi et al., 2000]
ND, not detected; S, sporadic case; F, familial case.
Fig. 1A), in intron 2 of G6PD [Fusco et al., 2006]. The IKBKG
gene, located in LCR1, and the nonfunctional IKBKGP/NEMOP,
in LCR2 (Fig. 1A), share >99% identity and the presence of mul-
tiple repeat sequences (SINEs, LINEs, and LTRs; Supp. Fig. S1),
micro-/macro-homologies and tandem repeats, make the IP locus
highly vulnerable to damage, generating aberrant IP locus alleles
named recurrent and/or nonrecurrent rearrangements, by differ-
entmolecularmechanisms (nonallelic-homologous-recombination
[NAHR], nonhomologous-end-joining [NHEJ], fork-stalling-and-
template-switching [FoSTeS], and microhomology-mediated-end-
joining [MMEJ]) [Fusco et al., 2012a].
Recurrent rearrangements in IP locus
The most frequent pathologic variant in IP is a deletion (IK-
BKGdel, 78% of IP cases, Fig. 1B), spanning exons 4–10 in the
IKBKG gene [Smahi et al., 2000; Aradhya et al., 2001c; Fusco et al.,
2004, 2008]. The deletion removes the region of∼11.7 kb, between
two MEdium Reiterated 67B (MER67B) repeats located in intron 3
and intron 10 of IKBKG, respectively (Fig. 1A).
Two benign variants of IP locus, which do not affect the basic
structure of the IKBKG, were found in healthy parents of IP children
with de novo IKBKGdel [Fusco et al., 2009, 2010]. These variants
are: MER67Bdup allele, which contains the duplication of region
betweenMER67B in the IKBKG [Variation 74087, Table 3; Aradhya
et al., 2001a, Fusco et al., 2009; Conrad et al., 2010], and IKBKGPdel,
which contains the deletion of the same segment between MER67B
in the IKBKGP. Both variants are present in the control popula-
tion with frequency of 1.9% and 2%, respectively (Supp. Fig. S2,
Table 3).
Genetic evidence demonstrated that the IKBKGPdel and
MER67Bdup variants should be considered as risk alleles for
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Table 3. Large Variants in IP Locus
Genomic variation Genomic regiona Extention (kb) CNV Reference
Variation 74087 153,785,404–153,798,129 12.7 dup/del [Conrad et al., 2010]
IKBKGdel c.399-? 12601?del 11.7 del [Fusco et al., 2008]
153,786,231–153,797,928 [Smahi et al., 2000]
MER67Bdup c.399-? 12601?dup 11.7 dup [Aradhya et al., 2001a]
153,786,231–153,797,928 [Fusco et al., 2009]
IKBKGPdel 153,875,307–153,863,607 11.7 del [Bardaro et al., 2003]
[Fusco et al., 2009]
IP-48 153,763,394–153,878,592 115 del [Fusco et al., 2012]
IP-51 153,763,394–153,828,643 65.2 del [Fusco et al., 2012]
IP-11 153,757,815–153,821,090 63.2 del [Fusco et al., 2012]
IP-47 153,757,815–153,803,560 45.7 del [Fusco et al., 2012]
IP-50 153,769,487–153,796,055 26.6 del [Fusco et al., 2012]
IP-14 153,774,414–153,796,632 22.2 del [Fusco et al., 2012]
Dup, duplicated region; del, deleted region; CNV, copy number variation.
aGenomic region involved in the variations mapped in UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19).
sporadic IP cases because they promote or facilitate the onset of
the pathologic IKBKGdel [Fusco et al., 2009, 2010].
Nonrecurrent rearrangements in IP locus
Seven de novo deletions of different lengths (from 4.8 kb to more
than 111 kb, Table 3) were reported as nonrecurrent rearrangements
in IP locus. They were isolated in IP cases, and their main feature is
that they affected not only IKBKG, but also the overlapping G6PD
and the neighboring genes (Fig. 1B) [Fusco et al., 2012a].
The involvement of G6PD gene in the deletions found in IP
cases raised some important questions about the clinical presenta-
tion of patients. Indeed, G6PD encodes for the initial enzyme of
the pentose phosphate pathway [Luzzatto and Mehta, 1989] and its
deficiency (MIM #305900) is the most common X-linked disease
reported in human metabolic enzyme defects. The patients, most
frequently male, develop a nonimmune haemolytic anemia in re-
sponse to physiologic stress or to ingestion of triggering substances
including some antibiotics andVicia faba, commonly known as faba
beans or broad beans. Heterozygous females for G6PD deficiency
have almost normal G6PD levels due to a selective advantage of cells
expressing the wild-type allele [Martini and Ursini, 1996]. More-
over, although a remarkable polymorphism in human populations
(>400 variants) and more than 140 different hypomorphic muta-
tions have been reported so far in the G6PD gene, large deletions
were undiscovered, leading geneticists to suppose that the lack of
G6PD was lethal for males [Vulliamy et al., 1993; Luzzatto, 2006;
Cappellini and Fiorelli, 2008]. Hence, the survival of IP alleles with
G6PD deletions in female patients without clinical manifestations
matching the classic G6PD deficiency, makes stronger the previous
hypothesis suggesting that a very early somatic selection against
cells expressing the mutated allele (carrying bothG6PD and IKBKG
deletion) has occurred [Fusco et al., 2012a].
Genetic mechanisms producing de novo rearrangements
in IP locus
The genomic context analysis of the IP locus reveals that many
substrates for different mutational forces such as NAHR, NHEJ,
MMEJ, and/or FoSTeS are located there [Fusco et al., 2012a].
In addition, the presence of the LCRs (LCR1 and LCR2) and
of the IKBKGP/NEMOP pseudogene make risk alleles each benign
polymorphism of pseudogene, which can be easily transferred or
copied into the IKBKG, becoming de novo pathologic mutation.
Indeed, the number of de novo mutations in IP is enriched by other
alterations that, as reported, derive from the pseudogene through
mechanisms such as gene conversion and inversion [Fusco et al.,
2009, 2012a].
The NAHR causes the recurrent rearrangements. The NAHR is
the most frequent mechanism occurring in the IP locus able to gen-
erate aberrant alleles, because it causes the recurrentpathologicdele-
tion (78% of IP cases, IKBKGdel allele) and the two benign variants
(MER67Bdup and IKBKGPdel) that are very frequent in control pop-
ulation (1.9% and 2.0%, respectively). These deletions/duplication
alleles clustered around the MER67B elements, located as in the IK-
BKG as in IKBKGP (>99.1% of identity for 612 bp), suggesting that
they are the major substrate for intrachromosomal or interchromo-
somal NAHR during meiosis germline (Supp. Fig. S3A).
The NHEJ causes the nonrecurrent rearrangements. The NHEJ
is, instead, considered themost likelymechanism involved in the on-
set of nonrecurrent rearrangements. The breakpoint assessment of
the junction sequences, essential prerequisite to establish the nature
of recombination occurring, showed that the hot-spots of the differ-
ent nonrecurrent deletions identified in the IP locus were located in
a high content of SINEs (33% vs. 15% in IP locus, Supp. Fig. S1C),
tandem repeat elements and in the 5′ and 3′ breakpoint junctions
mapped an high-density region of repeat sequences and micro-
/macro-homologies (16–118 bp; Fig. 1C), well-known substrates
for NHEJ [Lieber, 2010]. The heterogeneity and the wide range of
the deletions as well as the high content of repeat sequences, micro-
/macro-homology regions strongly suggests that DNA repair events
occurred, generating different deletions by NHEJ mechanism. The
NAHR mechanism cannot be excluded. Indeed, an instance of
Alu–Alu-mediated recombination was proposed to explain the on-
set of a nonrecurrent rearrangement (IP-43; Fig. 1B) [Fusco et al.,
2012a].
The FoSTeS, MMEJ, and microhomology-mediated break-
induced replication cause the new insT/del36 bp mutation. In
the present report, we provide evidence on a de novo IKBKG exon
4 indel mutation, previously unreported. The sequence analysis at
breakpoints/junction enabled us to reveal that a complex rearrange-
ment was present: a deletion of 36 bp and the insertion of a thymine
(T) at the junction point (chrX:153786783–153786818, deleted re-
gion; UCSC Genome Browser on Human Feb. 2009 GRCh37/hg19)
(Fig. 2A). The mutated sequence predicted an altered open read-
ing frame of NEMO/IKKgamma protein synthesis by a premature
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Figure 2. New genomic rearrangement in IKBKG gene: c.436_471delinsT. The electropherograms and protein sequences related to wild type (A)
and to mutated alleles (B) isolated from IP-545 patient after cloning of fragment obtained by gene-specific PCR [Bardaro et al., 2003] are shown. The
amino acid sequence and position (from 140 to 162) of NEMO/IKKgamma protein is reported on the wild-type allele (A). The position of premature
stop codon (∗) at 146 position is predicted on the mutated allele (B). C: Alignment of the junction sequences of the IKBKG c.436_471delinsT. The
proximal and the distal reference sequences separated by the junction sequences (in the middle) are reported. The micro-homology sequences
(5′-CCAG-3′, 4 bp) and the T nucleotide insertion, underlined in (A andB), are boxed in (C). The genomic position at junction is shown (UCSC Genome
Browser on Human Feb. 2009 GRCh37/hg19).
stop codon (p.Val146X, Fig. 2A, Table 1). The bioinformatic analy-
sis at breakpoint site of the indel mutation, here reported, showed
two micro-homology sequences (5′-CCAG-3′) (Figs. 2 and 3) and
a non-B DNA structure (tetraplex, favored by stretches of oligonu-
cleotidesG) predicted in the deleted region (Fig. 3A). Recently, it has
been reported that non-B DNA conformations, repetitive elements,
and micro-homology sequences might increase the susceptibility
for DNA breakage or promote replication fork stalling [Lobachev
et al., 2007;Wells, 2007]. Hence, in the etiology of nonrecurrent mi-
crodeletions,MMEJ [Truong et al., 2013;Verdin et al., 2013], FoSTeS
[Mirkin, 2013], orMicrohomology-Mediated Break-InducedRepli-
cation (MMBIR) had occurred [Verdin et al., 2013].
According to thesemodels, we suggest that themechanismunder-
lying the onset of our indel mutation (c.436 471delinsT, p.Val146X)
is a FoSTeS /MMEJ or MMBIR event able to bypass the DNA lesion
at stalled fork and to restart the DNA replication (Fig. 3B).
It is likely to suppose that this mutation could have arisen in
somatic cells, making the patient a mosaic composition of cells with
different alleles. We cannot exclude that this is the case, although no
trace of somatic mosaicism was revealed (Supp. Fig. S4).
Inversion and gene conversion events cause de novo mutations.
Genetic evidences have demonstrated that variants of pseudogene
should transfer to the gene by inversion mechanism mediated by
NAHR between LCRs (Supp. Fig. S3B) [Chen et al., 2007].
An instance was reported in one IP family: the unaffectedmother
had the pseudogene mutation IKBKGPdel and the affected daugh-
ter had a pathologic IKBKGdel on her maternal X chromosome
[Fusco et al., 2009]. In that case, it was hypothesized that during the
mother’s germline development, a NAHR event between the LCRs,
mediated by an intrachromosomal loop mechanism, repositioned
the exon 4 10 deletion (IKBKGPdel) from the pseudogene to the
gene making dangerous (Supp. Figs. S3b and S5A) [Fusco et al.,
2009, 2010].
In 2001, Aradhya et al. (2001a) have reported that the high degree
of identity betweenLCR1andLCR2(>99%identity)was theproduct
of frequent gene-conversion events between the IKBKG gene and its
pseudogene that homogenize the two sequences. It is likely to assume
that inter- or intra-chromatid gene conversion can occur also in
IP families generating de novo pathologic alterations (Supp. Fig.
S3B). Indeed, in two sporadic IP females carrying de novo IKBKG
mutations, gene-conversion events were documented [Fusco et al.,
2012a]. In both cases, the father had a benign polymorphism in the
pseudogene (c.1167delC or IKBKGPdel) that perfectly matched the
mutation identified in the affecteddaughters.Thehaplotype analysis
of each member of the family demonstrated that gene-conversion
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Figure 3. A: G-quadruplex predicted structure in the deleted region in mutation c.436_471delinsT. The sequence from chrX:153786774–
153786821 (UCSC Genome Browser on Human Feb. 2009 GRCh37/hg19) on Xq28 chromosome region is shown. The deleted region
is boxed by dashed lines and in box is indicated the nucleotide involved in G-quadruplex structure predicted by QGRS software
(http://bioinformatics.ramapo.edu/QGRS/analyze.php) [Kikin et al., 2006]. The underlined nucleotide indicates the microhomology sequences.
The dashed lines indicate the nucleotides that are predicted to give the secondary structure of single-stranded nucleic acids by using The
mfold Web Server (http://mfold.rna.albany.edu/?q=mfold/dna-folding-form) [Zuker, 2003] and free energy determination is shown (G = −2.99). B:
DNA-replication models able to explain the onset of IKBKG/NEMO c.436_472del/insT. During DNA replication (STEP1), the replication fork can
stall/collapse and FoSTeS Model1 or MMEJ Model2 can occur. FoSTeS Model1 (on the left): the replication fork can stall, an exposed single-
stranded lagging strand template might acquire a secondary structure (G-quadruplex mediated, indicated by DNA hairpin region), which can block
the progress of the replication fork (STEP2). The 3′-end then becomes free from its template and after insertion of novel nucleotide may alight
on another exposed single-stranded template by sharing the microhomology sequences, restarting the replication (STEP3). MMeJ, Model2: the
replication fork can collapse and specific 5′->3′ resection acts (STEP1). The repair of break is mediated byMMEJmechanism (STEP2). The 3′-end of
leading strand may then alight on exposed single-stranded template sequence that shares the microhomology sequence restarting the replication.
Then, the pairing of microhomology sequences stabilizes the broken ends and ligation can occur (STEP3).
events in paternal germline occurred, generating de novo altered
alleles causing IP (Supp. Fig. S5B).
Biological Relevance
Functional Studies of NEMO/IKKgamma Mutant Proteins
Irrespective of the type of IKBKG mutation occurring, X-
inactivation skewing, caused by selection against cells expressing
the mutation, is often observed in blood cells of IP patients [Sebban
and Courtois, 2006]. This aspect of the disease, besides having an
impact upon the phenotype developed by IP patients, impairs any
further functional analysis of IKBKGmutations in cells from female
patients. However, many tools are available to perform molecular
analysis of the impairedNF-kB functiondue to IP-associated IKBKG
mutation.
IKBKG encodes for the NEMO protein (also called IKKgamma),
which has a key role in the NF-kB pathway as a regulatory subunit
of the IKK complex. Among the variety of stimuli and molecules
involved in the activation of the “canonical” NF-kB pathway, the
activation of the IKK complex is required for the IkB inhibitor
proteins (IkBs) phosphorylation and proteasomal degradation. The
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Figure 4. A: Schematic representation of NEMO/IKKgamma protein and the protein domains are shown. B: Dual mode of recognition between
NEMO/IKKgamma and TRAF6. Data gathered from our molecular studies indicate that NEMO/IKKgamma directly interacts with TRAF6 through its
N-terminus and recognizes ubiquitinated (Ub) TRAF6 through its NUB domain. IP-associated E57K and A323P mutations distinctly affect these two
modes of interaction [Gautheron and Pescatore et al., 2010].
freed NF-kB transcription factors move into the nucleus, where
they bind to specific sequences of target genes, encoding essen-
tial proteins for innate and adaptive immunity, inflammation and
cell survival [Hayden and Ghosh, 2012]. NEMO/IKKgamma does
not have enzymatic activity, however, genetic and biochemical ap-
proaches have shown that it is absolutely required for IKK activa-
tion in response to various stimuli. How NEMO/IKKgamma par-
ticipates in IKK activation, however, is still unclear. It is known
that NEMO/IKKgamma can be modified through posttranslational
modifications that regulate its function. They include phosphory-
lation, sumoylation, or nondegradative ubiquitination [Gautheron
and Courtois, 2010]. Adding another level of complexity to the
mechanism(s) of IKK complex activation, NEMO/IKKgamma is
also an ubiquitin-binding protein. It interacts, through its NEMO
Ubiquitin Binding (NUB) domain, with the ubiquitin chain in a
variety of signaling cascades, allowing IKK complex recruitment
through its affinity for Ub chains [Lo et al., 2009; Grubisha et al.,
2010].
IKBKG nonrecurrent rearrangements in IP result in the absence
of NEMO/IKKgamma protein, whereas in recurrent rearrangement
(IKBKGdel), a truncated version of NEMO/IKKgamma (amino acid
1–133) is synthesized, which was revealed byWestern blotting of cy-
toplasmic extracts from primary embryonic fibroblasts of a male
aborted fetus carrying this deletion [Smahi et al., 2000]. Interest-
ingly, few missense mutations of IKBKG have also been identified
as cause of IP, suggesting that distinct molecular abnormalities are
sufficient to generate a fully penetrant disease.
Many data on the functional characterization IKBKG missense
mutations found in EDA-IDmale patients were reported, providing
crucial information on the NEMO-affected interaction in human
disease [Bustamante et al., 2011; Picard et al., 2011]. However, we
will here focus our discussion exclusively on the data obtained by
the analysis of IP-associated IKBKGmissense mutations, as the two
diseases have nonoverlapping clinical presentation.
Several lines of evidence explained the impaired NF-kB signal-
ing as due to incorrect interaction between IP-NEMO mutant and
TRAF6. TRAF6 is a crucial signaling molecule participating in sev-
eral signaling pathways controlling immunity, osteoclastogenesis,
skin development, and brain functions [Wu and Arron, 2003].
TRAF6 works as an E3 ligase responsible for K63-linked NEMO
polyubiquitination, which is essential for signaling downstream the
IL-1/Toll-like receptor superfamily [Sebban et al., 2006]. In this
specific pathway, NEMO is ubiquitinated by TRAF6, in addition
to participating in IKK recruitment. Remarkably, two IP mutations
of NEMO (p.Glu57Lys and p.Ala323Pro) have been characterized
in detail, illustrating the power of using pathology-derived NEMO
mutations to gain insights into the IKK/NF-kB activation process
(Fig. 4) [Sebban-Benin and Pescatore et al., 2007; Gautheron and
Pescatore et al., 2010].
The Alanine 323 to proline (p.Ala323Pro or p.A323P) mutation
of NEMO/IKKgamma, which falls in the proximity of the NUB do-
main, has been identified in a girl suffering from a severe form of IP
[Sebban-Benin and Pescatore et al., 2007]. This NEMO/IKKgamma
mutation caused a major defect in NF-kB activation, not only
downstream of TNFR1 but also in several other signaling path-
ways (such as TNF-, IL-1-, LPS-, and PMA/ionomycin-induced
NF-kB activation) as observed in Nemo(–)cells complemented with
theNEMO/IKKgamma-A323P expressing plasmid. Themechanism
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underlining this ineffectiveness is the reduced binding of A323P–
NEMOtoubiquitinated-TRAF6 and the completely abolished ubiq-
uitination of surrounding lysines. Thus, evidencing that TRAF6
binding and K63-linked polyubiquitination of NEMO/IKKgamma
is a key event in IKK activation whose perturbation may cause hu-
man pathophysiology [Gautheron and Pescatore et al., 2010]. The
combination of genetic and biochemical evidence strongly suggests
that ubiquitin-mediated regulation of IKK activation has a criti-
cal role in human physiology and that its dysregulation can have
devastating consequences [Lo et al., 2009].
Ubiquitin binding and ubiquitination of a protein are of-
ten coupled. Similarly, mutations that affect NEMO/IKKgamma
ubiquitin binding also affect its ubiquitination, making it diffi-
cult to determine whether ubiquitin binding or ubiquitination of
NEMO/IKKgamma is important for IKK activation [Skaug et al.,
2009].
Such a potentially important interaction between NEMO/
IKKgamma and TRAF6 was defined in more detail by uncover-
ing a new binding site at the N-terminus of NEMO/IKKgamma,
recognized by the coiled-coil domain of TRAF6. The p.Glu57Lys
(E57K) mutation of NEMO/IKKgamma, found in a mild form of
IP, resulted in impaired TRAF6 binding and IL-1beta signaling.
These data demonstrate that NEMO/IKKgamma/TRAF6 interac-
tion is a crucial step in signaling and its impairment might trigger
the disease. Moreover, a fragment encompassing amino acid 57–69
of NEMO/IKKgamma is responsible for binding to the CC domain
of TRAF6, which is required for NF-kB activation. The N-ter site of
NEMO/IKKgamma appears to work in concert with the previously
identifiedNUBdomain,which binds polyubiquitinated chains. This
evidence suggested a dual mode of TRAF6 recognition that may
allow the design of positive and negative regulators of NF-kB activa-
tion, with specificity restricted to TRAF6-dependent stimuli, which
uncover many aspect of the IP disease [Sebban-Benin and Pescatore
et al., 2007; Gautheron and Pescatore et al., 2010].
Animal Model of IP
Soon after the genetics study in 2000 from the International In-
continentia Pigmenti Consortium showing that the mutation in the
IKBKG account for the majority of human IP, two reports of mice
with targeted Ikbkg deletions were published [Makris et al., 2000;
Schmidt-Supprian et al., 2000]. As expected, Ikbkg-deficient males
died in utero from liver apoptosis at day E12, and heterozygous fe-
males were viable. These females displayed skin findings strikingly
similar to human IP-lesions on dermatological examination and on
histologic study of skin biopsies.
Most importantly, while 55% of the heterozygous females died
prematurely with a highly runt appearance, the remaining 45%
recovered the cutaneous phenotype that was almost indistinguish-
able from normal age-matched Ikbkg+/+ females. As in human, the
surviving heterozygous females were fertile and could transmit the
disease to their progeny.
Remarkably, similar skin manifestations have also been observed
after invalidating nemo or ikkbeta specifically in the epidermis, using
conditional recombination [Pasparakis et al., 2002; Nenci et al.,
2006]. This suggests that keratinocyte dysfunctionmay be sufficient
to trigger the disease. In both strains of mice, it has been shown
that IL-1beta and TNF-alpha are likely participants in dermatosis
occurrence and development. At very early stages (P2/P3), before
detecting any skin abnormalities, an increase of IL-1beta synthesis
was observed in the epidermis. Interestingly, such accumulationwas
not seen with ikkbetaKO keratinocytes cultured ex vivo. Later on, at
P4/P7, an accumulationofTNF-alfa in the dermiswas detected. This
cytokine plays a key role in the dermatosis process since crossing the
mice with tnfr-1 KO mice abolishes all its manifestations.
On the cellular side, keratinocytes (detailed above), and
macrophages [Stratis et al., 2006] appear to play an important func-
tion in IP dermatosis, whereas B and T lymphocytes are not nec-
essary. From these observations, it has been proposed that the mo-
saic status of the neonatal skin/epidermis of IP females, composed
of cells expressing either wild-type or mutant NEMO/IKKgamma,
might be a trigger for the whole dermatosis process. Mutant cells,
most likely keratinocytes, for reasons that are not yet clear, would
start to overexpress pro-inflammatory cytokines such as IL-1 after
birth. Then, IL-1beta would induce TNF-alfa synthesis by neighbor-
ing wild-type cells, and this cytokine would in turn act on mutant
NEMO/IKKgamma-expressing cells, inducing their death and clear-
ance. This sequence of events may explain the final atrophic stage of
IP dermatosis linked to lesion disappearance.
TNF- and IL1-mediated inflammation is an essential compo-
nent of the disease. Therefore, the NEMO/IKKgamma-dependent
molecular principles that enable the correct functioning of these
NF-kB-independent signaling pathways implicated in the induc-
tion of the inflammatory reaction might mediate the triggering of
the disease. The identification of player in this signaling will pro-
vide putative targets for an early pharmacological treatment of the
disease.
Clinical and Diagnostic Relevance
Differential Diagnosis in IP
The diagnosis of IP is fairly easy in the presence of classical fea-
tures, but can be difficult in cases with partial or nonclassical clinical
features, especially in the parents. The demonstration that the dis-
ease is caused by mutations in IKBKG, has remarkably improved
genetic counseling for this disorder and the ability to identify addi-
tional signs of the disease, which were previously neglected due to
the uncertainty of the IP diagnosis [Fusco et al., 2012b].
The most severe consequences of IP, leading to major morbid-
ity and even mortality, are those affecting the CNS, awareness of
which has significantly increased due to the improvement of the
method of molecular diagnosis, and has encouraged the epidemio-
logical data collection of IP. Currently, in systematic review among
795 neurologically investigated IP patients, the presence of CNS
anomalies is reported in 30.44% of the IP patients, most of them
(61.98%) suffered from severe CNS anomalies [Minic´ et al., 2013a].
The most frequent types of CNS anomalies were seizures, motor
impairment, and mental retardation, microcephaly, and rare or
unclassified anomalies [Minic´ et al., 2013a]. In analyzed 139 IP
patients, the first neurological manifestations occurred in the first
week (58.3%), in the first month of life (66.9%), and in the first year
(87.8%) of IP patients [Minic´ et al., 2013a]. In 89 IP patients, the
most frequently registered CNS lesions found using brain imaging
methods were brain infarcts or necrosis, brain atrophies, corpus
callosum lesions, and rarely diagnosed or unspecified CNS lesions
[Minic´ et al., 2013a]. For the time being, there are several hypothesis
explaining pathogenesis of CNS manifestations in IP: apoptosis of
neurons and glia cells [Aradhya et al., 2001c], apoptosis of CNS vas-
cular cells [Minic et al., 2013a], disorder of myelinization [Philippe
et al., 2013], influences of IKBKG genemutation onVEGF [Aradhya
et al., 2001c], and eotaxin expression [Jean-Baptiste et al. 2002].
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Currently, no specific treatment is available for IP neurological
symptoms and the seizure is treated as in other infantile seizure
forms [Scheuerle and Ursini, 2010].
Genotype–Phenotype Correlation in IP
The clinical phenotype of IP is widely variable, even within the
same family. It can range from mild skin alterations (mild IP) to
stroke and functional CNS abnormalities (severe IP) [Fusco et al.,
2004].
Abundant data show that the same IKBKGmutation (IKBKGdel)
might produce mild IP in the mother and severe IP in the daughter
in the same family. It has been assumed that such heterogeneity is
due to an X-inactivation in heterozygous IP females, coupled with
the pleiotropic role of the NEMO. Because the NEMO/IKKgamma
protein is involved in a complex signaling pathway that regulates
the expression of hundreds of genes, its mutation produces dif-
ferent phenotypic outcomes and may explain the entire spectrum
of anomalies seen in IP [Nelson, 2006]. Moreover, as observed in
many Mendelian diseases, additional genetic factors, as modifier
genes, might in part explain the differences in disease expression in
patients carrying the same IKBKGmutation (IKBKGdel) in different
genomic backgrounds.
At the milder end of the disease spectrum, we would expect
to find patients who carry missense mutations that only slightly
affect NEMO/IKKgamma function. However, the missense mu-
tations are very few in IP thus impairing any statistical analysis
of genotype–phenotype correlation. Nevertheless, for those IKBKG
missensemutations with establishedNF-kB signaling defect, at least
a partial genotype–phenotype correlation can be drawn. The spec-
trum of clinical outcome may range from very severe phenotype as
in the case of p.Ala323Promutation, which caused a generalized im-
pairment of NEMO/IKKgamma activity affecting many triggering
signaling, to very mild form of IP such as the case of p.Glu57Lys,
which presented only an IL-1-specific impairment in vitro. There-
fore, we might tentatively conclude that the variability in IP clinical
outcomewould then result from a combination of the type ofmuta-
tion, the functional domain affected, X-inactivation, and eventually,
the genomic background.
Molecular Diagnostic Strategies in IP
Twelve years of genetic analysis of IP have produced the important
assumption that IP belongs to the class of pathologic conditions
known as genomic disorders, and that the IKBKG IP locus must
be considered a genomic instability region linked to an inherited
disease [Fusco et al., 2012a].
As the consequence of this assumption, centers involved inmolec-
ular diagnosis of IP have improved their general ability to perform
an IP molecular diagnosis, by applying a three-step protocol for the
molecular identification of IKBKGmutation: (1) recurrent deletion,
(2) small exonmutations (indel), and (3) nonrecurrent deletions, at
the IP locus. Collectively, this analysis has revealed a IKBKG muta-
tion in 88% of IP patients (recurrent deletion in 72%, nonrecurrent
deletions in 4%, and small indel/missense in 12%), whereas the re-
maining 12% of IP patients do not have any identifiable alterations
of the IKBKG gene. Given that IKBKG gene mutations are consid-
ered the only genetic cause of IP, we cannot definitively exclude that
unexplored regions in the IP locus could have alterations causing
IP in the remaining 12% of patients. Moreover, as in about 76%
of IP patients, the genetic defect is a copy-number loss of IKBKG
paralogous copies, a step of quantitative analysis of IKBKG copies
should be introduced as routine screening in IPmolecular diagnosis
[Fusco et al., 2012b].
Future Prospects
Here, we have presented a review of past and present findings
on the IKBKG mutations by exploring with a high accuracy both
genomic context in which the mutations occur and the functional
effects on the mutated proteins. To these ends, we have compiled a
collection of data on published and previously unreported IKBKG
mutations associated with IP disease.
The availability of amore extensive description of the clinical phe-
notype of IP patients, together with their mutational genotype as
reported in the IKBKG-LOVD database, might provide insight into
genotype–phenotype correlation. Moreover, genetic studies enable
us to understand different mechanisms of mutagenesis that char-
acterize IP to apply this knowledge in genetic diagnosis of disease.
On the other hand, further elucidation of the function of selected
IP-associated IKBKGmutants in several cell lines will provide essen-
tial information on the role and on activity of NEMO/IKKgamma
that could suggest new targets for the development of therapeutic
strategies.
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3.3 Unraveling the Link Between Ectodermal Disorders and Primary  
Immunodeficiencies 
 
Since both epidermal and thymic epithelium have ectodermal origin, skin abnormalities may 
represent warning signs of PIDs. This review, published on International Review of 
Immunology, will be focused on PIDs associated to skin and skin annexa abnormalities, 
highlighting the alarm signs that should lead the clinician to consider a deeper immunological 
assessment, investigating both molecular and functional aspects. This approach would be 
very helpful in the early detection and treatment of very complex disorders. In particular, 
ectodermal dysplasia, hyper IgE syndromes and Nude/SCID syndrome will be discussed.  
Conclusive remarks 
The association between developmental abnormalities of the skin and immunodeficiencies 
suggest a role of the skin as a primary lymphoid organ. In support of this hypotesis, there is 
the evidence that human skin-derived keratinocytes and fibroblasts, are able support the in 
vitro differentiation into T-lineage committed cells, in the absence of thymic components. 
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Unraveling the Link Between Ectodermal Disorders
and Primary Immunodeficiencies
Roberta D’Assante, Anna Fusco, Loredana Palamaro, Giuliana Giardino,
Vera Gallo, Emilia Cirillo, and Claudio Pignata
Department of Translational Medical Sciences, Federico II University, Naples, Italy
Primary immunodeﬁciencies (PIDs) include aheterogeneousgroupofmostlymonogenic diseases
characterized by functional/developmental alterations of the immune system. Skin and skin an-
nexa abnormalitiesmaybe awarning sign of immunodeﬁciency, since both epidermal and thymic
epitheliumhave ectodermal origin. In this review,wewill focus on themost common immunedis-
orders associated with ectodermal alterations. Elevated IgE levels represent the immunological
hallmark of hyper-IgE syndrome, characterized by severe eczema and susceptibility to infections.
Ectodermal dysplasia (ED) is a group of rare disorders that aﬀect tissues of ectodermal origin. Hy-
poidrotic ED (HED), themost common form, is inherited as autosomal dominant, autosomal reces-
sive or X-linked trait (XLHED). HED and XLHED are caused bymutations inNEMO and EDA-1 genes,
respectively, and showsimilarities in the cutaneous involvement but diﬀerences in the susceptibil-
ity to infections and immunological phenotype.Alterations in the transcription factor FOXN1gene,
expressed in themature thymic and skin epithelia, are responsible for human andmurine athymia
and prevent the development of the T-cell compartment associated to ectodermal abnormalities
such as alopecia and nail dystrophy. The association between developmental abnormalities of the
skin and immunodeﬁciencies suggest a role of the skin as a primary lymphoid organ. Recently, it
has been demonstrated that a co-culture of human skin-derived keratinocytes and ﬁbroblasts, in
the absence of thymic components, can support the survival of human haematopoietic stem cells
and their diﬀerentiation into T-lineage committed cells.
Keywords: ectodermal dysplasia, FOXN1, hyper-IgE, primary immunodeﬁciencies, T-cell
development
INTRODUCTION
Primary immunodeficiencies (PIDs) include a heterogeneous group of diseases,
mostly monogenic, which are characterized by functional/developmental alterations
of the immune system. In the last decades, the field of PID has been deeply studied,
eventually leading to an overall better knowledge and nosografic re-classification of
the different forms so far identified. In particular, several novel forms have been de-
scribed unraveling new clinical and genetic aspects. Nevertheless, it has been docu-
mented that an inappropriate or late diagnosis of PID by clinicians often occurs, thus
indicating the strong need of an update on the novel clinical associations of different
forms and alarm signals. An overview on this topic would favor an early diagnosis.
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 R. D’Assante et al.
Recent evidence highlights that the skin participates in a host defenses either act-
ing as a primary boundary for germs, as the principal site of environment–host inter-
actions, or directly in the developmental process of the immune system. As a matter
of fact, skin and skin annexa abnormalities, such as skin dryness, brittleness of hair,
nail abnormalities and abnormal dentition, can be not infrequently associated with
distinct forms of immunodeficiency.
In this review,wewill focus on the link between skin developmental alterations and
PIDs that could help in the early detection of some immunologic disorders.
ECTODERMAL DYSPLASIA AND IMMUNE DEFECTS
Ectodermal dysplasia (ED) is a groupof rare inheriteddisorders that affect twoormore
tissues of ectodermal origin. Ectodermal dysplasia has an incidence of seven cases
per 10,000 live births and to date nearly 200 different forms of ectodermal dysplasia
have been described.Themain abnormalities involve the skin, whichmay be dry, thin
and hypopigmented, and prone to rashes, eczema or infections. Furthermore, sweat
glandsmay functionabnormally, ormaynotdevelopat all, andhair isusuallyhypopig-
mented, thin and sparse.
Theabnormal sweatproductionmay impairbody temperaturecontrol, thus leading
to overheating, especially in hot environments. Airways seromucous glands may also
beaffectedpredisposing to respiratory infectionsbecauseof theabsenceof thenormal
protective secretions of the mouth and nose. Defect in meibomian/tarsal glands may
lead to dryness of the eye, cataracts, and vision defects. Teethmay be congenitally ab-
sent, peg-shaped or pointed.The enamel may also be defective. Typical cranial-facial
features include frontal bossing, longer ormore pronounced chins andbroader noses.
Abnormalities in the ear development may cause hearing problems.
Hypoidrotic ED (HED) is themost common formwith an incidence of 1:10,000 [1].
This form is inherited as an autosomal dominant (AD), autosomal recessive (AR) or
X-linked trait (XLHED). HED derives from mutations in the ectodysplasin-A (EDA)
signaling pathway, which leads to the expression of genes implicated in the develop-
ment of the skin and skin appendage. Mutations in the EDA gene on X-chromosome
cause approximately 80% of cases of HED (OMIM 305100, XLHED, ectodermal dys-
plasia, type 1, ED1). A smaller subset of cases is caused by mutations in the EDA re-
ceptor (EDAR), the adapter protein (EDARADD), or WNT10A [2, 3], being inherited
in an autosomal recessive (ectodermal dysplasia anhidrotic; EDA; OMIM 224900) or
autosomal dominantmanner (ectodermal dysplasia type 3; ED3;OMIM129490). EDA
regulates organogenesis atmultiple levels, from the initiation to the terminal differen-
tiation [4, 5]. The activation of EDA pathway is implicated in the appearance of focal
thickenings of the epithelium known as placodes, implicated in the very early stage
of skin appendage development. EDA gene is a member of the TNF superfamily. EDA
ligand binds to the trimeric EDAR receptor, which, in turn upon binding, recruits the
EDARADDadaptor via death-domain–death-domain interactions.This cascade, from
EDAandEDAR to EDARADD, leads to the activation of theNF-kBpathway. In unstim-
ulated cells, NF-kB is sequestered in the cytoplasm by the inhibitor of the kBproteins
(IkB). NF-kB essential modulator (NEMO), also called IkB Kinase (IKK) gamma pro-
tein, acts as a regulatory subunit of the IKK complex, comprising two kinase subunits
(IKK1/a and IKK2/b), required for the activation of canonical NF-kB pathway. Upon
stimuli, IkB is phosphorylated by the IKK, resulting in IkB degradation, NF-kB translo-
cation into the nucleus, and eventually regulation of the target gene expression [6].
Hypomorphic mutations in the NEMO encoded by the IKBKG/NEMO gene on the
X-chromosome result inHEDwith immunodeficiency (HED-ID,OMIM300291) [7–9].
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Ectodermal Disorders and PIDs 
In spite of the similarity of the cutaneous involvement, difference in the suscepti-
bility to infections and in the immunological pattern between HED-ID and XLHED
patients is well documented. Due to the pleiotropic role of NEMO, mutations in IK-
BKG/NEMO gene lead to a heterogeneous and severe immunodeficiency. In patients
with XLHED, immunologic alterations have never been reported. However, in these
patients recurrent bronchial or eye infections have been described and interpreted
as a result of reduced bronchial or meibomian/tarsal gland function. The difference
between HED-ID and XLHED immune defect may rely on the distinct pathways in
which NEMO and EDA-1 are involved. In fact, while both molecules are involved in
the ectodysplasin pathway, thus explaining the similarity in the cutaneous involve-
ment,NEMO is also involved in signalingpathwaysdownstream todifferent receptors,
including toll-like (TLRs), interleukin-1 (IL-1Rs), tumor necrosis factor (TNFRs), and
B- and T-cell receptors (TCR and BCR).The participation of NEMO in these pathways
explains the wider immune defect in HED-ID and its complexity. HED-ID is charac-
terized by unusually severe, recurrent, and sometimes life-threatening bacterial infec-
tions of the lower respiratory tract, skin, soft tissues, bones and gastrointestinal appa-
ratus as well as meningitis and septicemia in early childhood. These patients display
high susceptibility to infections by Gram-positive bacteria (S. pneumoniae and S. au-
reus), followed by Gram-negative bacteria (Pseudomonas spp. and Haemophilus in-
ﬂuenzae) andmycobacteria, as well.
Laboratory features include hypogammaglobulinaemia with low serum IgG (or
IgG2) levels, and variable levels of other immunoglobulin isotypes (IgA, IgM and IgE).
Elevated serum IgM levels have been described in a number of HED-ID patients with
the hyper-IgM6 phenotype [10, 11]. In some patients, a defective ability of B cells to
switch in response to CD40 ligand (CD40L) has been described, which may help ex-
plain the hyper-IgM phenotype. Defective antibody response to polysaccharide and
proteic antigens is the most consistent laboratory feature. Recently, impaired NK ac-
tivity has also been reported in some [12] but not all [13] patients with EDA-ID. NEMO
also acts downstream to TLRs [13–15]. As a consequence, NEMOpatients exhibit poor
inflammatory response, also due to impaired cellular responses to pro-inflammatory
cytokines (IL-1β, IL-18 andTNF-α) [15]. Impaired IL-1β- and IL-18-dependent induc-
tion of IFN-γ , impaired cellular responses to IFN-γ -inducible TNF-α, and impaired
signaling through TLRS may explain the occurrence of severe mycobacterial disease
in these patients.
DifferentNEMOmutations have also been associatedwithdistinct disorders.While
loss-of-function mutations cause incontinentia pigmenti (IP), hypomorphic muta-
tions cause two allelic conditions, namely HED-ID and a clinically more severe
syndrome, in which osteopetrosis and/or lymphoedema associate with HED-ID (OL-
HED-ID; MIM 300301). Mutations in the coding region are associated with the HED-
ID phenotype (MIM 300291), while stop codon mutations cause a OL-HED-ID [11,
16–21]. IP (OMIM#308300), which specifically affects females, being lethal in males
[22], is caused by a complex rearrangement of NEMO gene that results in the dele-
tion of exons 4–10, coding for a shortened protein unable to elicit an NF-κB response.
This recurrent rearrangement accounts for 85%of IP patients [16, 17]. Affected females
present with Blashko linear skin lesions [23] variably associated with developmental
anomalies of teeth, eyes, hair and the central nervous system.
Mutations in other genes involved in NF-κB pathway are responsible for different
forms of HED-ID. Gain-of-function mutations of IκBα are able to enhance the in-
hibitory capacity of IκBα through the prevention of its phosphorylation and degra-
dation, and result in impaired NF-κB activation leading to HED-ID.The developmen-
tal, immunologic and infectiousphenotypes associatedwithhypomorphicNEMOand
hypermorphic IKBA mutations largely overlap and include EDA, impaired cellular
Copyright C© Informa Healthcare USA, Inc.
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TABLE 1. Clinical and immunological features of hyper-IgE syndrome (HIES).
Immunodeficiency Gene Immunological phenotype Clinical features OMIM
HIES-AD STAT3 ReducedTh17
lymphocytes; reduced
specific antibody response;
reduced switched and no
switched Bmemory
lymphocytes
Facial anomalies, eczema,
osteoporosis and
pathological fractures, teeth
anomalies, joint laxity,
Stafilococcus aureus
infections (pulmonary and
cutaneous abscesses,
pneumatocele), candidiasis
#147060
HIES-AR TYK2 Altered cytokine signaling Increased susceptibility to
fungi, viruses and
intracellular bacteria
(mycobacterium, salmonella
spp.)
#611521
DOCK8 Reduced T, B and NK cells,
hyper-IgE, reduced IgM
levels
Severe atopy,
hypereosinophilia, recurrent
infections, severe viral and
bacterial cutaneous
infections, predisposition to
cancer
#243700
responses to ligands of TIR (TLR-ligands, IL-1β and IL-18), and TNFR (TNF-α,
LTα1/β2 and CD154) super family members leading to severe bacterial diseases.
Recently, mutations in NF-kB2 gene have been described as responsible for the
early onset of common variable immunodeficiency, inherited as an autosomal domi-
nant trait. In the cases so far identified, ectodermal abnormalities, including nail dis-
trophy and alopecia together with endocrine alterations, have been reported.
PRIMARY IMMUNODEFICIENCIES WITH HYPER-IgE
Elevated IgE levels represent the immunological hallmark of a growing group of PID
termed as hyper-IgE syndrome (HIES). The clinical phenotype of these syndromes,
along with very high IgE levels (>2000 IU/L), comprises severe eczema and suscepti-
bility to a spectrum of infections, especially staphylococcal and fungal infections, in-
volving the skin and lungs. These disorders can be inherited in an autosomal domi-
nant or autosomal recessive manner (Table 1). Sometimes, sporadic cases have been
described. It isn’t always easy to differentiate the syndromes from the severe forms of
atopic dermatitis, in which high levels of serum IgE, and sometimes viral or bacterial
infections, could also occur, since the complete clinical phenotype of HIES often be-
comes evident only over years. This may cause delay in diagnosis, especially in those
patients who have milder forms of the disease.
In 2007, Holland et al. [24] found that hypomorphicmutations of signal transducer
and activator of transcription 3 (STAT3) gene are responsible for the autosomal dom-
inant form of HIES, characterized by the classic clinical triad represented by recurrent
cutaneous “cold” abscesses, recurrent pulmonary infections and increased concen-
tration of serum IgE. Such triad is present in 75% of autosomal dominant cases and
in 85% of children with a disease onset before 8 years of age. In many cases, eczema,
often with a neonatal onset, is the first sign of the disease.
In the patients with a STAT3 defect, in addition to Staphylococcus aureus,
often methicillin-resistant, infections with other pathogens, such as Haemophilus
influenzae and Streptococcus pneumonia, may also be found. Moreover, the recur-
rent sinopulmonary infections, through the formation of bronchiectasis and some-
International Reviews of Immunology
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Ectodermal Disorders and PIDs 
times pneumatoceles, represent predisposing factor to colonization by opportunistic
agents such as Pseudomonas aeruginosa and Aspergillus fumigatus, with the risk of
developing invasive aspergillosis and systemic fatal infections. Another frequent in-
fection is chronic mucocutaneous candidiasis and, to a lesser extent, Pneumocystis
jirovecii lung infection. In addition, other fungal pathogens, including Histoplasma,
Coccidioides and Cryptococcus, have been reported to cause gastrointestinal infec-
tions as well as meningitis in patients with HIES [25]. This increased susceptibility to
infections is due to the impairment of Th17-cell function through the alteration of
signaling mediated by various cytokines, and in particular IL-6 and IL-22 [26]. Be-
yond the immunological and infectious features, patients also exhibit different non-
immunological features, including craniofacial, neurological, dental, vascular and
musculoskeletal anomalies.
In 2004, Renner et al. [30] have described the case of a novel form of HIES, sharing
some of the clinical features of the AD-HIES, but with an AR inheritance and a differ-
ent profile of susceptibility to infections. In addition, these patients have a neurolog-
ical involvement and a high predisposition to autoimmunity and proliferative disor-
ders. The genetic defect was first identified in 2006, with the recognition of mutations
in the TYK2 gene [27]. In particular, the patient suffering from this variant showed al-
terations of the signaling pathway mediated by IFNα, IL-6, IL-10, IL-12 and IL23, re-
sulting in an impairment of both innate and adaptive immunity.The TYK2 deficiency
remains, however, a very rare form, whose clinical features are still controversial, as
demonstrated from the description of the second case, with very different clinical pre-
sentation, characterized by disseminated BCG infection, recurrent zoster and neuro-
brucellosis in the absence of high levels of IgE [28].
On the other hand, many cases of AR-HIES have been ascribed to alterations in
the DOCK8 gene, which encodes a protein involved in the regulation of cytoskele-
ton [29]. Patients with DOCK8 deficiency show a more severe phenotype than AD-
HIES patients, characterized by severe viral infections primarily involving the skin
(HPV, VZV, MCV), recurrent bacterial infections, severe atopy and high risk of early
onset malignancies to the extent of 10–36% of patients. Notably, DOCK8 deficiency
may be associated with IgE levels within the normal range or only moderately ele-
vated as compared with AD-HIES form. In addition, AR-HIES patients do not display
somatic features, such as dental abnormalities, craniofacial or skeletal abnormalities,
compared with the STAT3-dependent AD-HIES [30]. Eventually, neurological mani-
festations, such as facial paralysis, hemiplegia, cerebral aneurisms, andCNS vasculitis
have been observed [30]. Within the malignancies, HPV-associated carcinomas, EBV-
associated Burkitt lymphoma and diffuse large B cell lymphoma clearly predominate,
not infrequently with an onset during the childhood [31].
A recent study described the case of a patient with Olmsted Syndrome due to tran-
sient receptor potential cation channel, subfamily V, member 3 (TRPV3) gene mu-
tations, characterized by hyperkeratotic cutaneous lesions and palmoplantar kerato-
derma associated with a peculiar immunological and infectious phenotype charac-
terized by high IgE levels, recurrent hypereosinophilia, increased IgA levels, reduced
IgG3 subclasses and frequent skin infections sustained by bacteria and fungi, particu-
larly by Candida albicans.The clinical phenotype is highly suggestive of a primary role
of TRPV3 gene, which is expressed in keratinocytes and langerhans cells of the skin in
the immune response [32].
As amatter of fact, elevated serum IgE levels, although at a lower extent than HIES,
are often found in many other PIDs, including Omenn Syndrome, due to hypomor-
phic mutations of RAG1, RAG2, ARTEMIS, ADA and RMRP genes; Wiskott–Aldrich
Syndrome due to mutations in the WAS gene; atypical DiGeorge Syndrome
with deletion of chromosome 22q11.2; IPEX Syndrome (immuno-disregulation,
Copyright C© Informa Healthcare USA, Inc.
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polyendocrinopathy, enteropathy, X-linked) caused by mutation of the FOXP3 gene
and finally, Comel–Netherton Syndrome due to defect of SPINK5 (Table 2) [33]. Each
of thesedisorders showsapeculiar clinical phenotype that stronglydistinguishes them
from the classical forms of HIES. Such a strong association between the number of
PIDs, whichever is the form, and the elevated IgE levels, would argue in favor of a still
unappreciated biologic role for IgE in these patients and, in general, in the immune
system physiology.
NUDE/SCID PHENOTYPE
Ectodermal Disorders and FOXN1 Transcription Factor
As previouslymentioned, ectodermal dysplasias include disorders sharing abnormal-
ities of the skin, its appendages, such as hair, nails, teeth, sweat glands and seba-
ceous glands, and of other organs, which develop from ectoderm, such as the nervous
system, the lens of the eye, and the mammary glands. These disorders may appear
separately or together with other clinical manifestations involvingmesoderm and en-
doderm [7]. Due to the huge number of different ectodermal dysplasias, there is a re-
markable overlapping of clinical phenotypes.
A few overlapping signs with ectodermal dysplasia, associated with immunologi-
cal abnormalities, are found in immunodeficiencies, such as those caused by the al-
terations of the NEMO gene [34], and of the RNA component of mitochondrial RNA
processing endoribonuclease gene (RMRP), responsible for cartilage hair hypopla-
sia syndrome [35], or the FOXN1 gene, the latter being responsible for the human or
murine athymia, associatedwith the skin andhair defects, and, putatively, neural tube
abnormal development [36, 37]. FOXN1 gene is a “winged helix” transcription factor
belonging to the forkhead-box gene family, which comprises genes implicated in a va-
riety of cellular processes, such as development, metabolism, cancer and aging [38].
These transcription factors are developmentally regulated and direct tissue-specific
transcriptionandcell fatedecisions. In thepre-natal life,FOXN1 is expressed in several
mesenchymal and epithelial cells, including those of the liver, lung, intestine, kidney,
and urinary tract, while in the post-natal life FOXN1 is expressed only in the epithelial
cells of the skin and thymus. In the epidermis, FOXN1 is expressed within differenti-
ated epidermal and follicular cells. Differently, in the thymus, FOXN1 acts early in the
organ development, promoting TEC progenitor proliferation and directing specifica-
tion of thymic epithelial precursor cells to cortical andmedullary lineages [39–42].The
tissue specificity expression of FOXN1 is probably due to the presence in its sequence
of two exons, exons 1a and 1b, that undergo to alternative splicing to either of the two
splice acceptor sites of the exon 2.The alternative usage of exon 1a or 1b is due to the
presence of distinct promoters: promoter 1a, which is active in both the thymus and
the skin, and promoter 1b, which is active only in the skin [43].
The Nude/SCID Syndrome and Its Associated Skin Abnormalities
ThehumanNude/SCID syndrome is characterized by the absence of a functional thy-
mus,which results in a severeT-cell immunodeficiency [36].This phenotype is thefirst
example of SCID due to mutations of gene not expressed in hematopoietic cells [44].
Studies performed on human Nude/SCID fetus have added novel information
on T-cell development in humans and, in particular, on the crucial role of FOXN1
in early prenatal stages of T-cell ontogeny in humans. FOXN1 gene mutations pre-
vent the development of the T-cell compartment, affecting the CD4+ cells more than
the CD8+ ones, as early as at 16 weeks of gestation [45]. Of note, in the absence of
FOXN1, the thymic functionality is almost absent, as demonstrated by the absence of
CD4+CD45RA+ naive cells [45]. However, very few CD3+CD8+CD45RA+ naive cells
International Reviews of Immunology
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can be detected in the peripheral blood. Most of the T-cells bear TCRγ δ instead of
TCRαβ [45] and, although altered, the TCR gene rearrangement occurs in the absence
of the thymus, suggesting an extrathymic site of differentiation for TCR chains, which
isFOXN1-independent. Indeed, recent evidence suggests that, during embryogenesis,
in the absence of FOXN1, a partial T-cell development can occur at extrathymic sites
[46].
TheNude/SCIDsyndrome ismore severe than theDiGeorgeSyndrome, an immun-
odeficiency due to a complete or partial absence of the thymus, not associated with
hairlessness or gross abnormalities in skin annexa. Peculiar features of theNude/SCID
syndrome are ectodermal abnormalities, such as alopecia andnail dystrophy [47].The
first identifiedmutation of FOXN1 gene responsible in homozigosity for the disease is
the C-to-T shift at 792 nucleotide position in the exon 4 (formerly exon 5) of the cDNA
sequence. This mutation results in a non-sense mutation (R255X) and the complete
absence of protein [48]. The second one, described in a French patient, is the C987T
transition in exon 6, resulting in a mis-sense mutation (R320W) of the DNA binding
domain [49]. A third novel mutation in FOXN1, resulting in TlowB+NK+SCID with
alopecia [50] has been described recently.
Thefirst twopatients, identifiedbyPignata et al., in 1996,were two sisterswithT-cell
immunodeficiency and alopecia of the scalp, eyebrows, eyelashes and nail dystrophy
[36]. Alopecia and nail dystrophy are also the characteristics of dyskeratosis congenita
(DC) [51, 52], whose diagnostic criteria include a reticular pattern of hyper- and hypo-
pigmentation of the skin, nail dystrophy, and mucosal leucoplakia [53]. However, in
the two patients described, two diagnostic criteria of DC (abnormal pigmentation
of the skin and mucosal leucoplakia) were lacking. Moreover, also the immunologic
abnormalities were different from those associated with DC [54, 55].
The causal relationship between alopecia, nail dystrophy, and immunodeficiency
does exist in Nude/SCID patients, and is also found in athymic mice that completely
lack body hair (Table 3). Mice homozygous for the FOXN1 mutation have retarded
growth, decreased fertility, die of infections and are hairless (from which the term
“nude” derived).The hairless feature is due to an abnormal epidermal developmental
process, since in the skin of the nude mouse there are a normal number of hair fol-
licles but not capable to enter the skin surface [56, 57]. In addition, the epidermis of
the nudemouse fails to differentiate the spinous, granular and basal layers and shows
a reduced number of tonofilaments. As in humans, also in mice the thymus is absent
at birth [58], thus leading to a profound T-cell deficiency, which also affects humoral
immunity. Of note, in a few strains of nude mice, alterations of digits and nails have
been reported.
In 1999, a screening search for this FOXN1 mutation in order to provide genetic
counseling and prenatal diagnosis support to the community where the first patients
were identified, led to the identification of healthy subjects carrying the heterozygous
FOXN1 mutation. These subjects were further examined for ectodermal alterations
and showed nail abnormalities, such as the koilonychia (spoon nail), characterized
by a concave surface and raised edges of the nail plate and the canaliform dystrophy
associated to a transverse groove of the nail plate (Beau line), and the leukonychia
(half-moon), characterized by a typical arciform pattern involving the proximal part
of the nail plate [47]. This is not surprising, since FOXN1 is selectively expressed in
the nail matrix where the nail plate originates, and where it is involved in the matu-
ration process of nails. In keeping with the expression of FOXN1 in the murine ep-
ithelial cells of the developing choroids plexus, a structure filling the lateral, third, and
fourth ventricles, additional studies revealed, in humanNude/SCID aborted fetus, the
presence of severe neural tube defects, including anencephaly and spina bifida. How-
ever, since the anomalies of brain structureshavebeen reportedonly inconstantly, this
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Ectodermal Disorders and PIDs 
TABLE 3. Main similarities shared between humanNude/SCID andmurine “nude” phenotype.
Human Nude/SCID Nudemouse
Clinical features
Thymus absence + +
Retarded growth + +
Omen-like syndrome + -
Severe infections + (interstitial pneumopathy) +
Neural tube defects + (anencephaly and spina bifida) -
Severe infertility Unknown +
Small ovaries with low eggs
count (female)
Unknown +
Motile sperm absence
(male)
Unknown +
Altered serum levels of
estradiol, progesterone
and thyroxine
Unknown +
Immunological features
Presence of normal T-cell
precursors
+ +
Lymphopenia + (T-cells) + (T-cells)
Absence of specific
thymus-derived cells
+ +
Absence of proliferative
response to mitogens
+ +
Very few lymphocytes in
the thymus-dependent
areas of the spleen and the
lymph node
+ +
Presence of antibody
forming cell precursors
+ +
Low levels of serum
immunoglobulins
+ +
Very low/absent
production of specific
antibodies
+ +
Skin and skin annexa
features
Hairlessness + (alopecia of the scalp, eyebrows and eyelashes) +
Alterations of digits and
nails
+ (leukonychia, koilonychias, canaliform dystrophy) +
Unbalance between
proliferation and
differentiation of
keratinocytes in the hair
follicle
+ +
Coiling of incomplete hair
shafts in the dermis
+ +
would suggest that FOXN1 plays a role of a cofactor only in brain development during
embryogenesis [37].
SKIN ELEMENTS TO SUPPORT T-CELL ONTOGENY
Given the association between skin developmental alterations and immunodeficien-
cies, a possible explanation is that a remarkable number of similarities are shared
between the epidermal and the thymic epithelium. Similarities between the human
thymic epithelial cells (TECs), a key cell component of the thymic stroma, and human
Copyright C© Informa Healthcare USA, Inc.
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 R. D’Assante et al.
FIGURE 1. Representative scanning electron micrographs of keratinocytes and fibroblasts co-
cultured on the PCL scaffold. Expanded fibroblasts and keratinocytes were seeded together onto
artificial 3D PCL scaffolds, and after cell infiltration, the structure was studied by scanning electron
microscopy (SEM). (A) Each cell type established physical contacts with the PCL scaffold and orga-
nized on the surface of its inner pores. (B) In particular, a strong interaction of keratinocytes with
fibroblasts occurred. (C and D) Fibroblasts formed focal adhesions with the matrix, thanks to their
thin filopodi (D). After 3 weeks of culture, interaction of each cell type with material (E) and with
each other (F) was clearly visible.
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Ectodermal Disorders and PIDs 
keratinocyteswere identified through comparison of gene andprotein expression and
in vitro analysis [59, 60]. The development of both epidermal and thymic epithelium
requires the expression of p63, the p53 family transcription factor [61–63], which was
earlier expressed in the development of both epithelial lineages [63–65]. Epidermal
development is abrogated in mouse models with the loss of p63 function, resulting
in few keratinocytes and lack of stratification, which causes rapid dehydration and
early postnatal lethality of these mice [66, 67]. A similar epithelial phenotype occurs
in p63−/−mice’s thymus, which showed defects in the proliferative rate of TECs that
leads to thymic atrophy.
Along with FOXN1, another transcription factor is shared between epidermal pro-
genitor cells in the epidermis and the thymus, the T box gene Tbx1. The absence of
Tbx1 results in the loss of hair follicle stem cell renewal in the epidermis [68], and in
the loss of thymic epithelial development [69–71]. Furthermore, thymic stroma and
skin elements also share the Notch pathway, which plays an important role in the reg-
ulation of epidermal differentiation [72]. Within the thymus, it is necessary for T-cell
linage commitment and the early stage of thymocyte maturation [73].
A major regulator of both hair follicle placode formation and thymic epithelial de-
velopment is the fibroblast growth factor (FGF) signaling pathway [74, 75]. Several
studies revealed the importance of FGFsmesenchymal expression to promote epithe-
lial proliferation and invagination to generate mature thymic rudiments and epider-
mal hair placodes [76, 77].
Additional similarities between the twoorgans concern the cellular organization, in
that medullary TECs are able to formHassall’s corpuscles, following a developmental
program, analogous to skin epidermal basal cells, which form cornified cells [60]. Fur-
thermore, proliferating TECs, derived from rats transplanted into the skin, formed epi-
dermis and skin appendages such as the sebaceous gland and hair follicle [61], high-
lighting the responsiveness of TECs to the skin tissue environment.
Thus, although the functionsof the skinand thymic epithelial components arequite
distinct, both tissues have primary roles in establishing immunity [78]. TECs create an
environment that promotes the expansion, maturation and specification of immature
T cells. Epidermal keratinocytes are also essential for driving the activation of the in-
nate and adaptive immune system through the production of cytokines, which direct
the fate of discrete lymphocyte populations, known as the “epimmunome” [79].
Not by chance, recently it has been demonstrated that a co-culture of human
skin-derived keratinocytes and fibroblasts, in the absence of thymic components, can
support the survival of human hematopoietic stem cells and their differentiation into
T-lineage committed cells [80], suggesting that skin keratinocytes can promote T-cell
development, such as TECs, although at a low efficiency (Figure 1).
In addition, it has been shown that murine skin fibroblasts, enforced by FOXN1 ex-
pression, are able to reprogram into induced TECs (iTECS), an in vitro generated cell
type that exhibits phenotypic and functional properties of in vivoTECs. iTECS are able
to promote full T-cell development in vitro, providing the basis for thymus transplan-
tation therapies aimed at boosting adaptative immune system function in immuno-
compromised patients [81].
CONCLUSIONS
Primary immunodeficiencies are severe early onset immunological disorders often fa-
tal in thefirst years of life.Many forms showcutaneous features in associationwith im-
munological defects. In fact, the presence of skin and skin annexa abnormalities may
be considered a warning sign in patients with a suspicion of a primary immunodefi-
ciency. In this review, we focused on themost common forms of PIDs associated with
Copyright C© Informa Healthcare USA, Inc.
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 R. D’Assante et al.
ectodermal disorders, highlighting the alarm signs that should lead the clinician to
consider a deeper immunological assessment, investigating bothmolecular and func-
tional aspects. Moreover, this approach would be very helpful in the early detection
and treatment of such complex disorders.
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3.4 FOXN1 in organ development and human diseases. 
The thymus is the primary lymphoid organ that supports T cell differentiation and repertoire 
selection (163, 164). 
Thymus anlagen originate from the third pharyngeal pouch in the embryonic foregut 
(165, 166). From embryonic day 11.5 in mice and at the eighth week of gestation in humans, 
the lymphoid progenitor migrate to the thymus (167, 168). Following the entry into the 
thymus through the corticomedullary junction, the differentiation of T cells require a dynamic 
relocation of developing lymphocytes within different structures composing this organ 
lymphoid progenitor cells. The developmental pathway is a multistep process, in which each 
step is defined by peculiar immunophenotypic patterns: the CD4−CD8− double negative 
(DN) stage, the CD4+CD8+ double positive (DP) stage, and the CD4−CD8+ or CD4+CD8− 
single positive (SP) stage. The journey of the immature thymocytes through the thymus plays 
an important role in the generation of the thymic microenvironment, by promoting the 
differentiation of stromal precursors into mature thymic epithelial cells TECs (169-172). 
Appropriate crass-talk between thymocytes and thymic stromal cells is necessary to 
guarantee the prenatal thymus development, the maintenance of a proper thymic 
microenvironment, and the efficient T-cell production (173).  
FOXN1 is a developmentally regulated transcription factor, which belongs to the 
forkhead-box gene family, absolutely required for the normal differentiation of hair follicles 
and TECs (174). During embryogenesis FOXN1 is expressed in several mesenchymal and 
epithelial cells, including those of the liver, lung, intestine, kidney, and urinary tract. Later 
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in life, its expression is limited to skin and thymus epithelia. FOXN1 gene spanning about 
30 kb (175, 176), has two different noncoding first exons (176), the exons 1a and 1b, that 
undergo to alternative splicing. The alternative usage of the exon 1a or 1b seems to direct the 
tissue specificity (177), in that promoter 1a is active in thymus and skin, while promoter 1b 
is active only in skin. Studies suggest that FOXN1 modulate the thymic stroma differentiation 
and thymopoiesis through upregulation of the expression of fibroblast growth factor (FGF) 
receptors (178). Wnt proteins which belong to a family of secreted glycoproteins with 
important roles in cell-fate specification, upregulate FOXN1 protein expression in both an 
endocrine and paracrine fashion (179). Even though the role foxn1 in thymus fetal 
differentiation process has been largely studied, its postnatal role in the mature thymus still 
remains to be fully elucidated. Foxn1 is expressed in all TECs being required for the initial 
phase of their differentiation (180-182), and for the induction of both cortical and medullary 
differentiation (183, 184). The inborn null mutation in foxn1 (185) halts thymic development 
at a rudimentary stage, in which the epithelial cells are not able to induce the entrance of 
hematopoietic precursor cells (HPCs) into the epithelial cluster and thus preclude the 
generation of thymocytes (186), suggesting a failure in thymocytes-epithelial crosstalk (180, 
187).  
The human equivalent of the “nude” murine phenotype has been described for the 
first time in two sisters, more than 30 years after the initial mouse description. Subsequently, 
it was associated to alterations in FOXN1 gene. The human Nude/SCID is an autosomal 
recessive disorder (188), characterized by a complete absence of the thymus and consequent 
T-cell immunodeficiency. This immunodeficiency is similar to the classical SCID phenotype, 
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and more severe than Di George Syndrome. Along with the severe infections, other features 
of the syndrome are ectodermal abnormalities, as alopecia and nail dystrophy (189). The nail 
dystrophy has been described also in subjects carrying the heterozygous genetic alterations. 
FOXN1 is expressed in the nail matrix and is involved in the maturation of nails (189). 
Anomalies of brain structures, have also been described in Nude/SCID, suggesting a potential 
role of this transcription factor in brain embryogenesis. The brain anomalies have been 
considered potentially responsible for the high rate of in utero mortality observed in a 
geographic area with high frequency of FOXN1 alteration (190). Human FOXN1 deficiency 
impairs the development of the T-cell compartment since the 16th week of gestation (191). 
The other hematopoietic compartment including stem cells, B, and NK lymphocytes are not 
impaired. Both CD4+ and CD8+ cells are profoundly reduced cells even though FOXN1 
deficiency affect more CD4+ cell compartment than CD8+. CD4+CD45RA+ naive cells are 
completely absent (191) while CD8 cells coexpressing CD3 are detectable, even though at 
very low levels and only few CD3+CD8+CD45RA+ naıve cells can be detected (191). The 
number of lymphocytes expressing TCRγδ is usually normal (191). TCR gene 
rearrangement, occurs to some extent, suggesting the existence of an extrathymic and 
FOXN1-independent site of differentiation. However, the low number of T cells, which 
escape the blockage, are unable to sustain a productive peripheral immune response.  
Because of the significant expression levels of FOXN1 in skin elements, 
keratinocytes have been successfully used to support a full process of human T-cell 
development in vitro, resulting in the generation of mature T cells from HPCs. This finding 
would imply a role for skin as a primary lymphoid organ (192). Our and other groups reported 
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on the ability of human skin-derived keratinocytes and fibroblasts co-cultured on 3D poly ε-
caprolactone scaffold to support in vitro HSC differentiation into T-lineage committed cells. 
The ex vivo reproduction of microenvironments of the native tissue through approaches 
based on the use of porous and biodegradable matrices is useful to repair or replace tissues 
damaged at a molecular or functional level (193). This approach has been successful in 
achieving the regeneration of many tissues, such as skin (194), cornea (195), blood vessels 
(196) and in the bone replacement process (197, 198). Optimal scaffold materials should 
exert the properties of excellent biocompatibility, suitable microstructure, controllable 
biodegradability and suitable mechanical properties to sustain and facilitate a proper 
intercellular connection (199, 200). Scaffold surfaces need to be organized to allow optimal 
cell–cell contact, growth, maintenance of morphology and viability over time to meet the 
demands of the specific application (201). In congenital immunological disorders and, in 
particular, in athymic disorders, a scaffold mimicking the 3D structure of primary lymphoid 
organs may be potentially used for the differentiation of haematopoietic cell precursors and, 
eventually, allows the re-setting of immunological response through functional or molecular 
manipulation of precursor cells. In keeping with this, it has been recently documented that a 
3D tantalum coated carbon matrix is able to support the development of functional T cells 
from haematopoietic precursor cells in the context of a heterogeneous multicellular system 
(202), even though the capability of the system to ensure a complete process, resulting in 
mature type T cells, is still under debate (203).  
These data have been published as Reviews on International Reviews of Immunology and 
Frontiers Immunology for the manuscripts see below. 
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FOXN1 gene belongs to the forkhead box gene family that comprises a diverse group of “winged-
helix” transcription factors that have been implicated in a variety of biochemical and cellular pro-
cesses, such as development, metabolism, aging and cancer. These transcription factors share the
common property of being developmentally regulated and of directing tissue-speciﬁc transcrip-
tion and cell-fate decisions. Foxn1 is selectively expressed in thymic and skin epithelial cells, where
it acts through its molecular targets to regulate the balance between growth and diﬀerentiation.
In particular, Foxn1 is required for thymic epithelial patterning and diﬀerentiation from the initial
epithelial thymic anlage to a functional cortical andmedullary thymic epithelial cells (TECs)mesh-
work necessary for the crosstalk with the lymphoid compartment. Amutation in FoxN1 generates
alymphoid cystic thymic dysgenesis due to defective TECs, causing primary T-cell immunodeﬁ-
ciency, named Nude/SCID syndrome, and leads to a hairless “nude” phenotype in both mice and
humans. This immunedefect represents the ﬁrst example of a Severe Combined Immunodeﬁcien-
cies (SCID) phenotype not primarily related to an abnormality intrinsic of the hematopoietic cell,
but rather to a peculiar alteration of the thymic epithelia cell. This review focuses on the key role
of FOXN1 in cell development and its clinical implication in humans.
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FOXN1 gene belongs to the forkhead gene family that comprises a diverse group of
“winged-helix” transcription factors that have been implicated in a variety of bio-
chemical and cellular processes, such as development, metabolism, aging and can-
cer [1, 2]. It was first well characterized both in mouse and humans by Schropp et al.
in 1997. First designated as winged helix nude gene, because of the presence in its
sequence of a forkhead domain (Whn), it has been then renamed forkhead box n1
(FOXN1). The human FOXN1 gene is localized on chromosome 17q11–12, spanning
about 30kb and being closely linked to the neurofibromatosis-1 gene [3]. Similarly to
the mouse Foxn1 gene, it contains eight coding exons and two different first exons,
exons 1a and 1b, that undergo to alternative splicing to either of two splice acceptor
sites of the exon 2, located upstream of the initiation codon. Exon 1a and exon 1b do
not contribute to the protein sequence but, interestingly, they are under the control of
two promoters, which confer FOXN1 gene tissue specificity, in that the promoter 1a is
active both in thymus and skin and the promoter 1b only in the skin [3, 4].
FOXN1 gene encodes an evolutionarily high conserved forkhead/winged helix
transcription factor [5], which contains 648 amino acids and exerts an 85% homology
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 L. Palamaro et al.
between rodents and humans [3]. Structural characteristics of the protein include a
transcriptional activation domain, encoded by exons 8–9 and a forkhead DNA bind-
ing domain, encoded by three exons (5–7), this structure being peculiar of the fork-
head/winged helix transcription factors [3]. The presence of the transactivation do-
main in FOXN1 C-terminal region has been first proven by Brissette et al. [6] and
then confirmed by the study of Schuddekopf et al., in which it was shown that the
domain consists of approximately 50 amino acids between aa 511 and 563, rich of
acidic residues [7]. Using site-directed mutagenesis, the authors replacing aspartic
acid residues with alanine, found that these acidic residues are essential for the trans-
activation activity of the protein. Notably, not only the structural integrity of the amino
acidic sequence, but also the physical proximity of both domains are essential for
FOXN1 transcriptional activity [8].
Postnatally, Foxn1 gene ismainly expressed in thymic epithelial cells (TECs), some
keratinocyte populations and hair follicles, where it acts through its molecular targets
to regulate the balance between growth and differentiation [6, 9, 10]. It exerts its func-
tion after activation through phosphorylation that promotes its nuclear translocation
[11–13]. Into the nuclei, it interacts with DNA as amonomer through its forkhead box,
but the target genes and the specific biochemical mechanism of interaction with the
promoter regions remain to be elucidated [3, 14].
Themolecular mechanisms by which FOXN1 expression and activity are regulated
are not fully understood, even though evidence suggests that FOXN1 expression is
strongly regulated by wingless (Wnt) proteins [15], a family of secreted glycoproteins
that play a role in the cell-fate specification [16], and bone morphogenetic protein
(BMP) signaling, required for a normal thymus development [17], in both autocrine
and paracrine fashion (Figure 1) [15]. Foxn1 target genes have not been completely
identified due to technical difficulties in isolating physiologically intact TECs at differ-
ent stages of the differentiation process, even though growing evidence is now avail-
able documenting that several genes are molecular target of Foxn1 (Figure 1), includ-
ingNotch ligands,DLL-1andDLL-4 [18] and thechemokines,CCL25andCXCL12 [19].
FIGURE 1. FOXN1 regulators and target genes. FOXN1 expression is regulated by wingless (Wnt)
proteins, sonic hedgehog (Shh) and bone morphogenetic protein (BMP) signalings. Several genes
are molecular target of Foxn1, including Notch ligands, Delta like ligand- (DLL-)1 and DLL-4, the
chemokines CCL25 and CXCL12 and the fibroblast growth factor receptor (FGFR).
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FOXN1 in Organ Development and Human Diseases 
Moreover, it has been documented that FOXN1 up-regulates the expression level of fi-
broblast growth factor receptor (FGFR), which are able to regulate the differentiation
of thymic epithelia and thymopoiesis, as well [16].
Even though the complete pattern of FOXN1 expression and its role are not yet
completely unraveled, the knowledge of the prominent role of FOXN1 came out from
studies on nude mouse and the human equivalent model determined by gene alter-
ations.Mutation in Foxn1 generates alymphoid cystic thymic dysgenesis due to defec-
tive TECs [5, 9] and leads to a hairless phenotype in both mouse and humans [10].
THE ROLE OF FOXN1 IN THE THYMUS
The thymus provides a specializedmicroenvironment for the development and selec-
tion of mature T cells bearing the T-cell receptor (TCR) complex [19, 20]. The thymic
microenvironment is composed primarily of an integrated meshwork of TECs or-
ganized in three-dimensional (3D) architecture. TECs are differentiated in cortical
(cTECs) andmedullary epithelial cells (mTECs), required forpromotingmost stagesof
the thymocyte differentiation [21]. The intrathymic development of T cells consists of
discrete phases that require a dynamic relocation of developing lymphocytes within
multiple architectural structures of this organ. In the T-cell developmental pathway,
hematopoietic progenitor cells (HPCs) emigrate from the bonemarrow to the 3D thy-
mus, where the developing T-cell precursors, namely, thymocytes, interact with TECs
and other thymic stromal cells (TSCs).Thymocytes relocate within the organ, prolifer-
ate and acquire lineage specification. At molecular level, TCR rearrangement occurs
resulting in the emigration from the thymus of a fully differentiated mature T cell [22,
23].
In particular, the epithelial cell-autonomous gene Foxn1 is required for thymic ep-
ithelial patterning and differentiation from the initial epithelial thymic anlage to a
functional cTEC and mTEC meshwork during crosstalk with the lymphoid compart-
ment. In particular, the development and maturation of TEC subsets during the thy-
mus organogenesis occurs through two genetic stages [9, 24], first stage being Foxn1-
independent and under the control of genes such asHoxa3 [25] and Tbx1 [26], during
which induction and outgrowth of the thymic epithelial anlage from the third pharyn-
gealpouch takeplace. InFoxn1-dependent step,precursor epithelial cellsdifferentiate
intomature and functional cTECs andmTECs from the same bipotential TEC progen-
itor [24, 27–29]. Of note, Foxn1 is expressed in all TECs during embryogenesis, but not
in all TECs of the adult thymus [30], indicating that the gene is strictly developmentally
regulated. However, studies on K5- and K18-CreERT-mediated Foxn1-deleted mouse
models have revealed that Foxn1 plays a different role in mTEC and cTECs. In partic-
ular, during the postnatal life, mTECs, expressing keratins type K5 and K14, which are
similar to epithelial stem cell markers and exhibit progenitor activity in the skin and
mammary gland [31, 32], are affected in the case of loss of Foxn1. Conversely, cTECs,
whose markers are the keratins K8 and K18 expressed in terminally differentiated ep-
ithelial cells in the apical layer of stratified squamous skin epithelium, arenot sensitive
to the loss of Foxn1 [33]. Thus, this evidence suggests that cTECs and mTECs are not
equally Foxn1-dependent and cTECs are insensitive to Foxn1missing. Since Foxn1 is
widely expressed during embryogenesis, its expression in the adult thymus reveals the
presence of TEC progenitors [34], expressing K5+/K14+ markers, which support TEC
homeostasis in the adult thymus.
Of note, a new component of proteasome, the β5-thymus (β5t) subunit, selectively
expressed in the cTECs has been identified. β5t subunit leads to the production of
peptides presented by class IMHCmolecules, thus playing a pivotal role in generating
the immunocompetent CD4−CD8+ T cells. In murine cTECs, the expression of β5t is
Copyright C© Informa Healthcare USA, Inc.
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 L. Palamaro et al.
strictly dependent on Foxn1, which might regulate β5t transcription. These data are
in keeping with the central role of this transcription factor in the stroma functionality
[35].
Additionally to the well-defined role of the Foxn1 to regulate the thymic epithelial
patterning anddifferentiation, it has recently beendemonstrated that Foxn1 is also in-
volved in the 3D thymicmicrostructure morphogenesis andmaintenance [36], which
is very important for the functionality of the thymus.
Eventually, Foxn1 must be considered as a prime downstream mediator of agents
or pathways also capable to induce thymic involution or rebound. Normal aging is ac-
companied by thymic involution, reduced thymocyte output and reduced expression
of Foxn1 [37, 38]. It has been shown that the progressive loss of Foxn1 causes accel-
erated premature thymic involution, with gross and microanatomic changes similar
to age-related involution [38]. Furthermore, intrathymic injection of Foxn1 cDNA to
aged mice increased thymic size and thymocyte numbers [38]. Consistent with these
results, down-regulation of Foxn1 occurs early in thymic involution [37], while trans-
genic overexpression of Foxn1 delays this process [39].
Of note, most of the pathogenic mechanisms underlying a primary T-cell disorder
are related to molecular alterations of genes selectively expressed in hematopoietic
cells. However, since the differentiation process relies on a proper crosstalk among
thymocytes and thymic microenvironment, a severe T-cell defect may also be due to
an alteration of the stromal component of the thymus [40].
THE ROLE OF FOXN1 IN THE SKIN
FOXN1 gene expression in the skin, as also seen in the thymus [9], is restricted to ep-
ithelial derived cells [41]. Using in situ hybridization and a murine model in which a
beta-galactosidase reporter gene was placed under the control of the wild-type Foxn1
promoter, Foxn1 genewas found to be expressed sinceDay 13 of gestation in the nasal
region of mice. Then, Foxn1 expression becomes detectable in developing whisker
pads, nail primordial, hair follicles of eyebrows and the epidermis ofmouth, nose, ears
and tail. At last, Foxn1 expression involves the entire skin, particularly interfollicular
epidermis and hair follicle [41]. A detailed analysis of the Foxn1 expression in mouse
skin has revealed a specific pattern of expression, suggesting its involvement in the
regulation of cell growth and differentiation.
In the interfollicular epidermis, which is composed by four cell layers (basal,
spinous, granular and cornified), Foxn1 is mainly expressed within the nucleus of the
cells in the first suprabasal layer. Its expression in these cells corresponds to the onset
of terminal differentiation, having the cells left the cell cycle and started the full pro-
gram of differentiation [41]. However, Foxn1 expression has been found, along with
Ki-67 expression, also in rare cells in the basal layer.These findings allow to speculate
that the double positive cells (Foxn1+ Ki-67+) could be markers of the very first stage
of terminal differentiation, being daughter cells of transient amplifying keratinocytes,
which are committed to differentiate and are just leaving the cell cycle and the basal
layer [42].
In thehair follicle, Foxn1 is expressed in the supramatrical region. Inparticular, dur-
ing hair follicle morphogenesis, its most prominent expression has been detected in
the precursor cells of the inner root sheath and hair shaft, in the outer root sheath and
in the periphery of the matrix [41, 43]. All these cells derive from the matrix cells af-
ter hair bulb formation and are characterized by the end of proliferation, in order to
achieve their terminal differentiation [44]. After hair follicle formation, a cycle con-
sisting of three phases takes place: anagen, hair follicle growth; catagen, hair follicle
regression; telogen, resting period. Notably, Foxn1 expression is strongly dependent
International Reviews of Immunology
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on the phase of hair cycle. Indeed, the gene transcript was easily found only during
anagen, while it was poorly or not at all detectable in the two further phases [43].
As far as concerned FOXN1 function in the skin, its role, its target genes and the
molecular mechanism of action still remain to be fully clarified. The observation that
Foxn1 is mainly expressed in the keratinocytes of the first suprabasal layer, together
with the findings that nu/numouse keratinocytes showed amuch higher susceptibil-
ity compared towild-type keratinocytes to the growth-arresting effect of phorbol ester
12-O-tetradecanoyl-13-acetate (TPA), allows to speculate that FOXN1 is a key tran-
scription factor involved in the regulation of keratinocytes growth and differentiation
[6]. In addition, an increased proliferation and an impaired keratinocyte differentia-
tion have been found in interfollicular epidermis, hair follicle and urotheliumofmice,
which overexpress Foxn1 in terminally differentiating cells [45]. Strong evidence sug-
gests that Foxn1 is involved in keratinocyte differentiation through regulation of target
genes, such as protein kinase C (PKC) and protein kinase B (AKT). Indeed,mouse ker-
atinocytes, missing functional Foxn1, showed an up-regulation of PKC activity, while
the overexpression of Foxn1 led to the suppression of PKC activation and inhibition of
keratinocyte differentiation [46]. In addition, evidence indicates that PKC is a potent
inhibitorofhumanhair follicle growth invitro [47–49]. Janeset al. have investigated the
function of FOXN1 in the regulation of interfollicular epidermis by means of cultures
of primary human epidermal keratinocytes. They found that FOXN1 was responsible
of initiation of keratinocyte differentiation but it was not sufficient to induce the final
stages of terminal differentiation. Indeed, in the reconstituted human epidermis only
differentiating cells of the spinal layer could be detected, while cells of the granular
and cornified layers are lacking. Moreover, usingmicroarrays analysis, approximately
30 genes have been identified, which are up-regulated following FOXN1 activation
during keratinocyte differentiation. Among these genes, the serine/threonine kinase
Akt is able to trigger the later stages of differentiation, leading to the development of
the granular and cornified layers. Together all these findings allow to hypothesize that
while FOXN1 promotes the early stage of keratinocyte differentiation, the increasing
levels of AKTand its subsequent activationmaybring to completion the process of ter-
minal differentiation [50]. In keeping with this, keratinocytes from nudemice express
lower level of keratin 1 (a marker of the early stages) [6], whereas overexpression of
Foxn1 increases the expression keratin 1 [45, 51].The acidic hair keratin 3 (mHa3), the
murine ortholog of the human acidic hair keratin 3 and Foxn1 are coexpressed in the
same anatomic structure. Reduced levels of mHa3 and other hair keratins were found
in nudemice epidermis [4, 43] and transfection of FOXN1 in HeLa cells (tumoral cells
derived from human cervical carcinoma) induces a high expression of mHa3, mHb3
andmHb5, hair keratins normally not expressed in this cell line [8].
Furthermore, it has been demonstrated, by using an engineered-keratin-5-driven
Foxn1 (K5-Foxn1) transgenic (Tg) mouse, that Foxn1 provides the necessary cues to
transfer the pigment from melanocytes to keratinocytes of the hair shaft cortex, this
effect being mediated by Fgf2 [52]. The Foxn1-null nude mouse completely lacks pig-
mentation in the hair cortex, while the K5-Foxn1 Tg confers ectopic acquisition of the
pigmentation in hair cortical cells.
CLINICAL IMPLICATIONS OF FOXN1MUTATION IN HUMANS:
THE NUDE/SCID MODEL
The absence of FOXN1 transcription factor results, both in mice and humans, in con-
genital athymia and hairlessness. In man, the phenotype has been described in asso-
ciationwith a C792T homozygous transition in the FOXN1 gene, which resulted in the
nonsensemutation R255X in the exon 4 (formerly exon 5), with a complete absence of
Copyright C© Informa Healthcare USA, Inc.
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FIGURE2. Hallmarksof thehumanNude/SCIDphenotype. (A)Alopeciaof the scalp, eyebrowsand
eyelashes.Nail dystrophypatterns: (B) leukonychia, (C) koilonychias and (D) canaliformdystrophy.
a functional protein [53], or with a C987T (R320W) transition in the exon 6, resulting
in a missense mutation of the DNA binding domain [54]. In particular, the genetic al-
teration of the transcription factor, inherited as an autosomal recessive disorder, leads
to a severe T-cell immunodeficiency, congenital alopecia of scalp, eyebrows and eye-
lashes (Figure 2A). This phenotype, referred to as Nude/SCID (MIM 601705; Pignata
Guarino Syndrome), was described for the first time in humans in 1996 in two sisters
originating from a small community in the south Italy [55].This immune defect repre-
sents the first example of a Severe Combined Immunodeficiencies (SCID) phenotype
not primarily related to an abnormality intrinsic of the hematopoietic cell, but rather
to a peculiar alteration of the TEC [40, 55–57].
This phenotype is widely accepted as the human equivalent of the similar murine
phenotype, reported for the first time by Flanagan in 1966 [58]. Over the time, the Di-
George syndrome (DGS), similarly characterized by thymic hypo/aplasia with sub-
sequent impaired thymocyte development, was erroneously considered the human
counterpart of nudemouse phenotype.Themolecular defect responsible for the DGS
is a 22q11.2 region deletion in which Tbx1, the gene putatively responsible for the
athymia, is located. A DGS-like phenotype could also be due to other molecular de-
fects, such as the deletion of a critical region on chromosome 10p13/14 [59, 60].More-
over, the CHARGE syndrome, due tomutations in theCHD7 gene encoding for a chro-
modomain helicase DNA-binding protein, shares considerable phenotypic overlap
withDGS [61].The spectrumof DGS defects is very heterogeneous and, inmost cases,
the phenotype is mild [62]. In the majority of patients with DGS, referred to as “par-
tial,” the T-cell pool is usually normal or, in very few cases, low normal, and T cells
are only rarely poorly responsive to common mitogens, while patients affected with
the “complete” form of the disease (accounting for 0.5%–1.5% of patients) have a se-
vere T-cell immunodeficiency, with a naı¨ve T-cell pool and mitogen responsiveness
usually absent [63–65]. Thus, even though the Nude/SCID and a few DGS share the
absence of the thymus, by a clinical and immunological point of view there are several
differences, which lead to consider these disorders two completely distinct entities.
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FOXN1 in Organ Development and Human Diseases 
By contrast, Nude/SCID patients exhibit a quantitative and qualitative T-cell defect
much more severe than that observed in DGS.The Nude/SCID immune deficiency is
characterized by a severe blockage of the T-cell differentiation and absence of prolif-
erative response to the commonmitogens [55]. Naı¨ve T cells are lacking in the periph-
eral blood, as a consequence of the absence of a T-cell differentiation process. InDGS,
differently from Nude/SCID patients, CD4+CD45RA+ naı¨ve cells are usually found,
suggesting that a certain level of thymic functionality is still present also in the com-
plete forms of the syndrome.The comparison of the clinical phenotype of the two syn-
dromes reveals that inDGShairlessness ismissing and gross abnormalities of skin an-
nexa are lacking, differently from Nude/SCID. As above described, the transcription
factor FOXN1 is also expressed in the epithelial cells of the skin, where it participates
to the homeostasis between growth and differentiation.This evidence argues in favor
of the essential role of FOXN1 in T-cell development and leads to suggest that skin
might express a major role as an alternative primary lymphoid organ. In keeping with
this, it has been recently documented that in the absence of thymic cellular epithe-
lial elements, skin-derived keratinocytes and fibroblasts seeded on the 3D scaffold, by
mimicking the configuration of the thymus, are able to support the differentiation of
stem cells into T-cell precursors [66].
By taking advantage of the congenital athymia, the human Nude/SCID phenotype
was used as disease model to investigate the development of the T-cell compartment
in theabsenceof a functional thymus.Theresults obtained from these studies revealed
the presence of some circulating T cells of non-maternal origin in patients carrying al-
terations of FOXN1, thus raising important questions regarding the site of differentia-
tion of these cells.These cells have been shown to be predominantly double-negative
(CD4negCD8neg, DN) αβ T cells and to exhibit a regulatory-like T-cell phenotype
(FoxP3+). One hypothesis was that a thymic rudiment could persist, allowing a partial
T-cell development, but with alterations in positive/negative selection, as suggested
by the expansion of DN αβ and FoxP3+ T cells [67]. Further evidence indicates that
the TCRBV spectra-type repertoire in Nude/SCID patients is oligoclonal in both pre-
natal andpostnatal life [54, 68]. Further studies aimed at characterizing the phenotype
of lymphocytes in the Nude/SCIDmodel in human prenatal life revealed that FOXN1
alteration leads to a total blockage of CD4+ T-cell maturation and severe, but not to-
tal, impairment of CD8+ cell differentiation, with an apparent trend toward a γ δ T-cell
production.This finding thus suggested a crucial role of this gene in the early prenatal
stages of the T-cell ontogeny in humans [68]. Of note, different mutations in the same
gene lead to different immunological phenotypes. No circulating T cells were found
in a patient with the C987T (R320W) substitution identified in the exon 6 of the hu-
man FOXN1 gene, resulting in a missense mutation of the DNA binding domain [54].
These partially divergent features raise intriguing arguments about the role of FOXN1
in theT-cell development,whichdeserve further explorationusingmousemodels and
comparative structural studies [4, 8, 9].
To date, there is no curative therapeutic approach for Nude/SCID syndrome. Bone
marrow transplantation has been performed in one childwith theNude/SCIDpheno-
type due to FOXN1 deficiency but without the production of the naı¨ve T-cell pool and
long-lasting immunological reconstitution [69].This would be expected given the ab-
sence of a functional thymus and to the necessary role of the FOXN1 transcription fac-
tor for aproperT-cell development.Thus, becauseof theathymia inFOXN1deficiency,
an attempt to use thymus transplantation was chosen to obtain an immune reconsti-
tution. Remarkably, naı¨ve T cells with a diverse TCR repertoire were generated, which
paralleled the normalization of T-cell proliferative responses and Ig levels. This ther-
apeutic intervention was also useful to achieve the clearance of the ongoing dissemi-
nated infections [54]. Of note, in one patient undergone to thymus transplantation, it
Copyright C© Informa Healthcare USA, Inc.
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 L. Palamaro et al.
has been described, for the first time, an unusual leukoderma, which the authors hy-
pothesized as related to FOXN1 deficiency [70]. Upon transplantation of FOXN1 com-
petent thymic epithelia, also the peripheral pool of FoxP3+ T cells normalized, while
the number of circulating DNαβ T cells remained constantly high up to 6 years after
transplantation [67].This finding raises the question about the origin of DNαβ T cells
in that their reduced sjTREC levels, used as a marker of thymic functionality, suggest
that they were not produced after transplantation [67], and that they probably did not
require a functional thymus to develop. The evidence that other sites, alternative to
the thymus, could sustainT-cell development anddifferentiation alsoderives from the
identification, in aNude/SCID fetus, of a limited number of CD8+ cells, not expressing
the CD3 and bearing TCRγ δ, thus suggesting an extrathymic origin for these cells [68].
Nude/SCID phenotype is also characterized by nail abnormalities. Nail dystrophy
in mice and humans is a feature of the syndrome. In man, also heterozygous gene
alterations are associated with minor ectodermal anomalies, as well. Leukonychia
or koilonychia (“spoon nail”) are the more frequent abnormalities, the former being
characterized by the typical arciform pattern resembling a half-moon and involving
the proximal part of the nail plate (Figure 2B), the latter being characterized by a con-
cave surface and significant thinning of the nail plate (Figure 2C) [71]. Also canaliform
dystrophy and a transverse groove of the nail plate (Beau line) are observed, but less
frequently (Figure 2D) [71]. These features are in keeping with the observation that
FOXN1 is expressed in the nail matrix, thus being involved in the nail maturational
process [41, 72]. Therefore, nail dystrophy could be considered an important sign to
recognize heterozygous subjects [71, 73].
It should be noted that recently, multiple-site neural tube defects including anen-
cephaly and spina bifida have been reported in a human fetus homozygous for the
mutation R255X [74]. However, the analysis of a second Nude/SCID fetus did not re-
veal any gross abnormality in the central nervous system (CNS) anatomy but only the
absence of the corpus callosum and cavum septi pellucidi (CSP), and an enlargement
of the interhemispheric fissure. Of note, FOXN1 is expressed inmurine epithelial cells
of the developing choroids plexus in the embryonic brain [74], thus suggesting a pos-
sible role of FOXN1 in the development of the CNS in a similar fashion to other FOX
family members, such as FoxP1, that helps Hox proteins regulate the genes, control-
ling the motor-neuron diversification [75, 76]. However, these variable abnormalities
reported in theNude/SCIDphenotype suggest that FOXN1may be implicated as a co-
factor in the development of vital systems required for a proper fetus development.
This would explain the high mortality rate during the first trimester of pregnancy re-
ported among consanguineous carriers of the mutation [74], which is not justified by
the SCID per se due to the maternal protection until the third month after birth.
CONCLUSIONS
The simultaneous occurrence of severe functional T-cell immunodeficiency and skin
abnormalities associatedwith FOXN1 alterations indicates that the factor exerts a crit-
ical role in the development and homeostasis of these epithelia and suggests shared
functions of the gene in both thymus and skin epithelium. Evidence is available show-
ing that a co-culture containing skin-derived cells and hematopoietic precursor cells
(HPCs), reconfigured in 3D arrangement, expressing high levels of FOXN1, reproduce
a thymus organoid able to generatemature and functional T cells fromprecursor cells
even in theabsenceof thymic cells [77].This central roleof FOXN1 inensuringaproper
T-cell ontogeny is also indirectly sustainedby the presence of functional T cells inDGS
but not in Nude/SCID.
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FOXN1 in Organ Development and Human Diseases 
Despite the significant progress to date made, the detailed mechanism by which
FOXN1 controls the T-cell differentiation process through intercellular cross-talk still
remains to be clarified.Most of the target genes regulatedbyFOXN1are sill undefined,
also due to the technical difficulties to isolate intact TECs at different developmental
stages.
Additional knowledge in this field would be very helpful in conclusively defining
the role of FOXN1 in the biological process, in clarifying the intimate mechanisms of
FOXN1 action and in the development of novel therapeutic strategies for congenital
disorders of immune system.
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T cell ontogeny is a sophisticated process, which takes place within the thymus through a
series of well-defined discrete stages.The process requires a proper lympho-stromal inter-
action. In particular, cortical and medullary thymic epithelial cells (cTECs, mTECs) driveT cell
differentiation, education, and selection processes, while the thymocyte-dependent signals
allow thymic epithelial cells (TECs) to maturate and provide an appropriate thymic microen-
vironment. Alterations in genes implicated in thymus organogenesis, includingTbx1, Pax1,
Pax3, Pax9, Hoxa3, Eya1, and Six1, affect this well-orchestrated process, leading to dis-
ruption of thymic architecture. Of note, in both human and mice, the primordial TECs are
yet unable to fully support T cell development and only after the transcriptional activation
of the Forkhead-box n1 (FOXN1) gene in the thymic epithelium this essential function is
acquired. FOXN1 is a master regulator in the TEC lineage specification in that it down-
stream promotes transcription of genes, which, in turn, regulate TECs differentiation. In
particular, FOXN1 mainly regulates TEC patterning in the fetal stage and TEC homeostasis
in the post-natal thymus. An inborn null mutation in FOXN1 leads to Nude/severe com-
bined immunodeficiency (SCID) phenotype in mouse, rat, and humans. In Foxn1−/− nude
animals, initial formation of the primordial organ is arrested and the primordium is not col-
onized by hematopoietic precursors, causing a severe primary T cell immunodeficiency. In
humans, the Nude/SCID phenotype is characterized by congenital alopecia of the scalp,
eyebrows, and eyelashes, nail dystrophy, and a severe T cell immunodeficiency, inherited
as an autosomal recessive disorder. Aim of this review is to summarize all the scientific
information so far available to better characterize the pivotal role of the master regulator
FOXN1 transcription factor in the TEC lineage specifications and functionality.
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INTRODUCTION
The thymus is the primary lymphoid organ with the unique func-
tion to produce and to maintain the pool of mature and functional
T cells. This process is strictly dependent on specialized func-
tions of thymic stromal cells (TSCs) and requires the thymus
peculiar tridimensional (3D) architecture, which allows a proper
intercellular cross talk (1). For a long time, the difficulty in the iso-
lation and characterization of the thymic cellular components has
limited studies on the peculiar role of individual stromal compo-
nents. Novel experimental tools, including stromal cell isolation by
phenotype-based cell sorting (2), dissociation and reaggregation
of stromal cell subsets (3, 4), or global gene expression analysis
and the evaluation of the pattern of self-antigen expression within
the individual thymic epithelial cells (TECs) subset (5), allowed to
acquire important knowledge on the cellular and molecular basis
of thymus organogenesis and TECs functionality.
The recent discovery of disease models associated to genetic
alterations of molecules implicated in thymus specification and
TECs differentiation,provided new and conclusive insights regard-
ing the pathways, the genes, and the molecular mechanism
governing these processes and stromal functionality.
THE THYMUS ARCHITECTURE: REQUIREMENT OF A 3D
STRUCTURE FOR A PROPER LYMPHO-EPITHELIAL
CROSSTALK
The thymus provides the microenvironment essential for the
development of T cells. T cell progenitors originate in the bone
marrow, enter into the thymus (6, 7) and, through a series of
well defined and coordinated developmental stages, differentiate,
undergo selection process, and mature into functional T cells.
The steps in this process are tightly regulated through a complex
network of transcriptional events, specific receptor-ligand inter-
actions, and sensitization to trophic factors, which mediate the
homing, proliferation, survival, and differentiation of developing
T cells (1, 8, 9).
The thymus is organized in two lobes, which are already present
in mice at 21 days of thymic organogenesis and is completely
organized at 1 month of post-natal life. The lobes are divided
in three areas: a cortical and the dark cortical area, with a high
number of lymphoid cells and epithelial cells, cortical thymic
epithelial cells (cTECs); a light medullary area with a low number
of mature T cells, named medullary TECs (mTECs), Hassall’s bod-
ies (HB), macrophages, dendritic cells (DCs), B lymphocytes, and
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rarely myoid cells. Eventually, there is a transitional area, named
cortico-medullary junction (CMJ), characterized by abundant
blood vessels (10).
The unique function of the thymus in the establishment and
maintenance of the T cell pool is intimately linked to this peculiar
thymus architecture and to the specialized functions of the TSCs.
LYMPHO-EPITHELIAL CROSS-TALK REQUIRED FOR
THYMOCYTE AND TECs DIFFERENTIATION
An important feature of the thymic microenvironment is its
3D organization, consisting of an ordered architecture of TSCs,
that represents a heterogeneous mixture of distinct cell types,
including cTECs, mTECs, fibroblasts, endothelial cells, DCs, and
macrophages (11). Among these stromal elements, TECs are the
most abundant cell types, which form a delicate 3D cellular
network spanning throughout both the thymic cortex and the
medulla. The requirement for the 3D-supporting stroma appears
to be unique to the T cell development, as the in vitro differenti-
ation program of other hematopoietic lineages, including B and
NK cells, does not require a 3D structure (12).
Thymocyte development is not a cell-autonomous process, and
the transition to the next stage in development relies on the proper
interaction of HSCs with thymic stroma. The 3D configuration
of the thymus maximizes this interaction, allowing intercellular
cross-talk integral to the development of both T cells and TSCs
(13). Paralleling the T cell precursor proliferation and differentia-
tion program, immature TECs undergo a developmental sequence,
resulting in the establishment of mature cTECs and mTECs orga-
nized in this 3D network. Several studies on mutant mice with
an abnormal organization of thymic epithelium substantiated the
concept that a reciprocal signaling between thymocytes and TSCs
is required, not only for the production of mature T cells but
also for the development and organization of the thymic microen-
vironment in a bi-directional fashion (14, 15). Mice showing a
blockage of the T cell development process, in the absence of T
cell receptor (TCR)-expressing cells, have a defective organiza-
tion of the thymic medulla, as well (16, 17). Of note, under this
condition, thymic medullary organization can be restored by the
addition of mature T cells, which follows stem cell transplanta-
tion (17, 18). In adult CD3etg26 mice, lacking intra-thymic T
cell precursors, a severe alteration of the cortical thymic archi-
tecture has been documented (19), even though a restoration of
the architecture and TEC development in these mice can occur.
Recently, the injection of either fetal or adult T-committed pre-
cursors into adult CD3etg26 mice leads to the reconstitution of
thymic microenvironment, as indicated by thymocyte differen-
tiation, organization of functional cortical and medullary areas,
and generation of Foxp3+ Treg and Aire+ mTECs (20). These
data suggest that adult TECs maintain the receptivity to cross talk
with thymocytes despite a prolonged absence of T cell precursors.
Moreover, the absence of both thymocytes and of the 3D frame-
work may result in changes of the keratin genes expression, thus
inducing the cTECs and mTECs to undergo a de-differentiation
process and to reacquire the precursor K5+K8+ cellular pheno-
type. Taken together, these findings suggest that signals from early
CD4–CD8– DN T cell precursors and/or their immediate prog-
eny provide necessary signals to promote the formation of the
thymic cortex, while, later in ontogeny, the differentiation of TECs
into a medullary phenotype are clearly dependent on the presence
of CD4+CD8− and CD4−CD8+ single positive (SP) thymocytes
(21–23). However, the precise molecular nature of the signals pro-
vided by developing thymocytes, which lead to the generation of
the thymic stromal compartment are still incompletely defined.
Eventually, a better understanding of the developmental process
through which a normal thymus structure is built, is essential
for a better comprehension of the intimate mechanisms which
take place within the thymus to promote the T cell development
in vivo. This knowledge may also be useful in designing future
therapeutic strategies, as alterations of the thymus structure and
function may result in serious health consequences, including
immunodeficiency or autoimmunity.
mTECS AND cTECS ARE SPECIALIZED CELLS PLAYING A
DIFFERENT ROLE IN THE T CELL EDUCATION PROCESS
T cell ontogeny is a sophisticated process, which takes place
through discrete stages during which developing thymocytes
dynamically relocate in different thymic areas, following a cortico-
medullary gradient.
The initial colonization of the thymus anlagen by migrant lym-
phoid progenitors occurs at an early stage, embryonic day 11.5
(E11.5) in mice and 8 week of gestation in humans (24, 25). Stud-
ies documented that chemokines CC ligand (CCL)21 and CCL25
play a major role in the early stage of fetal thymus colonization
(26, 27). Indeed, mice deficient for these chemokines or for the
cognate receptors, showed a significant reduction in the number
of thymocytes compared to normal mice (28). In post-natal thy-
mus, lymphoid progenitor cells through their cell surface adhesion
molecules, such as platelet-selectin glycoprotein ligand 1, inter-
act with P-selectin, expressed on the TECs, and thanks to this
interaction they are allowed to migrate from the blood into the
thymic parenchyma, in correspondence of the area around the
CMJ [Figure 1; (29)].
Entered thymocytes started to intensely proliferate and to
acquire T cell hallmarks. In this phase, T cell proliferation and
differentiation are triggered by a potent combination of signals
provided by cTECs. Delta-like 4 (DL4), which is an essential, non-
redundant ligand for Notch1 during thymic T cell development,
and IL-7 are critically involved in the activation of signaling path-
ways, leading to the proliferation and migration of thymocytes
(30–32). In particular, these intra-thymic ligands induce the devel-
opment of DN CD25+ cells, which migrate toward the subcapsular
region of thymic cortex (33). Several chemokine receptors have
been suggested to guide the migration of immature thymocytes,
such as CXCR4, CCR7, and CCR9 [Figure 1; (34)]. In the thymic
cortex DN thymocytes begin V(D)J rearrangement of their TCRβ
gene. Successfully rearranged TCRβ protein, assembled with the
pre-TCRα chains, forms the pre-TCR complex. Membrane expres-
sion of pre-TCR complex, along with the Delta-Notch interaction,
provides the signal necessary to induce the expression of the co-
receptors CD4 and CD8, as well as V-J rearrangement of the TCRα
genomic region. Subsequently, DP thymocytes with a functional
TCR-αβ receptor are generated [Figure 1; (35)].
Thymic cortex is also the area where takes place the positive
selection of DP thymocytes. Positive selection is the process by
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FIGURE 1 | Lympho-stromal interactions andT cell development. Bone
marrow HSCs enter into the thymus through CMJ, a process mediated by
CCL12 and CCL25 in the embryonic thymus and by the interaction between
P-selectin and its cognate ligand PSGL-1 in adult thymus. Stimulation by IL-7
allows the relocation of DN thymocytes from the cortex to the subcapsular
region. DP thymocytes bearing TCR and capable of binding to self-MHC
ligands are positively selected. This process is regulated by Pssr6 and b5t,
which are expressed in cTECs. Developing thymocytes are relocated from
cortex to the medulla by chemotactic attraction between CCR7 and the
ligands CCL19/CCL21, expressed on the mTECs. Into medulla, self-reactive
thymocytes are deleted through the negative selection, a process mediated
by dendritic cells and Aire-expressing mTECs.
which developing thymocytes, that recognize and bind with mild
avidity peptide-major histocompatibility complex on cTECs sur-
face, get a rescue signal through their TCR and are allowed to
further maturate to the CD4+CD8− or CD4−CD8+ SP stage.
Only a small fraction (1–5%) of DP cells survive to positive selec-
tion. By contrast, the majority of DP cells, that bind with too low
affinity to MHC complex, are programed to undergo death by
neglect (36, 37).
Cortical thymic epithelial cells have a crucial role in the posi-
tive selection process of T cells within thymus cortex (38). Recent
studies have found that cTECs exclusively express a specific form
of proteasome, referred as thymoproteasome, which contains a
peculiar catalytic subunit, the β5-thymus (β5t) (39). β5t subunits
exhibit an unique peptidase activity, compared to other β5 sub-
units found in common immunoproteasome, which leads to the
production of a set of self-peptides with a high affinity for class I
MHC molecules (40). Moreover, β5t-deficient mice show a severe
decrease in the number of CD8+ SP thymocytes, but no alteration
in the CD4+ number or in the thymic architecture. In addition, the
small fraction of CD8+ T cells, positively selected by β5t-deficient
cTECs, show altered immune responses toward several stimuli.
Taken together these results suggest that the thymoproteasome is
essential for the production of self antigens involved in the positive
selection of functional CD4−CD8+ T cells (41).
As for the positive selection of CD4+ T cells, two other pro-
teins predominantly expressed in cTECs, the lysosomal protease
Prss16 and Cathepsin L, have been demonstrated to be essential to
generate an immunocompetent repertoire of CD4+CD8− T cells
[Figure 1; (42, 43)].
TCR engagement by peptide-MHC complex also triggers the
expression of the chemokine receptor CCR7 in positively selected
thymocytes. Thanks to the chemotactic attraction between CCR7
and its ligands, CCL19 and CCL21, expressed on the mTECs,
developing thymocytes are relocated from cortex to the medulla
[Figure 1; (44, 45)].
In order to create a repertoire of mature T cells able to recognize
foreign antigens and, at the meantime, to ignore self antigens, SP
thymocytes have to undergo the negative selection process in the
thymic medulla. Both mTECs and DCs, play a pivotal role in this
last stage of thymocyte development, which is critical to establish
the central tolerance and, eventually, to prevent autoimmunity. In
contrast to cTECs, mTECs are characterized by a high expression
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of clustered tissue-restricted autoantigens (TSAs), the so called
promiscuous gene expression (46). To date, the autoimmune reg-
ulator (AIRE) transcription factor represents the only molecule,
so far identified, which contributes to the mTECs function and,
in particular, to the molecular regulation of the promiscuous gene
expression [Figure 1; (47)]. However, not all TSAs are regulated
in an AIRE-dependent manner, suggesting that other molecular
mechanisms, such as epigenetic mechanisms, may be involved in
mTECs function regulation. TSAs associated with class II MHC
molecules are presented directly by mTECs or indirectly by DCs
to developing thymocytes (48). T cells which recognize with a high
avidity self antigens are deleted. Remarkably, only a few number
of mTECs express a given TSAs (about 50–500 per thymus), and
lead to apoptosis by negative selection of a few thymocytes (37, 49,
50). A possible explanation is that the high motility of thymocytes
within the thymic medulla during a period of 4–5 days, allows each
of them to interact with mTECs (51). DCs play a similar role in
the negative selection process. They are attracted in the thymic
medulla by the chemochine XCL1 (lymphotactin), produced by
mTECs in an AIRE-dependent manner. Differently from mTECs,
DCs are not able to produce TSAs and the TSAs expressed mostly
derive from the phagocytosis of apoptotic mTECs (52, 53). mTECs
and DCs not only contribute to the establishment of central toler-
ance through the deletion of self-reactive T cells, but, also, through
the generation of regulatory T cells (Tregs) (54, 55, 65, 153), which
act in the periphery by suppressing autoreactive T cells, which have
escaped to the process of the central tolerance.
A body of evidence documents that the expression of an autore-
active TCR leads to the entry of the thymocyte into the Treg lineage.
Tregs, that are about 5–10% of peripheral T cells CD4+, constitu-
tively express the CD25 molecule and share several immunological
features, in humans and mice (56, 57). These cells specifically
express the transcription factor FOXP3 (Foxp3 in mice) that
plays a pivotal role in Tregs differentiation and function (58). The
Foxp3 promoter region and the conserved non-coding sequence 2
(CNS2) (known as TSDR, the Treg-specific-demethylated-region)
are fully methylated in immature thymocytes (59, 155). At the
beginning of Treg development, an appropriate TCR/CD28 signal
is needed to make available the Foxp3 promoter through shift of
the Protein Inhibitors of Activated STAT 1 (PIAS1), a signal cas-
cade, which results in the NF-κB-mediated transcription of genes
playing a role in Treg differentiation (60, 61).
THYMIC FORMATION: NEW INSIGHTS IN EPITHELIAL
LINEAGES SPECIFICATION
In the mouse, mTECs and cTECs originated from the third pha-
ryngeal pouch endoderm and the thymus anlage are located next to
that of the parathyroid. The expression of Forkhead-box transcrip-
tion factor n1 (Foxn1) approximately at E11.5 is crucial for the sub-
sequent epithelial differentiation, since in its absence, the coloniza-
tion of the anlage by T cell progenitors from the bone marrow fails
(62) and the subsequent T cell development and TECs formation is
aborted, resulting in a severe immunodeficiency (63, 64, 66, 154).
The maturation process of TECs during thymic organogen-
esis could be divided in two genetic phases. The first stage is
independent from the Foxn1 expression and consists in the induc-
tion and outgrowth of the thymic epithelial anlage from the third
pharyngeal pouch, through the expression of genes including the
Eya1 and Six (67), Hoxa3 (68), and Tbx1 (69, 70). During the sec-
ond genetic phase, epithelial patterning and differentiation take
place and the Foxn1 expression drives the immature epithelial cells
to differentiate into functional cTECs and mTECs (71).
FOXN1-INDIPENDENT GENETIC STAGE OF TEC
DIFFERENTIATION
In the first phase of the thymus organogenesis an interaction
between epithelial and mesenchymal cells occurs, while at the
later phase lympho-epithelial interaction predominates (72). In
mice, at about E10.5 the mesenchymal cells are able to respond
to the endodermic signals, which induce the development of
the primordial thymic epithelium (73, 74). Subsequently, at
about E12.5, the thymic rudiment is colonized by progenitors
come from the fetal liver, thus resulting in a tight epithelial-
thymocyte interaction within the mesenchymal derived capsule.
This thymic rudiment contains the EpCam+Plet1+ epithelial pop-
ulation (72, 75), which includes a common thymic epithelial
precursor (TEPC), from which both cTECs and mTECs will be
subsequently generated (72, 76).
Through studies on animal models carrying molecular alter-
ations of distinct genes, the key role of several transcription factors
involved in the thymus organogenesis and TEC-sublineage spec-
ification process, have thus far been identified (77). In particular,
several genes, including Tbx1 (69, 70), Pax1, Pax3, Pax9 (78–80),
Hoxa3 (68), Eya1, and Six1 (67) have been shown to play a central
role in the thymus ontogeny. Indeed, their molecular alteration
affects this well-orchestrated process, leading to disruption of the
thymic architecture. Abnormalities of the paired box (Pax) family
transcription factors Pax1 or Pax9 result in a blockage of the thy-
mus organogenesis (79, 81). Mutations in the Hox transcription
factor family member, Hoxa3, expressed on both thymic epithe-
lium and mesenchymal cells, result in athymia (68). Furthermore,
the homozygous loss of Tbx1, related to the DiGeorge syndrome
phenotype, leads to thymic a/hypoplasia in humans (69, 82), while
mice heterozygous for a null allele of Tbx1 show a mild pheno-
type without thymus anomalies (83). Therefore, the expression
of Tbx1 both in the pharyngeal core mesoderm and in the pha-
ryngeal endoderm is required for a proper thymus development.
However, it remains to be elucidated whether the expression of
Tbx1 in the TECs occurs and whether the gene participates in the
TECs development (4).
FOXN1-DEPENDENT GENETIC STAGE OF TEC
DIFFERENTIATION
In both humans and mice, the primordial TECs are yet unable to
fully support T cell development and only after the transcriptional
activation of the FOXN1 gene in the thymic epithelium this essen-
tial function is acquired. FOXN1 is a master regulator in the TEC
lineage development in that it promotes down-stream the tran-
scription of genes implicated in the thymus organogenesis and
TECs full differentiation.
Forkhead-box n1 transcription factor belongs to the FOX tran-
scription factor family implicated in a variety of biochemical and
cellular processes, including development, metabolism, aging, and
cancer (84, 85). During the post-natal life, Foxn1 is selectively
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expressed only in thymic and skin epithelia, where it regulates
the expression of several molecular targets to maintain the bal-
ance between growth and differentiation (86, 87). The signals
required for FOXN1 expression, and its activity, are still unclear,
even though the wingless (Wnt) proteins (88) and bone mor-
phogenetic protein (BMP) signaling have been shown to regulate
FOXN1 expression (89). Even though the complete pattern of
FOXN1 expression over the time and its role are not yet com-
pletely defined, studies on mouse and human model of gene
alterations enormously helped unravel important issues on its role.
Mutations in Foxn1 gene lead to alymphoid cystic thymic dysge-
nesis due to a defective TECs differentiation process (63, 90). In
both mice and humans FOXN1 abnormalities lead to a hairless
phenotype (87, 154).
In the Foxn1-dependent step of thymus organogenesis, precur-
sor epithelial cells differentiate into mature and functional cTECs
and mTECs from the same bi-potential TEC progenitor (4, 72, 76).
It has been reported, that Foxn1 is differentially expressed during
the TE-lineage specification, since it is expressed in all TECs dur-
ing the pre-natal life, but not in all TECs postnatally, indicating
that the gene is highly developmentally regulated. There is a body
of evidence documenting different effects of Foxn1 expression in
mTEC and cTECs. Particularly, studies on K5- and K18-CreERT-
mediated Foxn1-deleted mouse models suggested that during the
post-natal life, the loss of Foxn1 affected mTECs, characterized by
the expression of K5 and K14 keratins type. Conversely, the loss
of Foxn1 did not affect cTECs, which express the keratins K8 and
K18 (91, 92). Taken together, these data suggest that cTECs and
mTECs are not equally Foxn1-dependent in the post-natal life.
Recent reports highlighted a central role for Foxn1 in TECs
homeostasis in the adult thymus and its necessary role for the
functionality and survival of adult TEC progenitors (92), express-
ing K5+ and K14+ markers. This role in adult thymus seems to
be exerted in cooperation with other stem cell-related genes, such
as p63. Of note, the transcription factor p63, encoding for multi-
ple isoforms (93), plays a pivotal for the development of stratified
epithelia of several tissues, such as epidermis, breast, prostate, and
thymus (94). In the thymus, the p63 protein drives the prolifera-
tion of epithelial progenitor cells (94, 95). Therefore, it has been
hypothesized that p63 and Foxn1 could act synergistically through
the formation of a p63-Foxn1 regulatory axis aimed at regulating
TECs homeostasis. However, the molecular mechanism through
which the proliferation regulator p63 and differentiation regulator
Foxn1 collaborate in this axis are still unclear.
FOXN1-MEDIATED GENE EXPRESSION FOR TEC
DIFFERENTIATION
Forkhead-box n1 is directly or indirectly implicated in the tran-
scriptional regulation of a panel of genes involved in thymus
development and function.
Pax1 is a key regulator of TEC differentiation/survival balance.
Pax1 is expressed in the third pharyngeal pouch from E9.5 dur-
ing the thymus ontogeny, while in the post-natal thymus only in
cTEC (96). Even though the regulation of Pax1 is still unclear,
from E11.0 its expression requires Hoxa3 (68). Of note, the loss
of Hoxa3 impairs the intrinsic ability of the neural crest cell pop-
ulation to differentiate and/or to lead to the differentiation of the
tissues of pharyngeal arch and pouch. Indeed, in Hoxa3 mutant
mice the thymus is absent and thyroid hypoplasia has been docu-
mented (68). Moreover, the first step of thymus development is the
expansion of mesenchymal neural crest in the posterior part of the
third pharyngeal pouch. Prior to this event, in the Hoxa3 mutant
embryos a marked reduction in Pax1 expression has been shown.
Similarly, Pax1 mutant mice also show thymic hypoplasia, suggest-
ing a role for Hoxa3 in maintaining Pax1 expression in these cells
(68). In the thymic primordium, Pax1 expression is under the con-
trol of Foxn1 (71). This finding indicates that Foxn1 and Hoxa3 are
both involved in the network of molecular signals that regulates
Pax1 expression, thus demonstrating the existence of a molecular
and/or functional interaction between Hoxa3 and Foxn1 [Figure 2;
(71)]. In keeping with this, Hoxa3+/−Pax1−/− compound mutant
mice display a few phenotypic hallmarks of the Foxn1R/R mouse
model, which expresses low-dose of Foxn1, such as hypomorphic
post-natal thymus, and reduced levels of MHC class II expres-
sion on the TECs surface (80). These data suggest two alternative
hypothesis: Hoxa3 may regulate Foxn1, which, in turn, regulates
Pax1 expression in the thymic primordium, in a Foxn1-dependent
manner, or Hoxa3 and Foxn1 induce Pax1 expression in the third
pharyngeal pouch and in early thymus primordium.
It has also been shown that Foxn1 regulates the expression of
CCL25 and Dll4 (Figure 2). These genes play a pivotal role in the
thymocyte development, since CCL25 regulates the colonization
of the fetal thymus (97), while the Notch ligand Dll4 is involved in
the commitment of hematopoietic progenitors to the T cell lineage
(30). In both early fetal TEC and in the post-natal thymus, Dll4
expression is directly related to the Foxn1 expression (71). Fur-
thermore, these molecules are absent in the Foxn1 null thymus,
even though there is evidence indicating that their expression may
occur in a Foxn1-independent manner in TECs (98, 99). Eventu-
ally, in a recent report it has been shown that Foxn1 is upstream
of dll4a and ccl25a expression in medaka fish, thus confirming the
relationship with this transcription factor (100).
THE HUMAN NUDE/SCID PHENOTYPE: A MODEL OF THYMIC
MICROENVIRONMENT DISRUPTION AND FAILURE OF THE T
CELL DEVELOPMENT
The Nude/severe combined immunodeficiency (SCID) pheno-
type represents the prototype of thymic architecture disruption
due to alterations of the FOXN1, which is the master regulator of
TE-lineage specification (71).
In humans, as in mice and rats, mutations in the “nude” Foxn1
gene induce the hairless phenotype, associated with a rudimen-
tary thymus gland (T cell related primary immunodeficiency).
The human Nude/SCID phenotype (MIM 601705; Pignata Guar-
ino Syndrome) was first identified in 1996, after more than 30 years
from the initial mouse description, in two sisters originated from
a small community with a high grade of inbreeding, who showed
congenital alopecia of the scalp, eyebrows, and eyelashes, nail dys-
trophy, and a severe T cell immunodeficiency, inherited as an
autosomal recessive disorder (154). This phenotype was associ-
ated with a C792T transition in the FOXN1 gene, which resulted
in the nonsense mutation R255X in the exon 4 (formerly exon
5), with a complete absence of a functional protein similar to the
previously described rat and mouse Foxn1 mutations (101–103).
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FIGURE 2 |The thymus organogenesis. The thymus organogenesis is
characterized by two genetic phases. The first stage is independent from
the Foxn1 expression (1) and consists in the induction and outgrowth of
the thymic epithelial anlage from the third pharyngeal pouch, through the
expression of genes including the Eya1, Six, Hoxa3, andTbx1. Hoxa3 and
Eya1 are also required in neural crest cells (NCCs). In the phase 2, Foxn1
regulates the expression of CCL25, Dll4, and Hoxa3, necessary for the
thymocytes and TECs differentiation. During this step, cTECs (expressing
K8 and K18 keratin type) and mTECs (expressing K5 and K14 keratin type)
originate from the same bi-potential TEC progenitor. The crosstalk between
TECs and developing thymocytes is required to generate fully mature TECs
and functional T cells.
In the absence of Foxn1 expression, thymic development is
halted at a rudimentary stage. As a consequence, in the affected
patients the thymic lobe is still present but intra-thymic lym-
phopoiesis is completely blocked (63, 104) leading to severe pri-
mary T cell immunodeficiency (105–107) and to death in early
childhood from severe infections (105, 108–112, 154). Foxn1 is
also involved in morphogenesis and maintenance of the 3D thymic
micro-structure, which is necessary for a fully functional thymus
(113, 114). In fact, evidence is available that in an in vitro 2D
culture system consisting of a monolayer of mouse bone mar-
row stromal OP9 cells it is possible to generate mature T cells,
only if these cells are transduced with the Notch ligand Delta-
like 1 (OP9-DL1) (115, 116), whose pathway exerts a pivotal and
necessary role in promoting the induction of T cell-lineage com-
mitment (117–119). Of note, in all these co-culture systems, the
stromal cells are enforced to overexpress Notch ligands, and their
expression by TECs seems to be maintained only in a 3D thy-
mus structure (120). In human Nude/SCID, the T cell defect is
characterized by the absence of proliferative response to the com-
mon mitogens and a severe blockage of the T cell differentiation
(154). Recent studies revealed the presence of some circulating
T cells of non-maternal origin in patients carrying alterations of
FOXN1 gene. These cells have been shown to be predominantly
double-negativeαβT cells (CD3+CD4−CD8−, DN) and to exhibit
a regulatory like T cell phenotype (FoxP3+). This finding raised
important issues regarding the site of differentiation of these cells.
One hypothesis is the persistence of a thymic rudiment, which
allows a partial T cell development (109). Alternatively, a T cell
differentiation, even though partial and ineffective to result in a
productive immunity, could occur at an extra-thymic site. In both
pre-natal and post-natal life, the TCRBV spectratype repertoire in
Nude/SCID patients is oligoclonal, thus confirming the immatu-
rity of the process and, at the same time, that developmental events
do take place at some extent (111, 112).
For many years, the human counterpart of the nude mouse phe-
notype has been erroneously considered the DiGeorge syndrome,
Frontiers in Immunology | T Cell Biology July 2013 | Volume 4 | Article 187 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Romano et al. FOXN1 in thymic epithelial development
which occurs spontaneously and is mainly characterized by thymic
hypo/aplasia and a mild T cell defect. However, several lines of
evidence argue against the analogy between these two disorders.
In fact, the DiGeorge syndrome is often associated with neona-
tal tetany and major anomalies of great vessels. These defects are
due to malformation of the parathyroid and heart, derived from
a major embryologic defect in the third and fourth pharyngeal
pouch from which the thymus primordium emerges. In addition,
in this syndrome hairlessness is missing and gross abnormalities
of skin annexa are not found. Children with DiGeorge syndrome
may also have lymphopenia, with a mild reduction of T cells, that
are however usually responsive to common mitogens.
In Nude/SCID patients, skin is tighter than usual and is charac-
terized by basal hyperplasia and dysmaturity. Alopecia is primitive
in nature, in that it can be observed at birth and persists after bone
marrow transplantation, thus ruling out the acquired nature of the
disorder. In keeping with this, in athymic mice, completely lacking
body hair, restoration of the thymus did not lead to hair growth,
indicating a direct participation of FOXN1 to hair follicle develop-
ment (87). The most frequent phenotypic alteration affecting the
nails is koilonychia (“spoon nail”), characterized by a concave sur-
face and raised edges of the nail plate, associated with significant
thinning of the plate itself; canaliform dystrophy and a transverse
groove of the nail plate (Beau line) may also be observed (121).
However, the most specific phenotypic alteration is leukonychia,
characterized by a typical arciform pattern resembling a half-moon
and involving the proximal part of the nail plate. These alter-
ations of digits and nails were also reported in a few strains of
nude mice. Of note, nail dystrophy has also been observed in het-
erozygous subjects carrying FOXN1 alterations (121). FOXN1 is
known to be selectively expressed in the nail matrix, where the
nail plate originates, thus confirming that this transcription factor
is involved in the maturation process of nails and suggesting nail
dystrophy as an indicative sign of heterozygosity for this molecular
alteration (121).
Autoptical study of a fetus homozygous for R255X muta-
tion revealed multiple-site neural tube defects, including anen-
cephaly and spina bifida. This finding may help explaining the
high rate of mortality in utero observed in the population where
the first patients were identified (105). Intriguingly, the other
forms of SCID become clinically evident only during the post-
natal life, when the protection of the newborn transferred from
the mother immune system declines. This observation, suggests
that other causes different from immunodeficiency, are respon-
sible for the high rate of mortality in utero and led to consider
the Nude/SCID mutation and anencephaly causally related. Of
note, in a recent study, the mouse Foxn1 gene was found to be
expressed also in epithelial cells of the developing choroids plexus,
a structure filling the lateral, third and fourth ventricles of the
embryonic brain (105). Moreover abnormality in the develop-
ment of corpus callosum were also found in another FOXN1
mutated fetus even in the absence of anencephaly, indicating that
the transcription factor may play a role as a co-factor in the brain
ontogeny (105).
Altogether these findings suggest that FOXN1 may also be
implicated as co-factor in the development of vital systems
required for a proper fetus development, thus explaining the
mortality in the first trimester in fetuses carrying the genetic
alterations, which is not justified by the SCID per se.
FOXN1 MUTATION PREVENTS THE PRE-NATAL T CELL
DEVELOPMENT IN HUMANS
It is now clear that FOXN1 acts as a transcription factor impli-
cated in the differentiation of thymic and skin epithelial cells, even
though many of its molecular targets still remain to be discov-
ered. Most of the knowledge so far available has been achieved in
humans in the post-natal life, while little is known about FOXN1
role during the pre-natal life.
Of note, other FOX family members, including Foxq1 and
Foxm1b, are important during embryogenesis, being involved
in a variety of biological processes (122). Approximately 50%
of Foxq1−/− murine embryos die in utero, thus suggesting the
requirement of this gene during embryogenesis (123). Similarly,
Foxm1b is important during liver regeneration (124).
Studies on thymus organogenesis revealed that Foxn1 is
expressed in all TECs during fetal stages. Of note, Foxn1−/−
mice showed undifferentiated TECs responsible for a blockage
of thymopoiesis and severe immunodeficiency (125). Recently,
the identification of a human FOXN1−/− fetus gave the unique
opportunity to study in humans the T cell development in utero,
in the absence of a functional thymus. Vigliano et al. documented a
total blockage of the CD4+ T cell maturation and a severe impair-
ment of CD8+ cells, with an apparent bias toward TCRγδ+ cells
(112). In this case in the congenital absence of the thymus was
due to R255X missense mutation in the FOXN1 gene. In particu-
lar, it has been reported that in the absence of FOXN1 a few not
functional CD8+ cells, mostly bearing TCRγδ in the absence of
CD3, presumably of extra-thymic origin could develop in both
humans and mice (126–128). Further analysis of the fetal RNA,
performed to evaluate the variable-domain β-chain (Vβ) fami-
lies’ usage among T lymphocytes, revealed that the generation of
TCR diversity occurred at some extent in the FOXN1−/− fetus,
but was abnormal. Thus, these data provided a further evidence
of the crucial role for FOXN1 in the early pre-natal stages of T
cell development and not in the B and NK-cell differentiation,
these populations being normally present in the Nude/SCID fetus
(112). A similar impairment of the T cell differentiation with a
selective blockage of CD4 differentiation but not of CD8, was
detected in murine models characterized by the absence of the
nuclear high-mobility group (HMG) box protein TOX (107).
The identification of a limited number of CD8+ cells bear-
ing the TCRγδ suggests that this cell population may develop at
extra-thymic sites in a FOXN1-independent manner, even though
they are unable to sustain a productive immune response into the
periphery. Indeed, evidence exists indicating that T cells may also
differentiate at extra-thymic sites, as intestine and liver (129–133).
Of note, the majority of thymus-derived T lymphocytes bears the
αβ chains of TCR and a few of them express the γδ heterodimer
(134), while the T cell pool developed outside the thymus is char-
acterized by a higher proportion of TCRγδ+ T cells expressing the
CD8αα homodimer, instead of the CD8αβ (135, 136). Moreover,
also DN T cells (CD3+CD4–CD8–) and lymphocytes expressing
CD7 and CD2 in the absence of CD3 (CD2+CD3–CD7+) are
generally considered of extra-thymic origin (135–137).
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In spite of the well documented knowledge on the role of the
primary lymphoid organ to foster T cell development, some still
unsolved issues in human athymic conditions indicate that an in-
depth information of the overall process is still to be achieved and,
in particular, the involvement of different tissues in T cell ontogeny
must be definitively clarified. Since FOXN1 is selectively expressed
in the thymus and skin, one possibility to explain the presence of
the few non-functional CD8+TCRγδ+ cells in Nude/SCID fetus is
that skin epithelial cells could play a partial role in T cell ontogeny,
as already shown in in vitro models (138, 139).
THYMUS TRANSPLANTATION: A PROMISING TREATMENT
TO ATHYMIC DISORDERS
Forkhead-box n1 deficiency is a very rare immunodeficiency with
unfortunately poor chance of curative treatments. Recently, thy-
mus transplantation has emerged as a promising treatment for
children affected with congenital athymia (140–143), as that
observed in complete DiGeorge anomaly and in FOXN1 deficiency.
Conceptually, the thymus transplant seems to be in principle the
more appropriate therapeutic strategy, taking into account that
bone marrow transplantation performed in one child with FOXN1
deficiency, failed to induce a long-term sustained immune recon-
stitution. In particular, in this patient no reconstitution of the
naïve T cell pool was observed (144).
Thymus transplantation has been first used in children affected
with complete DiGeorge anomaly, with excellent clinical and
immunologic results (141). In order to achieve immune recon-
stitution, cultured post-natal allogeneic thymus tissue slices were
transplanted into the quadriceps muscles of the athymic host
(145). The migration of host bone marrow stem cells to the donor
graft allow them to develop into naive T cells, which then emi-
grate out of the engrafted thymic tissue into the peripheral blood.
Thymopoiesis is observed in biopsies of the transplanted thymus
within 2 months of transplantation (140) and naive T cells are
detected in the peripheral blood approximately 3–5 months after
transplantation (146, 147). Taking advantage from this previous
experience, a few years ago an allogeneic thymus transplantation
has been used for the first time in two unrelated infants with
Nude/SCID phenotype due to a deficiency of the transcription
factor FOXN1 (111). The clinical phenotype of the two subjects
was characterized by the absence of naïve T cells, total alope-
cia, nail dystrophy, and severe infections, as disseminated Bacillus
Calmette–Guérin in subject 1 and severe respiratory infections
in subject 2. Molecular analysis, performed to confirm the clin-
ical suspect of the Nude/SCID phenotype, revealed the presence
of a homozygous R255X mutation in the FOXN1 gene in subject
1, the same of that previously described (107), and a homozy-
gous R320W novel missense mutation in the subject 2. Moreover,
subject 1 showed, like a small percentage of complete DiGeorge
patients, referred as atypical complete DiGeorge, circulating oligo-
clonal T cells of non-maternal origins, which were predominantly
double-negative T cells, and a T cell proliferative response to PHA
within the normal range. Because of that, before thymus trans-
plantation subject 1 have required immunosuppression regimen
to prevent graft rejection. Differently, immunosuppression was not
used for the subject 2, who had, like typical complete DiGeorge
patients, very few T cells (141, 146).
Results obtained with thymus transplantation were encourag-
ing in both FOXN1-deficient subjects, and led to a full T and B
cell reconstitution and functional rescue. Indeed, both subjects
developed naïve T cells, diverse TCR repertoires and an in vitro
proliferative T cell responses against different antigens. Eventually
they reached normal serum Ig levels with generation of protective
antibody specific titers. Of note, HLA matching for class I and II
did not seem to interfere with T cell counts after thymus transplan-
tation, being subject 2 transplanted without any HLA matches.
However, CD8+ T cell number, although apparently functional,
was disproportionally low compared to CD4+ T cells (111). A
poor CD8 recovery has also been described in complete DiGeorge
patients, who underwent HLA-mismatched thymic transplanta-
tion (141, 148). Possible explanations are that the phenomenon is
related to the HLA mismatch between host hematopoietic precur-
sors and allograft thymic epithelia or to alterations in the thymic
graft due to transplantation procedures.
Functionality of the thymic allograft has been assessed for
the first time through signal joint (sj) and DβJβ T cell recep-
tor rearrangement excision circle (TREC) analyses (109). The
sj/βTREC represents a ratio between early and late products of
TCR rearrangements, which directly correlate with thymic output
and provide an indirect measurement of thymocyte division-
rate (149–151). The sj/βTREC ratio quantification, conducted
in subject 1 with R255X mutation, was very low during the
peri-transplant period and comparable to those observed in
healthy children at 2.5 years post-transplant. Of note, 4 years post-
transplantation a decrease of sj/βTREC ratio associated with a
reduction in sjTREC levels and in the number of naïve cells
were found, suggesting the decline in thymic allograft output
(109). This decline might be due to the reduced longevity of
the thymus allograft or to peripheral homeostasis of the T cell
pool maintenance following its replenishment. Overall, the thy-
mus transplantation seems to be a promising curative strategy
for subjects with athymia due to FOXN1 deficiency or com-
plete DiGeorge syndrome in the perspective of long-term clinical
benefit.
CONCLUSION
The integrity of the thymic epithelial architecture allows the
growth, the differentiation, and TCR repertoire selection of imma-
ture T cells, thus originating fully mature and functional T cells.
Of note, the failure to generate or to maintain the proper 3D
thymic architecture leads to severe immunodeficiency or autoim-
munity. The unique function of the thymus in the establish-
ment/maintenance of the T cell pool is related not only to the
peculiar 3D structure, but also to the specialized functions of the
thymic stroma. Indeed, lympho-stromal interactions within the
multicellular thymic microenvironment play a crucial role in the
regulation of the T cell development. Moreover, these interactions
are based on a bilateral crosstalk between stromal cells and trav-
eling thymocytes, which, in turn, are able to provide important
signals for the TECs differentiation.
Thymus organogenesis and T cell development are sophisti-
cated biological processes, which require the activation of a wide
panel of genes. There is evidence that the master regulator of
the thymus development is the Foxn1 gene, since it is required at
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multiple intermediate stages of the TE-lineage specification either
in the fetal and adult thymus, through the direct or indirect regu-
lation of genes involved in the thymus development and function.
These genes include Pax1, Hoxa3, CCL25, Dll4, p63.
Studies on the animal and human model of the Nude/SCID
phenotype have provided an enormous contribution in identify-
ing the crucial role of Foxn1 to drive the thymus development,
even though many issues regarding the transcriptional regula-
tion of the TECs specification and homeostasis still remain to be
solved. The development in vitro of cellular models of TEC lineage
differentiation, by using the technology of nuclear reprograming,
will be certainly useful to better characterize the discrete stages of
the TECs differentiation and the molecular mechanism involved
in the process.
Eventually, the in vitro re-build of a thymic environment capa-
ble to reproduce tissue features of primary lymphoid organs (139,
152) could be a promising and valuable tool for the treatment of
congenital athymia, including FOXN1 deficiency, along with the
thymus transplantation, which is emerged as a potential treatment
for these disorders.
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CHAPTER 4 
“Rare genetic syndrome involving immune system” 
 
4.1 Severe combined immunodeficiencies – an update 
Severe combined immunodeﬁciencies (SCIDs) includes a number of different inherited 
disorders characterized by a complete absence or  severe dysfunction of the T and B cells, 
leading to a combined immunodeficiency, which involves both cellular and humoral adaptive 
immunity. The incidence calculated on the basis of the newborn screening programs in US 
is of 1 in 58,000 live-births, an incidence much higher than the previous estimate of one in 
100,000 based on retrospective clinical diagnosis of SCID (4). SCIDs are classified according 
to the presence or absence of T, B and NK cells. This classification is representative of the 
stage where the blockage occurs during the differentiation process and is, therefore, very 
useful to direct the molecular studies toward a certain genetic alteration (Figure 10). 
Figure 10: T, B and NK cells ontogeny in SCIDs.  Hematopoietic stem cells (HSC) originate 
into the bone marrow, which is the only normal site of hematopoiesis in the adult.  These 
cells have self-renewal capacity and can give rise to all the blood cell types from the myeloid 
and lymphoid lineages.  All lymphocytes originate from a common lymphoid progenitor 
(CLP) that can only give rise to T, B and NK cells.  B and NK cells complete their 
development in the bone marrow, while T cells migrate to and mature into the thymus.  Sites 
of action of different genes involved in lymphocytes ontogeny are indicated.  Alterations in 
single genes affect one or more cell lineage development.  Blue lines represent the site where 
the blockage occurs and the populations affected. 
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Even though children with SCID appear healthy at birth, early in life, as the maternal 
transferred antibodies decline, they suffer from severe bacterial, viral or fungal infections. 
Interstitial lung disease, chronic diarrhea and failure to thrive are the hallmarks of these 
syndromes at the onset.  Skin rashes may be found in some patients as a consequence of 
transplacental engraftment of maternal T cells during pregnancy or activation of autologous 
T cells against skin components as a sign of a wide autoreaction (204). According to the 
ESID diagnostic criteria SCID should be diagnosed in patients who exhibit an absence or a 
severe reduction of T cells (CD3+ < 300/μL), absence or severe reduction of the proliferative 
response to phytohemagglutinin (<10% of the lower limit), or a maternal lymphocyte 
engraftment (17). CID should be diagnosed in the presence of one of the following 
 
 
 
 
165 
parameters: one severe infection, an immunodysregulation disorder, cancer, familial CID 
associated with moderate age-related reduction of CD3+,CD4+,CD8+ T cells or of naive T 
cells. However, a cutoff to distinguish SCID from CID has not yet been well deﬁned. 
SCIDs are often fatal when the diagnosis is made too late (205). HSCT represents the only 
curative treatment for most patients (17). To date, gene therapy offers a cure for two speciﬁc 
forms of SCID (206). The conventional classification based on the speciﬁc immunologic 
phenotype may be very useful in directing molecular studies toward a certain genetic 
alteration. However, the identification of many new causative gene alterations with peculiar 
clinical and immunological phenotypes and the identification of hypomorphic mutations in 
some SCIDs genes, and the identification of extra-hematopoietic alterations, which leads to 
complex phenotypes can make the diagnostic process very complex by standard methods. 
Taking this into account, the traditional international classiﬁcation of SCIDs may no longer 
be optimal for both clinical and research purposes (38, 207). 
Recently, T cell receptor excision circles (TREC)–based newborn screening has been 
introduced in several countries. Patients identiﬁed through newborn screening programs, 
similar to children identiﬁed because of a positive familial history, can receive an earlier and 
accurate diagnosis by one month of life and then undergo HSCT or gene therapy by 3 months 
of age, before the occurrence of severe complications. This results in a signiﬁcantly improved 
outcome (208, 209). 
In this review, published on Annals of New York Academy of Sciences, different forms of 
SCID and CID, were discussed in detail, paying attention to the distinctive peculiar clinical 
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and laboratory features, in order to provide information to clinicians for recognizing and 
carefully managing these novel forms of PIDs. 
 
Conclusive remarks 
SCIDs are a heterogeneous group of syndromes caused by alterations of distinct genes 
implicated in the maturation and/or function of T, B, and/or NK cells. The advent of next 
generation sequencing lead to the identification of new gene alterations responsible of 
different forms of SCID and CID. The phenotypic and the molecular heterogeneity of SCIDs, 
as revealed by the expanding phenotypes observed, is making traditional classiﬁcation of this 
group of disorders very intricate. This is further complicated by the evidence that different 
mutations in the same gene can lead to different clinical phenotypes, that may even be 
inherited with different mechanisms. 
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Severe combined immunodeficiencies (SCIDs) are a group of inherited disorders responsible for severe dysfunctions
of the immune system.These diseases are life-threateningwhen the diagnosis ismade too late; they are themost severe
formsof primary immunodeficiency. SCIDpatients oftendie during thefirst twoyears of life if appropriate treatments
to reconstitute their immune system are not undertaken. Conventionally, SCIDs are classified according either to the
main pathway affected by the molecular defect or on the basis of the specific immunologic phenotype that reflects
the stage where the blockage occurs during the differentiation process. However, during the last few years many new
causative gene alterations have been associated with unusual clinical and immunological phenotypes. Many of these
novel forms of SCID also show extra-hematopoietic alterations, leading to complex phenotypes characterized by a
functional impairment of several organs, which may lead to a considerable delay in the diagnosis. Here we review
the biological and clinical features of SCIDs paying particular attention to the most recently identified forms and to
their unusual or extra-immunological clinical features.
Keywords: severe combined immunodeficiency; SCID; primary immunodeficiency; nude/SCID;DiGeorge syndrome;
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Introduction
Severe combined immunodeficiencies (SCIDs) are
a group of inherited disorders responsible for se-
vere dysfunctions of the immune system that lead
to the absence or dysfunction of the T and B cells
derived from the thymus gland and bone marrow,
thus affecting both cellular and humoral adaptive
immunity. Recently, Kwan et al., on the basis of data
obtained from 11U.S. newborn screening programs
in the general population, reported an incidence of
SCID of 1 in 58,000 live-births, an incidence much
higher than the previous estimate of one in 100,000
based on retrospective clinical diagnosis of SCID.1
This group of diseases belongs to the most severe
forms of primary immunodeficiency (PID), which
are often fatal when the diagnosis is made too late.2
Even though children with SCID appear healthy at
birth, they are predisposed to severe bacterial, vi-
ral, and fungal infections as the maternal trans-
ferredantibodiesdecline.During thefirst yearof life,
failure to thrive, diarrhea, and oral candidiasis are
common findings; Pneumocystis jiroveci may fre-
quently cause a severe interstitial pneumopathy;
andmaternal engraftment of lymphocytes can cause
graft-versus-host disease (GVHD).3 SCID patients
often die during the first two years of life if appropri-
ate treatments to reconstitute their immune system
are not undertaken.4 For most patients, the only
curative treatment is the allogeneic hematopoietic
stem cell transplantation (HSCT).5 Gene therapy
offers a cure for two specific forms of SCID and,
although other SCID forms may become amenable
to this treatment in the future, it is likely that HSCT
will continue to be used for the majority of SCID
patients.6
Conventionally, SCIDs canbe classified according
either to the main pathways affected by the molecu-
lar defect or on the basis of the specific immunologic
phenotype related to that genetic defect, as T cell–
deficient but normal B cell (T−B+) SCID and both
T cell– and B cell–deficient (T−B−) SCID, with a
further subdivision depending on the presence or
doi: 10.1111/nyas.12849
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absence of NK cells (NK+ or NK–, respectively).2
This classification, traditionally considered as rep-
resentative of the stage where the blockage occurs
during the differentiation process, was, until a few
years ago, very useful in directing molecular studies
toward a certain genetic alteration.However, during
the last years many new causative gene alterations
have been identified with peculiar clinical and im-
munological phenotypes. In a few cases, the genetic
alteration allows for a normal T cell differentiation
program but compromises T cell functionality by
affecting the initial or final phase of intracellular
signaling. These functional T cell disorders are
characterized by immune dysregulation and cancer
predisposition, as well as infections. In addition,
hypomorphic mutations in some SCIDs genes
make possible the development of nonfunctional
oligoclonal T cells that are responsible for a complex
of clinical conditions thatmay include hyperinflam-
mation or autoimmunity. Many of the novel forms
of SCID also show extra-hematopoietic alterations,
leading to complex phenotypes characterized by
functional impairment of organs different from
primary lymphoid organs, which can make the
diagnostic process very complex by standard
methods. Taking this into account, the traditional
international classification of SCIDs based on
immunophenotype may no longer be optimal
for clinical and research purposes7,8––diagnostic
criteria have to be continuously updated to take into
account these unusual phenotypic presentations. In
his work of 2014, Shearer emphasizes that currently
there is no consensus among clinical immunologists
on how best to diagnose and treat these rare disor-
ders. It is not surprising that an important clinical
dilemma concerns the distinction of SCIDs from
other diseases such as combined immunodeficien-
cies (CIDs). Recently, it was proposed that patients
who exhibit an absence or a severe reduction of
T cells (CD3+ < 300/L), absence or severe reduc-
tion (<10% of the lower limit) of a proliferative
response to phytohemagglutinin, or a maternal
lymphocyte engraftment should be defined as hav-
ing typical SCID.5 Moreover, the European Society
for Immunodeficiency suggested as criteria for the
diagnosis ofCID thepresence of oneof the following
parameters: one severe infection, an immunodys-
regulation disorder, cancer, familial CID associated
with moderate age-related reduction of CD3+,
CD4+, CD8+ T cells or of naive T cells. However,
a cutoff to distinguish SCID from CID has not yet
been well defined.
A main aim of this review is to report on the
biological and clinical features of SCID, paying at-
tention to the most recently identified forms and
to the unusual or extra-immunological clinical fea-
tures (Table 2). An attempt to relate together patho-
genetic mechanisms to specific clinical features is
proposed (Table 1).
SCID due to defective survival of
hematopoietic lineage precursors
Reticular dysgenesis (RD) is an autosomal recessive
form of SCID characterized by both early myeloid
lineage differentiation arrest and impaired lym-
phoid development.9 It is considered the most se-
vere form of SCID, accounting for less than 2%. A
peculiarity of this disorder is the presence of sen-
sorineural deafness. RD is caused by biallelic muta-
tions in the adenylate kinase 2 gene (AK2), which
cause the absence or the strong reduction of the
expressionofAK2protein.9,10 The syndrome is char-
acterized by the absence of granulocytes and lym-
phocytes in peripheral blood. Compared to all the
other forms of SCID, RD-associated neutropenia,
which is unresponsive to granulocyte-colony stim-
ulating factor (G-CSF), predisposes the patients to
severe infections.11 The only available treatment for
RD is allogeneic HSCT, which indicates that the
inherited defect is cellular and not linked to the
micro-environment, as previously thought. Neu-
trophil differentiation abnormalities of RD patients
are corrected by the restoration of AK2 expression
in the bone marrow, thus confirming the specific
role of AK2 in the development of the myeloid
lineage.12 Moreover, AK2 is specifically expressed in
the stria vascularis region of the inner ear, which ex-
plains the sensorineural deafness observed in these
individuals.10 AK2 is localized in the mitochondrial
intermembrane space where it regulates adenine
nucleotide interconversion within the intermem-
brane space;13 a very similar function is mediated
by the cytoplasmatic enzyme AK1. The function
of AK1/2 is classically described to be the main-
tenance of a constant concentration of adenine
nucleotides and the monitoring of mitochondrial
energy state through a finemechanismof nucleotide
sensing and signaling. The molecule also plays a
central role in the control of apoptosis through the
Fas-associated protein with death domain (FADD)
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Table 1. New clinical phenotypes associated with old forms of nonsyndromic SCID/CID and new genetic defects
Gene defect Old phenotype New phenotype Pathogenetic mechanism
Reference
AK2 Absence of granulocytes, severe
lymphopenia sensorineural
deafness
OS Peripheral expansion of
oligoclonal T lymphocytes
15
IL2RG (c)
JAK3
T–B+NK– SCID, leaky T+B+NK–
SCID, immune-dysregulation
and autoimmunity
Hodgkin like features,
invagination and HLH
Selective CD4+
T lymphopenia
Not clear; maternal GVHD
Hypomorphic mutation
associated with somatic
chimerism
55,56
51
RAG Severe hypogamma-
globulinemia, marked
reduction of T and B cells, OS,
incomplete OS
Granulomatous lesions,
EBV-related lymphoma,
Idiopatic CD4+ T
lymphopenia with
extensive chickenpox
Hypomorphic mutations 70
CORO1A T–B–NK+ SCID, severe
postvaccination chickenpox,
language delay, behavioral and
cognitive impairment
EBV B cell
lymphoproliferation
Not clear; null and
hypomorphic mutations
of Coro1A in mice are
associated with defects
in T cell survival and
migration
79
FOXN1 Human nude/SCID Eczematous rash,
erythroderma, severe
diarrhea and alopecia
Residual T cell development
sustained by rudimentary
thymus or extrathymic
lymphoid sites
80
IL21R NA Cryptosporidiosis, chronic
cholangitis and liver
disease, abnormal IL-21
induced proliferation,
defect of immunoglobulin
class-switching, and NK
cell cytotoxicity
Abrogation of IL-21 ligand
binding, defective
cytokine secretion
99
ZAP70 Selective CD8+ lymphopenia and
normal/elevated numbers of
not functional CD4+ T cells
Late onset disease, cutaneous,
erythematous lesions,
immune dysregulation
erythroderma
Possible role of hypomorphic
mutations on T
lymphocytes effector and
suppressive function
113
MALT1 NA CID Abnormal IL-12 production,
failure of IB degradation
114
BCL10 NA Profound T and B memory
cell deficiency, severe
hypogammaglobulinemia
Impairment of NF-B
pathways
115
CARD11 NA CID Abnormal IL-12 production,
Treg cells deficiency
101
TTC7A NA CID-MIA Defective thymopoiesis 116
LCK, UNC119 NA CD4+ lymphopenia,
restricted T cell repertoire,
immune dysregulation
Impaired TCR signaling 122
IKBK2 NA Mycobacterium avium and
tuberculosis infections,
neurological impairment,
hypogammaglobulinemia,
normal T cells count with
absence of Treg and  /
T cells
Impairment of IKK2–NF-B
signaling
124
Note: OS, Omenn syndrome; HLA, hemophagocytic lymphohistiocytosis, GVHD, graft versus host disease; MIA,
multiple intestinal atresia; NA, not applicable.
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Table 2. Pathogenetic mechanisms of SCID
Pathogenetic mechanism Defect Phenotype Inheritance
Defective survival of haematopoietic
precursors
AK2 T–B–NK– AR
Toxic metabolite accumulation ADA T–B–NK– AR
PNP T–B+NK– AR
Cytokine signaling anomalies IL-2RG T–B+NK– XL
JAK3 T–B+NK– AR
IL-7RA T–B+NK+ AR
V(D)J recombination and TCR
abnormalities
RAG1/RAG2, Artemis,
DNA-PKcs, Cernunnos,
LIG4
T–B–NK+ AR
TCR abnormalities CD45 T–B+NK+ AR
CD3ε, ,  T–B+NK+ AR
CORO1A T–B–NK+ AR
Thymic abnormalities FOXN1 T–/lowB+NK+ AR
DiGeorge sindrome T–B+NK+ De novo or AD
and caspase 10 pathways.14 Omenn syndrome (OS),
resulting from residual development and periph-
eral expansion of oligoclonal T lymphocytes, has
recently been described in a patient with RD due
to missense mutation in AK2.15 OS is a clinical
condition characterized by generalized skin rash,
hepatomegaly, splenomegaly, lymphadenopathy
(similar to that which occurs in SCID patients
with detectable CD3+ T cells), absent or low
T cell proliferation to common antigens, and no
maternal engraftment. Increased IgE serum levels
and eosinophil count are also common features.
In rare patients with RD, no mutations in AK2
have been found, suggesting a potential role for
other molecules involved in this pathway. For in-
stance, a similar phenotype has been described in
a murine models either deficient for growth factor
independence-1 (Gfi-1) or transgenic for expression
of Gfi-1b nucleoproteins, suggesting a role for these
two factors in the pathogenesis of RD.16
SCID due to accumulation of toxic
metabolites
Adenosine deaminase (ADA) deficiency and purine
nucleoside phosphorylase (PNP) deficiency are
inherited disorders of the purine metabolism char-
acterized by abnormal accumulation of toxic nucle-
oside products.17 ADA deficiency is responsible for
a T cell–, B cell–, and NK cell–deficient (T–B–NK–)
form of SCID associated with thymic hypoplasia
and absence of lymphocyte proliferative response.
Before the introduction of newborn screening, the
incidence of this autosomal recessive disorder was
estimated tobebetween1:375,000and1:660,000 live
births.18 However, a recent trial on a population-
based neonatal screening revealed that the inci-
dence of ADA-SCID is much higher, and closer to
1:50,000.19 The ADA gene of 12 exons is located in
a 32 kb region on chromosome 20q13.11. Several
genetic alterations, with more than seventy muta-
tions, have been identified in ADA-SCID patients.20
The product of ADA is an ubiquitous enzyme that
catalyzes the irreversible deamination of adenosine
(Ado) and deoxyadenosine (dAdo) to inosine and
deoxyinosine, respectively. Despite ADAprotein be-
ing present in virtually every cell of the humanbody,
it is particularly expressed in the lymphoid system,
especially in the thymus, where it plays a key role in
its differentiation and maturation. The absence of
ADA activity is responsible for a massive accumula-
tion of Ado and dAdo, in particular in thymocytes,
lymphocytes, and erythrocytes.17,21 dAdo phospho-
rylation by nucleoside kinases leads to the pro-
duction of deoxynucleotide triphosphates (dATP)
whose accumulation, altering lymphocyte signaling
pathways and serving as a danger signal, may cause
the severe lymphopenia observed inADAdeficiency.
Another alternative pathogenic mechanism pro-
posed is the inhibition of S-adenosylmethionine–
mediated transmethylation reactions required for
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cell viability and normal differentiation.22 By the
first 6monthsof ageup to80%ofpatients showmul-
tiple recurrent opportunistic infections that rapidly
may become fatal and hypoplasia or apparent ab-
sence of lymphoid tissue. However, in the remain-
ing patients, a late-onset phenotype, presenting at
two or three years of life, or even later,23 has been
reported. These patients may also present with au-
toimmune diseases and usually exhibit a milder T
cell immunodeficiency, which gradually progresses.
Owing to its ubiquitous expression normally, ADA
deficiency can affect several organs, leading to the
development of skeletal alterations, such as anterior
rib cupping, scapular spurring, and pelvic dyspla-
sia, which can be reversible with appropriate ther-
apy. In addition, pulmonary alveolar proteinosis,
probably caused by a surfactant metabolism defect,
and hepatic, gastrointestinal, and neurological dis-
orders, mainly due to Purkinje cell damage, may be
found. Bone marrow hypocellularity and myeloid
dysplasia also have been observed in some ADA-
deficient patients; in others, renal impairment.24,25
A genotype–phenotype correlation has been docu-
mented and, in particular, severity of disease seems
to correlate with residual ADA activity and the types
of substrates that accumulate.26 The therapeutic ap-
proach currently available for this particular formof
SCID includes three options: enzyme replacement
therapy with polyethylene glycol-modified bovine
adenosine deaminase, HSCT, or gene therapy.27–29
The use of dried blood spot samples tested by tan-
demmass spectrometry has been recently proposed
as part of a neonatal program of screening in several
countries.
Purine nucleoside phosphorylase gene (PNP)
mutations result in an extremely rare autosomal
recessive disorder accounting for 4% of all form
of SCIDs.30 Autoimmunity, recurrent infections,
failure to thrive, and neurologic dysfunction are
some of the main features of PNP deficiency. PNP
maps to chromosome 14q13 and encodes a pro-
tein that catalyzes the phosphorolysis of guano-
sine, deoxyguanosine, inosine, and deoxyinosine,
to their respective purine bases.17,31,32 Mutations in
the PNP pathways result in elevated deoxyguano-
sine triphosphate storage and in T cell toxicity due
to the inhibition of the mechanisms of DNA syn-
thesis and repair, resulting in an increased sensitiv-
ity to DNA damage and apoptosis, especially in T
lymphocytes during selection within the thymus.33
T cell defects typically become evident by the first
year of life, with a milder phenotype than what is
normally seen in ADA deficiency. PNP deficiency
can be suspected when lymphopenia is associated
with reduced PNP enzymatic activity in red blood
cells in a patient with recurrent respiratory infec-
tions and other typicalmanifestations.34 Low serum
uric acid (hypouricemia) is usually found, although
PNP deficiency should not be ruled out if patients
do not exhibit it. The immunodeficiency in these
patients is progressive, since the severe T cell de-
ficiency usually appears after the second year of
life and is characterized by a normal B cell com-
partment. Among the neurological disorders asso-
ciated with PNP deficiency, ataxia, developmental
delay, and spasticity have been described. Autoim-
mune diseases observed include hemolytic anemia
and sclerosing cholangitis,35 and in some patients
megaloblastic or dysplastic bone marrow has been
described.33
SCID due to cytokine signaling anomalies
Cytokines are soluble regulators of immune system
homeostasis. Alterations of their signaling are im-
plicated in the pathogenesis of the major SCIDs.
In particular, SCIDs caused by defects of the com-
mon gamma chain (c), Janus kinase 3 (JAK3), or
the IL-7 receptor  chain (IL-7R) are prototypic
cytokine-associated disorders, accounting for 67–
74% of all cases of SCIDs.36,37
Mutations of c gene cause X-linked SCID
(X-SCID), one of themost common forms of SCID,
accounting for50%of all cases.Thec gene (IL2RG)
maps to chromosome Xq13.1 and encodes a trans-
membrane protein that is a component of several
cytokine receptors, including IL-2, IL-4, IL-7, IL-9,
IL-15, and IL-21, all critical for lymphocyte devel-
opment and function.38 The c interacts with the
intracellular tyrosine kinase JAK3, which acts as a
transducing element39 indispensable for cell growth
and control of hematopoietic cell development. Ev-
idence indicates that c is widely expressed in non-
hematopoietic cells as well, even though its function
in these cells has not yet been clearly elucidated.
It has been reported that c is implicated in the
growth hormone receptor signaling, suggesting the
existence of a subtle interaction between endocrine
and immune systems.40–44
JAK3, mainly expressed in lymphoid and
myeloid cells, is essential for the differentiation of
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hematopoietic precursors;45–47 its deficiency is re-
sponsible for an autosomal recessive SCID. Molec-
ular alteration of JAK3 may affect any of its
functional domains and results in a T–B+NK–
form of SCID, with a clinical phenotype simi-
lar to that observed in c deficiency.48 The im-
munological phenotype is due to the key role of
c/JAK3 signaling in both early T and NK cell,
but not B cell, differentiation programs. However,
B cell–intrinsic abnormalities, suchas impaired class
switch recombination and defective antibody pro-
duction, have been documented. The identification
of IL-7R–deficient SCID patients with a selective
T cell defect37 implies that the T cell defect observed
in SCID due to mutations of c/JAK3 results from
defective IL-7 signaling. The ability of IL-15 to drive
NK cell development49 explains the lack of NK cells
in c/JAK3-deficient patients as a consequence of
defective IL-15 signaling.50 The molecular basis of
the B cell functional abnormalities in patients with
c/JAK3 deficiency is probably linked to a defect
in IL-21 secretion, a cytokine involved in prolifer-
ation, Ig isotype switching, plasma cell generation,
and antibody secretion through activation of the
JAK/STAT pathway.
Recently, hypomorphic mutations in JAK3 asso-
ciated with somatic chimerism have been reported
in a patient with predominant CD4+ lymphope-
nia.51 This observation suggests that hypomorphic
mutations and/or somatic chimerism inother genes,
which usually cause a SCID phenotype, eventu-
ally could be implicated in selective CD4+ lym-
phopenia. Individuals with mutations that result in
the production of a small amount of gene prod-
uct or a protein with residual activity are less fre-
quently seen. These individualsmayhave an atypical
“leaky” disease characterized by T+B+NK– pheno-
type that is associated with immune dysregulation
and autoimmunity, rashes, splenomegaly, gastroin-
testinal malabsorption, and/or short stature;52,53 a
fewpatientshavepresentedwithanOSphenotype,54
which is characterized by elevated IgE, erythro-
derma, and an expansion of cells with a lymphocyte
profile.
A peculiar extranodal lymphoproliferative dis-
order characterized by a polymorphous CD20+
B lymphocyte infiltrate, resembling Hodgkin Reed-
Sternberg cells, has also been observed in two
patients affected with X-SCID.55 Recently, a novel
mutation in exon 5 of the c gene has been reported
that causes a classical severe immunological pheno-
type associated with invagination and hemophago-
cytic lymphohistiocytosis (HLH).56 The HLH
phenotype, previously described in two other cases
with c gene mutations,57 is probably explained by
maternal GVHD, and highlights the need for a fine-
grained evaluationof the immunological phenotype
and associated genotypes in patients with HLH.58
As for the mechanism by which maternal engrafted
T cells may be responsible for HLH in such cases, it
is reasonable to hypothesize that unchecked T cell
dysregulation of CD8+ cells, activated by alloanti-
gens, may result in cytokine hypersecretion and
massive macrophage activation, eventually leading
to hemophagocytosis.
The mutations of IL-7R gene (IL7R) cause a
T–B+NK+ SCID with an autosomal recessive trans-
mission that is responsible for 10% of all SCIDs.
The human IL7R maps to chromosome 5p13.2 and
encodes for a protein59 that is a component of
two cytokine receptors, namely IL-7R and thymic
stromal lymphopoietin receptor (TSLPR). Follow-
ing the binding of IL-7 to IL-7R, JAK1 (coupled
to IL-7R) and JAK3 are activated, which induces
the phosphorylation of IL-7R, the recruitment of
STAT5, and phosphatidylinositol 3-kinase (PI3K) at
the receptor signaling apparatus. STAT5 molecules
dimerize and translocate to the nucleus, leading to
the transcription of IL-7–dependent genes. PI3K
induces Akt activation, which prevents cell death
through inhibition of Bad and regulates the kinase
activity of Tor, eventually leading to the induction
of several nuclear targets, including nuclear factor
of activated T cells (NF-AT), NF-B, and cyclin D1.
Finally, activation of the Ras/MAPK/ERK pathway
results in the inductionof other nuclear targets, such
as c-Myc, STAT1/3, and the Ets transcription fac-
tors. IL-7R is almost exclusively expressed by cells of
the lymphoid lineage and is involved in thymocyte
survival and maturation, particularly during CD8+
positive selection.60
TSLPR, expressed mainly on monocytes, den-
dritic cells (DCs), and some types of T lymphocytes,
is able to activate JAK2/STAT5 pathway, although
this does not lead to cell proliferation. Human TSLP
acts primarily on DCs, promoting DC-mediated
expansion of CD4+ T lymphocytes that acquire a
memory T cell phenotype. The clinical phenotype
of this form of SCID is quite heterogeneous and in-
cludes peculiar features such as OS,61 cytopenia,62
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severe and unresponsive cytomegalovirus (CMV)
infection, or diarrhea of probable viral origin.61
SCID due to V(D)J recombination and TCR
abnormalities
V(D)J recombination is a complex process that oc-
curs in early B and T cell development. It is re-
sponsible of the introduction of site-specific DNA
double strand breaks (DSBs) by the recombina-
tion activating genes (RAG) 1 and 2.63,64 The
cleavage of the hairpin and the joining of these
segments requires the DNA nonhomologous end-
joining (NHEJ) DNA repair factors, which generate
the diversity through recombination of theV,D, and
J segments and junction.
NHEJ also plays a role in preserving the genomic
stability of cells exposed to X-ray DNA damage.
Consistent with these functions, it is not surprising
that mice lacking NHEJ components exhibit a SCID
phenotype and radiosensitivity (RS), a phenotype
referred to as RS-SCID. In humans, several muta-
tions in NHEJ genes have been identified, including
mutations in genes for DNA ligase IV (LIG4),
XLF/Cernunnos (NHEJ1), DNA-PKcs (PRKDC),
and Artemis (DCLREIC), that are associated with
SCID.64–66 Of note, the increased radiosensitivity
peculiar to these forms of SCID can be used as a
diagnostic tool.67,68
Owing to the essential role of RAG1/RAG2 genes
in V(D)J recombination,mutations ofRAG1 and/or
RAG2, associated with partial protein expression
and limited production of T and B cells, have
been associated with a T–B–NK+ SCID, OS, and
autoimmunity.69 Hypomorphic RAG gene muta-
tions have also been described in patients with gran-
uloma formation70 and EBV-related lymphoma.71
Since different clinical phenotypes have been as-
sociated with similar RAG mutations resulting in
the same biological effect, a complex pathogenetic
mechanism, based not only on the residual recom-
binase activity but also on the type and the moment
of antigenic pressure has been postulated.
Artemis deficiency causes T cell maturation and
B cell differentiation arrest at the pre-B cell check-
point, resulting in a T–B–NK+ SCID.68 DNA-PKcs
is involved in Artemis regulation and activation by
both phosphorylation and complex formation, thus
regulating enzymatic activities critical for V(D)J
recombination.64,72 Deficiency of DNA-PKcs causes
a phenotype similar to Artemis deficiency.
The deficiency of XLF/Cernunnos causes
a T–B–NK+ SCID phenotype associated with
microcephaly.73 Inparticular, the phenotype is char-
acterized by a progressive decrease of B cells and the
presence of only memory T cells. Crystallography
studies showed that XLF/Cernunnos is a compo-
nent of the LIG4/XRCC4 complex, which exerts a
role in aligning the twoDNAends in theDNA repair
complex machinery. Deficiency of LIG4 is respon-
sible for facial dysmorphisms, microcephaly, and
variable forms of PID, ranging from SCID/OS to
hypogammaglobulinemia or moderate defects in T
and B cell functions.74
Gene mutations that abrogate early TCR signal-
ing are associated with profound abnormalities of
T lymphocyte development and function. CD45
(leukocyte common antigen) is a transmembrane
tyrosine phosphatase involved in both TCR signal-
ing and T cell development within the thymus and
B cell development and maturation. CD45 de-
ficiency is responsible for a very rare form of
T–B+NK+ SCID in which lymph nodes lack germi-
nal centers.75 Despite a normal monocyte numbers,
T lymphocyte numbers are considerably decreased,
with normal expression of TCR  chains but a
reduction of TCR+ cells. B cells, even though
nonfunctional, are increased in number.
CD3 is a multimeric complex involved in TCR
signaling and required for T cell differentiation.
Defects of the complex can involve all the chains,
resulting in a T–B+NK+ phenotype. Alterations of
the subunits epsilon (CD3ε), delta (CD3), and zeta
(CD3 ), have been reported in patients with severe
forms of SCID, while alterations of the CD3 have
been associated with a more benign course. These
disorders are rare and inherited as autosomal reces-
sive SCIDs. Some mutations can allow residual T
cell maturation, even though the cross-talk between
thymocytes and thymic epithelial cells may be im-
paired, thus compromising central tolerance and
regulatory T cell (Treg) development. Autoimmune
manifestations, including autoimmune hemolytic
anemia, vitiligo, Hashimoto’s thyroiditis, autoim-
mune enteropathy, Evans syndrome, autoimmune
hepatitis, and nephrotic syndrome are frequently
observed in such patients.76
Coronin-1A is important for regulation of actin
polymerization of cytoskeleton and essential for
T cell migration from the thymus to the secondary
lymphoid organs.77 The human coronin-1A gene
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(CORO1A) maps to chromosome 16p11.2 and
encodes a highly conserved 57-kDa actin-binding
protein expressed in both hematopoietic and
immune cells. Coronin 1A–deficient neutrophils
of mice have a normal adherence, membrane
dynamics, migration, phagocytosis, and oxidative
burst; dendritic cells are similarly not impaired.
However, coronin 1A–deficient mice exhibit T cell
lymphocytopenia and a normal number of B and
NK cells, thus confirming its prominent role in
T cell homeostasis and TCR signaling. In humans,
deficiency of coronin 1A is associated with the
absence of peripheral T cells.78 However, different
from other SCIDs due to other genetic alterations,
a normal size thymus has been observed in the
context of coronin 1A deficiency.79 Hypomorphic
CORO1A mutations have been associated with
aggressive Epstein Barr virus–associated B cell
lymphoproliferation, occurring at an early age.79
SCID due to thymic abnormalities: from
DiGeorge syndrome to nude/SCID
The prototype of athymic disorders caused by
abnormalities of the stromal component of the
thymus––the primary lymphoid organ for T cell
differentiation––is the nude/SCID syndrome, de-
scribed in humans in 1996.80 This form of SCID is
the only one not primarily related to an intrinsic
abnormality of the hematopoietic cell, but rather
to a defect in hematopoietic cell–supporting thymic
epithelial cells.81–83 This human SCID is the equiva-
lent of the murine nude/SCID phenotype described
in 1966, although in humans the phenotype is more
severe. It is one of the rarest forms of SCID, and
only three mutations have been associated thus far
with nude/SCID.84 The gene responsible for the
disease in humans is FOXN1, located on chromo-
some 17,85 which encodes a member of the fork-
head/winged helix class proteins; this same gene is
mutated in the same type of SCID in mice and rats.
Forkhead/winged helix proteins is a large family of
transcriptional factors implicated in several biolog-
ical processes governing development, metabolism,
cancer, and aging. FOXN1 ismainly expressed in the
epithelial cells of the skin and thymus, where it plays
a role in maintaining the balance between growth
and differentiation. Thymic epithelial cell precur-
sors require FOXN1 for full differentiation into
cortical and medullary thymic epithelial cells capa-
ble of supporting T cell development. In epithelial
cells, FOXN1 contributes to keratinocyte prolifera-
tion and differentiation in hair follicles, and to the
development of the choroid plexus epithelium; this
could explain the major features that characterize
patients with nude/SCID, namely the absence of the
thymus,with a severe T cell defect (thoughnormal B
and NK cells) and abnormal skin development, in-
cluding congenital alopecia and nail dystrophy. The
syndrome belongs to the T–B+NK+ subgroup of
SCIDs.81 Usually, there is a significant reduction of
CD3+CD4+ T helper lymphocytes, while the num-
ber of CD3+CD8+ T cells is less reduced. Function-
ally, there is a severe impairment of the proliferative
response to mitogens, as found in the other forms
of SCIDs.
The mutations described in nude/SCID cause a
complete absence of functional FOXN1protein. The
first known mutation identified in humans, R255X,
truncates the protein before the start of the forkhead
domain, while a secondmutation, R320W, leads to a
substitution in the protein’s DNA binding domain.
A third mutation, c.562delA, results in a frameshift
and premature truncation of the protein (p.S188fs)
after thefirst 24aminoacidsof the forkheaddomain.
The disease is inherited as an autosomal recessive
trait.Heterozygous patients showminor ectodermal
anomalies, such as nail dystrophy and, in particular,
leukonychia or koilonychia (spoon nail).86,87 Recent
studies support a role for FOXN1 as cofactor in
the development and differentiation of the central
nervous system.88
Bonemarrow transplantation (BMT) to treat this
nude/SCID, despite the favorable clinical course,
often results in a progressive decline of the CD4+
T cell compartment89 owing to the fact that a nor-
mal thymus is necessary for the generation of the
CD4+ naive subset. Conversely, the production of
CD8+ naive lymphocytes after BMT is less thymus
dependent and even occurs in nude/SCID patients.
In addition, a recent study showed the presence of T
lymphocytes in aFOXN1–/– human fetus, suggesting
partial T cell ontogeny in a thymus- and FOXN1-
independent process.90 Thymus transplantation has
been shown to lead to immune reconstitution in
two nude/SCID patients affected with disseminated
BacillusCalmette-Gue´rin infectionandcytopenia.91
Before the identification of human nude/SCID,
the DiGeorge syndrome (DGS) was long consid-
ered the model of a severe T cell differentiation
defect. DGS is a complex disorder that typically
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comprises T cell deficiency due to thymic hypo/
aplasia, hypoparathyroidism, conotruncal cardiac
defects, facial abnormalities, cognitive defects,
speech delay, other birth defects, and gastrointesti-
nal disorders.92 Deletion of 22q11.2 is the most fre-
quent chromosomal change associated with DGS,93
with an incidence of one in 4000–5000 live births.
The alteration is inherited in a familial autosomal
dominant pattern in 8–28% of the cases.94 Most pa-
tients have a deletion of 3 Mb that includes about
30 genes, while in 8% of the cases a smaller dele-
tion of 1.5 Mb containing 24 genes is detected. No
specific genotype–phenotype relationship has been
documented. Both deletions include the gene T-
box transcription factor 1 (TBX1), which seems to
be necessary for normal development of the thymus
and parathyroid, the large arteries of heart, and the
muscles and bones of face and neck. Thymic hy-
poplasia, responsible for the thymic dysfunction,
is observed in more than 80% of patients. The
syndrome may be associated with variable T cell
deficiencies, ranging from close to normal T cell
numbers and functions, to complete DGS with a
T–B+NK+ SCID-like phenotype accounting for less
than 1% of DGS.95 Recently, a phenotype charac-
terized by a T–B–NK+ SCID has been described
in two DGS patients with a concomitant Artemis
deficiency.96 Patients with complete DGS, like other
infants with SCID, suffer from severe opportunis-
tic infections and exhibit a high risk of acquired
GVHD if transfused. Furthermore, a few patients
affected with an atypical complete DGS have ma-
ture T cells derived from maternal engraftment or
oligoclonal expansion of memory T cells responsi-
ble for a severe inflammation. These patients may
develop an OS, characterized by erythrodermia,
enteropathy, and lymphadenopathy. On the other
hand, there are also subjects carrying the deletion
who only have a mild phenotype. Some patients di-
agnosed as 22q11.2DS in early childhood remain
clinically asymptomatic and exhibit only minimal
immune alterations. Increased prevalence of atopic
and autoimmune diseases has been reported in
patients with partial deletion syndrome.97 While
normal B, NK, and T cell numbers are frequently
observed in 22q11.2DS individuals, sometimes, a
decrease of CD4+ and CD8+ T lymphocytes may
be found97 due to lower thymic output of the naive
T cell subset, oligoclonal T lymphocyte expansion,98
or altered T cell differentiation. These observations
can be explained by the dysregulation of peripheral
T cell homeostasis due to a defect in IL-7 signal-
ing, crucial for T lymphocyte survival and expan-
sion and for homeostasis of the naive CD4+ T cell
pool. Indeed, subjects with 22q11.2DS show a sig-
nificant decrease ofCD3+ T lymphocytes expressing
IL-7Ra; adults have accelerated conversion of naive
to memory cells, shorter telomeres, and a defect in
the variability of the TCR repertoire.98
A DGS phenotype has been described in pa-
tients carrying a 10p deletion, the clinical features
being almost undistinguishable from 22q11.2DS.
Even though low numbers of T cells, reduced
immunoglobulin,80 and thymus hypoplasia have
been observed in 28% of such patients, none have
been affected with a severe SCID-like phenotype.95
SCID/CIDs associated with syndromic
features
According to the International Union of Immun-
ological Societies (IUIS), there are forms of PID
associated with highly pleomorphic extra-immu-
nological features responsible for complex syn-
dromes with a genetic basis. Typical features of
these syndromes comprise peculiar facial dysmor-
phism, growth delay, microcephaly, and ectodermal
abnormalities. While an increased susceptibility to
autoimmunity and (occasionally) cancer associ-
ated with the depletion of other blood cell lines is
frequently reported, an increased susceptibility to
infections is usually less frequent, and its clinical
relevance is lower than in other PIDs. The patho-
genetic mechanism resides in the involvement of
several genes expressed in multiple cell lines, genes
responsible for both ontogenesis and maturation
of the immune system, as well as morphogenesis
and organogenesis of other organs. Some of these
conditions may be associated with a SCID/CID
phenotype. Several syndromes are included in
this group (Table 3), such DGS and CHARGE
syndrome. Patients with CHARGE syndrome ex-
hibit variable grades of immune defects, ranging
from severe to mild T cell lymphopenia and ab-
normal T cell functionality, sometimes associated
with hypogammaglobulinemia.102 The incidence of
SCID in patients with CHARGE is unknown, even
though it may be, as in DGS, rare.103 These pa-
tients, whose clinical phenotype is characterized by
coloboma, heart defect, atresia choanae, retarded
growth and development, genital hypoplasia, and
98 Ann. N.Y. Acad. Sci. 1356 (2015) 90–106 C© 2015 New York Academy of Sciences.
Cirillo et al. Severe combined immunodeficiencies
Table 3. Peculiar clinical and laboratory findings in the main genetic syndromes which in a few cases may be
associated with a SCID/CID phenotype
Disorder Genetic defect Clinical phenotype Immunological features
CHARGE syndrome CHD7 Coloboma, hearth defect,
atresia choanae, retarded
growth and development
T–B+NK+ SCID, OS,
T cell lymphopenia,
hypogamma-
globulinemia
Cartilage–hair hypoplasia
(CHH)
RMRP Short limb with metaphyseal
dysostosis, sparse hair,
neural dysplasia of intestine
T cell lymphopenia,
hypogammaglobuline-
mia, antibody
deficiency
Schimke immuno-osseous
dysplasia
SMARCAL1 Short stature, IUGR,
spondiloepiphyseal
dysplasia
T cell lymphopenia, bone
marrow failure
Hyper IgE syndrome PGM3 Short stature, brachydactyly,
facial dysmorphism,
intellectual disability
Congenital leucopenia,
neutropenia, B and
T cell lymphopenia
Hoyeraal-Hreidarsson
syndrome (HHS)
DKC1 Microcephaly, cerebellar
hypoplasia, IUGR
Bone marrow failure, CID
or T+B–NK– SCID
Folate and cobalamin
metabolism defect
PCFT, TCN2,
MTHFD1
Failure to thrive, weakness,
mental retardation,
megaloblastic anemia,
neurological disease
Pancytopenia, SCID-like
phenotype, hypogam-
maglobulinemia
Anhydrotic ectodermic
dysplasia with
immunodeficiency
NEMO Hypohidrosis, hypodontia,
conical teeth, facial
dysmorphism
SCID/CID-like phenotype
IUGR, intrauterine growth restriction.
ear anomalies/deafness, may suffer from a T–B+
NK+ SCID and, in some cases, OS.103 The disor-
der is caused by mutations in the chromodomain
helicase DNA binding protein 7 gene (CHD7), a
member of the chromo domain helicase DNA bind-
ing domain family of adenosine-5′-triphosphate de-
pendent chromatin remodeling enzymes. CHD7
is expressed throughout the neural crest contain-
ing mesenchyme of the pharyngeal arches, suggest-
ing a pathogenetic overlap between CHARGE and
DGS.
In other syndromes, several peculiar skeletric ab-
normalities are the main feature, which lead the pa-
tient to themedical attention, as observed inpatients
with cartilage–hair hypoplasia (CHH), character-
ized by severe disproportionate short stature due
to short limb with metaphyseal dysostosis, sparse
hair and neural dysplasia of the intestine,104 or in
Schimke immuno-osseous dysplasia, which some-
times may show a CID phenotype.
In humans, defects in gene involved in telom-
ere maintenance (TERT, TERC, DKC1, WRAP53/
TCAB1, NOP10, NHP2, and TINF2) are respon-
sible for the dyskeratosis congenita (DC), a rare
congenital disorder characterized by progressive
bone marrow failure, premature aging, mucocuta-
neous abnormalities, and cancer predisposition.106
The most sever infantile variant of X-linked DC is
the Hoyeraal-Hreidarsson syndrome (HHS), whose
main clinical features are microcephaly, cerebellar
hypoplasia, and intrauterine growth retardation.
The early-onset bonemarrow failure usually leads to
either a combined immunodeficiencyor aT+B–NK–
SCID, which may require HSCT.107
Recently, several inborn errors in folate and
cobalamin metabolism have been described as hav-
ing a profound impact on many systems, including
hematopoiesis and neuronal function. Immuno-
deficiency of variable degrees has been associated
with defects in these pathways. A CID phenotype
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characterized by lymphopenia, responsiveness to
folate replacement therapy, and severe bacterial and
viral infections has been described in patients with
functional methionine synthase deficiency caused
by hereditary folatemalabsorption due to deficiency
in the proton coupled folate transporter (PCFT)
and in transcobalamin II (TCN2); this CID usually
presents in early infancy in untreated patients
as failure to thrive, weakness, pancytopenia, and
intellectual disability. Recently, exomic sequencing
demonstrated that heterozygous mutations in the
trifunctional protein MTHFD1 is responsible for
a SCID-like phenotype characterized by T–B–NK–
lymphopenia, marked hypogammaglobulinemia,
megaloblastic anemia, and neurologic disease.108
A partial immune reconstitution after vitamin B12
and folate replacement therapy has been docu-
mented.
In summary, it must be noted that several syn-
dromes, together with the more typical severe man-
ifestations, can share clinical and immunological
signs of SCID/CID, as for example patients affected
by NEMO deficiency.
Recently identified combined
immunodeficiencies
Combined immunodeficiency (CID) is a group of
genetic heterogeneous disorders characterized by
severe recurrent infections, moderate reduction of
T and B lymphocytes, and impaired cellular and
humoral functionality that may reflect late defects
in T cell development and function.109,110 In most
cases, it is not always easy to distinguish between
patients affected with more severe forms and those
with CID. Furthermore, a greater difficulty in mak-
ing a clear classification is due to the fact that many
inborn defects, which underlie these immune dis-
orders, have recently been associated with both
SCID and CID, in particular hypomorphic mu-
tations. Several genetic defects responsible for a
wide number of clinical conditions are comprised
in this group (Table 2).111 Besides the well-known
genetic defects responsible for MHC class I (TAP1,
TAP2, TAPBP) or class II deficiency (CIITA,
RRFX5, RFXAP, RFXANK) associated with a pre-
dominant CD8+ or CD4+ selective deficiency
respectively, the very rare CD8A defects and many
others (see the new International Union of Im-
munological Societies classification, Ref. 111)
have been identified recently. Since the number
of these conditions is large, we have chosen to
discuss only the most common form associated
with new phenotypes and novel ones reported over
the past 3 to 4 years.
ZAP70-related immunodeficiency is inherited in
an autosomal recessive manner. It is caused by ab-
normal TCR signaling, which leads to a selective
absence of CD8+ T cells and normal or elevated
numbers of non-functional CD4+ T cells. ZAP70
has a key role in bothmatureT cell signaling anddif-
ferentiation of thymic precursors. Finally, in some
patients peculiar phenotypes have been observed.
In particular, some patients exhibit an attenuated
phenotype with a late onset disease and preserved
production of CD4+ T follicular helper (TFH),
T helper type I (TH1), TH17, and Treg cells. Immune
dysregulation and severe erythroderma resembling
OS have also been described, characterized by skin
infiltrative lesionswith activatedCD4+ T cells in the
peripheral blood.113
Thanks to next generation sequencing technolo-
gies, which have provided a powerful tool to identify
themolecular cause of PIDsof unknowngenetic ori-
gin, new defects have been detected, even though in
most cases the genetic cause still remains unknown.
Whole-exome sequencing recently demonstrated
the presence of deleterious mutations in the phos-
phoglucomutase 3 gene (PGM3) in three unre-
lated subjects with recurrent infections, congenital
leukopenia, neutropenia, B and T cell lymphope-
nia, and progression to bone marrow failure due to
a congenital disorder of glycosylation (CDG). Two
of the three children also had skeletal anomalies
characterized by short stature, brachydactyly, dys-
morphic facial features, and intellectualdisability.105
Thanks to this technology, Kotlarz et al. identi-
fied in 2013 two distinct homozygous loss of func-
tions mutations in the interleukin-21 receptor gene
(IL21R) in two unrelated children affected with
cryptosporidiosis, chronic cholangitis and liver dis-
ease, recurrent upper and lower airway infections,
and failure to thrive.99 IL-21R binds to common
c and signals via JAK/STAT pathways.100,101 The
authors observed that the mutation was responsi-
ble for the aberrant trafficking of the IL-21R to the
plasma membrane and for the abrogation of IL-21
ligand binding. These molecular alterations lead to
defective phosphorylation of STAT1, STAT3, and
STAT5. The immunophenotype of these patients
was normal, but abnormal proliferation induced by
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IL-21 and defects in immunoglobulin class-
switching in B cells and NK cell cytotoxicity were
documented. A defect in T cell secretion of sev-
eral cytokines, including TH17-associated cytokines
IL-17F and IL-22, was reported, thus putatively
explaining the increased susceptibility to crypto-
sporidial infection in these patients.
In the last few years mutations in the CARD9–
BCL10–MALT1 (CBM) complex involved inNF-B
signaling have been associated with PID. In partic-
ular, autosomal recessive mutations in MALT1 gene
have been described in patients with CID and se-
vere bacterial, fungal and viral infections.114 The
MALT1-deficient T cells are not able to degrade
IB or produce IL-2 following T cell activation.
BCL10 has a role in several immune pathways crit-
ical for the function of the innate and the adaptive
immune systems, and for the response to bacte-
rial and fungal infections. Mutations in BCL10 and
other genes encoding for proteins interacting with
MALT1, such as CARD11 and CARD9, have also
been recently described. Patients with BCL10 defi-
ciency show a profound defect of memory T and
B cells and severe hypogammaglobulinemia, with
a reduction of CD69 and CD25 percentages and
ICOS levels.115 Even though CARD9 deficiency has
been shown to selectively compromise defenses to-
ward a limited number of fungal infections, mu-
tations in CARD11, which plays a crucial role in
the differentiation of both neuronal and immuno-
logic tissues as a scaffold protein, are associated
with a more profound CID characterized by abnor-
mal T cell proliferation to anti-CD3/CD28 stimula-
tion, expansion of late transitional B cells, mature
B cells deficiency, and hypogammaglobulinemia.101
Furthermore, CARD11-deficient T cells do not pro-
duce normal amounts of IL-2 or upregulate the
IL-2 receptor chain (CD25) afterTCRstimulation,
which contributes to Treg cell deficiency in these
patients.
Mutations in tetratricopeptide repeat domain
7A (TTC7A), a member of the large family of
proteins containing the tetratricopeptide repeat
(TPR) domain, have recently been found in
patients affected with CID and multiple intestinal
atresia (MIA).116 MIA is a clinical condition that
can be isolated or may occur in association with
variable grades of immunodeficiency ranging from
SCID to a mild decrease of T cells and partially
preserved thymic function. However, in all these
genetic forms, profound CD8+ T cell lymphopenia,
reflecting the impaired cellular immunity and
the defective thymopoiesis, has been observed.
Severe hypogammaglobulinemia is also frequent. A
higher frequency of bloodstream infections due to
intestinal microbes has also been reported.
The clinical and immunological phenotypes of
Ras homolog family member H gene (RHOH)
deficiency is characterized by naive CD4+ T cell
deficiency, absence of recent thymic emigrants,
increased number of effector memory T cells, re-
stricted T cell repertoire, and reduced in vitro pro-
liferation via CD3 stimulation.117 Expressed mainly
in hematopoietic cells, RhoH is a small GTPase
that mediates interaction between Zap70 and LCK.
RhoHdeficiency determines both alterations in pre-
TCR–mediated signaling and in positive selection,
as observed inZap70 deficiency. Expansion ofmem-
ory T cells has also been observed in other CIDs,
such as deficiency of DOCK8 or MST1. DOCK8
deficiency is an autosomal recessive form of CID
associated with a hyper-IgE phenotype. Viral infec-
tions (especially of the skin) and malignancies are
very common. Lymphopenia of CD4+ and CD8+
T cells, or predominantly CD4+ lymphocytes, may
be found. In addition, DOCK8 deficient patients
exhibit defective differentiation of TH17 cells and a
reduction of B lymphocytes.118
The lymphocyte specific kinase LCK is involved
in the initiation of signaling from the TCR 121
through the adaptor protein unc-119 lipid binding
chaperone (UNC119). Recently, mutations in LCK
or UNC119, which impairs LCK activation and
signaling, have been identified. Main features of
this phenotype include CD4+ T cell lymphope-
nia, a restricted T cell repertoire, and impaired
TCR signaling.122 Patients with LCK deficiency
frequently present with immune dysregulation
and autoimmunity. Mutations in the magnesium
transporter protein1 gene (MAGT1) result in a CID
phenotype characterized by CD4+ lymphopenia
and abnormalT cell proliferation,which are respon-
sible for chronic viral infections and EBV-related
lymphoma, respectively.123 Recently, a CID was ob-
served in four unrelated patients with mutation of
inhibitor of kappa light polypeptide gene enhancer
in B-cells, kinase beta (IKBKB); the patients had se-
vere bacterial, viral, fungal,mycobacterial infections
associated with failure to thrive and neurological
impairment. The immunological phenotype was
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characterized by a/hypogammaglobulinemia and
absence of Treg and  / T cells. Even though T cell
counts were normal, all the patients exclusively
showed naive T and B lymphocytes.124
Newborn screening for SCID
Recently, T cell receptor excision circles (TREC)–
based newborn screening has been implemented
in several countries. Compared with patients iden-
tified by the clinical features, patients identified
through newborn screening programs, similar to
children identified because of a positive familial his-
tory, can receive an early and accurate diagnosis
by one month of life and then undergo HSCT or
gene therapy by 3 months of age, before the oc-
currence of severe complications. This results in a
significantly improved outcome.125,126 The TREC
assay, based on the detection of intracellular accu-
mulation of products derived from process of T cell
receptor gene splicing and rearrangement, is able to
detect several defects, which result in either SCID or
profound T cell lymphopenia that is also seen in
patients affected with 22q11.2DS, CHH, CHARGE,
and AT.127 However, one limitation of the TREC
assay is that it is not able to identify all forms of
CID or atypical SCID. Some genetic disorders, such
as deficiency of ZAP70, late onset ADA, Nijmegen
breakage syndrome, MHC class II deficiency, and
many others, are likely to be missed because TRECs
are usually found at normal levels. The identifica-
tion of kappa-deleting recombination excision cir-
cles (KREC), a sensitive marker of newly formed B
cells, increases the possibility of identifying other
forms of SCID/CID that are associated with low
numbers of B lymphocytes, such asNBS and late on-
setADA. Furthermore, it has been reported that tan-
demmass spectrometry caneasily identify abnormal
purine metabolites in newborns with typical or late
onsetADAandPNPdeficiency,19 thus increasing the
spectrum of disorders detectable through newborn
screening.
Conclusions
SCIDs are a heterogeneous group of syndromes re-
lated to alterations of distinct genes that cause ab-
normalities in the maturation and/or function of
T, B, and/or NK cells. Recently, advances in next
generation DNA sequencing have allowed new gene
identification through whole exome sequencing or
whole genome sequencing of several forms of SCID
and CID of unknown cause. The phenotypic and
the molecular heterogeneity of SCIDs, as revealed
by the expanding phenotypes observed, is making
traditional classification of this group of disorders
very intricate. Frequently, differentmutations in the
same gene can lead to different clinical phenotypes,
such as OS, leaky SCID, or CID, that may even be
inherited with different mechanisms.
In this review we have focused in detail on dif-
ferent forms of SCID and CID, paying attention to
the distinctive peculiar clinical and laboratory fea-
tures, in order to provide information to clinicians
for recognizing and carefully managing these novel
forms of PIDs.
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4.2 Phenotypic characterization and outcome of paediatric patients affected with 
haemophagocytic syndrome of unknown genetic cause 
Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory condition, potentially 
fatal, characterized by prolonged and unexplained fever, unresponsive to conventional 
treatment, hepatosplenomegaly, cytopenia, hypertriglyceridemia and hypofibrinogenemi 
(210). Histological examination of involved organs typically reveals infiltration of 
lymphocytes and histiocytes with haemophagocytosis (211, 212). Alterations in six genes, 
Perforin 1 (PRF1), UNC13D, Syntaxin 11 (STX11), Syntaxin-binding protein 2 (STXBP2), 
RAB27A and SH2 domain containing 1A (SH2D1A), have been, associated with the familial 
forms the syndrome. Unrespectively of the etiology, alterations in the mechanisms involved 
in intracellular trafficking and lysosomal exocytosis, which impair cytotoxic function of T 
and natural killer (NK) cells, are responsible for the disease pathogenesis. This functional 
inappropriateness to achieve pathogens clearance leads to a persistent activation and 
proliferation of cytotoxic T lymphocytes (CTLs) and NK cells (213-215), which, in turn, 
produce large amount of cytokines and activate histiocytes (macrophages and dendritic cells).  
The process eventually results in histiocytes tissue infiltration culminating in 
haemophagocytosis. This syndrome is generally triggered by an infection, notably by a 
human herpes family virus.  
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Figure 11: Antigen-specific CD8+ T cell response to viral infection in normal individuals 
and in patients with haemophagocytic lymphohistiocytosis (216) 
 
 
Cytotoxic T Lymphocytes and NK cells have a similar mechanism for target cell killing, 
which occurs through polarized release of the contents of cytotoxic granules towards the 
target cell. Naive CD8+ T cells require 5–8 days after antigen recognition in secondary 
lymphoid tissues to differentiate into CTLs, proliferate and migrate to affected tissues. 
During this differentiation process, granzymes and perforin are synthesized and stored in 
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developing cytotoxic granules. Lytic granules are secretory lysosomes specialized for the 
secretion of the cytotoxic effector molecules that function as conventional lysosomes (217-
219). Molecules responsible for hemophagocytosis impairs the mechanisms of targeted cell 
killing, which occurs through different steps including tethering, docking, priming, fusion 
(Figure 12).  
 
Figure 12: A model depicting the biogenesis and exocytosis of cytotoxic granules (216) 
 
LYST, responsible for Chediack-Higashi syndrome (CHS), is involved in sorting of 
lysosomal proteins to late endosomes and in regulating fusion or fission of lysosomes.  
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AP3B1, responsible for type 2 Hermanski Pudlak syndrome (HPS2), encodes AP-3, which is 
required for the shuttling of cargo proteins from the trans-golgi network to endosome- or 
lysosome-related organelles (220). RAB27a, responsible for type 2 Griscelli syndrome 
(GS2), is important regulators of vesicle trafficking and compartmentalization. Patients 
affected with CHS, HPS2 and GS2 also show hypopigmentation, resulting from aberrant 
formation of melanosomes. PRF1, responsible for type 2 FLH, encodes perforin, which is 
required for the delivery of granzymes into the cytoplasm of the target cell. MuNC13-4, 
responsile for FHL3, mediates the tethering of cytotoxic granules to the plasma membrane. 
Fusion of the cytotoxic granules to the plasma membrane is mediated by SNARE proteins, 
including Syntaxin 11 and MuNC18-2, responsible for FHL4 and FHL5, respectively. 
In the majority of cases a genetic defect cannot be identified. In a few of these cases without 
a known genetic alteration, various infectious, malignant and autoimmune triggers have been 
suggested as implicated in the pathogenesis (221). 
A clinical and laboratory characterization of HLH has been provided mainly for genetic 
forms.  In this study, published Letter to the Editor on British Journal of Hematology, we 
characterized the clinical and laboratory features and the outcome of pediatric patients 
diagnosed as HLH of unknown genetic cause, in the attempt to define clinical and laboratory 
hallmarks to help distinguish these patients from those with a known genetic cause.  
Compared to what is known in the familial cases, median age at onset was higher in HLH 
than in FHLH (222). A predominance of affected males was observed in our cohort with a 
male-to-female ratio of 1.6:1. The difference in male-to-female ratio seems to rely 
predominantly on the underlying disorder. The clinical course of paediatric HLH with 
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unknown genetic alteration is in general more favorable then FHLH, as suggested by later 
onset, lower prevalence of neurological involvement and better outcome.   
 
 
 
 
 
 
 
Cancer Institute ALL 91-01 Consortium used a higher cumu-
lative dose of Peg- Asparaginase (30 000 iu/m2) (Kearney
et al, 2009). Asparaginase dose intensity is however, not the
only factor likely to be important in the pathogenesis of
pancreatitis. Regimen B patients had a three-fold higher
incidence of pancreatitis compared to Regimen A despite
having a similar Asparaginase exposure. This suggests that
anthracycline induction and the additional cylophosphamide/
cytarabine exposure in the Berlin-Frankf€urt-M€unster consoli-
dation in Regimen B may be risk factors for the development
of pancreatitis.
In our series, Asparaginase withdrawal due to pancreatitis
did not affect EFS and OS, though the overall numbers of
cases with pancreatitis was small. However, in the current
UKALL 2011 trial, we continue to recommend that Aspara-
ginase be withheld following pancreatitis. Our analysis
demonstrates that increasing treatment intensity and Aspara-
ginase exposure are the biggest risk factors for developing
pancreatitis.
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Phenotypic characterization and outcome of paediatric
patients affected with haemophagocytic syndrome of
unknown genetic cause
Haemophagocytic lymphohistiocytosis (HLH) is a hyperin-
flammatory condition caused by a highly stimulated, but
ineffective, immune response (Trottestam et al, 2011). To
date, alterations in six genes have been identified in the
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familial forms. However, in the majority of cases the genetic
defect cannot be identified. Studies in humans indicate that
alterations in the mechanisms involved in intracellular traf-
ficking and lysosomal exocytosis, which impair cytotoxic
function of T and natural killer (NK) cells, may be impli-
cated in the pathogenesis. The inappropriateness in patho-
gens clearance leads to persistent activation and proliferation
of cytotoxic T lymphocytes (CTLs) and NK cells (Crozat
et al, 2007), which, in turn, produce large amount of cyto-
kines and activate histiocytes.
This study aimed to retrospectively characterise the clinical
and laboratory features and outcome of 21 paediatric
patients diagnosed as HLH of unknown genetic cause, in the
attempt to define clinical and laboratory hallmarks to help
distinguish these patients from those with a known genetic
cause.
Patients alive, with no disease activity for >1 year off-ther-
apy, were considered as non-familial HLH (FHLH) (Trotte-
stam et al, 2011). We also included three patients who
underwent haematopoietic stem cell transplantation (HSCT)
after disease reactivation, as all the known causes of FHLH
were excluded through molecular or functional analysis.
Detailed materials and methods are provided in the support-
ing information section.
Mean age at disease onset was 3.7 years (range:
2 months–15 years), higher than in FHLH, where onset is
within the first year of life in 70–80% of cases (Trottestam
et al, 2011). Six patients (28%) were diagnosed during the
first year of life.
Differently from FHLH, which is inherited as a recessive
trait, thus implying the same probability to be affected for
males and females, a predominance of affected males was
observed in our cohort (male-to-female ratio: 1.6:1), in keep-
ing with previous reports of adult patients with secondary
HLH, mainly affected with haematological malignancies
(Shabbir et al, 2011). In contrast, female sex was reported to
be more frequent in patients with Epstein–Barr virus (EBV)
triggered HLH (Trottestam et al, 2011), thus suggesting a
role for the underlying disorder rather than to the pathoge-
netic mechanism for the gender prevalence. Comorbidities
were found in 52% of the patients (visceral leishmaniosis,
9.5%; haematological malignancies, 18.9%; other genetic-
metabolic diseases, 18.9%; rheumatoid arthritis, 4.7%)
(Table 1). The association between HLH and several underly-
ing disorders, including autoimmune diseases, malignancies,
primary or acquired immunodeficiencies, metabolic disorders
and infections (Kaito et al, 1997) is a well-documented
feature. In six patients, a viral or bacterial infection preceded
the onset of a HLH overt clinical manifestation. The most
common infectious triggering agents were herpes viruses,
mainly EBV and cytomegalovirus (CMV), although bacteria,
protozoa and fungi may also be involved. In particular,
Leishmania infection, may mimic or trigger HLH with a still
poorly understood mechanism (Rajagopala et al, 2008).
All patients had fever at onset, while hepatomegaly and
splenomegaly were observed in 91% and 71% of patients,
respectively; 86% of the patients had anaemia at diagnosis,
with a mean haemoglobin of 77  10.5 g/l, and 90% had
Table I. Demographic and clinical findings of 21 patients with haemophagocytic lymphohistiocytosis.
Case Age at onset (years) Gender Comorbidity Infectious trigger
1 8.7 F Bibasic aminoaciduria; jaundice;
alveolar proteinosis

2 0.4 M  
3 1.9 F  
4 6.2 M  + (Staphylococcus, EBV)
5 15.0 M Hodgkin lymphoma 
6 1.6 F Langerhan hystiocytosis + (EBV)
7 5.0 F Visceral leishmaniosis 
8 14.2 M Gitelman syndrome 
9 5.0 M Chronic granulomatous disease + (Staphylococcus)
10 2.1 M  
11 4.6 M Visceral leishmaniosis 
12 0.2 M  
13 0.6 M Reumathoid artrhitis 
14 1.2 F Muscolar glicogenosis 
15 0.7 M  
16 0.8 M  + (unidentified)
17 0.8 F Acute myeloid leukaemia + (CMV)
18 2.4 M Acute myeloid leukaemia 
19 1.4 F  + (Parvovirus)
20 2.3 M  
21 2.5 F  
F, female; M, male; EBV, Epstein-Barr virus; CMV, cytomegalovirus.
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thrombocytopenia (mean platelet count, 57.5  37.75 9 109/l).
Only 14% of patients had a tri-lineage cytopenia, the most
common feature of FHLH (Kaito et al, 1997; Trottestam et al,
2011). Neurological involvement, a prominent feature in about
50% of patients with FHLH (Trottestam et al, 2011), was
found only in the 9% of our patients as seizures, somnolence
or rigour nucalis. Of note, liquor examination was always neg-
ative. Bone marrow examination revealed haemophagocytosis
in 71% of the cases. Patients were treated according to HLH-
04 protocol. Seven patients (33%) required a 3-drug regimen,
four patients (20%) achieved a full remission with a 2-drug
treatment (steroid and ciclosporin or steroid and etoposide)
and three patients (14%) only with steroids. The two patients
with leishmaniosis achieved remission after amphotericin-B
and steroid. Two patients had a spontaneous remission. Three
patients underwent a successful HSCT (Table II). In the two
patients with the neurological involvement at onset, a full
recovery was observed in one patient, while seizures persisted
in the other one.
A recent case series, analysing risk factors for early death
in children with HLH, documented that jaundice, hyperbi-
lirubinaemia, hyperferritinaemia, elevated aspartate transami-
nase (AST) and lactate dehydrogenase levels at onset, and
fever, thrombocytopenia, hyperferritinaemia, anaemia and
elevated AST and fibrinogen levels after 2 weeks of therapy
were associated with worse outcome (Trottestam et al, 2012).
In our cohort (Table II), 18/21 patients had three or less
negative outcome predictors before the start of the therapy.
Among the patients with more than three negative outcome
predictors, two underwent a successful HSCT, while the third
achieved a full remission after 3-drug regimen. Regarding the
post-treatment outcome predictors evaluation, the only
patient who had more than three negative outcome predic-
tors pre- and post-treatment, required HSCT.
Perforin (PRF1) expression on peripheral blood NK cells
(CD3CD56+) was impaired in four of 17 tested patients
and in three of them the molecular analysis revealed a
heterozygous PRF1 A91V mutation, whose relevance in the
disease pathogenesis remains controversial (Busiello et al,
2004, 2006). Recent studies suggest that PRF1 A91V genotype
is present in the normal population, thus being insufficient
per se to cause FHLH, although it may represent a genetic
susceptibility factor for immune dysregulation (Zhang et al,
2007). One of these patients also carried a heterozygous
UNC13D R967E mutation.
In eight patients and 13 controls, the degranulation of NK
cells, through CD107a expression, and IFNc production after
incubation with K562 line cells was evaluated. The percentage of
CD107a+CD56+CD3 cells and IFNc+CD56+CD3 lymphocytes
<10th percentile of normal values were considered reduced.
CD107a expression in CD56+CD3 population revealed a lower
percentage of CD107a+ cells in the patients as compared with the
controls (49.98  7.43% vs. 84.60  2.07%, respectively;
P < 0.0001). Moreover, patients showed a significantly lower
percentage of IFNc+ cells than controls (20.89  3.57% vs.
62.61  4.20%, respectively; P < 0.0001). Of note, all patients
had a low percentage of IFNc+ NK cells; only one of them exhib-
ited a normal CD107a expression. Studies on mouse models indi-
cate that defects in the production of IFNc or cytotoxicity may
render mice more susceptible to CMV infection (Lee et al, 2007).
This would suggest that abnormal intracellular trafficking, along
with a reduction in the IFNc production, could be implicated in
the pathogenesis of HLH under condition of challenge by viral
infections or other types of environmental stress.
In conclusion, the clinical course of paediatric HLH with
unknown genetic alteration is more favorable then FHLH, as
suggested by later onset, lower prevalence of neurological
involvement and better outcome. Given that HLH is a poten-
tially life-threatening condition shared by distinct unrelated
clinical entities, the definition of the underlying common patho-
genetic mechanism is mandatory to better define the manage-
ment of such patients and open new therapeutic options.
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Fig S1. Functional analysis. Panel (A) There was a signifi-
cant lower percentage of CD107a+cells in the patients as com-
pared with the controls (49.98  7.43% vs. 84.60  2.07%,
respectively; P < 0.0001). Panel (B) A significant lower per-
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P < 0.0001).
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More on normal prothrombin times in the presence of
therapeutic levels of rivaroxaban – early experience from
King’s College Hospital
We read with interest the letter by van Veen et al (2013)
describing their experience on the performance of the Inno-
vin and Thromborel S prothrombin time assays in a 74-
year-old patient with renal impairment who was commenced
on rivaroxaban for the treatment of deep vein thrombosis. It
was interesting to observe that with both assays, the pro-
thrombin time (PT) was not prolonged, despite therapeutic
concentrations of rivaroxaban, and we thank van Veen and
colleagues for highlighting this important observation to the
wider clinical community. To complement their report, we
would like to share our experience of how a different PT
assay to those utilized by van Veen et al (2013) performed in
a group of patients attending King’s College Hospital who
were prescribed rivaroxaban.
During the past 6 months, we have been prescribing
novel oral anticoagulants (NOAC) for selected patients,
if they fit the local South London Cardiac and Stroke
network criteria for NOAC use (http://www.slcsn.nhs.uk/
noacs.html). For these patients, when clinically indicated
(e.g. extremes of body weight, renal dysfunction, or pres-
ence of interacting drugs), we measured the activity of the
rivaroxaban, in order to satisfy ourselves that the desired
response was being achieved. Our laboratory uses the
STA-Neoplastine (Diagnostica Stago, Asnie`res-sur-Seine,
France) CI Plus PT assay for detection of the presence of
the drug (rivaroxaban), and the STA-liquid anti-Xa assay
(Diagnostica Stago, Asnieres-sur-Seine, France), with appro-
priate rivaroxaban calibrators and controls for quantifi-
cation of the actual rivaroxaban concentration in the
patients plasma.
Table I describes the results of the anti-Xa rivaroxaban
concentrations, along with the respective PT assay results
from 18 patients in whom we measured these activities. In
all cases (except Patient 10), the patients had been prescribed
Correspondence
ª 2013 John Wiley & Sons Ltd 717
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4.3 Intergenerational and intrafamilial phenotypic variability in 22q11.2 Deletion 
syndrome subjects 
 
Chromosome 22q11.2 deletion syndrome also known as DiGeorge syndrome (DGS) 
(OMIM#188400), is a rare disorder due to chromosome 22q11.2 deletion.  Although most 
cases of DGS occur as de novo deletions, approximately 5% of cases are inherited in an 
autosomal dominant pattern (223-227). The incidence has been estimated at 1:4000 live 
births but recent evidence indicates that the syndrome is more common than previously 
thought (228, 229).  In fact, an increasing number of individuals with mild features has been 
identified carrying the 22q11.2 deletion. Major clinical features include facial anomalies, 
conotruncal cardiac defects, palatal anomalies, neonatal hypocalcaemia, mild to moderate 
immune deficiency related to thymic a/hypoplasia (230-232), developmental and speech 
delay (233). Ocular, renal and skeletal anomalies may also be found. Psychiatric or 
autoimmune disorders (234) can be the features leading to the diagnosis in adolescents and 
adults, and, in particular, among adults, they may be the unique clinical feature (235, 236). 
However, the syndrome has a very wide spectrum of phenotypic features (224, 237). The 
identification of subjects with attenuated phenotypes is leading to the understanding that the 
syndrome is more frequent than previously thought and to focus on novel atypical 
presentations. A wide clinical variability has also been reported even within the same family 
(223, 238-240) and a phenotypic discordance has been described among monozygotic twins 
(241, 242). Genetic modifiers, chance association or environmental interactions have been 
proposed to explain the intrafamilial variability. Somatic mosaicism or post zygotic second 
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hit have also been hypothesized as potential mechanisms underlying such phenotypic 
discordance, even though, to date, no definitive explanation is available. 
  In this study published on BMC Medical Genetics, realized in collaboration with the Centers 
member of Italian Primary Immunodeficiencies Network (IPINET), we compared the 
intergenerational variations of the clinical phenotype between patients affected with DGS 
and their affected parents carrying 22q11.2 deletion. 
 
Conclusive remarks 
A more severe clinical phenotype characterized by highest prevalence of life-threatening 
manifestations in the last generation, suggesting the worsening of the phenotype generation 
by generation was observed.  This evidence highlights the importance for the clinicians to 
look for milder manifestations in order to suspect the diagnosis of DGS and for the physicians 
to better define the relationship between clinical phenotype and genetic alteration in DGS.   
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http://www.biomedcentral.com/1471-2350/15/1RESEARCH ARTICLE Open AccessIntergenerational and intrafamilial phenotypic
variability in 22q11.2 Deletion syndrome subjects
Emilia Cirillo1, Giuliana Giardino1, Vera Gallo1, Pamela Puliafito2, Chiara Azzari3, Rosa Bacchetta4, Fabio Cardinale5,
Maria Pia Cicalese6, Rita Consolini7, Silvana Martino8, Baldassarre Martire9, Cristina Molinatto8, Alessandro Plebani10,
Gioacchino Scarano11, Annarosa Soresina10, Caterina Cancrini2, Paolo Rossi2, Maria Cristina Digilio12†
and Claudio Pignata1,13*†Abstract
Background: 22q11.2 deletion syndrome (22q11.2DS) is a common microdeletion syndrome, which occurs in
approximately 1:4000 births. Familial autosomal dominant recurrence of the syndrome is detected in about 8-28%
of the cases. Aim of this study is to evaluate the intergenerational and intrafamilial phenotypic variability in a cohort
of familial cases carrying a 22q11.2 deletion.
Methods: Thirty-two 22q11.2DS subjects among 26 families were enrolled.
Results: Second generation subjects showed a significantly higher number of features than their transmitting parents
(212 vs 129, P = 0.0015). Congenital heart defect, calcium-phosphorus metabolism abnormalities, developmental and
speech delay were more represented in the second generation (P < 0.05). Ocular disorders were more frequent in the
parent group. No significant difference was observed for the other clinical variables. Intrafamilial phenotypic heterogeneity
was identified in the pedigrees. In 23/32 families, a higher number of features were found in individuals from the second
generation and a more severe phenotype was observed in almost all of them, indicating the worsening of the phenotype
over generations. Both genetic and epigenetic mechanisms may be involved in the phenotypic variability.
Conclusions: Second generation subjects showed a more complex phenotype in comparison to those from the first
generation. Both ascertainment bias related to patient selection or to the low rate of reproductive fitness of adults with a
more severe phenotype, and several not well defined molecular mechanism, could explain intergenerational and
intrafamilial phenotypic variability in this syndrome.
Keywords: 22q11.2 deletion syndrome, DiGeorge syndrome, Immunodeficiency, Phenotypic variabilityBackground
Chromosome 22q11.2 deletion syndrome (22q11.2DS),
also known as DiGeorge or velocardiofacial syndrome
(OMIM#188400), occurs in approximately 1:4000 live
births [1,2]. Major clinical features include facial anoma-
lies, conotruncal cardiac defects, palatal anomalies, neo-
natal hypocalcaemia, mild to moderate immune deficiency
related to thymic a/hypoplasia [3-5], developmental and
speech delay [6]. Ocular, renal and skeletal anomalies may* Correspondence: pignata@unina.it
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reproduction in any medium, provided the oralso be found. However, the syndrome has a very wide
spectrum of phenotypic features [7,8]. Evidence high-
lighted that subjects carrying the deletion may have only
mild phenotypes [9,10]. Psychiatric or autoimmune disor-
ders [11] can be the features leading to the diagnosis in
adolescents and adults, and, in particular, among adults,
they may be the unique clinical feature [12,13]. The identi-
fication of subjects with attenuated phenotypes is leading
to the understanding that the syndrome is more frequent
than previously thought and to focus on novel atypical
presentations. A wide clinical variability has also been
reported even within the same family [9,10,14,15] and a
phenotypic discordance has been described among mono-
zygotic twins [16,17]. Genetic modifiers, chance asso-
ciation or environmental interactions have been proposedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or post zygotic second hit have also been hypothesized as
potential mechanisms underlying such phenotypic dis-
cordance, even though, to date, no definitive explanation
is available.
The deletion results from non allelic homologous re-
combination, occurring during meiosis and mediated by
low-copy repeats (LCR) on chromosome 22 [18-20].
Most patients have a deletion of the same 3 Mb region
on 22q11.2, including about 30 genes, whereas in 8% of
the cases a smaller deletion of 1.5 Mb, which contains
24 genes, is found. So far, no correlation between the
severity of the phenotype and the different size of the
deletion has been documented [21]. Both deletions in-
clude the TBX1 gene, a member of the T-box family
genes. Mice, haploinsufficient for TBX1, share several
features with humans carrying the homologous deletion,
and, in particular, structural cardiac anomalies [22]. In-
terestingly, both gain or loss of function mutations in
TBX1 have been reported in human subjects exhibiting
a DiGeorge-like phenotype [23].
In most cases, the deletion is a sporadic event, while
in 8-28% of the cases the syndrome is inherited in an
autosomal dominant fashion [8,10,24-26].
Several studies have analyzed the phenotypic varia-
bility of the syndrome, but an extensive and conclusive
intergenerational and intrafamilial comparison has not
yet been reported.
The aim of this study is to perform an interge-
nerational and intrafamilial comparison of the clinical
phenotype in a cohort of patients affected with inherited
chromosome 22q11.2DS.
Methods
Patients
Thirty-two subjects (18 females) affected with familial
22q11.2DS from 26 families, were enrolled into the study.
The study and data collection, approved by the local Ethics
Committee for Biomedical activities “Carlo Romano”,
have been performed upon informed consent and in com-
pliance with the Helsinki Declaration (http://www.wma.
net/en/30publications/10policies/b3/index.html). Within
the group, 17 subjects were from the Italian Network for
Primary Immunodeficiencies (IPINET) Registry, followed
at 8 Italian Centers, and 15 were referred to two Genetic
Units. In 4 families, 2 affected siblings were diagnosed and
in one further family, 3 subjects were identified. Mean
age +/− SD was 10.4 +/− 7.23 years (range 4 months-
31 years). The parent carrying the deletion was the
mother in 17 cases (65%) and the father in 9 (35%).
Mean age +/− SD of carrier parents was 39.8 +/− 7.9 years
(range 21–58 years). We found a preferential maternal
transmission, in keeping with the recent observation that
female sex represents a significant positive predictor offitness. All the parents were identified as affected by
22q11.2DS after the birth of a child with the deletion. All
patients, but two, were Caucasian. Demographical features
are reported in Additional file 1: Table S1. Clinical data of
the second generation subjects were obtained, upon in-
formed consent, through the IPINET Registry or from the
referring Units. Data on parents carrying the deletion were
collected at each Center. Each subject underwent a clinical
and laboratory evaluation protocol (IPINET protocol for
22q11.2DS) available at the site http://www.aieop.org. The
protocol included cardiologist examination, echocardiog-
raphy and abdominal ultrasound, which were performed
in order to exclude subclinical cardiac or abdominal de-
fects in asymptomatic subjects. To exclude thyroid and
calcium-phosphorus abnormalities, the serum levels of
calcium, phosphorus, parathyroid hormone, TSH and FT4
were evaluated. History of speech therapy or speech pa-
thologist interventions were recorded for the evaluation of
language disorders. The Wechsler Intelligence Scale for
Children (WISC) and the Wechsler Adult Intelligence
Scale (WAIS) were used for the assessment of cognitive
function in subjects of the second generation and in their
parents, respectively. Each Center reported the presence/
absence of intellectual disability which was defined as an
IQ under 70. Neuropsychiatric evaluation was performed
by skilled clinicians using the Schedule For Affective
Disorders and Schizophrenia for School-aged Children,
Present and Lifetime (K-SADS-PL). The second gene-
ration subjects, older than 18 years, and their parents were
interviewed with the Structured Clinical Interview for
Axis I DSM IV Disorders (SCID).
Among the clinical features, birth defects, facial anom-
alies, gastrointestinal disorders, infections and auto-
immune manifestations were recorded. History of
neonatal hypocalcaemia was also considered. In 6 fam-
ilies, data were also obtained from the non-deleted par-
ent, to exclude potential interfering factors not related
to the 22q11.2 deletion.
Intrafamilial phenotypic variability was assessed through
the evaluation of the clinical phenotype in each parent–
child couple. Since in 5 families more than 1 subject with
the inherited deletion was detected, the phenotype was
analyzed in a total number of 32 parent–child pairs from
the 26 families.
Cytogenetic analysis
The diagnosis of 22q11.2DS was performed by fluore-
scence in situ hybridization (FISH) analysis and/or multi-
plex ligation-dependent probe amplification (MLPA) using
probes for 22q11 region in all affected patients. In one
case, the diagnosis was obtained through a CGH array
with whole-genome oligonucleotide microarray Agilent
Technologies (Santa Clara, CA) according to the manufac-
turer protocol.
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Statistical analysis was performed using the Student”s
t test or the Fisher exact Test. Values of P < 0.05 were
considered statistically significant. The calculations
were performed using InStat software.
Results
Intergenerational clinical phenotypic comparison
Seventeen clinical variables were evaluated in subjects of
the second generation and their parents (Table 1), for a
total number of 544 and 442 variables in the first and
second group, respectively. Overall, affected subjects of
the second generation showed a significantly higher num-
ber of features than their parents (212 vs 129, P = 0.0015).
In particular, congenital heart defect (CHD) (62.5 vs
7%, P < 0.0001), developmental delay (71.8 vs 42.3%,
P = 0.032), speech delay (75 vs 46.1%, P = 0.031)
and calcium-phosphorus abnormalities (37.5 vs 3.8%,
P = 0.0033) were more represented in the second gene-
ration. Conversely, ocular disorders were more frequent
in the parents than in their affected children (3.1 vs 23%,
P = 0.037). Psychiatric (12.5 vs 34.6%), autoimmune (12.5
vs 19.2%) and dental disorders (25 vs 38.4%) tended to be
more frequent in the older generation, even though the
differences did not reach a statistical significance. NoTable 1 Clinical characteristics of second generation
subjects and parents carrying the 22q11.2 deletion
Second generation Parents
Total number of subjects 32 26
N (%) N (%) p
Facial anomalies 29 (90.6) 24 (92.3) 1
Congenital heart defect 20 (62.5) 2 (7) <0.0001
Ca-P abnormalities 12 (37.5) 1 (3.8) 0.0033
Palatal anomalies 18 (56.2) 13 (50) 0.79
ENT anomalies 4 (12.5) 2 (7) 0.68
Renal disorders 7 (21.8) 2 (7) 0.16
Ocular disorders 1 (3.1) 6 (23) 0.037
Neurological disorders 3 (9.3) 1 (3.8) 0.62
Dental anomalies 8 (25) 10 (38.4) 0.39
Skeletal anomalies 15 (46.8) 10 (38.4) 0.6
Gastrointestinal disorders 8 (25) 2 (7) 0.16
Psychiatric disorders 4 (12.5) 9 (34.6) 0.06
Language delay 24 (75) 12 (46.1) 0.031
Developmental delay 23 (71.8) 11 (42.3) 0.032
Learning difficulty 23 (71.8) 16 (61.5) 0.57
Autoimmunity 4 (12.5) 5 (19.2) 0.71
Infections 9 (28.1) 3 (11.5) 0.19
Only severe infections (sepsis, pneumoniae), requiring hospitalization, or
history of recurrent infections were considered. Bold indicate P values
considered statistically significant.statistically significant difference was observed for the
other phenotypic features. About 15% of the clinical fea-
tures were diagnosed during the study.
We next compared the anatomic type of CHD bet-
ween the 2 groups. We found that in the 20% of the
subjects of the second generation with CHD, each indi-
vidual patient had more than 1 abnormality, whereas in
the parent group none of them had a more severe defect.
A cyanotic CHD was found only in the 35% of the group
with the cardiac defect. In particular, among these pa-
tients, we found that 7/20 subjects of the second gene-
ration exhibited a tetralogy of Fallot (TOF) and only 1/20
truncus arteriosus (TA). Among those with non cyanotic
CHD, a patent ductus arteriosus (PDA) was observed in
4/20, atrial septal defects (ASD) in 4/20, interrupted aortic
arch (IAA) in 4/20, ventricular septal defects (VSD) in
3/20, pulmonary valve stenosis (PVS) in 1/20 and other in
2/20. In the parent group, the anomalies found were a
PDA in one case and a double aortic arch (DAA) in the
other one.
With regard to calcium-phosphorus metabolism abnor-
malities, 9 subjects in the second generation presented
with neonatal hypocalcemia, and in 2 of them a hypopara-
thyroidism was later diagnosed. Overall, at any age, a total
of 5/32 (15.6%) of them received a full diagnosis of hypo-
parathyroidism. Only 1 subject of the parent group was
affected with asymptomatic hypoparathyroidism.
Although the prevalence of the palatal defects was simi-
lar in the 2 groups (56 and 50%, respectively), we next
compared the type of the defect and made a comparison.
Within the group of patients of the second generation, 1
subject had cleft palate and bifid uvula, 16 velopharyngeal
insufficiency, 4 hypernasal speech and 4 high arched
palate. In the parent group, 11 had velopharyngeal insuf-
ficiency, 3 hypernasal speech, 1 high arched palate. Only
in two parents, a cleft palate was observed. Thus, no re-
markable difference was found for these variables.
Psychiatric disorders were more frequent in the parent
group, even though the difference did not reach statistical
significance (P = 0.06). We found that in the parent group,
anxiety was observed in 5/26, mood disorders in 3/26,
attention-deficit/hyperactivity disorders in 3/26, beha-
vioral anomalies in 3/26, schizophrenia in 2/26, psychotic
disorders not otherwise specified (NOS) in 2/26 and
phobia in 1/26. Within the second generation group, 2 of
them had behavioral abnormalities represented by trend
to social isolation and rejection, impairment in social and
daily living skills and low self-esteem, 1 also showed adap-
tive abnormalities, and the other one an attention deficit
disorder. Schizophrenia was observed in 1 subject of the
second generation, who, however, was 31 years-old.
Ocular defects were the only anomaly frequently ob-
served in the parental generation, consisting in refractive
defects (3/6), strabismus (2/6), retinal vessel abnormalities
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child with ocular defect had retinal vessels abnormalities.
Intrafamilial clinical phenotypic comparison
With regard to the intrafamilial phenotypic variability, in
23 out of the 32 child/parent couples a higher number
of features was found in the second generation, although
in 6 couples the number of features was higher in the
parents’ generation and in the remaining 3 couples no
difference was found (Figure 1). None of the couples
with higher number of features in the parents’ gene-
ration had a CHD or hypoparathyroidism.
We then performed an intrafamilial evaluation of the
clinical severity of the phenotype with regard to the
prominent clinical features, whose prevalence was statis-
tically different between the 2 groups, namely CHD,
anomalies of the calcium-phosphorus metabolism, deve-
lopmental and/or speech delay (Table 2).
In particular, we observed that CHD was present in 18
couples only in the second generation and, in one case,
only in the first generation. In the couple in which both
members were affected, the parent exhibited a PDA,
whereas his child was affected with IAA, thus confir-
ming the lack of phenotypic correspondence. Calcium-
phosphorus abnormalities were found in 11 subjects of
the second generation, and the only parent with asymp-
tomatic hypoparathyroidism had a child who presented
with hypocalcaemia. In 15 couples speech delay was ex-
clusively observed in the second generation whereas in 5
couples only in the first generation. In the remaining 9
couples both members were affected. In 16 couples, de-
velopmental delay was exclusively found in the second0
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Figure 1 Intrafamilial phenotypic comparison. A higher number of feat
couples the number of features was higher in the parents’ generation and
indicate the families with 2 or more second generation affected subjects. *generation, in 4 cases only in the first generation and in
8 couples both subjects were affected.
To rule out the interference of factors not related to
the 22q11.2 deletion, in 6 families, data were collected
also from the non-deleted parent. Of note, none of them
had a CHD, while 2 children in this subgroup were
affected. One subject reported learning and behavioral
problems, but not intellectual disabilities, while in an-
other case a borderline IQ of 68 was determined.
Furthermore, in the families with more than one af-
fected child, a milder phenotype was observed in parents
than in children, even though the 5 subjects of the second
generation, who were diagnosed first, had a higher num-
ber of the major clinical features compared to their 6 sib-
lings (16 core features vs 11).
Discussion and conclusions
We have compared the clinical phenotype of a cohort of
32 subjects affected with inherited 22q11.2DS and their
transmitting parents.
In this study, we found a higher number of clinical
features and a more severe phenotype in the second
generation, which exhibited a higher number of more
severe conditions. CHD, abnormalities of the calcium-
phosphorus metabolism, developmental and/or speech
delay were more represented in children than in parents.
It should be considered that, in the past decades, severe
CHD was associated with a high neonatal and infant mor-
tality. This evidence was thought to have an appreciable
impact on reducing the reproductive fitness of 22q11.2DS
patients with CHD. More recently, however, with the
improvement of cardiac surgery strategies, it is suggested6 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
uple
**
ures were observed in the second generation in 23 couples. In 6
in the remaining 3 couples no difference was found. The brackets
indicates the proband within these families.
Table 2 Intrafamilial comparison of the clinical severity of the phenotype
Couple Congenital heart defect Ca-P abnormalities Speech delay Developmental delay
Affected subject Parent Affected subject Parent Affected subject Parent Affected subject Parent
1 yes no yes yes no yes yes no
2 yes no yes no yes no no no
3 yes no no no no yes yes no
°4 no no yes no no yes yes no
°5δ yes no yes no yes yes yes no
6 yes no no no yes yes yes yes
7 yes no yes no yes no yes no
8 no no no no yes no yes no
9 no no no no yes no yes no
10 no yes yes yes yes yes no no
°11 yes no yes no no no yes no
°12δ yes no no no yes no yes no
13 no no no no yes no no yes
°14 no no no no yes no yes yes
°15δ yes no no no yes no no yes
16 no no no no yes no yes no
17 yes no no no yes yes yes yes
18 yes no no no yes yes yes yes
19 yes no no no yes yes no yes
20 yes yes no yes yes yes yes no
21 yes no yes no yes yes yes yes
22 yes no yes no yes yes yes yes
23 yes no yes no yes no yes yes
°24 no no no no yes no yes no
°25 no no no no yes no yes no
°26δ yes no yes no yes no yes no
27 yes no yes no no yes no yes
28 no no no no yes yes yes yes
29 no no no no yes no yes no
°30δ yes no no no yes no yes no
°31 no no no no no no no no
32 yes no no no no no no no
°Couple of siblings; δFirst individual to seek medical attention for genetic evaluation.
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transmission of 22q11.2 deletion is primarily due to the
severity of the neuropsychiatric phenotype and intellectual
disabilities [27].
The only anomalies more frequent in the parental
generation were ocular abnomalities. Since most of
them, in particular refractive defects and cataract
usually develop during older age, we could not exclude
a bias related to the different ages of the subjects in the
two groups.When an intrafamilial comparison of the phenotypic
complexity was performed, a higher prevalence of clinical
features were found in the second generation. When the
comparison concerned the prominent clinical features,
whose prevalence was statistically different between the 2
groups, namely CHD, calcium-phosphorus metabolism
anomalies, developmental delay and speech delay, we
observed that in almost all parent/child couples these
major features were more frequent in the second gene-
ration. In previous studies [9,10,13-15,24], an intrafamilial
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comparison of intergenerational clinical features has not
been performed. An ascertainment bias could partially ex-
plain this finding, since the first subject diagnosed within
a family is likely to be more severely affected. Moreover,
our observation may also be explained by a bias related to
the low rate of reproductive fitness of adults with a more
severe phenotype.
As to developmental delay, the presence of environmen-
tal intellectual disabilities may obviously per se influence
the mental development of the offspring, because of psy-
chosocial deprivation. However, it should be emphasized
that in our cohort the majority of the subjects with
developmental delay have a parent without intellectual
disability. Moreover, in the 6 families in which also the
non-deleted parent was studied, the lack of a clear corre-
lation between environment and the child’ development
was noted. As expected, psychiatric disorders were more
represented in the first generation, however, the difference
was not significant thus suggesting the need of an accurate
psychiatric management since childhood.
Several genes, such as TBX1 [28], HIRA, UFD1L [29]
and CRKL [30], within the 22q11 region have been consid-
ered to be implicated in the pathogenesis of the syndrome.
The 22q11.2 phenotype is a developmental field defect,
and a DiGeorge-like phenotype may also occur in the ab-
sence of the deletion [31], as in diabetic [32] and retinoic
acid embryopathy, fetal alcohol syndrome, CHARGE [33]
and Fraser syndromes, as well as other chromosomal
anomalies, such as 10p13, 17p13, 4q34.1q35.2 [34-36],
indicating that several molecules in a common genetic
pathway or in functionally related pathways may be
involved in 22q11.2DS clinical manifestations.
Several hypotheses have so far been proposed to explain
intergenerational and intrafamilial phenotypic variability
in genetic syndromes. Deletions of different sizes and
location and the extension of an unstable mutation at the
22q11.2 locus could explain the clinical variability [37].
Evidence indicates that TBX1 gene is sensitive to
altered dosage [38], thus leading to the hypothesis that
additional alterations of the other allele may explain the
clinical variability. In humans, this does not seem to be
the case, in that so far DNA variations in TBX1 locus on
the remaining allele were not found in 22q11.2DS pa-
tients exhibiting a variable cardiovascular expression and
palatal defects. Thus, it is likely that gene modifiers not
related to chromosome 22 may be implicated [39,40].
The increased risk of cardiac defects observed in un-
affected relatives of 22q11.2DS subjects with CHD, sug-
gested a potential role for genes outside the DiGeorge
critical region [41,42]. However, studies aimed at identi-
fying genetic factors outside of the 22q11,2 region, such as
VEGFA [43] or folate-related genes [44] failed to reveal
any association. It should be noted that in the subgroup offamilies in whom also the non-deleted parent was studied,
no CHD was noted suggesting the absence of interfering
genetic factors not related to the 22q11.2 deletion in this
context.
A copy-number variation may explain a reduced pene-
trance of some disease-causing mutations [45]. A genetic
compensatory effect has also been documented in families
of 22q11.2DS subjects, whose clinically normal parent
carried 22q11.2 deletion compensated by an insertion of
the 22q11.2 critical region inside the other copy of the
chromosome [46]. Finally, a mosaic status in the carrier
parent, even though rare, could be the explanation of the
variable and more benign phenotype. At the moment, we
cannot yet exclude the presence of a concomitant duplica-
tion or copy number variations in the former generation,
since further studies with interphase FISH or array-CGH
are required to rule out this hypothesis.
During development, gene expression is accurately or-
chestrated in time and space in a program that involves
enzymes controlling nucleosome remodeling, histone mo-
dification and DNA methylation [47]. A demonstration
that an epigenetic alteration could result in a DiGeorge
syndrome phenocopy has been recently documented in
mutant mice lacking the MOZ histone acetyltransferase
[48]. Thus, failure of these fine tuned mechanisms could
result in an interference of the phenotypic expression.
In our study we also observed that some clinical fea-
tures were more represented in the previous generation,
although the difference did not reach the statistical sig-
nificance for the limited number of subjects studied. In
keeping with recent findings, we observed a higher inci-
dence of psychiatric disorders in the older generation.
The identification of adults with a milder phenotype de-
serves careful attention since a later onset illness associ-
ated with 22q11.2DS has been reported, highlighting the
possibility that along with psychiatric disorders, also treat-
able conditions such as symptomatic or asymptomatic
hypocalcaemia, thrombocytopenia and hypothyroidism
may occur [49]. Early recognition of these features [50]
could provide the benefit of an early treatment [51-53].
Advantages and limitations of the study
This is the largest cohort of subjects affected with familial
22q11.2DS. A detailed characterization of the clinical fea-
tures of such subjects, and an intergenerational/intrafa-
milial clinical comparison has been performed. The
observation that within the families, the patients who were
first diagnosed had a higher number of core features as
compared to their siblings or parents would suggest an as-
certainment bias, even though the clinical phenotype of
the parents was milder compared to their children. An-
other possible explanation could be the co-inheritance of
a further genetic defect from the non-affected parent. This
seems unlikely since this co-inheritance should have
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phenotype. As for the CHD, it should be noted that none
of the non-affected parents had a CHD, thus excluding, at
least for this feature, this hypothesis.
Additional file
Additional file 1: Table S1. Demographic characteristics of the
22q11.2DS subjects.
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4.4 Gastrointestinal involvement in patients affected with 22q11.2 deletion syndrome. 
 
Gastrointestinal (GI) alterations, including feeding disorders (237, 243) and congenital 
abnormalities (224), are often reported in patients with Del22 and other athymic disorders  
(188, 231). The commonest disorders are: gastroesophageal reflux disease (GERD), 
esophagitis and chronic constipation. Feeding disorders, mostly due to dysmotility in the 
pharyngoesophageal area, are characterized by difficulties in coordinating the 
suction/deglutition/breathing reflex and result in slow feeding and episodes of regurgitation 
(237, 243). The GI congenital abnormalities include: esophageal atresia, jejunal atresia, 
umbilical hernia, diaphragmatic herniation, intestinal malrotation, congenital megacolon, 
anorectal malformations (atresia, anterior displacement) and dental anomalies, such as 
delayed formation and eruption of permanent teeth and enamel hypoplasia (224). However, 
a systematic and well detailed clinical and laboratory characterization of the GI alterations in 
Del22 syndrome is missing.  In this monocentric study published on Scandinavian Journal 
of Gastroenterology we defined the GI involvement in a cohort of patients affected with 
Del22. 
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TECHNOLOGIES 
 
§ Patients 
Concerning the study on NGS, patients, heterogeneous for ethnic origin, age and sex, were 
accurately selected according to clinical and immunological criteria, highly suggestive for 
primary immunological defect. The clinical criteria adopted included one or more of the 
following: opportunistic infections; granuloma; CMC; intractable diarrhea; bronchiectasis; 
severe autoimmunity; variably associated to syndromic features and/or familiarity for similar 
phenotype. Any clinical criteria was considered if associated to one or more of the following 
quantitative and/or qualitative immunological criteria: abnormal lymphocyte subsets 
(absolute count < 2 SD of normal values according to ESID criteria); proliferative response 
to mitogens <10% of the CTR; absent/poor specific antibody response; 
hypogammaglobulinemia; high IgE levels (>2000 KU/l); absent cytolytic activity; alteration 
of class switch recombination (CSR) with or without hyper-IgM.  
Concerning the study on CMCD, patients carrying STAT1 GOF mutations were 
prospectively included in the study from January 2011 to January 2015. They were from 30 
different countries. Physicians caring for the patients completed a detailed questionnaire, 
after the eligible patient had agreed to participate and was enrolled in the study. Relatives of 
patients with STAT1 GOF mutations who displayed CMCD but could not be genotyped 
(deceased, lost to follow up) were considered to carry the respective STAT1 GOF mutations 
and were included in the study. Asymptomatic relatives of included patients were genotyped 
when possible. Data were collected for the patients, from their birth until January 2015 or 
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their death. Data were centralized at the coordinating center at Necker-Enfants Malades 
University Hospital. Patients with CMCD for whom no STAT1 mutation was identified 
during the study were excluded.  
 
§ Cells and cell cultures 
Peripheral Blood Mononuclear cells (PBMC) were obtained from patients and healthy 
donors by Ficoll-Hypaque (Biochrom) density gradient centrifugation. Fibroblasts were 
isolated by mincing of dermal skin fragments and were grown in Dulbecco’s modified 
Eagle’s medium (Invitrogen) and 10% FBS (Gibco), supplemented with 100 U/ml Penicillin 
and 100 μg/ml Streptomycin (Invitrogen). The cultures were incubated at 37°C in the 
atmosphere supplemented with 5% CO2, with the cell culture media changed daily. 
Fibroblasts were passaged fewer than 5 times before use in experiments.  
To obtain polyclonal NK cell lines, NK lymphocytes were isolated from PBMCs using 
negative selection (NK cell isolation Kit, Miltenyi), then cultured on irradiated feeder cells 
in the presence of 100 U/mL recombinant human IL-2 (Proleukin; Chiron) and 1.5 ng/mL 
phytohemagglutinin (Gibco). CD4+ cells were separated from the patient and a healthy 
control by positive selection using human CD4 microbeads.  
U3C cells, a STAT1-deficient fibrosarcoma cell line, were grown in DMEM (EuroClone) 
and 10% FBS (Gibco), supplemented with 2mM L-Glutammine, 1000U/m Penicilline and 
Streptomycin (EuroClone). 
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§ DNA extraction and sequence capture array design 
DNA was isolated from peripheral blood lymphocytes with DNA Blood Mini Kit_ (Qiagen, 
Hilden, Germany). Quantity and quality were determined on the Nano-Drop_ ND-1000 
spectrophotometer (ThermoScientific,Waltham, MA, USA). A panel of 571 genes, including 
genes known or predicted to be related with PIDs and/or immune regulation, was selected. 
Basically, broad searches in literature, PubMed queries and expert suggestions defined the 
gene panel. We used BioMart (Ontario Institute for Cancer Research ⁄ European 
Bioinformatics Institute) to retrieve the coordinates of all exons for the specified genes from 
Ensembl. Coordinates were based on the current human reference genome (hGRC37, hg19). 
 
§ Next generation sequencing and variant analysis  
A TNGS panel, "TaGSCANv.2" (Targeted Gene Sequencing and Custom Analysis) was run, 
including 571 genes. Samples were prepared for sequencing using TruSight Rapid Capture 
with TruSight Inherited Disease Oligos (Illumina); the MT genome is covered at 1000x by 
the addition of MT oligos during enrichment (IDT). Samples were sequenced to at least 
2.5Gb on an Illumina MiSeq with TruSeq v3 reagents, yielding paired 250 nucleotide reads. 
Alignment, variant calling, and analysis was performed as previously described. Variant 
analysis was confined to coding and splice variants with a minor allele frequency (MAF) of 
1% or less in the CMH internal database.  
 WES was performed in 18 cases. Nucleotides (37.7 million) of exons (the exome) were 
enriched 44-fold from genomic DNA from the patients and sequenced to an average, 
uniquely aligned coverage of 135-fold. 
 
 
 
 
214 
§ Sanger sequencing  
Selected variants predicted to be damaging, along with consistent genotype-phenotype 
correlation were validated by Sanger sequencing using standard protocols, in both the 
proband and parents. gDNA was PCR-amplified using GoTaq polymerase (Promega) and 
specific primers (primer sequences available upon request). Amplicons were bi-directly 
sequenced using the BigDye Terminator version 1.1 cycle sequencing kit and an Applied 
Biosystems 3130xl Genetic Analyzer (Life Technologies).  
Exons 1 to 25 of STAT1 and their flanking intron sequences were amplified by PCR with 
specific oligonucleotide primers (available on request) and sequenced with the Applied 
Biosystems Big Dye terminator kit v1.1 (AB Foster City California) and an ABI Prism 
3130xl Analyzer (Applied Biosystems). For each GOF STAT1 mutation, the prediction 
scores of 5 algorithms — SIFT,S1 Polyphen2,S2 Mutation Taster, LRT,S3 and PhyloPS4— 
and a newly designed prediction score combining all five algorithms, rPred were used to 
predict the likely impact of an amino-acid substitution on STAT1 protein structure and 
function. Higher scores indicate a higher probability of the mutation being deleterious, and 
the maximum score is 1. 
IKBKG-specific primers were used to evaluate the full cDNAwith the following primer 
sets: forward, 5#-CCCTTGCCCTGTTGGATGAATAGGC-3#; reverse, 5#-
AGGCGGGAGAGGAAAGCGCAGACTG-3#; and forward, 5#-
AAGCTGGCCCAGTTGCAGGTGGCCT-3#; reverse, 5#-
AGGTGGCATCCCAGTTGTGG-3#.  
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The eight exons of EDA-1 and EDA-2 were amplified through PCR using the following 
primer sets: forward, 5#-GTCGGCCGGGACCTCCTC-3#; reverse 5#-
GCCGCCGCCCCTACTAGG-3#; forward, 5#-ATGTTGGCTATGACTGAGTGG-3#; 
reverse, 5#-CCCTACCAAGAAGGTAGTTC-3#; forward, 5#-
GATCCCTCCTAGTGACTATC-3#; reverse, 5#-CAGACAGACAATGCTGAAAGA-3#; 
forward, 5#-AAAAAAGTAACACTGAATCCTATT-3#; reverse 5#-
CTCTCAGGATCACCCACTC-3#; forward, 5#-GGAAGTCAAAAGATTATGCCC-3#; 
reverse, 5#-CTACCCAGGAAGAGAGCAAT-3#; forward, 5#-
CTGAGCAAGCAGCCATTACT-3#; reverse, GGGGAGAAGCTCCTCTTTG-3#; 
forward, 5#-ACTGAGTGACTGCCTTCTCT-3#; reverse, 5#-
GCACCGGATCTGCATTCTGG-3#; forward, 5#-TGTCAATTCACCACAGGGAG-3#; 
reverse, 5#-CACAGCAGCACTTAGAGG-3#. 
The exons 2 and 3 of the PRF1 coding region were amplified using standard polymerase 
chain reaction (PCR) conditions. PCR products were recovered from 1.5% agarose with a 
size marker, purified using the QIAquick Gel extraction kit (Qiagen, Hilden, Germany) and 
sequenced in an automatic ABI 377 DNAsequencer (Applied Biosystems, Foster City, CA). 
 
§ PCR and quantitative real-time PCR analysis 
Total RNA from patient samples and controls was extracted using TRIzol reagent 
(Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. RNA was reverse 
transcribed by Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). 
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The qPCR reactions were performed in duplicate. The amplification of the cDNAs was 
performed using the SYBR Green and analyzed with the Light Cycler480 (Roche Applied 
Systems, Germany).  
Total RNA was extracted from PBMC and fibroblasts left unstimulated or stimulated with 
TNFα, IL-1, LPS, I:C, and IFNγ. Total RNA was extracted from IL-2 activated NK cell left 
unstimulated or stimulated with IL-2 (100ng/ml) or IL-15 (100ng/ml) for 24 h using the 
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. 
For reverse transcription polymerase chain reaction (RT-PCR) experiments, 1 μg of DNase-
treated total RNA was used to synthesize the first strand of cDNA by the Improm-II Reverse 
Trascription System (Promega, Madison, WI, USA). For the RT-PCR analysis, Assays-on-
DemandTM Products and Taqman Master Mix from Applied Biosystems were used 
according to the instruction manual to analyze CCL2, CCL3, IL-1, IL-6, CCl5, CXCl9, 
CXCL10, ICAM-1, STAT1, IFNγ, IL2RA,SOCS1, SOCS3 and GAPDH, gene expression. 
 
§ Mutagenesis assay 
eGFP STAT1 WT vector (Addgene) was used to obtain mutated STAT1 form carrying 
L351F and L400V variants. Mutations were generated by site direct mutagenesis 
QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies). 
 
§ Plasmid transfection 
For the complementation of patients' fibroblasts with plasmids carrying wild-type MYD88, 
fibroblasts were incubated with a mixture containing Lipofectamine 2000 reagent (Invitrogen 
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#52887) and plasmids. This complex was then removed and fibroblasts were incubated for 
18 hours in Dulbecco modified Eagle medium supplemented with 10% FBS before 
stimulation.  
U3C cells were seminated into 96-well plates (1 X 104/well) and transfected with 100 
ng/well reporter plasmids and plasmids carrying alleles of STAT1 (L351F and L400V) or a 
mock vectorwith Arrest-in (Thermo Scientific). After 6 h, cells were transferred into medium 
containing 10% FBS and cultured for 24h. 
 
§ Luciferase reporter assay 
U3C cells seminated into 96-well plates (1 X 104/well) and transfected with 100 ng/well 
reporter plasmids and plasmids carrying alleles of STAT1 (L351F and L400V) were 
stimulated with IFNγ at different concentration (10, 100, 1000 UI/ml), and IL-27 (100 ng/ml) 
for 16h. Luciferase production was assesed with Dual-Glo luciferase assay system (Promega) 
and normalized with respect to Renilla luciferase activity. Data are expressed as fold 
inductions with respect to unstimulated cells. 
 
§ Western blot 
For Western blot analysis, cytoplasmic extracts were resolved on 8% polyacrylamide and 
subjected to immunoblots by standard procedures. Nitrocellulose membranes were first 
blocked for 1 h at room temperature in TBST containing 5% BSA and then incubated 
overnight at 4 °C with specific primary Abs in the same buffer. NK cells were cultured in IL-
2 (1200U/ml)-containing medium, and then starved, in order to reduce basal phosphorylation. 
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Cells were then coltured for 16 hours at 37°C in RPMI containing 2% serum left unstimulated 
or stimulated with IFN-α (Prepotech, 10000U/ml for 30 minutes); IL-2 (Prepotech, 100ng/ml 
for 12 minutes); IL-15 (Prepotech, 50ng/ml for 12 minutes); and IL-21 (Peprotech, 50ng/ml 
for 15 minutes). Following stimulation, cells were placed on ice and washed twice with cold 
PBS. Protein was extracted by extraction buffer (RIPA Buffer Millipore) containing protease, 
phosphatase inhibitors (Thermo Scientific) and EDTA (Thermo Scientific), and maintained 
on ice for 15 minutes with occasional mixing. Insoluble material was removed by 
centrifugation at 12000 x g for 15 minutes at 4°C. Protein lysates (5mcg per sample) were 
subjected to SDS PAGE separation on 10% BIS-Tris gel (NuPage Life Technologies) and 
proteins were transferred to a polyvinylidene difluoride membrane (GE Healthcare) and 
immunoblotted with primary antibody anti-pSTAT1-Tyr-701, anti-pSTAT5-Tyr-694 (both 
Cell Signaling Technology, Danvers, MA, USA), anti-STAT5, anti-STAT1 (BD 
Transduction Laboratory) and anti-β-actin or tubulin (Sigma-Aldrich, St. Louise, MO, USA) 
as loading control. Detection was carried out using horseradish peroxidase-conjugated anti-
rabbit IgG (Sigma-Aldrich) and revealed using the enhanced chemioluminescence system 
(Euroclone LITEAblot Extend) according to the manufacturer’s instructions. All images 
were captured with UVP Biospectrum AC Imaging System. Densitometric analysis was 
performed using the Gel Pro version 3.2 Analyzer Software. 
Western blotting of NEMO or actin was performed with 4% to 12% bis-Tris NuPage 
gradient gels, NuPage buffer systems, and polyvinylidene difluoride membranes 
(Invitrogen). Membranes were blocked for nonspecific protein binding by the use of 1% BSA 
 
 
 
 
219 
in phosphate buffered saline (PBS) with 0.1% Tween-20 for 1 h at room temperature, 
followed by overnight incubation with anti-NEMO or anti-actin antibodies. 
 
§ Proliferative assay 
Cell proliferation was analyzed by the thymidine incorporation assay. For the evaluation in 
vitro of proliferative response to mitogens of PMBC, cells were stimulated with 
phytohaemagglutinin (PHA; 8 μg/ml), concanavalin A  (ConA; 8 μg/ml), pokeweed (PWM, 
10 μg/ml) (Difco Laboratories), phorbol-12-myristate-13-acetate (PMA; 20 ng/ml) and 
ionomycin (0.5 mM) (Sigma Chemical Co). CD3 cross-linking (CD3 X-L) was performed 
by precoating tissue culture plates with 1 and 0.1 ng/ml purified anti-CD3 monoclonal 
antibody (Ortho Diagnostic). Cells were plated in triplicate at 1x105 viable cells/well in 96-
well plates (BD Biosciences), in 200 μl of complete medium for 4 days. Cultures were pulsed 
with 0.5μCi 3H-thymidine for 8 hours before harvesting and the incorporated radioactivity 
measured by scintillation counting. 
To analyse cellular proliferation of NK-cell lines derived from peripheral blood of patients 
and healthy donors, we detected intracellular Ki-67 protein, after 48h stimulation with IL-2 
and IL-15. Polyclonal NK-cell lines were permeabilized with saponin solution (0.1% in PBS) 
at 4°C for 20 minute. Then cells were incubated with MoAb Ki-67 as primary anti-body 
(IgG1, mouse anti-human, 1/40 dilution; Dako, Copenhagen, Denmark) for one hour at 4°C, 
to detect nuclear proliferation antigen. The secondary antibody used was PE-conjugated 
isotype-specific goat anti-mouse (Southern Biotechnology, Birmingham, AL) and was 
 
 
 
 
220 
incubated for 30 min at 4°C, then cells were re-suspended in 500 μl of PBS solution for flow 
cytometry analysis.  
 
§ Flow cytometry analysis 
Cells were stained with the appropriate antibody (CD45-APC, CD3-PerCP, CD19-PerCP, 
CD56-PE-Cy7, CD8-PE-Cy7, CD4-FITC, CD27-APC, CD24-FITC, IgD-PE, IgM-PE, 
CD45RO-FITC [BD Biosciences, San Jose, California], CD45RA-PE, CD38-PE, CD31-PE 
[Miltenyi Biotec, Bologna, Italy]) at 4 °C for 30 min, washed and finally analyzed using a 
FACSCanto II flowcytometer (BD Biosciences). The relative proportion of the following 
lymphocyte subpopulation was studied: T cells (CD3+), helper T cells (CD3+CD4+), 
cytotoxic T cells (CD3+CD8), B cells (CD3−CD19+), Natural Killer cells (CD3−CD56+), 
naïve helper T cells (CD3+CD4+CD45RA+), memory helper T cells 
(CD3+CD4+CD45RO+), naïve cytotoxic T cells (CD3+CD8+CD45RA+), memory 
cytotoxic T cells (CD3+CD8+CD45RO+), transitional B cells 
(CD3−CD19+CD24+CD38hiCD27−), mature B cells 
(CD3−CD19+CD24−CD38dim/loCD27−), IgMmemory B cells 
(CD3−CD19+CD24+IgM+CD27+), and switched memory B cells 
(CD3−CD19+CD24+IgM−CD27+).  
Percentage of CD4+IL-17A+ (TH17) and CD4+IFN- γ + (TH1) cells was evaluated 
following PMA plus Ionomycin stimulation for 6 h. For the evaluation of CD4+IL-17A+ and 
CD4+IFN-γ+ cell development, CD4+ cells were separated from the patient and a healthy 
control by positive selection using human CD4 microbeads, and then cultured with anti-
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CD28, anti-CD3 XL, IL-6, IL-1β, TGF-β1, IL-23 for 6 days. After 6 days cells were splitted 
and cultured for further 6 days with the addition of IL-2.  
For flow cytometric evaluation of STAT1 phosphorilation, cells were left unstimulated or 
stimulated with IFN-γ (40000U/ml for 30 minutes), IL-2 (100ng/ml for 12 minutes) IL-15 
(50ng/ml for 12 minutes) and were stained simultaneously using a fluorescein isothiocyanate 
(FITC)-conjugated mouse anti-CD3 IgG mAb and a R-Phycoerythrincyanin5.1 (PerCP-
Cy5.5)-conjugated mouse anti-CD56 IgG mAb. Cells were fixed and permeabilized, 
according to the BD protocol (Protocol III), and stained with phycoerythrin (PE)-conjugated 
mouse anti-pSTAT1-Tyr-701 and anti-pSTAT5-Tyr-694 IgG mAbs (BD Pharmigene) or 
isotype-matched mAb PE (BD Bioscence). Cells were acquired using a FACSCalibur flow 
cytometer (BD Bioscence) and analyzed by the FlowJo version 7.5 Software (TreeStar). Cells 
were fixed and permeabilized, according to the BD protocol (Protocol III), and stained with 
phycoerythrin (PE)-conjugated mouse anti-pSTAT1-Tyr-701, anti-pSTAT5-Tyr-694, anti-
STAT1, anti-STAT5 IgG mAbs (BD Pharmigene) or isotype-matched mAb PE (BD 
Bioscence). 
 
§ Analysis of NK cell cytotoxicity, degranulation and IFN-γ production 
For degranulation assay against erythroleukemia K562 human cell line, PBMCs derived from 
patients and from healthy donors were incubated with or without 100 U/mL rh-IL-2 
(Proleukin; Chiron) at 37°C overnight. Then, samples were co-incubated with target cells at 
a ratio of 1:3 (effector:target K562), in a final volume of 200 μl in round-bottomed 96 -well 
plates at 37°C and 5% CO2 for 3 hours in culture medium supplemented with anti-CD107a-
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PE mAb. After 1h of co-incubation, GolgiStop (BD Biosciences Pharmingen, San Diego, 
CA, USA) was added at a 1:100 dilution. Surface staining was done by incubating the cells 
with anti-CD3, anti-CD14, anti-CD20 and anti-CD56 mAbs for 30 min at 4°C. Cells were 
washed and analyzed by flow cytometry (FACSCanto, Becton Dickinson). Analysis of NK 
cells was made on CD56+CD3-CD14-CD20- gated cells. NK cytotoxic activity was 
investigated in a 4-h 51Cr release assay with 5 • 103cells/well at a final ratio of 1:20 (T:E) 
with unstimulated or IL-2-activated NK cells against K562 cells as target. 
To detect intracellular production of IFN-γ, PBMCs derived from patients and from healthy 
donors were incubated overnight at 37°C with IL-15 (20 ng/ml, Peprotech), or IL12 (20 
ng/ml, Peprotech) and IL18 (100ng/ml, Peprotech) combined. Cells were then washed, fixed 
and permeabilized with Cytofix/Cytoperm kit (BD Bioscience Pharmingen). IFN-γ 
production was detected by subsequent intracellular staining with anti-IFN-γ-PE (BD 
Bioscience Pharmingen) upon gating on CD56+CD3-CD14-CD20- cells. For both 
degranulation and IFN-γ expression experiments, the percentage of positive cells was 
calculated subtracting the baseline CD107a or IFN-γ expression in controls cultures in the 
absence of stimuli (target cells or cytokines). 
Perforin expression on peripheral blood NK cells (CD3-CD56+) was detected by 
intracellular staining after fixation and permeabilization with ΔG9 mAb (Becton-Dickinson 
Biosciences, Oxford, UK) and cytofluorimetric analysis.   
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§ Chromatin Immunoprecipitation (ChIP) assays 
ChIP experiments were performed as previously described with minor modifications. Briefly, 
after stimulation with the appropriate cytokine, polyclonal NK cell lines were fixed using 1 
% formaldehyde for 6 min followed by 0.125 M glycine for other 6 min to stop the cross-
linking reaction. After 3 washes with ice-cold PBS, nuclear extract were prepared from 
3.5x106 cells. Chromatin was then sheared by sonication and immunoprecipitated with 4 μg 
anti-STAT1 (sc-346) or 4 μg anti-STAT5 (sc-835) (Santa Cruz Biotechnology). To establish 
the background levels of ChIP experiments, the precipitation signal was quantified also at 
the promoter of prolactin (PRL). The coimmunoprecipitated material was subjected to qPCR 
analysis using the following promoter specific primers (purchased from Life Technologies): 
IL2RA forward: 5’-TTCCACAGTTCTGAGAAAGGTG-3’; IL2RA reverse: 5’-
CATGGCAAGGGTTTATGAGG-3’; IFIT1 forward: 5’-
GGCAGCAATGGACTGATGTTC-3’; IFIT1 reverse: 5’-
GGAAACCGAAAGGGGAAAGTG-3’; and PRL forward: 5’-
AGGGAAACGAATGCCTGATT-3’; PRL reverse: 5’-GCAGGAAACACACTTCACCA-
3’. Data from qPCR were expressed as percentage over input DNA and are displayed as 
means ± SEM. 
 
§ In vitro B cell proliferation and plasma cell differentiation  
B cells were labeled with 5-chloromethylfluorescein diacetate at the final concentration of 
0.1 mg/mL (Molecular Probes, Eugene, Oregon) and cultured at 1–2 × 105 cells per well in 
96 round-bottom plates (BD Biosciences) in complete RPMI-1640 (Invivogen, San Diego, 
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California) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, Utah). 
Human CpG oligodeoxynucleotides (Hycult Biotechnology, Plymouth Meeting, 
Pennsylvania) was used at the optimal concentration of 2.5 mg/mL. Cell proliferation was 
measured on day 7 by a FACSCalibur Flow Cytometer (BD Biosciences). To evaluate B-cell 
function a lymphocyte gate based on forward and side scatter characteristics was used. The 
B cell gate was based on CD19 expression. The CMFDA fluorescence of CD19+ B cells was 
then evaluated. Secreted Ig was assessed at day 7 by ELISA. Briefly, 96-well plates (Corning 
Incorporated, New York, USA) were coated overnight with purified goat antihuman IgA, 
IgG or IgM (Jackson ImmunoResearch, West Grove, Pennsylvania). After washing with 
PBS/0.05% Tween and blocking with PBS/gelatin 1%, plates were incubated for 1 h with the 
supernatants of the cultured cells. After washing, plates were incubated for 1 h with 
peroxidase conjugated fragment goat anti-human IgA, IgG or IgMantibodies (Jackson 
ImmunoResearch). The assay was developed with o-phenylenediamine tablets (Sigma, St 
Louis, Missouri) as a chromogenic substrate. Immunoglobulin concentration in the 
supernatants was measured by interpolation with the standard curve. As standard, human 
IgA, IgG and IgM (Jackson ImmunoResearch) were used. The standard curve was generated 
measuring seven successive 1:3 dilutions of each standard. Also for each supernatant seven 
successive 1:3 dilutions were tested.  
 
§ Cytogenetic analysis 
Karyotype was performed by standard GTG banding at 550 bands resolution (ISCN 2009). 
Array-CGH was performed with a 44 K whole-genome oligonucleotide microarray Agilent 
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Technologies (Santa Clara, CA) following the manufacturer protocol. Array data were 
visualized using the Genome Workbench standard edition ver. 5.0 Agilent Technologies 
(Santa Clara, CA) and compared with the human genome reference sequence hg19 (Feb. 
2009). 
 
§ Statistical analysis  
All results are shown as the mean ± DS. Clinical features were compared in Chi-squared or 
Mann-Whitney U tests, as appropriate. Variables with a p-value < 0.05 were considered to 
be significant. SPSS Version 21 was used for the analysis (SPSS Inc., Chicago, Illinois). 
Survival curves were plotted as a function of age, by the Kaplan-Meier method. Continuous 
variables are expressed as the median and range, to reflect the population distribution.  
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SUMMARY 
Primary immunodeficiency disorders (PIDs) represent a heterogeneous group of inherited 
disorders characterized by poor or absent function in one or more components of the immune 
system, that result in chronic, recurrent and life-threatning infections if not promptly 
diagnosed and treated. Traditionally, PIDs are classified according to the component of the 
immune system that is primarily disrupted: innate or adaptive immunity, the latter comprising 
antibody deficiencies and combined immunodeficiencies. In the last 20 years, thanks to the 
progress in molecular technologies, a remarkable improvement of the knowledge in the field 
of PIDs, concerning both their etiopathogenesis mechanisms and clinical features, has been 
observed. Nowadays about 300 forms of well-characterized PIDs have been identified 
underliyng complex phenotype which encompass a wide spectrum of clinical features 
ranging from recurrent bacterial infections to other unusual manifestations, such as 
autoimmune disorder, cancer susceptibility, allergy and autoinflammation. In many cases, 
children affected with novel forms of PIDs also show extrahematopoietic alterations, leading 
to complex phenotypes characterized by a functional impairment of organs different from 
immune system. Advances in next generation DNA sequencing (NGS) allowed new gene 
identification of several forms of PIDs of unknown cause making genetic identification of 
immunodeficiency syndromes more efficient. Only in the last two years, 34 new gene defects 
have been identified. In this context, my PhD program has been focused to the study of some 
Immunological disorders, in order to identify “Novel strategies in the approach to primary 
immunodeficiencies to discover new pathogenic mechanisms and complex clinical 
phenotype”. Particularly, I followed a first project focused on the novel insight in the 
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diagnosis and management of primary immunodeficiencies aimed at the characterization of 
novel aspect of the pathogenesis and treatment of already known immunodeficiency, 
diagnosed conventionally or through Next Generation Sequencing. In particular, I studied 
the role of Myd88 deficiency, identified through Targeted Next generation sequencing, in the 
pathogenesis of the immunological and clinical features observed in a patient who had an 
atypical presentation characterized by chronic Yersiniosis and granuolomatous 
lymphadenitis, in absence of pneumococcal infections. On this topic, I contributed to the 
description of the case and to the planning of the experiments aimed at demonstrating the 
defect of TLRs signaling and the rescue of the function after the tranfection of plamids 
containing WT Myd88 in the patient fibroblasts. The paper describing this patient has been 
accepted for the publication as Letter on Journal of Allergy and Clinical Immunology.  I also 
followed another project aimed at defining the broad spectrum of clinical manifestations 
caused by STAT1 gain of function mutation and at defining the role of STAT1 gain of 
function mutation in the pathogenesis of the clinical manifestation caused by mutations in 
this gene other than chronic mucocutaneus candidiasis. Moreover, my research effort has 
been devoted to the definition of the role of T-independent B-cell immunity in susceptibility 
to infections from encapsulated bacteria in Hypoidrotic Ectodermal Dysplasia with 
immununodeficiency (HED-ID). I also participated to the description of skin and skin annexa 
abnormalities associated to PIDs, which represent alarm signs that should lead the clinician 
to consider a deeper immunological assessment. I gave a contribution to better define the 
functional role of  FOXN1 transcription factor in the T-cell ontogeny. Eventually, I also 
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studied rare genetic syndrome involving immune system paying a particular attention to 
SCID, hemophagocytic lymphoistiocitosis (HLH) and Di George Syndrome (DGS). 
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